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Background: Hydroxyphenyl-γ-valerolactones (HPVLs) are microbiota-derived metabolites of 
monomeric catechins and comprise about 33 % of total human catechin metabolites. HPVLs could 
therefore contribute to the previously reported beneficial effects of (−)-epicatechin (EC) on high-
fat (HF) diet induced weight gain and insulin resistance (IR) in mice.  
Aims: Assess the bioavailability and metabolism of 3’,4’-dihydroxyphenyl-γ-valerolactone 
(34DHPVL) and determine its effects on IR, body weight gain, steatosis and hepatic gene expression 
changes when fed directly to mice on HF or low-fat (LF) diets. 
Methods: Male C57BL/6J mice were fed LF (10 % kcal) or HF (60 % kcal) diets with or without 20 
mg/kg body weight (BW) supplementation of EC or 34DHPVL for 15-weeks. A fasted glucose 
tolerance test was performed at week-13 to assess IR. Plasma and liver lipids were quantified, and 
the effects on global gene expression assessed via RNA-sequencing analysis of liver tissue.  
Results: Gavaged 34DHPVL was highly bioavailable and present in plasma solely as sulfated and 
glucuronidated conjugates. 34DHPVL dietary supplementation reduced plasma glucose A.U.C (p-= 
0.12) albeit non-significantly (ns), paradoxically increased plasma insulin (p-<-0.01) and liver lipids 
(ns) but had no effect on HF diet-induced BW gain. EC dietary supplementation improved insulin 
sensitivity (HOMA-IR, p-=-0.07), and mitigated HF diet-induced BW and liver weight gain and 
hepatic lipid accumulation (all p-<-0.05). Both EC and 34DHPVL protected against HF diet-induced 
increases in expression of genes involved in glucose production and increased expression of insulin 
signalling genes, but the effects of EC were much stronger. 
Conclusion: These data suggest that 34DHPVL may contribute modestly to the beneficial effects of 
EC consumption on HF-diet induced IR, but it is clear that the effects of the parent EC are stronger. 
34DHPVL is not responsible for the mitigation of HF diet-induced BW gain caused by EC, which 
suggests that this effect is caused by EC conjugates. 
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AN INTRODUCTION TO POLYPHENOLS AND THEIR 




Chapter 1: An introduction to polyphenols and their 
protective effects against insulin resistance 
1.1 Structure of the thesis 
The results presented in this thesis covers three main objectives, the first being an exploratory 
analysis of how (−)-epicatechin and 3’,4’-dihydroxyphenyl-γ-valerolactone differ in the 
bioavailability of their ring fission metabolites, second the effects of metabolites on the mitigation 
of insulin resistance and hepatic lipid accumulation in high-fat (HF) diet fed mice, and the third the 
mechanisms through which the metabolites may confer protective effects against HF diet induced 
insulin resistance using analysis of RNA-Sequencing data for gene and pathway changes in the liver 
tissue of the mice on dietary interventions. This general introduction will therefore provide 
information on polyphenols and more specifically flavan-3-ols and their health benefits, their 
bioavailability and metabolism, their effects on insulin resistance, and then set-out to investigate 
the current research gaps in this area through the overarching objectives of the research described 
in this thesis. Each results chapter focusses on different objectives and because the methods used 
in the experiments in each results chapter are distinct, the material and methods are included 
within each chapter.  
 
1.2 Classification of dietary polyphenols 
Polyphenols are naturally derived plant compounds that have been shown to possess bioactive 
properties. Rich polyphenol sources include fruits, vegetables, whole grains, nuts, seeds, flowers, 
tree barks, along with foods and beverages such as tea, chocolate, wine, and coffee (6, 7). The basic 
monomeric unit of polyphenols is the phenolic ring, but they are mostly characterised by at least 
two phenyl rings (7, 8). There are four main groups of polyphenols, one of the groups are flavonoids 
(flavonols, flavones, flavanols which include proanthocyanidins, flavanones, flavanonols, 
isoflavones, anthocyanidins – anthocyanins) and the other non-flavonoids are phenolic acids 
(hydroxybenzoic acids, hydroxycinnamic acids), stilbenes and lignans (Figure 1.1) (9). They are 
classified by the number of phenol rings present and from the nature of the substitutions and 
condensation of the rings (4, 10). 
Flavonoids are the most common polyphenol throughout the plant kingdom, constituting more 
than half of the 8000 phenolic structures currently recognised (6). They possess two phenolic rings 




structures are displayed in Figure 1.2 and describes the most common structures within each class 
(4). For catechins, they are isomers, where (+)-catechin has a cis configuration and (−)-epicatechin 
has a trans configuration, each having two stereoisomers. They can also exist in polymer forms as 
proanthocyanidins, for example procyanidin A1 is a dimer of epicatechin and catechin, whereas 
procyanidin B2 is a dimer of two epicatechin units, and there are oligomers of procyanidins which 
have three or more degrees of polymerisation (11). Anthocyanidins supply the dark blue/red/purple 
pigments of plants, fruits, vegetables and grains such as black rice (6).  
For relevance and food ubiquity, the rest of this review will be focussing on flavonoids rather than 
polyphenols in general, and their metabolism and effects on health.  
 
1.3 Flavonoid food sources 
Manach et al (2004) reviewed the food sources of most flavonoid groups and their respective 
concentrations by weight (4) (Table 1.1). Most flavonoids are typically found as parent compounds 
in foods with most of them glycosylated. Typically, the flavonol quercetin is the most common 
polyphenol in diets (12), whilst flavanones are present at high concentrations only in citrus fruits 
(4). Flavones are present at much lower concentrations than flavonols, but they are not very 
common in foods, with the exception of parsley that contains high apigenin. Isoflavones are almost 
exclusively found in legumes and found as aglycone or malonylglucoside derivatives and are 
glycosylated during industrial food processing, unless they are fermented which can cause 
deglycosylation. Flavanols are found in a diverse range of food and drink products, but are richest 





Table 1.1: The classes of flavonoids found in foods 
This information has been extracted from Manach et al (2004) (4) and the food sources are not exhaustive. 































Black tea infusion 






Table 1.1: The classes of flavonoids found in foods (continued) 














































Figure 1.2: Structures of the classes of flavonoids 
The most common flavonols are kaempferol, quercetin, and myricetin; flavones - apigenin and luteolin; 
isoflavones - daidzein and genistein; flavanones - naringenin, eriodyctiol and hesperidin; anthocyanidins - 
pelargonidin, cyanidin, delphinidin, petunidin and malvidin; and flavanols or flavan-3-ols - catechins ((+)-catechin 





1.3.1 Dietary flavan-3-ols – cocoa and green tea 
Daily dietary flavanol intakes vary greatly on the types of foods and drinks consumed, but on 
average it is estimated to be around 60 mg/day from a total polyphenol consumption between 1-2 
g/day (9, 13). Databases such as Phenol-Explorer (14-16) eBASIS (17) and USDA (18) exist to report 
the average polyphenol concentrations found in foods. But the levels still vary greatly depending 
on how old the foods are (there are reduced polyphenol concentrations in fruit the longer it is 
ripened), as well as how the foods are processed, cooked and stored (4).  
Pure cocoa has the highest flavan-3-ol content on a per weight basis over other foods (19-21). The 
phenolic levels of cocoa products are as follows: 72-87 % in cocoa powder, 45-49 % in baking 
chocolate, 20-30 % in dark chocolate, 15-19 % in milk chocolate and 5-7 % in white chocolate (22), 
where phenolic compounds compose 12-18 % of the total weight of dried cocoa nibs (19). It has 
been estimated that 11 g of 70 % cocoa content in chocolate can contain 100 mg flavan-3-ols, 
whereas 52 mg of milk chocolate or 50-100 mL of cocoa drink containing 8 % (w/v) pure cocoa is 
required to achieve the same amount (23). Polyphenols constitute around 5-6 % of the content of 
fresh cocoa beans mostly as flavonoids, which can be further subdivided as 58 % proanthocyanidins, 
37 % monomeric flavan-3-ols, and 4 % anthocyanins (24, 25). Of the flavan-3-ols (−)-epicatechin is 
the most abundant (~37 %) with much smaller quantities of (+)-catechin, (+)-gallocatechin and (−)-
epigallocatechin (25, 26). 
Meanwhile, tea, derived from the Camellia sinensis plant contain higher concentrations of flavan-
3-ols compared to other polyphenol groups. Catechins derive around 3-8 % of the total flavonoid 
content in black tea, and 30-42 % in green tea for a typical 235 mL serving and 2 minute brew time 
(27, 28). The four major catechins present in tea include (−)-epigallocatechin gallate, (−)-
epigallocatechin, (−)-epicatechin gallate, and (−)-epicatechin (29, 30), providing 142 mg, 65 mg, 28 
mg and 17 mg of the compounds respectively (30). The differences between green and black tea 
arise from their processing, where green tea is processed in a way that doesn’t lead to the 
enzymatic oxidation of catechins, whereas black tea is derived from the fermentation of green tea 
leaves which promote the oxidation of catechins which gives the brown colour and contributes to 
the complex flavour of black tea (29).  
Because of the high flavan-3-ol content of cocoa and green tea, these food products have been 





1.4 Absorption, metabolism and bioavailability of flavonoids 
Dietary flavonoids have been reported to be associated with several health benefits, including the 
prevention of cardiovascular diseases, cancers, osteoporosis, neurodegenerative disease and 
diabetes mellitus (31, 32). More specifically, flavonoids are known to trap and scavenge reactive 
oxygen species (ROS), upregulate nitric oxide (NO) production, inhibit cell mitosis, promote 
apoptosis, and decrease inflammatory leukocyte attachment to cell membranes (33). However, due 
to the rapid absorption, metabolism and conjugation and limited bioavailability of polyphenols, it 
becomes hard to identify the active compounds that drive these positive health effects. As such, 
this section will discuss these points from the onset of consumption through to absorption, 
metabolism and the excretion of compounds from flavonoid diets.  
 
1.4.1 Absorption  
Approximately 5-10 % of total ingested polyphenols are absorbed from the stomach and small 
intestine (34). As a brief overview of compound absorption and metabolism, polyphenol structures 
in their native glycosylated form are unable to be absorbed, hence the requirement for hydrolysis 
by intestinal enzymes or colonic microflora (4). Other than catechins and procyanidins, most 
polyphenols are glycosylated in foods, which for anthocyanins enhances their absorptive capacity 
(35), as an example, quercetin glucosides are absorbed at a two to three times higher rate than 
their aglycone forms (36) because of the instability of the aglycone and the different mechanisms 
of absorption and metabolism of anthocyanins (37, 38). For most other glycosylated polyphenols, 
the removal of the glycoside is required before passive diffusion, and it has been demonstrated 
that the β-glucosidase in the human small intestine can do this for O-glycosides and O-galactosides 
(39). The intestinal border contains the enzyme lactase phloridzin hydrolase (LPH), a luminal β-
glucosidase that can perform this action (40). If they are able to enter the enterocyte, cytosolic β-
glucosidase (CBG) may act on polyphenol glucosides (39, 41). Aglycones and acylated compounds 
are absorbed by enterocytes in the small intestine through passive diffusion without hydrolytic or 
deconjugating mechanisms (42). Since flavanols are almost always present in foods as aglycones, 
they do not require deconjugation/hydrolysis prior to intestinal absorption (12).  
However, anthocyanins that enter the small intestine can be transported into the enterocyte by a 
sodium-coupled glucose transporter (SGLT1) and then deglycosylated via β-glycosidases in the 





Following enterocyte absorption, phase II metabolic events for methylation, sulfation and 
glucuronidation occurs by catechol-O-methyltransferases (COMT), sulfotransferases (SULT), and 
uridine-5’-diphosphate glucuronosyl-transferases (UGT), respectively (12). These metabolites can 
then enter the circulatory system and pass to the liver via the hepatic portal vein; the liver can 
facilitate further phase-II metabolism of the compounds to give glucuronidated, methylated and 
sulfated derivatives (44). These can re-enter the bloodstream via hepatic veins and are later 
excreted in urine. Alternatively, compounds can undergo enterohepatic circulation, where they are 
excreted into bile and back into the small intestine and later may be re-absorbed (42). Methylation 
of polyphenols by COMT occurs in a wide range of tissues, whereas the liver is the main tissue for 
the site of glucuronidation, but it can be affected by environmental and genetic factors, 
consequently creating interindividual differences (12). Polyphenol sulfation by SULTs mainly occurs 
in the liver or colon and they are not largely affected by environmental factors (12).  
The colon will receive polyphenols that have either not been absorbed by the stomach or small 
intestine or have undergone enterohepatic circulation. Here they become deglycosylated and 
catabolised into more simple compounds, commonly to phenylacetic, phenylvaleric, benzoic, and 
phenylpropionic acids and phenyl-γ-valerolactones (12). Gut microbes also have the capacity to 
cleave O-glucuronides and catalyse carbon-carbon cleavage of heterocyclic and aromatic rings in 
flavonoids, in addition to dehydroxylation and decarboxylation (45). However, the composition of 
the gut microbiota does vary due to disease, diet and environmental and genetic factors, which can 
influence the metabolism of polyphenols (46, 47). 
Almost all polyphenols found in the plasma will have undergone conjugation to glucuronides or 
sulfates (35). The main exception to this is through the provision of pharmacological doses, which 
seems to saturate the conjugation process (8).  
 
1.4.2.1 Flavanol metabolism 
Flavanols are rapidly metabolised into phase I and phase II conjugates for glucuronidation, sulfation 
and methylation by the small intestine and liver in less than 1-hour (13). Whilst aglycones and 
conjugated flavanols that pass into the colon are further catabolised and re-absorbed into the blood 
or excreted by 6 hours and more. There are very few species of microbiota that have been currently 
recognised to metabolise polyphenols out of the 500-1000 different species present, e.g. 





Procyanidins are not well absorbed per se and are generally degraded into monomers and dimers 
prior to absorption (13), although the epicatechin dimer (procyanidin B2) has shown to be absorbed 
intact in small quantities. Almost all procyanidins are metabolised by the gut microbiota (48) and 
mostly form the metabolites 2-(3,4-dihydroxyphenyl)acetic acid and 5-(3,4-dihydroxyphenyl)-γ-
valerolactone (49). Anthocyanins are poorly absorbed in the small intestine and are extensively 
catabolised by the gut microbiota (50). They undergo hydrolytic conversion to their aglycone 
anthocyanidins through the removal of their glycoside, but both the glycosides and aglycone 
variants are found in the urine of mammals (51, 52). Anthocyanidins can be further metabolised to 
more than 30 different metabolites and include degradants protocatechuic acid and 
phloroglucinaldehyde, and further metabolites (53) which can be initiated by the neutral or basic 
pH conditions of the small intestine and further transformed by the gut microbiota (50). For 
quercetin, it can be metabolised into protocatechuic acid and 2-(3,4-dihydroxy)-phenylacetic acid 
(54) and further into O-methyl metabolites in the colon (55).  
Gut microbial metabolism of catechins involves an A-ring cleavage to form compounds such as 3-
hydroxyphenylpropionic acid, 3,4-dihydroxyphenylacetic acid and 3-hydroxyphenyl-γ-
valerolactone (49). The latter can be further metabolised into 3,4-dihydroxyphenyl-γ-valerolactone. 
A proposed mechanism for this is for a hydride attack on the methide carbon to yield a 3,4-
dihydroxyphenyl metabolite and eventually give rise to 3,4-dihydroxyphenyl-γ-valerolactone (45). 
Alternatively, catechins can undergo C-ring opening by Eggerthella lenta rK3 to form 1-(3,4-
dihydroxyphenyl)-3-(2,4,6-trihydroxyphenyl)propan-2-ols, which is then dehydroxylated to 1-(3-
hydroxyphenyl)-3-(2,4,6-trihydroxyphenyl)propan-2-ols (56, 57). Both these compounds then 
undergo ring fission of the phloroglucinol ring to form 5-phenyl-γ-valerolactones (5-(3,4-
dihydroxyphenyl)-γ-valerolactone), and 4-hydroxy-5-phenylvaleric acids (4-hydroxy-5-(3,4-
dihydroxyphenyl)-valeric acid) (56), a biotransformation that has been shown to be performed by 
Flavonifractor plautii aK2 (57). The 4-hydroxy-5-phenylvaleric acids are then dehydroxylated to 4-
oxo-5-phenylvaleric acid and further to 5-phenylvaleric acids (56). These can later be degraded to 
3-phenylpropionic acids most likely through a β-oxidation process (58). Please see Figure 1.3 for the 





Figure 1.3: Proposed pathways involved in the colonic metabolism and urinary excretion of catechins 
Unmetabolised catechins that pass from the upper gastrointestinal tract into the large intestine are subjected 
to colonic degradation. Kutschera et al (57) identified the role of the microbiota Eggerthella lenta to open the 




Figure 1.3 (continued): ring fission of the phloroglucinol ring. Following the identification of metabolites in 
urine and faeces (1, 5) alongside faecal slurry incubations with the catechins (56, 59), the proposed colonic 
degradation pathways are illustrated. Double arrows indicate where unknown intermediate metabolites are 
formed but are not detected. Please note, not all the compounds displayed are detected following 
consumption. Please refer to Figures 1.6 and 1.7 for the metabolites detected in urine, faeces and plasma 
following (−)-epicatechin consumption in humans and rats.  
 
1.4.3 The general features of flavonoid bioavailability 
Bioavailability is defined as the fraction of compound intake that reaches the circulation (13), and 
in this thesis the term refers to both the intact flavonoid and the fraction that is absorbed post gut 
microbiota transformation. The differences in flavonoid structures causes different metabolites to 
be produced and subsequently causes them to appear at different concentrations and times within 
the circulation and excretory products. Therefore, a summary of flavonoid bioavailability shall be 
provided, mostly using information reported in a review by Manach et al (2005) (9) and more 
recently by Williamson et al (2018) (60).   
Flavanone aglycones are generally reported to be absorbed and metabolised quickly and typically 
peak in the circulation within 30 mins (61), however, flavanone and flavonol glycosides take 
approximately 5-hours for the hydrolysis of the sugar rhamnoglycoside which can only occur via 
catalysis from the gut microbiota (9), and consequently appear at maximum concentrations in the 
plasma between 4-9 hours, dependent on the flavonoid (62-64). Because of the delayed absorption 
of flavanone glycosides, they can circulate for up to 36-hours, with urinary excretion being almost 
complete by 24-hours (62), but only 1-30 % of the ingested intake is found to be recovered in urine 
(65-68).  
For anthocyanins, there have been 35 metabolites reportedly recovered in the serum, urine and 
faecal samples of participants following consumption of an isotopically labelled anthocyanin, 
including anthocyanin degradation products, phase-I/II/III metabolites and very low concentrations 
of parent compounds (69). Plasma concentrations for parent compounds peaked around 1.8-hours 
whilst colonic metabolites peaked between 6-30 hours, and urinary excretion of anthocyanins and 
their metabolites appeared between 1-48 hours, and faecal samples were detected from 6-48 
hours, with an overall low recovery of 12 % of the ingested compound (53).  
The pharmacokinetic profile of isoflavones has been predominantly explored from the consumption 
of soy products, with plasma Tmax of ~6-7 hours and urinary and faecal concentrations detected 
from 6-72 hours, with peak concentrations detected between 6-12 hours and 24-48 hours, 




in faeces, and in urine for 9, 21, 22 and 62 % (71, 72). The profile of isoflavone metabolites detected 
were mostly O-glucuronides and O-sulfates and very low levels of aglycones and glycosides (9).   
For flavones, they have been reportedly detected up to 12-days in the plasma of rats due to their 
long-half-lives but peaked at ~24-hours (73). High recoveries have been detected from the ingested 
dose, 51 % in urine, 12 % in faeces and 1.2 % in plasma and mostly consisted of O-glucuronides and 
O-sulfates. In contrast, glycosylated flavones are very rarely absorbed but are quickly excreted (74). 
The extensive metabolism and bioavailability of flavanol’s epigallocatechin-3-gallate (EGCG) and 
(−)-epicatechin (EC) are discussed in detail in sections 1.4.3.1 and 1.4.3.2 respectively.  
 
1.4.3.1 EGCG metabolism and bioavailability 
The high absorptive capacity of flavan-3-ols and their metabolites have made them interesting for 
investigating their potential health benefits (1, 5). Epigallocatechin-3-gallate (EGCG) has been 
widely researched, mostly because of its high concentrations found in tea products, so it is 
important to understand its bioavailability in humans. However, its research has mostly been 
explored from the consumption of green tea extracts, with a few studies providing EGCG directly 
to mammals.  
Oral administration of EGCG has shown to provide poor absorption, poor bioavailability, and low 
accumulation in the body due to their poor stability in the gastrointestinal tract. Studies have shown 
that under simulated gastrointestinal conditions, 49 % of free EGCG was retained after digestion at 
simulated gastric pH, while 20 % of free EGCG was retained after digestion at simulated intestinal 
pH (75). In a rat study, 42 % of the provided oral dose of radiolabelled EGCG was present in the 
stomach within 15-30 mins and had mostly disappeared by 8 hours, but by 4-hours most of it had 
moved into the small intestine and by 8-hours into the cecum and large intestine (~42-45 %) (76). 
Although the stability and absorption of free EGCG is shown to be low, it undergoes extensive 
metabolism in the colon and their absorption and excretion accounts for most of the circulatory 
compounds detected (76-78).  
A few studies have reported a low (< 1 %) absorption of free EGCG into the blood via the small 
intestine (79-82), but its metabolites peaked within 1-2 hours post-consumption and are almost 
undetected by 24-hours (80, 82-85) and mostly consist of O-glucuronides which account for ~90 % 
of the EGCG detected in the urine of mice (80). However, in humans, glucuronidated and sulfated 
derivatives of EGCG were found in the plasma at very low concentrations (82), whilst only O-methyl 




To assess the metabolic distribution of EGCG and its metabolites, Kohri et al (2001) radiolabel 
tagged EGCG and provided it to rats via intragastric administration (76). Plasma and blood 
radioactivity had a small peak at 2-hours and a penultimate peak at 24-hours post dosage. Liver 
radioactivity followed the same trend (0.2 % and 0.5 % of the dose respectively), whilst tissues for 
the brain, eye, thymus, lung, heart spleen, kidney, and testis showed peaks at 24-hours. After the 
72-hour assessment period, 32.1 % of the dose appeared in the urine and 35.2 % in the faeces, 
where most of the radioactivity was excreted between 8-24 hours. The main compounds detected 
in urine and faeces were for epigallocatechin (EGC), EGCG, 5-(3’,5’-dihydroxyphenyl)-γ-
valerolactone and 5-(5’-hydroxyphenyl)-γ-valerolactone 3’-O-β-glucuronide. For 5-(3’,5’-
dihydroxyphenyl)-γ-valerolactone, this was absorbed through the colon after metabolic 
degradation of EGCG and later metabolised by the liver and/or the microbiota to produce the 
glucuronide derivative. The detection of free EGCG in the urine is conflicted by other studies, where 
only EGCG metabolites were detected, and therefore this requires more investigation (86). Further 
EGCG phase-II metabolites are found to mostly arise in the bile after liver metabolism of EGCG to 
produce 3’-O-methyl-EGCG, 4’-O-methyl-EGCG, 3’’-O-methyl-EGCG, 4’’-O-methyl-EGCG, and 4’,4’’-
di-O-methyl-EGCG, and their conjugates, although conjugates were unidentified due to β-
glucuronidase/sulfatase treatment prior to analysis (87). Because of this, most phase-II metabolites 
of EGCG do not reach the circulation but are instead excreted via the bile.  
In an earlier radiolabelled EGCG study performed in mice, they discovered that ~6.5 % and ~35 % 
of radioactivity was excreted in the urine and faeces respectively, where the largest concentrations 
were detected at 24-hours post-consumption (78). Radioactivity was detected in the systemic 
circulation within 1-hour, rising steadily till 6-hours and peaked at 24-hours, accounting for ~2 % of 
the total radioactive dose to be absorbed into blood.  
Takagaki et al (2010) investigated the metabolism of EGCG in-vitro with rat enterobacteria and in-
vivo in male Wistar rats to devise the image reconstructed in Figure 1.4 for EGCGs metabolism (77). 
They identified bacteria involved in hydrolysing EGCG and in its subsequent degradation steps. 
Initially, EGCG is hydrolysed to EGC and gallic acid, EGC then forms the basis for further metabolism. 
Following this is the opening of the C-ring through a retro-Michael reaction which reductively 
cleaves carbons 1 and 2 to liberate the hydroxyl group on the meta position to form the 
phloroglucinol ring in product 1-(3,4,5-trihydroxyphenyl)-3-(2,4,6-trihydroxyphenyl)propan-2-ol, 
which peaks at 24-hours post EGC formation. Later is the formation of 1-(3,5-dihydroxyphenyl)-3-
(2,4,6-trihydroxyphenyl)propan-2-ol, which peaks at 48-hours post EGC formation, and is subjected 
to decomposition of the phloroglucinol ring to form 5-(3,5-dihydroxyphenyl)-4-hydroxyvaleric acid, 




EGC formation. This pathway is shown to be route 1 in Figure 1.4, and accounts for more than 90 % 
of the microbial metabolites; encompassing this are two further less favoured degradation routes, 
routes 2 and 3 in Figure 1.4. As such, further metabolites for 5-(3,5-dihydroxyphenyl)-γ-
valerolactone, 5-(3,5-dihydroxyphenyl)valeric acid, and 5-(3-hydroxyphenyl)valeric acid are 
formed. 
To summarise, EGCG absorption and bioavailability is low, particularly when compared to (−)-
epicatechin (EC) and EGC flavanols. However, when assessing the metabolic profile of EGCG and 
their absorption and distribution profile, these contribute more greatly to the circulatory and tissue 
distribution. Thus, it is reasonable to suggest that EGCG colonic metabolites could contribute more 
greatly to the overall health benefits that have been seen to be induced following EGCG 







Figure 1.4: Proposed pathways involved in the colonic metabolism and urinary excretion of (−)-
epigallocatechin gallate (EGCG) 
This image has been reconstructed from Tagakai et al (2010) (3) and illustrates the colonic degradation of EGCG. 
Thick arrows demonstrate the main pathway of colonic degradation (route I). Thin solid arrows demonstrate a 
second route for colonic degradation (route II), and the thin dashed arrows represent the third route for colonic 




1.4.3.2 (−)-Epicatechin metabolism and bioavailability 
As with EGCG, EC has been widely researched for its protection against disease. Because of this, it 
is necessary to understand the bioavailability and metabolism of EC in-order to comprehend what 
metabolites of EC are responsible for the protective effects. For instance, if a metabolite circulates 
for a longer period of time in the system than other metabolites, then it may have a greater capacity 
to exert biological effects due to its long exposure to cells and their receptors.  
Bioavailability studies have been conducted to explore the metabolism of EC, and have been 
primarily investigated from the consumption of cocoa derived products (88). Once consumed, EC 
undergoes quick sulfation, methylation and glucuronidation (89-92), with rapid absorption by the 
upper GI tract into the circulatory system, resulting in detectable levels of these compounds within 
1-4 hours (1, 93-95). These rapidly absorbed compounds are known as structurally related EC 
metabolites (SREMs), and are also quickly excreted with elimination half-lives of around 2-hours (1, 
96). Later absorbed compounds are known as ring fission metabolites (RFMs), and are produced via 
catabolism by the gut microbiota (1). Approximately 70 % of SREMs formed in enterocytes efflux 
back into the intestinal lumen, along with unabsorbed EC, where they pass to the colon and are 
converted to RFMs (96). The main groups of RFMs from EC are hydroxyphenyl-γ-valerolactones 
(HPVL) and hydroxyphenyl-valeric acids (HPVA) (1, 5, 95), both of these compound types have much 
longer elimination half-life’s of around 6-hours in humans, compared to SREMs (1, 96) following the 
ingestion of EC or cocoa.  
Two major studies have investigated the metabolism of radioactively labelled (−)-epicatechin, one 
in humans (1) and one in rats (5). Ottaviani et al (2016), (1) explored in detail ECs absorption, 
distribution, metabolism and excretion by having participants to consume 60 mg of radiolabelled 
[2-14C](−)-epicatechin in a drink. They monitored the radioactivity levels in blood, urine and faecal 
matter and profiled the compounds on HPLC-MS (high performance liquid chromatography - mass 
spectrometry). Circulatory radiolabelled products appeared as soon as 15-minutes after ingestion 
for SREMs, with peaks at 1 and 6-hours for both plasma and whole blood. The sum of SREMs in the 
circulation was twice the concentration of the sum of RFMs, but the amounts were 3.5-fold less 
than the sum of RFMs in urine. Subsequently SREMs declined rapidly, with full clearance from the 
circulatory system after 8-hours. The complete clearance of whole blood radioactivity took 36-
hours and in plasma after 72-hours. Within 24-hours, 82 % of radioactivity was excreted in urine 
and 12 % in faeces. Almost half, ~42 % of total radioactivity was attributed to HPVLs, data for 
metabolites are depicted in Figure 1.7. Ottaviani also concluded that "70 % of the ingested 14C-EC 
was absorbed into the circulatory system via the colon compared to the 20 % absorbed from the 




and the production of bioavailable flavanol derivatives. Figure 1.5 depicts the metabolism of EC 
over time in humans.  
Borges et al (2016) (5) took a similar approach to Ottaviani, but investigated the metabolism of 14C-
epicatechin in rats, instead of humans, thus allowing for a detailed account of the species 
dependent differences (Figure 1.6). Due to the different measurement recordings of the 
radiolabelled samples, it is not feasible to compare the concentrations of the metabolites between 
studies, but it is possible to identify the metabolites produced at timed intervals. Table 1.2 




As an overview of the results, no sulfated SREMs were detected in the plasma of rats (5), which was 
also confirmed briefly by Ottaviani et al (1). Furthermore, the SREMs in rats were also detected up 
to 9-hours post intervention (5), whereas no SREMs were detected past 4-hours in humans (1). An 
additional contrast between the studies included the detection of only two RFMs in the plasma of 
rats, compared to the detection of six in humans. Urinary excretion products were also different 
between the two species; but both studies confirmed the lack of detection of any EC SREMs after 
24-hours, whilst RFMs appeared in human’s urine within 4-hours, and in rat’s urine after 6-hours. 
Figure 1.5: Metabolism of (-)-epicatechin in humans over 42-hours 
Time represents the number of hours following the consumption of (-)-epicatechin. This figure has been re-




Another disparity between both studies, was the presence of un-metabolised 14C-epicatechin in the 
plasma and urine of rats, which was not reciprocated in humans.  
Borges et al (5) continued to compare their data to that of Ottaviani et al (1) with some of the main 
differences relating to the types of metabolites found (5). The main variations in the two datasets 
were for the profiles of the methylated, sulfated and glucuronidated phase-II metabolites, where 




Table 1.2: Radioactivity of 14C-Epicatechin in rats 
The information in this table has been extracted from Borges et al (2016) (5). They monitored the radioactivity 
of EC, following EC consumption at 1.3 μM in rats, throughout organs and excretory products over 72-hours. 
Time Location Percentage of Radioactivity 
1-hour 
Stomach 52 % 
Duodenum 2 % 
Jejunum/Ileum 45 % 
Circulatory system 0.7 % 
6-hours Jejunum/Ileum 72 % 
12-hours Urine 52 % 
6-72 hours Urine 78 % of total intake 
9-hours Colon 13 % 
9-hours GIT 34 % remaining 
0-72 hours Faeces 19 % 
 
 
Ottaviani et al (1) also performed radiolabelled EC tracing in C57BL/6 mice, but only reported the 
major differences for the circulatory metabolites found to those of humans and rats (1). They 
revealed that the metabolic profile from EC is larger in mice than in rats, with plasma detection of 
(−)-epicatechin-3′-sulfate, (−)-epicatechin-5-O-β-D-glucuronide, 3′-O-methyl(−)-epicatechin-5-O-β-




glucuronide, in mice, versus the detection of 3′-O-methyl(−)-epicatechin-5-O-β-D-glucuronide and 
(−)-epicatechin-5-O-β-D-glucuronide in rat plasma.  
 
1.4.3.2.1 Colonic metabolites of EC and a focus on hydroxyphenyl-γ-valerolactones (HPVL) 
Section 1.4.2.1 discussed the microbial metabolism of flavan-3-ols that is specific to EC. In addition 
to the microbe specific roles involved in its metabolism, Chen et al (2020), investigated the time 
course for microbial conversion of EC and EC conjugates, via in-vitro fermentation of rat faecal 
samples (97). From this, they discovered that by 4-hours around 50 % of EC was converted to 
metabolites by C-ring opening, and by 8-hours, 95 % conversion had taken place. This was followed 
by A-ring opening of metabolites to result in complete conversion by 12-hours. The results were 
very much dependent on the mass of faecal matter used and the concentration of EC supplied. 
Throughout the experiment, HPVL production occurred immediately in the faecal slurry, with a 
sharp increase in their production after 4-hours and peaking at 12-hours. Accompanied, was a later 
peak at 18-hours for hydroxyphenyl-valeric acids (HPVA), that accounted for 90 % of all the 
metabolites. By the end of their study, at 24-hours, both groups of compounds still appeared at 
high concentrations (97).  
In Ottaviani et al’s (1) human study, RFMs appeared at peak concentrations in the circulatory 
system after 6-hours and expressed longer elimination half-lives than SREMs. HPVL was maximally 
detected in the serum of individuals after 8-hours of EC (1 mg/kg body weight) ingestion and up to 
48-hours later in some participants (1). There was a total of 6 RFMs detected in human plasma, 11 
RFMs in urine, and 3 RFMs but no SREMs in faeces (Figure 1.7). Up to 18.6 % of ingested EC was 
excreted in urine as HPVLs and conjugates. Unfortunately, measurements were only taken up to 
48-hours for urine and plasma and for no longer than 24-hours for faeces, but it is known that levels 
can be detected up to 72-hours following ingestion (1, 5).  
In rats, HPVLs appeared in the contents of cecum and colon after 6-hours following EC ingestion 
but peaked after 12-hours, the same also applied to its detection in urine (5). A total of 8 RFMs 
were detected in colon contents, 5 RFMs in faecal material and 11 RFMs in urine (Figure 1.6). There 
were no HPVLs detected in plasma between 0-9 hours (5), because they do not get absorbed into 





Figure 1.6: Pharmacokinetics of EC metabolism in rats 
The graphs have been drawn from data reported by Borges et al (5). Rats were fed 20 μCi radiolabelled (−)-epicatechin (EC) and levels were monitored 
in plasma, urine and faeces over time. A-C) Urine EC metabolites detected for structurally related EC metabolites (SREMs), and ring fission metabolites 
(RFMs). D) Faecal metabolites, and E) plasma metabolites. GlcA: glucuronide; M: methyl; S: sulfate; D: di-; H: hydroxy; PVL: phenyl-γ-valerolactone; 






Figure 1.7: Pharmacokinetics of EC metabolism in humans 
The graphs have been drawn from data reported by Ottaviani et al (1). Humans were fed 1 mg/kg body weight of radiolabelled (−)-epicatechin (EC) and levels 
were monitored in plasma, urine and faeces over time. A-C) Urine EC metabolites detected for structurally related EC metabolites (SREMs), and ring fission 
metabolites (RFMs). D) Faecal metabolites, and E-F) plasma metabolites for SREMs or RFMs. GlcA: glucuronide; M: methyl; S: sulfate; D: di-; H: hydroxy; PVL: 




There are more studies that detail the bioavailability of HPVLs following ingestion of specific food 
products in human, mice and rats (57, 81, 98, 99) which suggests their physiological levels from 
food consumption. Meng et al (2002) (99) studied human consumption of 20 mg/kg of body weight 
of green tea solids, which comprised of 2.78 mg EGCG (epigallocatechin gallate), 2.2 mg EGC 
(epigallocatechin), 0.64 mg EC (epicatechin) and 0.66 mg ECG (epicatechin gallate). 5-(3',4',5'-
Trihydroxyphenyl)-γ-valerolactone (345THPVL) peaked in the urine of the volunteers between 3-9 
hours at 14 μM, whilst 3’,4’-dihydroxyphenyl-γ-valerolactone (34DHPVL) peaked between 3-6 
hours at 4.7 µM. Very similar findings were reported by Lee et al (2002) for 34DHPVL detection in 
plasma following green tea solid consumption, but with a cumulative detection in urine of 5.0 ± 2 
mg (81). In a separate study, ingestion of 150 mg of green tea solids in humans caused urine levels 
of 345THPVL to peak at 2.8 ± 1.5 µM and 34DHPVL to peak at 36.7 ± 34.4 µM, with a 1.2 mg 
cumulative excretion of 345THPVL (100). Faecal matter contained a total net wet weight of 11 µg/g 
of 345THPVL and 34DHPVL up to 9 hours following ingestion, and plasma contained up to 6 ng/mL 
of the compounds (100). In rats and mice, following the provision of 0.6 % green tea solids, 0.3 % 
EGCG or 0.1 % EGCG for 3 days in drinking water (composition as a percentage of that spoken from 
the solids above), mice excreted 8.3 µM of 345THPVL and 6.6 µM of 34DHPVL in urine (plasma was 
not recorded) (99). They also reported lower levels of EGCG in the liver and kidneys of rats 
compared to mice, and so mice demonstrated a greater bioavailability of EGCG and its metabolites 
than rats. In comparison, mice fed epicatechin gallate (10 mg) had detectable levels of 34DHPVL in 
plasma (562 ± 307 pmol/mL) and urine (201 ± 113 nmol/mL) between 24-48 hours (73). 
The collation of evidence highlights that HPVLs are the main metabolites circulating in plasma and 
excreted after flavan-3-ol consumption, but their pharmacokinetics are highly dependent on the 
concentration consumed and the species used. There are larger differences in the metabolism of 
EC between rats (5) and humans (1) (Figures 1.6 and 1.7) than between mice and humans (101), 
where the latter have been shown to produce a greater more consistent metabolic profile following 
flavan-3-ol consumption. It is therefore very important to consider the model used when trying to 
relate to the health benefits in humans. Furthermore, dependent on the species, HPVLs have been 
shown to circulate in plasma over a 0-3-day period, which is vastly longer than other flavan-3-ols 
and their metabolites (102). Due to this, HPVLs may exert biological effects on organs, cells, 
signalling pathways and metabolic processes over a longer timescale than other compounds; 
however, very little is known about them and the effects (if any) they have on human physiological 
functions and disease. Nonetheless, because of the known health benefits of consuming the parent 
flavan-3-ol compounds, there is the suggestion that HPVLs could in part contribute to these effects, 




1.5 Current evidence of possible health beneficial effects of 
hydroxyphenyl-γ-valerolactones, gut microbiota-dependent 
metabolites of (−)-epicatechin  
With the knowledge that HPVLs are the main group of colonic metabolites from EC, they require 
further investigation for their potential bioactive effects. The following is a summary of the existing 
published data relating to the biological activities of HPVLs.  
HPVLs effects have been investigated using in-vitro models for anti-inflammatory activity in 
RAW264.7 macrophages where a 50 % reduction in nitric oxide was measured (NO) following 
treatment with 345THPVL (20 μM) (103) and with 34DHPVL (1.3 μg/mL); 34DHPVL also induced a 
dose dependent decrease in NO and iNOS expression at concentrations from 0.1-50 μg/mL (0.48-
240 μM) (104). In addition, evidence was provided to suggest the facilitated diffusion of 34DHPVL 
into the macrophages via GLUT1 transporters (104). Moreover, HepG2 cells incubated with 
34DHPVL dose dependently decreased tumour necrosis factor-α (TNF-α) induced NF-κB 
transcription (105). It is reported that NF-κB drives inflammatory marker expression and can 
directly influence iNOS activity and this could therefore be a mechanism for how 34DHPVL lowers 
iNOS and NO levels (106).  
Both 34DHPVL and 4’-hydroxy-3’-methoxyphenyl-γ-valerolactone (4H3MPVL) have also been 
explored for their effects on lowering matrix metalloproteinase (MMP) levels (107). MMPs are 
involved in the pathogenesis of atherosclerosis where they degrade collagen and allow for smooth 
muscle cell migration into the vessel (108). Grimm et al investigated inflammatory 
lipopolysaccharide-stimulated MMP release in a model of primary human monocytes and reported 
that 0.5 μg/mL of 34DHPVL or 4H3MPVL inhibited MMP-9 secretion by 50 % (107). In addition, 
incubation of MMP-1 or MMP-2 proteins with either HPVL inhibited enzyme activity by 50 % at 
concentrations between 10-23 μg/mL, while 2-10 μg/mL was sufficient to inhibit MMP-9 activity 
(IC50). Because MMP activity is dependent on zinc ions that reside within their active site, it was 
further shown that the addition of Zn2+ to the enzyme assay reversed the inhibitory activity of the 
HPVLs on MMP-2 and MMP-9 activity and thus may interact directly with the active site of MMPs.  
A further study that demonstrated the potential of HPVLs to mitigate the development of 
atherosclerosis involved the incubation of human umbilical vein endothelial cells (HUVECs) with 
34DHPVL (7.5-30 μM) following TNF-α incubation (109). In comparison to only TNF-α stimulated 
cells, the results showed a dose-dependent reduction in protein and mRNA expression of vascular 




following inflammatory stimulation to support cholesterol accumulation within the vascular intima 
(110). Reductions in monocyte chemotactic protein-1 (MCP-1) secretion, NF-κB mRNA levels and 
the TNF-α induced phosphorylation of IKK were also observed following 34DHPVL incubation (109).  
In a spontaneous hypertensive rat model, 100-200 mg/kg body weight of 34DHPVL or 3’,4’,5’-
trihydroxyphenyl-γ-valerolactone (345THPVL) was provided via gastric gavage and systolic blood 
pressure(SBP) was recorded (111). This study reported a decrease in SBP 4-hours post-gavage of 
100 mg/kg or by 2-hours following 150 mg/kg body weight of 345THPVL administration, and by 4-
hours following 200 mg/kg body weight of 34DHPVL administration, when compared to the saline 
control and to baseline. It was reported that these effects may have occurred from the inhibition 
of angiotensin converting enzyme (ACE), although there were marginal inhibitory effects seen from 
both these HPVLs (111) they were not able to influence endothelial elasticity in arteries collected 
from mice, alongside other HPVL metabolites (112).  
More recently, the therapeutic potential of HPVLs was investigated using a brown adipose tissue 
(BAT) thermogenic in-vitro model (113), where BAT activity has been reported to be inversely 
correlated with adiposity and body mass index. For this, brown pre-adipocytes were differentiated 
in the presence of 10 μM of either 34DHPVL, 3´-hydroxyphenyl-γ-valerolactone-4’-sulfate (3HPVL-
4S) or phenyl-γ-valerolactone-3´,4´-di-sulfate (PVL-34S) with or without hydrogen peroxide stress 
(113). However, the HPVLs used in this study were not able to induce gene transcriptional changes 
that were different from the control for adipocyte differentiation and neither were they able to 
modify norepinephrine stimulated lipolysis. Nonetheless, the antioxidant potential of the HPVLs 
was confirmed following their ability to counteract the increased reactive oxygen species (ROS) 
levels following hydrogen peroxide treatment (113).  
Furthermore, 34DHPVL, 3HPVL-4S, PVL-34S, 4HPVL-3S were assessed for their ability to decrease 
the adherence of uropathogenic E.coli (UPEC) to bladder epithelial cells (114), a situation that 
occurs in the presence of a urinary tract infection (UTI). All the HPVL metabolites caused inhibition 
of UPEC adhesion by 20-30 % when treated with concentrations in the range 50-100 μM.  
To assess HPVLs ability to mitigate cancer cell proliferation, incubations were performed with 
34DHPVL, 345THPVL and their O-methoxy derivatives on several cancer cell lines (103). 345THPVL 
was the most active metabolite with IC50 values between 15-73 μM for human oesophageal 
squamous cell carcinoma cells (KYSE150), human colon adenocarcinoma cells (HT-29 and HCT-116), 
immortalized human intestinal epithelial cells (INT-407), and an immortalized rat intestinal 
epithelial cell line (IEC-6). However, the loss of a hydroxy group significantly reduced the bioactivity 




34DHPVL, 35DHPVL, and 345THPVL were unable to initiate an anti-proliferative effect on human 
cervical ovarian cancer (HeLa) cells (0.4-50 μg/mL over 72-hours), however their hydroxyphenyl-
valeric acid (HPVA) metabolic derivatives were able to inhibit proliferative activity in HeLa cells 
(115). This highlighted the importance in the bioactive potential of the aliphatic side chain.   
To determine if HPVLs were able to protect against skin ageing (wrinkling), human dermal 
fibroblasts (HDF) were incubated with 1 μM of racemic (S) and (R)-DHPVLs. The results showed that 
DHPVLs inhibited photoinduced MMP-1 protein expression where the (S) isomer was two times 
more potent than the (R) isomer. MMP-1 was the marker assessed because ROS levels are increased 
in the skin following UV radiation and subsequently this increases the transcription factor AP-1 and 
its transcribed protein MMP-1, and is thus a marker of photo-ageing (116).  
The ability of HPVLs to cross the blood-brain barrier (BBB) was confirmed by Unno et al (2017) using 
a BBB model kit. The same authors also incubated human neuroblastoma SH-SY5Y cells with 
35DHPVL, which was shown to cause cell proliferation at 0.5-1.0 μM incubations, whilst its O-sulfate 
and O-glucuronide derivatives had no effect. All three metabolites were able to increase the 
number of neurites, whilst only 35DHPVL and its O-sulfate increased neurite length (although it was 
unconfirmed whether this was for both isomers) (117). A further study by Angelino et al (2019) also 
confirmed the ability of 34DHPVL, 3HPVL-4S and 4HPVL-3S to cross the BBB by use of in-silico, in-
vitro and in-vivo models (118). The in-silico model provided a predictive score for the HPVL and 
HPVAs to cross the BBB, whilst incubation of 5 μM of each of the metabolites for 2-hours on human 
brain microvascular endothelial cells (HBMEC) (trans-well inserts) showed that 4HPVL-3S crossed 
the barrier and was quantified in both the ‘brain’ and ‘blood’ sides of the chamber. To determine 
the ability of HPVLs to cross the BBB in-vivo, rats were intraperitoneally injected with 34DHPVL at 
2 mg/kg body weight per day for seven days; alternatively, rats were provided with 100 mg/kg body 
weight of lyophilised red grapes for 10-weeks; an additional swine model was used where the 
animals were provided with a 20 g/day cocoa powder supplement for 27-days; in all scenarios the 
brain was harvested and frozen (118). This study revealed that the aglycone 34DHPVL was not 
detected in the brains of any of the animals, but there was the presence of the O-sulfate 
metabolites (although it was unconfirmed whether this was for both variants). Despite this, there 
was also the detection of HPVL-sulfates in the brains of the control and treated grape supplemented 
mice but only in the treated cocoa supplemented pigs.  
Lastly, in a recent study, the effects of HPVLs were reported to reduce amyloid-β oligomers (AβO) 
in a mouse model of Alzheimer’s disease (119), these are aggregates that lead to 




AβOs pre-incubated with or without 4HPVL and it was shown that the AβOs induced memory 
impairment in the mice, but this was dose-dependently relieved with 4HPVL and object recognition 
was preserved at the highest concentration used (10 μM) (119). Alongside this result was a 
reduction in Iba1 immunoreactivity in the brain, which was assessed via immunostaining 
procedures; Iba1 are microglia markers that are active during immune defence. This research also 
supported the in-vitro work performed in the same study by Ruotola et al (2020) for the anti-
cytotoxic effects of HPVLs on AβOs (119).  
The scarce but current evidence on HPVLs therefore implies that these metabolites have bioactive 
potential and can mediate mitigations in disease. However, the lack of evidence means that more 




1.6 Glucose homeostasis and insulin resistance 
Body homeostasis of glucose and insulin is imperative to prevent the onset of insulin resistance and 
diabetes. The continual consumption of high fat and/or high carbohydrate diets is a driver for the 
progression of type-2 diabetes (121, 122) and in keeping with the observation that more than 90 % 
of those with type-2 diabetes are overweight or obese (123). It is known that the flavan-3-ols EGCG 
(124-126) and EC (127-130) can exert protective effects against the onset of type-2 diabetes even 
under the continual consumption of high calorie foods. This section will therefore cover the basic 
signalling processes involved in glucose and insulin signalling and how this can impact on insulin 
resistance when disturbed. It will go on to describe how EC has been shown to protect against 
insulin resistance using in-vivo and in-vitro models.  
 
1.6.1 Normal glucose homeostasis 
Glucose is a source of energy for the body but it is not synthesised by the brain (131). Therefore, 
the brain is the only organ that is insulin independent and maintains glucose uptake at the same 
rate in the absorptive and postabsorptive periods (132). In the hypoglycaemic state, glucagon is 
released by pancreatic α-cells, small intestine L-cells, and hypothalamic cells, all of which help to 
stimulate organs to release glucose, with an 85 % contribution by the liver (131, 132). An equal 50 
% split of glucose is produced by processes of gluconeogenesis and glycogenolysis (132). Glycogen 
is a polymer of glucose subunits through α-1,4 glucosidic bond and an α-1,6 glucosidic bond that is 
stored in the liver and muscles (133). Only liver glycogen can contribute to blood glucose via 
glycogenolysis, the breakdown of glycogen into glucose, whilst muscle glycogen provides glucose 
only to the muscle fibres. Gluconeogenesis is the alternative pathway for the production of glucose, 
and it does so through the use of amino acids and citric acid cycle intermediates (Figure 1.8) (131, 
133). 
Glycogenolysis is controlled by hormones, namely epinephrine in the muscles and glucagon in the 
liver (133). Glucagon binds to its G Protein Coupled Receptors (GPCRs) to activate adenylyl cyclase 
via its α-subunit and subsequently cAMP. Likewise, protein kinase A (PKA) becomes activated to 
stimulate a series of enzymes involved in glycogenolysis (134). Energy release by ATP stimulates a 
series of phosphorylation reactions in the sequence of: phosphorylase kinase, phosphorylase, and 
finally glycogen synthase (133, 134). Glucose 1-phosphate is the final product from glycogenolysis, 
so the liver enzyme phosphoglucomutase converts it to glucose-6-phosphate, and finally glucose-




degraded to AMP and when protein phosphatases PP1, PP2a, PP2b, PP2c, dephosphorylate the 
phosphorylated enzymes (133). This process is summarised in Figure 1.8.   
Gluconeogenesis is a reverse process of glycolysis using amino acids. When glucagon binds to GPCR 
and activates PKA, it stimulates CREB (cAMP Response Element Binding Protein) that initiates 
binding to CRE. CRE triggers transcription factors to synthesise PEPCK (phosphoenolpyruvate 
carboxy kinase), that converts oxaloacetate to phosphoenolpyruvate. Oxaloacetate is the 
intermediate formed from the conversion of pyruvate in the mitochondria, itself formed from 
amino acids but mostly alanine, and can also be produced as a keto acid of aspartate via aspartate 
aminotransferase and from citric acid cycle intermediates which can originate from fatty acids 
(135). Phosphoenolpyruvate undergoes a series of reactions to produce fructose-1,6-bisphosphate, 
this is further catalysed by fructose-1,6-biphosphatase to fructose-6-phosphate, and to glucose-6-
phosphate by phosphoglucose isomerase (Figure 1.8). The final transformation to glucose is 
mentioned previously.  
The reverse of the mentioned processes will occur in the presence of hyperglycaemia to allow for 
insulin release and ultimately lower blood glucose. In the pancreas, β cells possess GLUT2 receptors 
that facilitates the diffusion of glucose into the cytoplasm, and further enters into pathways for 
glycolysis and the TCA cycle (136, 137). An increase of cytoplasmic glucose causes depolarisation of 
the cell via efflux inhibition of K+ through an ATP dependent mechanism, leading to a rise in 
cytoplasmic current (137). Voltage-gated Ca2+ channels open in response to the polarisation and 
influx into the cell, resulting in the exocytosis of insulin containing vesicles to raise circulatory insulin 
concentrations. Additionally, insulin release can be stimulated through the binding of GLP-1 
(glucagon like peptide 1) and GIP (glucose-dependent insulinotropic peptide) to GPCRs, that are 
excreted by small intestinal endocrine cells. Their binding increases the sensitivity of β-cells for 





Figure 1.8: Mechanistic overview of glucagon initiating glycogenolysis and gluconeogenesis in liver cells 
Glucagon binds to its G-protein coupled receptor where its α subunit activates adenylyl cyclase and increases the 
levels of cAMP. In return this activates PKA that triggers a series of events to activate enzymes involved in 
glycogenolysis that ends with the formation of glucose. Gluconeogenesis is a backwards process of glycolysis, 




1.6.2 Insulin signalling pathway 
Insulin signalling promotes glycogenesis to lower blood glucose levels and restore homeostatic 
conditions. It is also stimulated by the ingestion of carbohydrates through GLP-1 and GIP (138), but 
half of insulin produced is metabolised by the liver (138). 
The insulin receptor is an allosteric enzyme consisting of an α-subunit and a β-subunit located in 
hepatocytes, skeletal muscle cells and adipocytes (139). Upon the binding of insulin or insulin like 
growth factors (IGFs), the receptor dimerises to form an α2β2 complex which causes 
autophosphorylation of tyrosine residues on the β-subunits at positions 1158, 1162, 1163 (140). 
This activation step recruits and further activates several substrates with SH2 (Src homology-2 
domains) (141), in return activating signalling pathways such as the PI3K, Akt (also known as protein 
kinase B - PKB), mTOR (mammalian target of rapamycin), MAPK (mitogen-activated protein kinase), 
GSK-3 (glycogen synthase kinase-3), and cbl-associated protein (CAP) pathways (142) as detailed 
below.  
The best understood signalling pathway is the PI3K/Akt pathway. PI3K possesses two SH2 domains, 
a catalytic subunit (p110) and a regulatory subunit (P85). P85 binds to the activated insulin receptor 
substrates (IRS), stimulating the PI3K enzyme to phosphorylate the second messenger molecule 
phosphatidylinositol 4,5-biphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3). This 
further leads to the recruitment of protein dependent kinase-1 (PDK1) towards the plasma 
membrane and thus the phosphorylation of its downstream target Akt. When Akt is phosphorylated 
it becomes active, initiating downstream effector pathways involved in cell survival, inhibition of 
apoptosis and cell proliferation (Figure 1.10). Its activation is mediated by the phosphorylation on 
two residues, Thr308 and Ser473; two different pathways lead to the phosphorylation of each 
residue. Thr308 is phosphorylated by active PDK1 whereas Ser473 is phosphorylated by rictor-
mTOR (RICTOR) – both phosphorylation sites are required to achieve maximal Akt activation. 
Phosphorylated Akt can then go on to de-phosphorylate GSK-3 and phosphorylate TSC-2 (tuberous 
sclerosis complex-2), SREBP-1c (sterol regulatory element binding protein-1c), and FOXO (forkhead 
box O), all of which are transcription factors. Deactivated GSK-3 can regulate glycogen synthesis by 
preventing the phosphorylation of a cluster of serine residues on the enzyme (143). TSC1/2 
regulates mTOR and protein synthesis. FOXO regulates gluconeogenic genes.  
Another important activated pathway from the insulin receptor is the Cbl-CAP complex that occurs 
in adipose tissue and muscles (144). This pathway is mainly involved in stimulating the translocation 
of GLUT4 (glucose transporter type 4) receptors to the membrane of the cell. Once insulin binds to 




(144). As a result, CAP binds to Cbl and the whole complex translocates to the plasma membrane 
where CrkII followed by C3G and TC10 binds to the complex. TC10 catalyses the conversion to GTP 
from GDP, resulting in a release of energy to signal to GLUT4 vesicles from inside the cell to 
translocate to the plasma membrane.  
 
 
In addition to insulin’s role in transforming glucose into glycogen, it also regulates cell growth 
through the MAPK/ERK pathway, as illustrated in Figure 1.10. If insulin insensitivity occurs or the 
pathway is inhibited, cell growth can become arrested. Insulin signalling is also involved in lipid 
synthesis via activation of the SREBP-1c transcription factor and inhibition of enzyme lipases such 
as lipoprotein lipase, adipose triglyceride lipase, hepatic lipase and hormone sensitive lipase, thus 
inhibiting lipid degradation (145). 
Figure 1.9: Mechanisms of insulin secretion 
Glucagon and GLP-1 bind to G-protein coupled receptors that activates adenylyl cyclase and increases cAMP 
levels that stimulates PKA. PKA can in turn trigger the exocytosis of insulin containing granules. Additionally, cell 
depolarisation from the influx of glucose via GLUT-2 receptors in pancreatic β-cells triggers insulin release 
through ATP dependent closure of K+ channel. This depolarisation initiates the opening of Ca2+ channels to 






1.6.3 Pathogenesis of insulin resistance 
Insulin resistance is defined to occur “when normal concentrations of insulin produces a less than 
normal biological response” (146), resulting in a decreased uptake of glucose in the periphery in 
addition to the increased production of glucose endogenously (132). Beta cell function is impaired 
in type-2 diabetes, although in early stages they release more insulin as a compensatory mechanism 
to lower glucose levels. Type-2 diabetes is inherently associated with metabolic associated fatty 
liver disease (MAFLD) (formerly known as non-alcoholic fatty liver disease, NAFLD (147)), such that 
over 90 % of obese patients with type-2 diabetes have MAFLD (148). 
Insulin resistance mostly arises when there is an interference between insulin and its receptor, 
which is normally due to a reduction in receptor numbers (149). Intracellular signalling 
interferences following insulin binding to its receptor will induce decreased responsiveness, which 
is defined differently to resistance. Type-2 diabetic patients have been shown to have a 30 % lower 
Figure 1.10: Insulin signalling in hepatic cells 
Insulin binds to IR/IRS-1 receptors and can trigger a series of activation pathways. One pathway is through the 
phosphorylation of PI3K which phosphorylates PIP2 to PIP3. This activates PDK1 by phosphorylation which 
phosphorylates Akt. Akt can then go on to activate several pathways: GSK3 to trigger glycogen synthesis; TSC2 
to trigger lipid synthesis through SREBP1C; and FOXO to initiate gluconeogenesis. Alternatively, insulin binding 
can recruit Shc to the receptor that binds to Grb2-SOS complex, to trigger the phosphorylation of Ras, Raf, Mek 
and Erk1/2, ultimately triggering cell growth through transcription factors. Another important pathway is the 
triggering of Cbl and Cap following insulin binding. Cbl is phosphorylated by the receptor and recruits Cap. The 
Cbl-Cap complex translocates to the plasma membrane and binds to CrkII-C3G-TC10 complex. TC10 causes a 
release of energy from GTP to GDP which stimulates the recruitment of GLUT4 vesicles to the plasma membrane 




glycogen store in muscle tissues in addition to a 50 % reduction in glycogen synthesis; reduced 
glucose transportation has been shown to be the rate limiting step in this process (150).  
An increase in the concentration of lipids, either from dietary consumption or from the accelerated 
lipolysis of adipose tissue, results in an increased delivery of fatty acids and overwhelms the 
capacity for cells to oxidise fats to diacylglycerols (DAGs) (151). The reduction in fatty acid oxidation 
induces the phosphorylation of protein kinase C-θ (PKC-θ), in turn phosphorylating IRS-1 on its 
serine/threonine amino acids, thereby inhibiting it. It’s inhibition prevents the activation of the 
PI3K/Akt pathway (152, 153), which desensitises the receptors to stimulation from insulin, in return 
leading to continued glycogenolysis and gluconeogenesis (153-158), and induces muscle insulin 
resistance over time. Although this process is the same in liver tissue, the PKC responsible is PKC-ε. 
Another method shown to desensitise insulin receptors is through the transportation by F-actin of 
PKC-ε to the cellular nucleus (159). This downregulates the expression of the insulin transcription 
factor HMGA1 (high mobility group AT-Hook 1) through phosphorylation, and drastically impacts 
upon the detection and signal transduction of insulin.  
Accumulation of free fatty acids (FFA’s) in the liver can also stimulate inflammatory pathways, in 
particular toll-like receptors (TLRs), that increases the synthesis of de novo ceramide (153, 160). 
Ceramides can inhibit Akt phosphorylation and therefore contribute towards insulin resistance. In 
addition to increasing ceramides, PP2a is activated by FFA’s and will phosphorylate and inactivate 
Akt. Its inactivation prevents the inhibition of transcription factor Forkhead Box-01 (FOXO1) that 
would otherwise activate gluconeogenesis enzymes (161). Despite these other pathways, hepatic 
diacylglycerol (DAG) accumulation is the best predictor for insulin resistance, as confirmed by liver 
biopsies in obese subjects (153, 155, 162). 
 
1.7 Flavonoids and insulin resistance 
Flavonoids have been reported to contribute to the prevention of cardiovascular diseases, cancers, 
osteoporosis, neurodegenerative disease, chronic inflammation and diabetes mellitus (6, 31, 32, 
163). More specifically, flavonoids have been reported to trap and scavenge ROS, upregulate NO 
production, inhibit cell mitosis, promote apoptosis, and decrease inflammatory leukocyte 
attachment to cell membranes (33). The focus of the rest of this review will be on flavonoids and 




Flavonoids have been shown to mitigate type-2 diabetes via improved insulin sensitivity, improved 
glucose tolerance, enhancing the uptake of glucose in tissues through an increase in the number of 
glucose receptors, and inhibit and regulate enzymes involved in carbohydrate metabolism (60).  
 
1.7.1 Associations of flavonoid consumption and protection from insulin 
resistance inferred from epidemiological studies 
The associations of polyphenol intake and the risks of type-2 diabetes have been explored by 
several authors. In the European Prospective Investigation into Cancer and Nutrition (EPIC) InterAct 
study (EPIC-InterAct), where polyphenol intake was estimated in 12,403 type-2 diabetic patients, it 
was reported that there were significant inverse associations for flavanol and flavonol intake 
against type-2 diabetes (164). EPIC-InterAct is a case-cohort study nested within the EPIC study, 
comprising cohorts recruited in the 1990s from 8 European countries (Denmark, France, Germany, 
Italy, The Netherlands, Spain, Sweden, and the United Kingdom) across 26 participating study 
centres. In this study they analysed 26,088 participants which included 11,559 who had type-2 
diabetes from the start of the trial, 729 who developed type-2 diabetes during and 15,258 who did 
not have type-2 diabetes. Dietary questionnaires were used to estimate polyphenol intake using 
the Phenol-Explorer database (15). For flavanol consumption, EGCG was found to be the highest 
contributor, followed by ECG, EGC, EC, catechin, catechin-3-gallate, and gallocatechin, comprising 
45.6 %, 14.2 %, 13.8 %, 13.2 %, 9.2 %, 2.5 % and 1.5 % of the ingested flavanols respectively (164). 
Alongside this was the consumption of flavonols quercetin, kaempferol, myricetin and 
isorhamnetin, comprising 70.2 %, 18.5 %, 9.3 % and 2 % of the flavonol intake. A significant negative 
association for the prevalence of type-2 diabetes was found for all the listed compounds except for 
isorhamnetin and quercetin but included proanthocyanidins.  
Del Bo et al (2019) reviewed the health effects of polyphenols from food related sources and 
highlighted 12 papers to have investigated these in the context of insulin resistance and/or type-2 
diabetes in humans based in the United States, South America, Europe and Asia (165). The results 
of this found the following associations for a decreased risk of type-2 diabetes, 15 % with total 
flavonoid intake (US males and females) (166), 8 % with myricetin consumption (European 
populations) (167), 14 % with proanthocyanidin dimer consumption (European populations) (167), 
7 % with EC consumption (European populations) (167), 6 % with (+)-catechin consumption 
(European populations) (167), 2 % with (+)-gallocatechin consumption (European populations) 
(167), 10 % with total flavonoid consumption (European populations) (164), 18 % with total flavanol 




populations) (164), 19 % with flavonol consumption (European populations) (164), and 32 % with 
total polyphenol intake (Polish males and females) (168). There was also a decreased risk for type-
2 diabetes with flavanol intake (US males and females) (169) and flavone intake (Korean women) 
(170), but not for total flavonoid consumption (US males and females) (169). Additionally, there 
were reductions in the homeostatic model assessment of insulin resistance (HOMA-IR) with 
anthocyanin and flavone intake (UK women) (171). Moreover, there was a 3.18 % reduction in 
insulin and 3.10 % reduction in HOMA-IR with flavone intake, and a 3.11 % reduction and a 4.01 % 
reduction in HOMA-IR with isoflavone intake (US males and females) (172). Sex specific reductions 
were found for insulin and HOMA-IR by flavonol consumption in men and flavanone consumption 
in women (Korean women) (170), but no gender differences were detected for decreased fasting 
plasma glucose with high total polyphenol intake (168).  
The current evidence therefore strongly supports an association for a decreased risk of type-2 
diabetes and insulin resistance with increased flavonoid intake. The differences between studies 
for the percentage reduction in type-2 diabetes risk highlights how study design and length can 
affect the outcome, alongside with how differently ethnic populations respond to diets, but may 
also reflect how the composition of the gut microbiota affects individual’s metabolism of the 
compounds that proceed to initiate protective effects (34).  
 
1.7.2 Associations of targeted dosing of flavonoids and protection from 
insulin resistance inferred from intervention studies 
To induce insulin resistance in mice, it is common to provide a HF diet for a period of time, as it 
imitates the western diet lifestyle. The effects seen in mice can be somewhat comparable to 
humans, although this model does not account for the many variables in a human’s lifestyle that 
can influence the effects induced by the diet, for example, mice are maintained in a strict 
environment for humidity, temperature and air flow whilst humans are faced with different 
environmental factors, and mice are maintained on a strict regulated diet, whereas humans diets 
will consistently vary. Before summarising the protective nature of flavonoids on insulin resistance, 
it is important to understand the tests performed to collate data. The most commonly used tests 
are the insulin tolerance test (ITT) and the glucose tolerance test (GTT). The ITT involves a bolus 
insulin injection into the subject and blood samples are taken to determine glucose levels over time 
to establish how the subject responds to insulin. In insulin resistance/type-2 diabetes, the glucose 
level will remain high despite the insulin injection, this is due to the subject’s resistance to insulin 




in previous sections. In the case of GTT, a bolus glucose dose is injected, and blood samples are 
taken to monitor the glucose and insulin levels. Type-2 diabetic patients have impaired recovery of 
their glucose levels - a rapid spike in their blood glucose concentration that is sustained for a long 
period of time despite the high recording of insulin in their blood. In contrast to this, a ‘healthy’ 
subject responds with a smaller rise in glucose concentration that returns to baseline more rapidly. 
The HOMA-IR is a model to assess insulin resistance and is calculated using the glucose and insulin 
levels following a GTT performed in the fasted state. To explore the mechanisms for how flavonoids 
protect against type-2 diabetes, this section will detail the glucose and insulin changes with 
treatments as well as the alterations in specific protein and gene markers linked to insulin resistance 
following the intervention of flavonoids in mice, rats and humans.  
Feeding Goto-Kakizaki rats 1 % (w/w) hesperidin for 4-weeks prevented the elevation of blood 
glucose and insulin levels and increased PPARα and PPARγ, signalling markers known to stimulate 
the insulin signalling pathway (173). PPARγ was also shown to be raised following oral 
administration of hesperidin (50 mg/kg body weight) for 15-days in diabetic Wistar rats induced by 
Streptozotocin (STZ) injections (174). In C57BL-KsJ-db/db mice, hesperidin and naringin (0.2 g/kg 
diet) lowered blood glucose and gluconeogenesis enzymes glucose-6-phosphatase (G6Pase) and 
phosphoenolpyruvate carboxykinase (PEPCK), and raised plasma insulin and hepatic glycogen and 
glucokinase levels after 5-weeks (175, 176). In addition to this, in the same study, hepatic glucose 
transporter 2 (GLUT2) protein expression was reduced whilst adipogenic GLUT4 and hepatic PPARγ 
were upregulated in both hesperidin and naringin groups (176). In diabetic Wistar rats (STZ diabetes 
induced), hesperidin (10 g/kg diet) lowered blood glucose through a reduction in hepatic enzymes 
G6Pase and glucokinase after 4-weeks (177). Furthermore, in humans, hesperidin (500 mg/day) 
supplementation for three weeks improved insulin sensitivity as shown by a lower QUICKI 
(quantitative insulin sensitivity check index) and reduced fasting plasma glucose levels (178).  
An intervention study in Djungarian hamsters administered orally with 10 mg/kg body weight of 
naringenin or quercetin prevented rises in plasma glucose levels when administered 15 mins prior 
to a fasted glucose challenge (179). Myricetin may also have anti-hyperglycaemic properties as has 
been reported in rat models following intravenous or intraperitoneal injections (180-182), 
accompanied with decreases in HOMA-IR (182), and increased hepatic glycogen associated with 
increases in glycogen synthase I activity, and is consistent with hepatic glycogen storage (180). 
Catechin (10 mg/kg body weight) had a similar effect in Sprague-Dawley rats after 60-days of 
feeding for the increase in hepatic glycogen and glycogen synthase activity, but with a decrease in 
glycogen phosphorylase levels (183). Quercetin (10 mg/kg body weight) reduced blood glucose in 




the glucose area under the concentration time-curve (A.U.C) following a glucose tolerance test 
(184).  
The effects of the flavan-3-ol EC are described in detail in section 1.7.2.1. Meanwhile, a 3-week 
administration of EGCG (200 mg/kg/day) in spontaneously hypertensive rats (SHR) was reported to 
improve insulin sensitivity (185). When EGCG was administered for seven weeks in db/db mice at 
0.25-1.0 % and in ZDF rats at 0.5 %, blood glucose levels decreased dose dependently alongside an 
increase in mRNA expression for glucokinase and a decrease for PEPCK in both the liver and adipose 
tissue (186). However, in humans, EGCG (400 mg) has not been reported to improve insulin 
resistance after 8-weeks, although there were effects seen to be positive such as a reduction in 
diastolic blood pressure (187). Green tea polyphenols (100 mg/kg body weight) that are high in 
EGCG lowered blood glucose levels in Wistar albino diabetic (alloxan treated) rats within 8-hours of 
oral administration (188), in db/db mice within 6-hours of administration (300 mg/kg body weight) 
(189), and in humans after 3-months of administration (379 mg) (190, 191), where the levels of 
insulin were also lowered alongside HOMA-IR (191). Despite this, there was a study that provided 
humans with 544 mg of green tea polyphenols for 2-months, but there was no improvement in 
blood glucose levels or insulin resistance (192). Green tea extract consumed at 500 mg for 16-weeks 
in humans with type-2 diabetes improved insulin resistance and increased GLP-1, a hormone that 
stimulates insulin release from the pancreas (193). 
Cocoa polyphenols, that are rich in catechins and mostly EC, have been routinely shown to 
positively influence insulin sensitivity through the lowering of blood glucose in humans (194-198) 
and rodents (199-206), reducing insulin in humans (194-198) and rodents (199, 201-203), improving 
HOMA-IR in humans (194-198, 207, 208) and rodents (201, 209), and reducing hepatic PEPCK and 
G6Pase accompanied with increased hepatic glucokinase in rodents (199). For a detailed example, 
in Zucker diabetic fatty rats, a 10 % cocoa diet (fed for 9-weeks) prevented hyperglycaemia in 
addition to improved insulin sensitivity which was associated with reduced serine phosphorylation 
of IRS-1, inactivation of GSK-3 and improvement in antioxidant defences (19, 199). The cocoa diet 
also suppressed the activation of JNK and P38 pathways which are otherwise active in insulin 
resistance (199). Meanwhile, human intervention studies have demonstrated that dark chocolate 
without polyphenols did not relay any health benefits, whilst the presence of polyphenols caused 
a decrease in blood pressure, increased insulin sensitivity, and improved HOMA-IR and β-cell 
function (197, 207, 210-212). The same improvements were also seen in patients who were type-2 
diabetic (195, 213). However, there have also been studies that show no effect on improving insulin 
sensitivity with cocoa intake, though these are largely thought to be due to the acute length of the 




For the isoflavones genistein and daidzein, their supplementation at a low dose of 0.02 % (w/w) for 
9-weeks in non-obese diabetic (NOD) mice caused a reduction in the hepatic mRNA expression for 
PEPCK, G6Pase and fatty acid β-oxidation together with a reduction in blood glucose levels (216). 
Accompanying this was a rise in insulin levels, where daidzein was 20 % more effective in raising 
insulin than genistein. Similar findings were found by genistein and daidzein supplementation at 
0.02 % in C57BL/KsJ-db/db mice after 6-weeks for the reduction in blood glucose and glucagon, 
whilst increasing the insulin/glucagon ratio and hepatic glucokinase, but reduced hepatic G6Pase 
and PEPCK, and lowered the expression of enzymes involved in fatty acid metabolism (217). 
Furthermore, STZ treated mice fed 10 mg/kg body weight of areca nut procyanidins for 4-weeks 
lowered blood glucose and hepatic PEPCK and G6Pase mRNA with increases in active AMPK (218). 
For the anthocyanin cyanidin-3-glucoside, when fed to db/db or high fat diet fed C57BL/6J mice at 
0.2 % for 12-weeks, there was an improvement in insulin sensitivity through the lowering of blood 
glucose levels accompanied with lower insulin levels, reduced JNK1 (c-JUN) protein expression, 
along with increased phospho-Akt (Ser473) and phospho-FOXO1 (Thr24) levels in adipose tissue 
(these are signalling molecules involved in insulin signalling) (219). Grape seed procyanidins 
administered orally to STZ rats at 250 mg/kg body weight also had an immediate anti-
hyperglycaemic effect, as determined following oral gavage of the compounds with or without 
insulin and recording blood glucose for 4-hours after(220). 
Flavonoids protect pancreatic β-cells from glucose induced damage and therefore restore insulin 
secretion in response to glucose, i.e. they are more sensitive. β-cell restoration has been shown to 
occur by quercetin-3-rutinoside and quercetin in STZ rats and diabetic mice through restoring the 
cell proliferation capacity and therefore raising insulin levels (184, 221-223).  
 
1.7.2.1 (−)-Epicatechin effects in-vivo on insulin resistance 
High-fat (HF) diet fed mice are routinely used as a model of insulin resistance, alongside the 
genetically induced models. Research has shown that mice fed EC supplemented into a 60 % kcal 
HF diet, enables the reduction of plasma glucose in response to insulin, therefore highlighting ECs 
potential to mitigate insulin resistant effects (127, 130, 224). 
Studies using EC in mice fed a HF diet have routinely shown that EC can improve the insulin response 
to a glucose injection where their blood glucose levels return to baseline comparably quicker than 
those on a HF only diet (130, 224-227). Mice on an EC supplemented HF diet have also been shown 
to express increased activity of insulin stimulated IR, IRS-1, Akt and ERK1/2 in adipose and liver, 




observations of adipose and liver from EC fed mice showed that EC prevented activation of IKK 
(kinase activating NF-kB pathway), JNK and adipose PKC (228). Transcriptomic studies from EC fed 
mice showed the reduced genetic expression of PTP1B when compared to HF mice; this gene is 
involved in negating the insulin signalling response, whilst the HF diet alone significantly increased 
its expression compared to control fed mice. Further findings using mice that were fed a 60 % kcal 
HF diet with or without 200 mg/kg body weight EC (224), or 20 mg/kg body weight EC (229), 
highlighted that EC prevented obesity in mice, and also resulted in lower adipose tissue weight, in 
addition to the reduction in serum levels of CCL19 and the downregulation of inflammatory genes 
TNF-α and IL-6, amongst others (130, 224, 229). EC was also able to restore mitochondrial proteins 
within adipose tissue and skeletal muscle (226, 230) and increase mitochondrial levels. 
Cremonini et al (2018) sought to understand how EC could mitigate steatosis and insulin resistance 
(130) based on the knowledge that increased intestinal permeability is associated with an increased 
risk for steatosis and insulin resistance (231, 232). They demonstrated that a 60 % kcal HF diet in 
mice increased intestinal permeability and made the gut ‘leakier’, evidenced by increased plasma 
TNF-α and inflammatory cytokine concentrations (130). The HF diet caused a reduction in tight 
junction proteins within ileal epithelial cells ZO-1, occludin, and claudin-1, where the 
supplementation of 20 mg/kg body weight of EC for 15-weeks prevented this. Additionally, EC 
prevented the increase in ERK1/2, AMPK, NF-kB (nuclear factor kappa-light-chain-enhancer of 
activated B cells) and p65 phosphorylation - pathways that are required to increase intestinal 
permeability. Oxidative stress is another factor that can increase intestinal permeability, and is 
reported to be significantly induced by HF diets via increases in NOX1 and NOX4 - changes that were 
mitigated by EC (130). Moreover, GLP-2 (glucagon like peptide-2) plasma levels were also raised by 
EC in the mice, this is a protein that can decrease intestinal permeability as well as exert a beneficial 
effect on glucose metabolism via the increase in the number of glucose transporters and the 
facilitation of glucose uptake (141, 142). This study therefore supports a further underlying role for 
how EC could mitigate insulin resistance and hepatic steatosis.  
Very few human studies have been performed with pure EC to investigate the effects on insulin 
resistance (233, 234). Gutierrez-Salmean (2014) investigated the effects of 1 mg/kg body weight of 
EC on blood glucose levels prior to consumption of a commercial supplement containing fat, 
protein, and carbohydrates, totalling 246 kcal (234). Respiratory quotient was assessed in the 
subjects to measure the ratio of CO2 consumed to O2 produced whilst food was being metabolised, 
and it was apparent that EC significantly lowered the respiratory quotient by sustaining fat 
oxidation in both normal weight and obese subjects. In addition, EC significantly lowered blood 




but bigger changes were observed in those who were obese. A double-blinded crossover study in 
humans was performed by Dower et al (2015) (233), with one arm of the study involving the daily 
intake of 100 mg/day EC for 4-weeks in a form of a supplement. After the 4-weeks there was a 
significant reduction in plasma insulin concentrations, ultimately leading to a lower HOMA-IR index 
(233). Although plasma lipids were lower, the change was not significant. After a 4-week washout 
period, the same participants were provided with quercetin-3-glucoside supplements, but caused 
no significant effects on insulin or HOMA-IR. These data support the notion that the effects of EC 
consumption on insulin resistance are somewhat specific, and this is not a flavonoid-wide effect 
(233).  
In addition, there are several clinical studies published on clinicaltrials.gov involving epicatechin 
and its effects on diabetes, and as of the 2nd April 2021 using the search criteria with ‘diabetes + 
epicatechin’ returns 10 completed study results. Of these, they were then narrowed down to 
studies that used cocoa and/or EC in the interventions to narrow down the data where EC is the 
most likely cause for any positive effects observed. A total of 5 intervention studies will therefore 
be highlighted, however two of the studies have already been mentioned previously under section 
1.7.2 with the references from Curtis et al (2012 and 2013) (195, 213).  In pre-diabetic participants, 
the consumption of 30 mg/day of (+)-epicatechin (please note this is the least naturally occurring 
epicatechin not found in cocoa) for seven days had no effects on plasma glucose or insulin levels 
when compared to placebo treatments, however, there was a tendency for the reductions in 
plasma TNF-α and MCP-1 levels (borderline significant) which tended to rise seven days after having 
stopped the intervention (235-237). A study in type-2 diabetic participants who consumed either 
high polyphenol content (3.5 % total polyphenols or 1 mg/day EC content) of milk or 70 % dark 
chocolate exhibited a non-significant reduction in P-selectin and E-selectin levels compared to 
those who consumed milk chocolate with low polyphenol content (0.9 % total polyphenols or 0.05 
mg/day EC content) which is reflective of EC’s antioxidant potential and ability to improve 
endothelial dysfunction, however, there was no improvement in other diabetic markers (214, 238). 
On the other hand, type-1 diabetes is associated with impaired cognitive function, and as such, a 
study was performed in type-1 diabetic patients to monitor cognitive reaction times via a ‘flanker’ 
test and functional magnetic resonance imaging (fMRI) following the consumption of a high (900 
mg cocoa flavanols: 185 mg (−)-epicatechin, 20 mg (+)-catechin, and 691 mg procyanidins) or low 
(15 mg cocoa flavanols) cocoa flavanol drink with a standardised breakfast (239, 240). The results 
of this demonstrated a marginal improvement in cognitive performance and an increased response 
in the supramarginal gyrus parietal lobe and inferior frontal gyrus in both healthy subjects and 




In summary, obesity caused by a western diet can increase the risk of developing type-2 diabetes 
and other disorders. This involves insulin resistance occurring via a reduction of insulin receptors 
on cells, causing a reduced capacity to respond to glucose through insulin secretion. It is apparent 
that EC protects against the effects of a western diet in inducing insulin resistance through: an 
increase in antioxidant defences, maintenance of insulin receptor number on cells, increased 
activation of the insulin signalling pathway, increased insulin secretion, a decrease in inflammatory 
responses, and an improved HOMA-IR. 
 
1.7.3 In vitro studies and cellular mechanisms 
1.7.3.1 Flavonoids and their effects on insulin resistance in-vitro 
Some flavanols have been shown to inhibit the enzymatic activity of α-amylase and α-glucosidase 
and thus reduce starch digestion. Hanhineva et al (2010) reviewed the effects of polyphenols on 
carbohydrate metabolism (241) and discussed the reported effects for all flavonoids and phenolic 
acids that have been shown to possess inhibitory activity. To summarise, the flavonoids that have 
been shown to inhibit α-amylase include: cyanidin 3-sambubioside (242), quercetin (243), myricetin 
(243, 244), luteolin (243, 245), and luteolin 7-glucoside (245), whilst the flavonoids that have been 
demonstrated to inhibit α-glucosidase include: cyanidin 3-galactoside (246), cyanidin 3-rutinoside 
(247, 248), cyanidin 3-sambubioside (242), acylated anthocyanins (249), (+)-catechin (250), (+)-
catechin gallate (250), EGC (250-252), EGCG (243, 253), theaflavin gallate (253), quercetin (243, 
250), quercetin 3-rhamnoside (254), myricetin (243), luteolin (243, 245), luteolin 7-glucoside (245), 
genistein (243, 255) and daidzein (243, 245). It is thought that the inhibition of starch digestion 
therefore contributes to the reduction in blood glucose levels in subjects on polyphenol 
interventions when compared to controls.  
Several flavonoids have also been shown to inhibit glucose transportation in Caco-2 cells at 100 μM 
(256) and between 31-2570 μM concentrations (257) and enhance insulin-mediated glucose uptake 
from EGCG (20-40 μM) stimulation of GLUT-4 in L6 myotubes (258); and by kaempferol and 
quercetin in 3T3-L1 cells (5-50 μM) (259); genistein in 3T3-L1 cells (50 μM) (260); grape-seed 
procyanidins in L6 myotubes and 3T3-L1 adipocytes (140 μg/mL) (220) (100 μg/mL) (261); acyl-EC 
in L6 myotubes (100 nM) (262); and by hesperidin and other fruits (0.1 % v/v) (263, 264). EGCG (20-
40 μM) can also stimulate the activation of AMPK and Akt, in return triggering the insulin signalling 
cascade (258, 261), and similar effects are reported for grape-seed procyanidins for Akt and MAPK 
activation (100 μg/mL) (261). Furthermore, glucose is also absorbed into enterocytes by active 




This process has been shown to be inhibited in porcine jejunum cells by quercetin glucosides (0.6 
mM) (266), in rat jejunum cells by ECG (1 mM) (267), and in Caco2 cells by ECG (100 μM) (256, 268), 
EGC (100 μM) (256), EGCG (100 μM) (256), and in rabbit and rat jejunum cells by naringenin (500 
μM) (269).  
Myricetin incubated with rat adipocytes caused increased glucose uptake that was not due to 
increased GLUT4 translocation (270). This was also reciprocated in soleus muscle cell culture from 
STZ rats, where myricetin increased glucose uptake dose dependently and caused an increase in 
glycogen (181), and increased the active phosphorylated levels of IR, IRS-1 and Akt, in addition to 
enhanced GLUT4 levels (182). All of this supports a myricetin-induced restoration of insulin 
signalling and glucose uptake. In contrast to these positive findings, naringenin incubation on 3T3-
L1 adipocytes was reported to exacerbate insulin resistance effects through the inhibition of insulin-
stimulated glucose uptake via Akt phosphorylation inhibition (271). The same was discovered for 
genistein treatments in the same cell model, but this did not occur through the alteration of GLUT4 
translocation, rather it affected their conformation and thus their activity to uptake glucose (272). 
A further study found inhibition of insulin-stimulated glucose uptake in isolated rat adipocytes by 
quercetin, myricetin and catechin-gallate but not by catechin through the direct interaction with 
GLUT4 (273).  
Isolated rabbit muscle cells treated with quercetin (5-21 μM), luteolin (16-29 μM), ECG (13-50 μM), 
EGCG (8-34 μM), cyanidin (3-9 μM), delphinidin (3-11 μM) and peonidin (25-18 μM) in enzyme 
assays have been reported to inhibit phosphorylated active glycogen phosphorylase-a and 
unphosphorylated glycogen phosphorylase-b, but quercetin, cyanidin and delphinidin were the 
most potent (274). This is evidence that the general flavonoid structure is capable of inhibiting 
enzymes involved in the production of glucose. However, it should be mentioned that these parent 
compounds rarely interact with these enzymes physiologically because they are rapidly degraded, 
conjugated and metabolised before being absorbed into the systemic circulation. Moreover, in 
purified rat liver microsomes, the flavonoids kaempferol 3-O-α-(2″-galloyl)rhamnoside, quercetin 
3-O-α-(2″-galloyl)rhamnoside, quercetin 3-O-α-rhamnoside, kaempferol 3-O-α-rhamnoside, 
quercetin 3-O-α-arabinoside, quercetin and kaempferol inhibited enzymatic activity of glucose-6-
phosphatase (G6Pase), listed by their order of potency (275). Quercetin 3-O-α-(2″-
galloyl)rhamnoside, purified from Bauhinia megalandra leaves, was further reported to 
competitively inhibit G6Pase dose dependently (276).  
Treatment with 10 μM EGCG on rat pancreatic β-cells (RIN-m5F) stimulated IRS2, Akt and AMPK 




and 10 μM EGCG (277). Additionally, there were increases in the expressions of GLUT2, glucokinase, 
β-cell differentiation, and PDX-1 (Pancreatic and Duodenal Homeobox 1), a transcription factor that 
regulates insulin transcription. Under a high glucose environment, the treatment of isolated rat 
islets with EC (0.8 mM) or quercetin (0.01 mM) induced insulin secretion but not in the presence of 
naringenin (278). However, these concentrations are not physiologically achieved from food 
consumption.  
Insulin secretion levels have been monitored in INS-1E cells after polyphenol treatment. Genistein 
treatments (1-5 μM) caused glucose mediated insulin secretion, but this was not due to modulation 
of insulin synthesis, and so the pancreatic cells responded better to glucose (279). This was found 
to mostly occur through a Ca2+ signalling AMPK dependent mechanism. Similarly, anthocyanins, 
specifically cyanidin-3-glucoside and cyanidin-3-galactoside, also increased insulin secretion in the 
presence of glucose (280).  
In HFIIE rat hepatoma cells, EGCG at 50 μM and 100 μM decreased PEPCK and G6Pase mRNA 
expression, along with many genes involved in lipid metabolism (186). Similar findings were 
reported for a study with HFIIE cells when treated with 12.5 μM and 25 μM EGCG, that caused a 
reduction in the mRNA levels of PEPCK and G6Pase mRNA, and a reduction in glucose production 
(281). These were accompanied by increases in IRS-1 phosphorylation levels, and active PI3K and 
MAPK. Furthermore, in primary mouse hepatocytes, 0.25-1.0 μM of EGCG significantly decreased 
glucose production, and the levels of PEPCK and G6Pase mRNA (282). Additionally, there were 
increases in the levels of active AMPK but without stimulation of insulin signalling proteins. Finally, 
when primary mouse hepatocytes were treated with areca nut procyanidins, the rate of 
gluconeogenesis was dose dependently inhibited via the reduction in mRNA levels of PEPCK and 
G6Pase (218).  
 
1.7.3.2 (−)-Epicatechin effects in-vitro on insulin resistance 
The liver is an organ that will encounter insulin resistance in response to a high fat diet prior to 
other organs such as the pancreas, kidney, skeletal muscle, adipose and cardiac tissue (283). There 
are a few reports that investigated effects of EC and its metabolites on liver cells. High glucose 
incubation is mostly selected as an in-vitro treatment on cells to induce insulin resistance effects. 
This is because hyperglycaemia is known to induce damage to cells by five major mechanisms 
concluded by Giacco and Brownlee (2010): increased flux of glucose and other sugars through the 
polyol pathway, increased intracellular formation of advanced glycation end-products (AGEs), 




activation of protein kinase C (PKC) isoforms and overactivity of the hexosamine pathway (284). 
Evidence suggests that the overproduction of ROS by mitochondria activates all the above.  
The incubation of cocoa polyphenol extract (CPE) (1 μg/mL) or EC (10 μM) with HepG2 cells 
(immortalised human liver carcinoma cells) stimulated the insulin signalling pathway through 
increases in the phosphorylation of tyrosine and total protein levels of IR, IRS-1 and IRS-2, in 
addition to the activation of PI3K and AMPK (285). The latter mitigated the phosphorylation of 
serine on IRS-1 and caused an induction of gluconeogenesis, when compared to cells in high glucose 
conditions (199, 286). Moreover, it initiated the recovery of hepatic GLUT-2 expression to uptake 
extracellular glucose and increase glycogen synthesis through glycogenesis (199, 286). The data in 
a report by Cordero-Herrera et al (2015) reinforced these findings above for the ability of EC and 
CPE to prevent the inhibition of insulin signalling caused by glucose (287).  
Rat kidney NRK-52E cells incubated with EC (10 μM) or one of its metabolites, 3,4-
dihydroxyphenylacetic acid (DHPAA) (10 μM), prior to or post to glucose challenge, prevented the 
induction of ROS and prevented the reduction in antioxidant defences for proteins SIRT1 (sirtuin 1), 
MAPK, and NOX-4 (NADPH Oxidase 4) (288). In brief, SIRT1 influences metabolism by regulating 
transcription factors in the liver, skeletal muscle, pancreas, adipose tissue and the brain (289). It 
can regulate lipolysis, adipogenesis, ROS production, and stimulate glucose uptake and GLUT4 
translocation. Impairment of NOX-4 can induce a distinct pattern of insulin 
resistance/responsiveness that includes the abolishment of FOXO1 activation and glucose uptake 
from insulin (290). Further evidence supporting the protective role of EC and DHPAA against ROS 
production, includes the restoration of GSH (glutathione), SOD (superoxide dismutase), GPx 
(glutathione peroxidase) and CAT (catalase), that are otherwise decreased under high glucose 
conditions; all these enzymes are actively involved in antioxidant defences and the scavenging of 
ROS (288).  
EC (10 μM) antioxidant effects were also demonstrated in HepG2 cells that had been previously 
exposed to a high glucose environment (287). Incubation with EC prevented glucose stimulated ROS 
production and prevented the depletion of GSH and GPx. Further observations included increases 
in NRF2 activity, a transcription factor that regulates antioxidant defences, alongside a reduction in 
active p38 and an increase in active ERK. Furthermore, cell incubation with an inhibitor of ERK, 
blocked the increase in NRF2 from EC or CPE (1 μg/mL), thus confirming that both these extracts 
act through the ERK pathway.  
EC treatment (5-20 μM) in rat pancreatic cells (INS-1E) exposed to high oxidative stress caused by 




Consistent with previously reported studies, EC prevented the depletion of GSH and GR (glutathione 
reductase) whilst recovering GPx and reducing the levels of phosphorylated JNK. Importantly, EC 
significantly increased insulin secretion from the cells in basal conditions and in the presence of 
glucose, which was otherwise depressed with t-BOOH treatment in the presence of glucose. To add 
to this, Fernandez-Millan (2014) studied the effects of phenolic metabolites from EC (3,4-
dihydroxyphenylacetic acid (DHPAA) (5 μM), 2,3-dihydroxybenzoic acid (DHBA) (10 μM) and 3-
hydroxyphenylpropionic acid (HPPA) (1 μM)) on glucose or t-BOOH stimulated INS-1E cells (292). 
DHPAA and DHBA were shown to increase insulin secretion from the cells only in the presence of 
glucose. However, in the presence of ERK and PKC inhibitors, DHPAA and DHBA failed to stimulate 
insulin release, indicating that these metabolites initiate effects via these pathways. Consistent with 
the other report, DHPAA and HPPA prevented oxidative stress from t-BOOH and restored insulin 
secretion from t-BOOH treated cells (292).  
The concentrations of EC used to exert protective effects varies across reports in the published 
literature and appears to depend on the cell line used and the conditions of the culture itself, and 
most effects were observed at physiologically relevant concentrations. Yang et al (2018) incubated 
INS-1 cells in a high glucose environment, and only in the presence with EC (30 μM) was there a 
significant reduction in ROS levels. In contrast, a low concentration of EC (0.3 μM) had no effect, 
but unfortunately there were no intermediate concentrations used to determine the bioprotective 
concentration of EC (293). Furthermore, following the induction of β-cell damage from glucose, EC 
at 0.3 μM increased insulin secretion via the activation of CaMKII, but no effects were observed for 
EC at 30 μM. Kim et al (2003) repeated similar effects in-vivo in rats and in-vitro in primary rat 
cultured cell islets (294). Meanwhile, Hii et al (1984) repeated the effects of EC for the induction of 
insulin secretion at concentrations of 1 mM in primary cultured rat islets (295). These data 
demonstrate bioactive effects of EC at different concentrations, which therefore causes 
inconsistency with regards to what EC concentration should be used.    
The co-culture of 3T3-L1 adipocytes with RAW264.7 macrophages in the presence of EC (50 μM, or 
0.5-10 μM) and challenged by lipopolysaccharide (LPS) (1 ng/mL, or 0.5 μg/mL) or TNFα (1 ng/mL, 
or 20 ng/mL), mitigated the increase in CCL19 (inflammatory cytokine) and TNF-α, alongside other 
inflammatory cytokines (224, 225) (concentrations are sourced from the references, respectively). 
This was evidenced to occur through the inactivation of the NF-kB signalling cascade, which would 
otherwise act to increase inflammatory precursors. Such effects were not seen in isolated 
adipocytes; thus, EC mitigated the inflammatory effects on adipocyte cells from macrophages. This 
finding was also supported in a HF diet fed mice study where EC mitigated the recruitment of 





1.7.4 Summary  
In conclusion, the evidence obtained from epidemiological, interventional and in-vitro studies for 
the protective role that flavonoids and polyphenol-rich foods play towards insulin resistance and 
type-2 diabetes is equivocal. Nonetheless, due to discrepancies in the literature and the differences 
found between humans and rodents from flavonoid effects, the mitigation of insulin resistance by 
flavonoids cannot be exclusively stated. Because of this, more tightly controlled interventions need 
to take place, specifically in humans to fully identify the role of polyphenols in insulin resistance.  
 
1.8 Conclusion and future perspectives 
High fat and high carbohydrate diets are known to cause metabolic syndrome and the induction of 
insulin resistance. Polyphenols have been investigated for their effects in controlling glycaemia and 
improving insulin resistance, but the exact mechanisms for their actions are not fully understood 
and require further investigation. There is a distinct shortage of human studies and animal studies 
for pure polyphenol compound interventions, and interventions using food sources does not allow 
for the identification of the active components in the diet that bring about the positive changes 
observed. As such, there is the requirement for intervention studies to be performed in humans 
and in rodents using isolated flavonoids to examine tissues and dissect the mechanisms involved. 
Because of the greater similarity in the metabolic profile of compounds from flavonoid/food 
ingestion in mice than other animals such as rats and rabbits, this model is recommended for 
investigative studies.  
Moreover, flavonoids are metabolised rapidly following consumption, where there are a subset of 
phase II/III and microbial metabolites that are most likely to reach the circulation and encounter 
endogenous organs. Therefore, it would be valuable to investigate specific metabolites in rodents 
and humans in intervention studies, and with more in-vitro studies specifically treating cells with 
these metabolites and measuring effects on metabolism and associated biomarkers. 
Although polyphenols are reported to confer many health benefits, this review has focussed 
primarily on insulin resistance and type-2 diabetes because that was the aim of the research in this 
thesis. EC has been investigated in rodents for their protective effects towards insulin resistance 
and it is known that hydroxyphenyl-γ-valerolactones (HPVLs) contribute around one third of the 
circulatory metabolites produced. Because of this, and the lack of understanding surrounding the 




beneficial effects of EC consumption to protect against insulin resistance. Thus, the rest of this 
thesis will focus on understanding the bioavailability of HPVLs following their ingestion in C57BL/6J 
mice, followed by an intervention study of this compound performed in a HF diet induced diabetic 




1.9 Thesis objectives 
The overall aims of this thesis were two-fold: 
(1) Assess the bioavailability of hydroxyphenyl-γ-valerolactones following oral consumption 
(2) Understand whether 3’,4’-dihydroxyphenyl-γ-valerolactone (34DHPVL), a metabolite of 
(−)-epicatechin, protects against the development of insulin resistance in a diabetic mouse 
model.  
For the reasons outlined in section 1.8, the next sections of this thesis are divided into 6 chapters 
which address the following objectives: 
1. Chapter 2 – Investigate the bioavailability of hydroxyphenyl-γ-valerolactones in C57BL/6J 
mice 
a. Develop a fit-for-purpose analytical method for the quantification of HPVLs and 
their phase-II conjugates from mouse plasma and urine. 
b. Design and execute a mouse single acute dose pharmacokinetic study investigating 
the absorption, metabolism and excretion of 34DHPVL with (−)-epicatechin (EC) as 
a control.  
c. Quantify the concentrations of 34DHPVL and its phase-II metabolites in mouse 
plasma and urine samples. 
d. Determine the pharmacokinetic parameters of HPVLs: maximum concentration 
(Cmax), time for maximum concentration (Tmax), and elimination half-life (T1/2).  
2. Chapter 3 - Directly compare the effects of (−)-epicatechin and its microbial metabolite 
34DHPVL on insulin resistance in a high-fat diet mouse model of diabetes  
a. Design a powered study using previous literature as a reference to guarantee 
insulin resistance and EC protection effects.  
b. Prepare mouse pellets for the inclusion of EC and 34DHPVL at carefully selected 
concentrations. 
c. Perform a glucose tolerance test in mice and measure plasma glucose and insulin 
levels to calculate an insulin-sensitivity index. 
d. Statistically evaluate the data at a 95 % confidence interval to extract conclusions. 
3. Chapter 4  - Evaluate the physiological actions of EC and 34DHPVL in the mice and other 
markers 
a. Quantify plasma lipids and liver damage markers. 
b. Histologically examine liver tissue for lipid deposition, fibrosis and inflammation. 




d. Perform enzyme assays on alpha amylase with 34DHPVL to assess inhibitory action 
on starch digestion.  
4. Chapter 5 – Assess the mechanisms involved from dietary supplementation with EC versus 
34DHPVL on gene expression in mouse liver tissue using transcriptomics  
a. Randomly select liver samples to extract RNA and quality check for RNA-
Sequencing preparation. 
b. Perform RNA-Sequencing through a third-party. 
c. Use bioinformatics to process the RNA-Sequencing data to compare the effects of 
the dietary interventions for 7-pairwsie comparisons on gene expressions and 
pathway enrichments. 
5. The final chapter 6 will bring the whole thesis together by way of discussion and explore 
the future directions and impact the findings of this work may have in terms of future 
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Chapter 2: A pharmacokinetic study of the oral 
bioavailability and phase-II metabolism of 5-(3’,4’-
dihydroxyphenyl)-γ-valerolactone in mice 
2.1 Abstract 
Background:  There is a substantial body of preclinical and clinical scientific evidence describing the 
beneficial effects caused by the consumption of (−)-epicatechin (EC) rich foods and beverages such 
as dark chocolate, cocoa, and apples. The absorption, distribution, metabolism, and excretion 
(ADME) of EC have been extensively reported, including after oral consumption of 14C-labelled EC. 
These studies have shown that a proportion of the EC is absorbed intact and undergoes phase-II 
metabolism so that it is found exclusively as EC O-methylated, -sulfated and -glucuronidated 
conjugates in plasma and urine. Meanwhile, a greater proportion is transformed into 
hydroxyphenyl-γ-valerolactones (HPVL) by the gut microbiota; these are also accumulated in 
plasma and urine as phase-II conjugates and may be responsible for the beneficial effects of EC 
consumption. It is not possible to determine the pharmacokinetic properties of HPVLs from EC 
because HPVLs are generated over an extended period of time, and the exact dose of EC that 
reaches the colon is unknown due to prior absorption of EC from upper gastrointestinal tract.  
Aim: To directly investigate the absorption, metabolism, and excretion of the most common HPVL, 
3’,4’-dihydroxyphenyl-γ-valerolactone (34DHPVL). 
Methods: Eighteen 12-week old C57BL/6J mice were oral gavaged with 80 mg/kg body weight of 
34DHPVL and sacrificed after 1, 2, 3, 6 or 24-hours when blood and urine were collected. An 
additional group of four mice were oral gavaged with 80 mg/kg body weight of EC and sacrificed at 
24-hours. Plasma and urine samples were processed prior to analysis using UPLC-MS2 in MRM mode 
for analysis of metabolites with quantification achieved using authentic standards.  
Results: The following metabolites were identified and quantified in mouse plasma/urine: 
34DHPVL; 3’-O-glucuronide, 4’-O-glucuronide, 3’-O-sulfate and 4’-O-sulfate of 34DHPVL; 3’-O-
methylated 4HPVL. No HPVL metabolites were detected in samples that had not been gavaged with 
34DHPVL. The highest concentration of total HPVL metabolites in plasma was observed at 1-hour 
with concentrations declining to 24-hours. Although HPVL-glucuronides accounted for 62 % of total 
plasma HPVLs at 1-hour, the balance between glucuronides and sulfates shifted dramatically with 
time such that HPVL-sulfates had the highest area under the pharmacokinetic curve (A.U.C0-24h) 




exhibited the longest plasma elimination half-lives, with the aglycone ≥ glucuronides. Together, 
these observations are consistent with a rapid early glucuronidation of 34DHPVL as a result of small 
intestinal phase-II conjugation, which is followed by a longer hepatic-driven process of de-
glucuronidation and subsequent sulfation occurring continuously post-absorption. A minor second 
plasma peak of 34DHPVL metabolites at 3-6 hours suggested that enterohepatic recirculation was 
occurring. Total urinary excretion of HPVL metabolites accounted for an estimated 45 % of the oral 
34DHPVL dose. The mean plasma concentrations of 34DHPVL metabolites were similar in 24-hour 
samples from mice gavaged with 34DHPVL or with EC.  
Conclusion: These data show that 34DHPVL is absorbed rapidly from the small intestine and 
undergoes phase-II conjugation, with small intestinal O-glucuronidation dominating early on 
followed by sulfation that later dominates, presumably as a result of hepatic metabolism. Evidence 
of enterohepatic recirculation shows that phase-II conjugated 34DHPVLs can be conjugated in the 





EC is widely distributed in the diet, with especially high levels being found in cocoa and green tea 
(14-16). These foods have been primarily investigated for their health protective effects in humans, 
with strong evidence supporting their protection towards cardiovascular disease, cancer, insulin 
resistance and cognition (296). Very few studies have assessed individual flavanols and their 
protective effects, but the collation of in-vitro and in-vivo studies provides a collection of evidence 
supporting specific flavanols and in particular EC for their strong bioactive potential (163, 297, 298). 
Nonetheless, there is a distinct lack of evidence in understanding the mechanistic actions of EC and 
polyphenols more general. Irrespective of this, the absorption, distribution, metabolism and 
excretion (ADME) of EC is becoming better understood and it will help in interpreting the modes of 
action of EC and/or its metabolites (299).        
Chapter 1 has reviewed extensively the ADME of EC following its ingestion in humans (1), mice and 
rats (5). Almost immediately, EC becomes phase-II conjugated by enterocytes of the small intestine 
to produce structurally related EC metabolites (SREMs), -O-sulfated, -O-glucuronidated and -O-
methylated. This is followed by the colonic metabolism of unmetabolised EC that has passed 
through the gastrointestinal (GI) tract, alongside the further metabolism of phase-II conjugates that 
re-enter the gut following enterohepatic circulation. These catabolites can be further conjugated 
by phase-II enzymes by intestinal enterocytes and/or the liver for -O-sulfates, -O-glucuronides, and 
-O-methylates. The large recovery of EC and their metabolites in urine for 78 % (5) and 82 % (1) in 
rats and humans respectively highlights how efficiently EC is absorbed. For the SREMs that efflux 
back into the intestinal lumen and also for those that appear following enterohepatic circulation, 
alongside unabsorbed EC, these pass into the colon, approximating 70 % of the ingested EC (96). 
The main colonic metabolites are those of HPVL and hydroxyphenylvaleric acids (HPVA), 
representing 42 % of the ingested EC that passes into urine, and ~74 % of the detected metabolites 
found in plasma (6.9 % of the ingested EC intake 0-24 h) (1, 96). Although the main catabolites of EC 
are HPVLs, it is not possible to identify their pharmacokinetic parameters due to the unknown 
concentrations of EC and phase-II metabolites that reach the colon. Due to the long half-life of 
HPVLs (5.7 ± 0.7 hours) (1) and the high exposure of tissues to these compounds, it is plausible that 
they are mostly responsible for the positive effects brought around by EC. Because of this, the 
pharmacokinetic profile of HPVLs requires investigation to understand the retention and 
elimination of these compounds by the body.  
This chapter reports on a study performed in C57BL/6J female mice for the plasma and urinary 









2.3 Aims and approach 
There are no published reports describing the pharmacokinetics of any orally ingested HPVL; the 
only available data currently available are for orally ingested catechins, especially EC, part of which 
is transformed to HPVLs in the lower gut over a period of many hours. The overall aim of the 
research presented in this chapter was to determine the pharmacokinetics of 34DHPVL following 
administration of a single dose to mice. The following approach was taken to achieve this:  
 
(1) Female C57BL/6J mice were orally gavaged with 80 mg/kg body weight of 34DHPVL or 
EC, and urine, plasma, and faecal samples collected after 1, 2, 3, 6 and 24 hours after.  
 
(2) A fit-for-purpose analytical method for the quantification of HPVLs and their phase-II 
conjugates from mouse plasma and urine was developed.  
 
(3) The concentrations of 34DHPVL and its phase-II metabolites in mouse plasma and urine 
samples were quantified after extraction using UPLC-MS2.  
 
(4) The pharmacokinetic parameters for Cmax, Tmax, area under the curve and elimination 
half-life (T1/2) were calculated.  
The resulting data was used to address the following questions:  
(1) How bioavailable is 34DHPVL and what is the profile of its phase-II metabolites when 
provided as an oral dose in female mice? 
 
(2) How does the bioavailability and metabolism of orally ingested 34DHPVL differ from 






2.4.1 Materials  
Seven hydroxyphenyl-γ-valerolactones: 5-(3’,4’-dihydroxyphenyl)-γ-valerolactone, 5-(3’,4’,5’-
trihydroxyphenyl)-γ-valerolactone, 5-(4’-hydroxy-3-methoxyphenyl)-γ-valerolactone, 5-(4’-
hydroxyphenyl)-γ-valerolactone 3-O-glucuronide, 5-(3’-hyroxyphenyl)-γ-valerolactone 4-O-
glucuronide, 5-(3’-hydroxyphenyl)-γ-valerolactone-4’-O-sulfate sodium salt, 5-(4’-hydroxyphenyl)-
γ-valerolactone-3’-O-sulfate sodium salt, were synthesised by in house chemist Dr Paul Needs using 
methods as described in sections 2.4.2 and 3.4.1. Taxifolin, dimethyl sulfoxide (DMSO), 
trichloroacetic acid (TCA), protocatechuic acid, syringic acid, N,N-dimethylformamide (DMF), 
hippuric acid, Whatman® Mini-UniPrep® syringeless filters (0.45 μM pore, cat: 
WHAUN203NPUORG), mouse serum, and animal feeding needles (sterile, disposable, PTFE, size 
18G, L × diam. 1.2 in. × 2 mm ball (cat: CAD9933-100EA), were purchased from Sigma Aldrich (UK). 
Methanol (MeOH), acetonitrile and UPLC glass vials with a 300 μL insert (cat: 10003264), were 
purchased from Fisher Scientific (UK). (−)-Epicatechin was purchased from Toronto Research 
Chemicals (Canada). Regular wall butterfly needles 25G¾” were purchased from Terumo (UK). 
Microvette 200 µl EDTA blood collection tubes were purchased from Sarstedt (Germany, cat: 
20.1288.100). 
 
2.4.2 Synthesis of hydroxyphenyl-γ-valerolactones 
5-(3’,4’-Dihydroxyphenyl)-γ-valerolactone (34DHPVL) was synthesised according to the procedure 
in chapter 3, section 3.4.1.  
5-(4’-Hydroxy-3’-methoxyphenyl)-γ-valerolactone (4H3MPVL) and 5-(3’,4’,5’-trihydroxyphenyl)-γ-
valerolactone (345THPVL) were synthesised according to the procedure by Chang et al (2010) (300).  
All remaining hydroxyphenyl-γ-valerolactones were synthesised by an in house synthetic organic 
chemist (Dr Paul Needs, Quadram Institute Bioscience, UK). The synthetic routes were designed by 
Dr Needs and full descriptions are reported in Hollands et al (2020) (2). 5-(4’-Hydroxyphenyl)-γ-
valerolactone 3’-O-glucuronide (4HPVL-3GlcA) and 5-(3’-hydroxyphenyl)-γ-valerolactone 4’-O-
glucuronide (3HPVL-4GlcA) were synthesised as shown in Figure 2.1. A mixture of 5-(4’-
hydroxyphenyl)-γ-valerolactone-3’-O-sulfate, ammonium salt (4HPVL-3S), 5-(3’-hydroxyphenyl)-γ-





Figure 2.1: Synthetic steps to produce 3HPVL-4GlcA and 4HPVL-3GlcA 
This Figure has been reproduced with permission by Hollands et al (2020) (2). Complete synthesis was 




Figure 2.1 (continued): 3-benzyloxy-4-hydroxybenzaldehyde 2 was silylated to give 3-benzyloxy-4-(tert-
butyldimethylsilyloxy)benzaldehyde 3. Reaction of 3 with 4 by the general procedure of Chang et al (22) gave 
5-[4-(tert-butyldimethylsilyl)-3-benzoxybenzylidene]furan-2(5H)-one as a mixture of its Z and E isomers 5a and 
5b. Hydrogenation of 5a and 5b led to debenzylation and reduction, but also induced tert-butyldimethylsilyl 
group migration between the 3- and 4-hydroxyl groups, to give a mixture of the 3-silylated and 4-silylated 
products 6 and 7. Glucuronidation of the mixture of 6 and 7 with 8 gave the expected products 9a and 10a. 
During chromatography, smaller amounts of the desilylated 9b and 10b were formed. De-esterification and 
desilylation of 9a and 10a and 9b and 10b were achieved by hydrolysis with methanolic sodium carbonate, 
and undesired lactone ring-opening was reversed by treatment of 11 and 12 with hydrochloric acid. Finally, 





2.4.3 Preparation of 34DHPVL and EC solution for use in the mouse study 
A dose of 400 mg/70 kg body weight of compound was selected on the basis that this is an average 
flavonoid dose from tea, cocoa, and fruit consumption for humans in a day (301-305). Although EC 
consumption is estimated to be around 25 mg/day in Europe (306), this study was designed to 
attribute the total flavonoid dose consumed to EC, and to detect analytes in mice plasma and urine 
at concentrations above the limit of detection (LOD). This equates to 5.71 mg/kg body weight and 
was converted to the mouse equivalent dose using Formula 2.1, according to Nair et al (2016) (307). 
A 70.29 mg/kg body weight of compound was therefore required for a mouse, which when based 
Figure 2.2: Synthetic steps to produce 4HPVL-3S and 3HPVL-4S 
This Figure has been reproduced with permission by Hollands et al (2020) (2). Complete synthesis was 
performed by synthetic chemist Dr Paul Needs at the Quadram Institute Bioscience, UK, via the following 
steps. A mixture of 5-(3’-hydroxyphenyl)-γ-valerolactone-3’-O-sulfate, ammonium salt, and 5-(4’-
dihydroxyphenyl)-γ-valerolactone-4’-O-sulfate, ammonium salt, was prepared by direct sulfation of 5-(3’,4’-




on the average weight of a 25 g mouse equates to 1.76 mg/25 g mouse. For convenience this value 
was rounded up to 2 mg/25 g mouse, which is equal to 8 mg/mL in solution. 34DHPVL and EC were 
given to the mice at equivalent doses to allow comparisons of plasma end-point concentrations.  
 
  a) 𝑀𝐸𝐷 (
𝑚𝑔
𝑘𝑔
) =  𝐻𝑢𝑚𝑎𝑛 𝑑𝑜𝑠𝑒 (
𝑚𝑔
𝑘𝑔




 × 12.3 human to mouse ratio = 70.29
𝑚𝑔
𝑘𝑔
 mouse equivalent dose  
Formula 2.1: Conversion of human equivalent doses to mice equivalent doses 
(a) Generic Formula where MED indicates mouse equivalent dose; (b) Actual calculation used to estimate the 
mouse equivalent dose for this study (307). 
 
34DHPVL and EC were not fully soluble at the target concentration of 8 mg/mL, and so the lowest 
concentration of DMSO for solubilisation was determined. This was 1.34 % DMSO for 34DHPVL and 
1.8 % DMSO for EC. Both 34DHPVL and EC were therefore dissolved in DMSO and made up to final 
volumes/concentrations with sterile ddH2O on the same day as use and kept at 4 °C and were 
warmed to room temperature for 1-hour prior to use.  
 
2.4.4 Study design  
All experiments described here were performed in compliance with the European Union regulations 
concerning the protection of experimental animals and with the UK Home Office Animals (Scientific 
Procedures) Act of 1986 under personal license I39D37621 and project license 70/8710. 
A total of 24 female C57BL/6J mice at 12 weeks old were purchased from the University of East 
Anglia’s in-house breeding facility (Norwich, UK) and separated into six groups of four animals: 
34DHPVL gavaged and sacrificed at 1, 2, 3, 6, and 24 hours, and a final EC gavaged group sacrificed 
after 24-hours. Female mice were selected because they are generally smaller than male mice and 
would thus require less weight-administered of the in-house synthesised 34DHPVL (308). All mice 
were maintained on the chow diet (RM3-P, SDS Special diet services, UK) provided by the housing 
facility before experimental procedures commenced. Baseline blood samples were obtained from 
all mice one week before the pharmacokinetic study commenced, to allow time for the removed 
blood to be replenished. Mice were warmed in a heating chamber at 39 °C for 10 mins prior to 
bloodletting. Afterwards, a tail bleeding procedure was performed, where a 25G¾” regular wall 




EDTA tubes. Baseline urine samples were obtained from the mice as and when they urinated during 
weighing or regular checks; a total of 8 baseline urine samples were obtained (in clean weighing 
chambers). All blood collections were centrifuged at 2000 g for 15 mins at 4 °C to collect the serum 
and stored at -80 °C until use. 
To perform oral gavage, a tight scruff of the mouse neck and body was performed to allow for a 
wide-open mouth and no movement. The mouse was then held vertically upright where an 18-
gauge feeding needle attached to a 1 mL syringe was inserted down through the mouth and into 
the stomach where 80 mg/kg body weight of 34DHPVL or 80 mg/kg body weight EC was released 
(prepared as per section 2.4.3). 34DHPVL was provided to five groups of 4 mice and EC was provided 
to one group of 4 mice. Each of the five 34DHPVL groups were sacrificed at either 1, 2, 3, 6 or 24-
hours after gavage. The EC gavaged group were sacrificed at 24-hours post gavage.  
Housing conditions consisted of 4 mice per cage which were kept in ventilation at 22 ± 2 °C with 55 
± 5 % humidity and 12-hour light-dark cycles. Mice cages were checked daily, and bedding, food 
and water changed weekly by housing facility staff. Pellets were kept in the cage hoppers and 
replenished weekly. All measurements and pellet changing was performed in ventilated cabinets.  
 
2.4.5 Terminal anaesthesia and biological fluid harvest 
Mice were sacrificed by cardiac puncture and PBS perfusion at times according to section 2.4.4. 
Initially, mice were anaesthetised using 4 % isoflurane (Abbott laboratories, US) in a mixture of 
nitrous oxide (70 %) and oxygen (30 %) and maintained throughout the whole procedure until death 
was confirmed. To determine the depth of the anaesthesia, patellar reflex measures were 
performed. Ethanol at 70 % was sprayed lightly onto the chest of the mouse and a lateral incision 
was made through the integument and abdominal wall. The diaphragm was cut through to allow 
access to the heart, and the sternum was clamped and placed over the head using a haemostat. 
Injection using a 1 mL syringe and 25G ¾”  BD Precision Glide syringe needle was made into the left 
ventricle of the heart and blood was drawn into the syringe. Once blood was extracted, the right 
atrium was snipped, and PBS supplemented with EDTA was perfused into the left ventricle of the 
heart until organs turned pale and PBS circulated out clear (~50 mL). To collect urine, an open 
Eppendorf was placed at the base of the urethral orifice throughout the cardiac puncture 
procedure, this ensured urine dripped into the tube upon loss of muscle control. The number of 
mouse urine samples obtained for 1-hour post gavage was two, 2-hour timepoint was one, 3-hour 
timepoint was three, 6-hour timepoint was three, and 24-hour timepoint was four for 34DHPVL 




All blood collections were centrifuged at 2,000 g for 15 mins at 4 °C to collect the plasma and stored 
at -80 °C until use. 
Two mice died before they were scheduled for termination, one because it was severely 
underweight and the second because of complete ingestion of the oral gavage tubing, and as a 
result only 3 sets of mouse biological fluids were collected for the 2 and 6-hours 34DHPVL gavaged 
mice.  
 
2.4.6 Development of a quantitative analytical method for 3’,4’-
dihydroxyphenyl-γ-valerolactone and its metabolites in mouse plasma  
Hydroxyphenyl-γ-valerolactones have proven difficult to extract from plasma and erythrocytes. 
Mülek and Högger have published several papers and a thesis that details the challenges and 
suggest suitable approaches for extraction and analysis of HPVLs from both plasma and erythrocyte 
samples (309-313). It has been reported that 34DHPVL strongly binds to serum proteins with the 
estimate of the bound fraction being 98.3 ± 4.4 % (309) and an erythrocyte/plasma partition ratio 
of 32.8 ± 64.6 (310).  
Mülek’s thesis (312) and subsequent published paper (311) highlights the method development 
steps for the extraction of HPVLs from plasma and erythrocytes. A method development protocol 
was devised for the detection of these compounds in the plasma of mice with aim for a reliable 
method to obtain good yields and consistent recoveries of the compounds. Due to the complexity 
to achieve this, Table 2.1 describes the 16 methods that were trialled. One of two final methods 
selected produced some unexplained disparities in the results of the run; this is detailed in section 
2.5.1 later in this chapter.  
Table 2.1 outlines the main methods attempted, the problems that surfaced and whether the 
method(s) were pursued further. To summarise, initial attempts provided low recoveries of 
4H3MPVL, and following suitable checks, Dr Shikha Saha (analytical chemist, Quadram Institute, 
UK) optimised the UPLC-MS2 parameters for compound detection. Consequently, good recoveries 
and low concentrations were detected.  
For other compounds, there were regular issues for providing consistent results. Method 6 in Table 
2.1, proved to provide strong recovery values for all compounds, but these were inconsistent 
between replicate standards. Because of this, new methods were trialled for protein precipitation 
(PPT), liquid-liquid extraction (LLE), solid-phase extraction (SPE) and combinations of these, 




replicates, but not for O-sulfates. Adjustment of the elution pH above the O-sulfates pKa value 
greatly improved this. An acidic elute step was used in conjunction to wash the aglycone and O-
glucuronides off the SPE cartridge, method 16.   
The two methods, 6 and 16, were selected for two final processes of the mouse plasma samples. 
The two methods would allow for the full detection of all HPVLs in the mouse plasma, where all 
compounds except for 34DHPVL and 345THPVL would have consistent reliable recoveries.  
The detection of  EC and conjugates were identified in plasma using a routine method from within 
our laboratory (2). The same applies for the detection of hydroxyphenyl-γ-valerolactones and EC 




Table 2.1: Method development steps for the processing of mouse plasma for UPLC-MS2 detection of hydroxyphenyl-γ-valerolactones 
The main methods attempted are listed alongside a brief overview of the results and whether it was pursued further or not. References are listed for those where the method 






Mobile phase Results Conclusion References 
1 10 µL of formic acid + 10 µL of N,N'-DMF, vortex, 
stand 20 mins, vortex centrifuge at 13,300  rpm. 
PPT A - 0.1 % FA in H2O 
B - 0.1 % FA in 
MeCN 
Only able to detect 
4HPVL-3GLcA and 3HPVL-
4GlcA 
Lack of detection of HPVLs In house 
method 
2 12 µL of 50 % H3PO4 +120 µL of KH2PO4, vortex, 
centrifuge 15 mins at 13,300 rpm.  ProElutTM PLS 
SPE cartridges (Dikma Technologies)  - 
preconditioning: 3 mLs MeOH, 3 mLs H2O; plasma 
loaded; wash: 3 mLs H2O, 3 mLs 60:40 0.1 % 
FA:methanol; elute: 0.1 % formic acid aqueous 
solution: methanol, 10:90 (v/v).  
SPE A - 0.1 % FA in H2O 
B - 0.1 % FA in 
MeCN 
1st run: No detection of 
4H3MPVL in the first run.  
  
2nd run: Poor recovery of 
all compounds.  
Further tests proved 4H3MPVL 
was not adhering to the column 
and had not degraded. There were 
also no signs of the solvent causing 
compound degradation. Further 
investigation showed poor 
ionisation of 4H3MPVL, to account 
for this the collision energy was 
altered to allow for increasing 
sensitivity in detection of the 
compound.  
 
The wash step was found to elute 
target analytes prior to sample 
collection (in 3x elution 
collections).  
(314) 
3 2 parts MeCN to 1-part plasma with 1 % FA, vortex, 
centrifuge 15 mins 13,300 rpm.  
PPT A - 0.1 % FA in H2O 
B - 0.1 % FA in 
MeCN 
Poor recovery of all target 
analytes.  
Lots of background noise. 












Mobile phase Results Conclusion References 
4 3:1 ratio of 2 % FA in MeCN to plasma, 
 vortex, sonicate 10 mins, centrifuge 3 mins 13,300 
rpm. Extract supernatant. To the same matrix: add 
in 3:1 ratio of MeCN with 0.1 mM NH4OH to plasma 
matrix, vortex, sonicate 10  mins, centrifuge 3 mins 
at 13,300 rpm (do this a total of 3 times). Collect all 
supernatants into one tube, evaporate to dryness 
and reconstitute in MeOH:H2O:FA (10:89:1). 
Vortex, centrifuge 13,300 rpm 3 mins.  
PPT A - 0.1 % FA in H2O 
B - 0.1 % FA in 
MeCN 
No detection of 
345THPVL at low 
concentrations.  




5 Dilute plasma 1:2 in H2O. ProElutTM PLS SPE 
cartridges (Dikma Technologies) - preconditioning: 
3 mLs MeOH, 3 mLs H2O; load diluted plasma; wash 
- 4 mLs H2O in 0.1 % FA; elution: - 500 μL 4:4:2 
MeOH:MeCN:FA, perform 3 times. Run elutes 
separately in the UPLC-MS.  
SPE A - 0.1 % FA in H2O 
B - 0.1 % FA in 
MeCN 
40-60 % recovery of all 
compounds.  
Target analytes lost during the 
wash phase; target analytes not 
fully eluted during first standard 
elution step, at least two 





6 50 µL plasma with 30 µL 35 % TCA, 10 µL  
MeCN. Ice 5  mins, centrifuge 15 mins at 13,300 
rpm 
PPT A - 0.1 % FA in H2O 
B - 0.1 % FA in 
MeCN 
Good recoveries of all 
target analytes, however, 
there were highly 
variable and inconsistent 
recovery values, even for 
duplicate standards.   
Good working method with minor 












Mobile phase Results Conclusion References 
7 3:1 ratio of 2 % FA in MeCN to plasma, 
vortex, sonicate 10 mins, centrifuge 3 mins at 
13,300 rpm. Extract supernatant. To the same 
matrix repeat 3 times. Evaporate supernatant to 
dryness and reconstitute in 4:4:2 MeOH:MeCN:FA, 
vortex, centrifuge at 13,300 rpm 3 mins.  
PPT A – 0.1 % FA in H2O 
B – 0.1 % FA in 
MeCN 
Poor recovery of all target 
analytes.  
No detection of 
345THPVL.  
   
8 Dilute plasma 1:2 in H2O. ProELUTTM PLS SPE -  
preconditioning: 3 mLs MeOH, 3 mLs H2O; load 
diluted plasma; wash – 4 mLs H2O in 0.1 % FA; 
elution: - 4:4:2 MeOH:MeCN:FA, perform 3 times. 
Dry down elutes and resuspend in volume of 
elution buffer. (The drying stage and pooling of 
elutions makes this different to method 5). 
SPE A – 0.1 % FA in H2O 
B – 0.1 % FA in 
MeCN 
No detection of 34DHPVL 
and 345THPVL. Lower 
recovery of all target 
analytes in comparison to 
method 5. 
The drying step caused significant 
loss of target analytes as the lack 
of a drying step (in method 5) 
resulted in higher recovery of the 
target analytes.  
In house 
method 
9 25 µL of 4 % H3PO4 and 450 µL EA (ethyl 
acetate)/MTBE (tert-butyl methyl ether) (1:1, V/V) 
to plasma. Collect the supernatant, repeat the 
process again on the matrix and pool the 
supernatants together. Vortex 1 min, centrifuge at 
3,300 g for 15 mins 4 °C. Evaporate to dryness, 
reconstitute in 100 µL MeOH. Vortex 15 mins 2500 
g, centrifuge at 18,000 g 15 mins 4 °C.  
LLE A – 5 mM NH₄HCO₂  
with 0.065 % (v/v) 
formic acid (Ph = 
3.2).  
B -  0.1 % formic 
acid in MeOH 
Better recoveries of 
34DHPVL and 345THPVL, 
but poorer recoveries for 
4HPVL-3GlcA, 3HPVL-
4GlcA and 4H3MPVL 
when compared to 
method 6. 
  (312) 
10 30 µL 35 % TCA, 10 µL MeCN. Ice 5  mins, centrifuge 
15 mins at 13,300 rpm. Extract supernatant, and on 
the same matrix add  25 µL of 4 % H3PO4 and 450 
µL EA/MTBE (1:1, V/V). Collect the supernatant and 
repeat the liquid liquid extraction on the same 
matrix. Pool the supernatants together and vortex 
1 min, centrifuge at 3,300 g 15 mins 4 °C. Evaporate 
to dryness, reconstitute in 100 µL MeOH. Vortex 15 
LLE & PPT A – 5 mM NH₄HCO₂  
with 0.065 % (v/v) 
formic acid (Ph = 
3.2).  
B -  0.1 % formic 
acid in MeOH 

















Mobile phase Results Conclusion References 
mins at 2500 g, centrifuge at 18,000 g for 15  mins 
at 4°C.  
11 25 µL of 4 % H3PO4 and 450 µL EA /MTBE (1:1, V/V). 
Collect the supernatant and then repeat the 
process again on the matrix and pool the 
supernatants together. Then on the same matrix 
add 30 µL 35 % TCA, 10 µL MeCN. Ice 5  mins, 
centrifuge for 15 mins at 13,300 rpm. Pool the 
supernatant with the other aliquots and vortex 1 
min, centrifuge at 3,300 g for 15  mins at 4°C. 
Evaporate to dryness, reconstitute in 100 µL 
MeOH. Vortex for 15 mins at 2500 g, centrifuge at 
18,000 g for 15  mins at 4°C.  
LLE & PPT A – 5 mM NH₄HCO₂  
with 0.065 % (v/v) 
formic acid (Ph = 
3.2).  
B -  0.1 % formic 
acid in MeOH  
 
The same samples 
were also run with 
different mobile 
phase A – 0.1 % FA 




and HPVL-GlcA signal 
intensities were slightly 
lower in comparison to 
method 6. 
 
The change of mobile 
phase produced better 
results which improved 
the detection of 
345THPVL and the 
glucuronides. But, this did 
not improve the 
inconsistencies. 
Overall, poor inconsistent 





12 Using a 96 well µ-SPE OASIS PRIME HLB plate. Pre-
condition: 250 µL MeOH, and 250 µL 0.2 % acetic 
acid. Load sample. Wash: 200 mL H2O and further 
with 200 mL of 0.2 % acetic acid. Samples eluted 
with 60 µL MeOH.  
SPE A – 0.1 % FA in H2O 
B – 0.1 % FA in 
MeCN 
Poor detection and 
recovery for all target 
analytes. 
Although this method has been 
published and used by several 
authors. It has provided poor 












Mobile phase Results Conclusion References 
13 STRATA-X cartridges of 33 μm pore size and a 30 
mg capacity with a 3 mL maximum used. 
Precondition: 3 mL 0.25 % FA in MeOH, 3 mL of 0.1 
% FA. Cartridge loaded with 500 µL of 0.1 % FA, do 
not drain.  Load 1:1 diluted plasma with 4 % H3PO4. 
Load 500 µL of 0.1 % FA. Drain. Wash: 3 mLs of H2O, 
3 mLs of 2 % MeOH. Dry cartridge for 20  mins. 
Elute: soak for 10  mins with 2 mLs 0.25 % FA in 
MeOH, collect elute, elute with a further 2  mLs 
0.25 % FA in MeOH. Centrifugal evaporated to 200 
μL. 
SPE A – 0.1 % FA in H2O 
B – 0.1 % FA in 
MeCN 
Poor and inconsistent 
recoveries for all target 
analytes. 




14 STRATA-X cartridges of 33 μm pore size and a 500 
mg capacity with a 6 mL maximum used. 
Precondition: 6 mL 0.25 % FA in MeOH, 6 mL of 0.1 
% FA. Load: 500 µL of 0.1 % FA, not drained.  Load 
1:1 diluted plasma diluted with 4 % H3PO4. 500 µL 
of 0.1 % FA loaded. Drain. Wash: 6 mLs of H2O, 6 
mLs of 2 % MeOH. Dry cartridge for 20 mins. Elute: 
soak for 10  mins with 5  mLs 0.25 % FA in MeOH, 
collect elute, elute with a further 2  mLs 0.25 % FA 
in MeOH. Centrifugal evaporate to 200 mL. 
SPE A – 0.1 % FA in H2O 
B – 0.1 % FA in 
MeCN 
Consistent recoveries 
around 50-60 % for all 
standards except for 
34DHPVL, with a recovery 
of 10-15 %. 345THPVL 
was almost undetectable 
with this method. Really 
low detection limits for 
the sulfate compounds. 
Method further optimised to allow 
for the detection of sulfate 





15 1. STRATA-X SPE Microelution in a 96 well plate. 
Precondition wells: 250 µL 0.25 % FA in MeOH, 250 
µL of 0.1 % FA. Load wells: 100 µL of 0.1 % FA, do 
not drain. Load 1:1 diluted plasma diluted with 4 % 
H3PO4. Load 100 µL of 0.1 % FA. Drain. Wash: 200 
µL of H2O, 200 µL of 2 % MeOH. Dry cartridge for 
10  mins. Elute: soak for 5 mins with 100 mL 0.25 % 
FA in MeOH, collect elute. 
SPE A – 0.1 % FA in H2O 
B – 0.1 % FA in 
MeCN 
Poor and inconsistent 
recoveries for all target 
analytes. 













Mobile phase Results Conclusion References 
16 STRATA-X cartridges of 33 μm pore size and a 500 
mg capacity with a 6 mL maximum volume were 
used. Precondition: 6 mL 0.25 % FA in MeOH,  
6 mL of 0.1 % FA. Load: 500 µL of 0.1 % FA, do not 
drain.  Plasma diluted 1:1 with 4 % H3PO4 loaded. 
500 µL of 0.1 % FA loaded. Drain. Wash: 6 mLs of 
H2O, 6 mLs of 2 % MeOH. Dry cartridge for 20  mins. 
Elute: soak for 10 mins with 5 mLs 0.25 % FA in 
MeOH, collect elute, elute with a further 2 mLs 0.25 
% FA in MeOH. Soak a further 5 mL of MeOH with 
2 % NH4OH (pH 10.50), soak for 10  mins. Elute 
through. Elute again with 1 mL (MeOH with 2 %  
NH4OH (pH 10.50). Centrifugal evaporate to 200 μL. 
SPE A:  10 mM 
Ammonium Acetate 
in water, Ph 5 
B:  10 mM 
Ammonium Acetate 
in acetonitrile, Ph 5 
The same samples 
were also run with 
different mobile 
phase A – 0.1 % FA 
in H2O. B - 0.1 % FA 
in MeCN. 
Good consistent 
recoveries for all target 
analytes around 50-60 %, 
except for 34DHPVL, with 
a recovery around 15 %. 
345THPVL was almost 
undetectable with this 
method.  
Almost 100 % recovery of 
the sulfates using this 
method.  
Good consistent recoveries with 
and reliable method. This method 
would be used on the mouse 
plasma samples  in conjunction 
with method 6. By using two 
methods, it allows for the 
detection of 34DHPVL and 
345THPVL in the samples whilst 
providing consistent recoveries for 









2.4.7 UPLC-MS analysis for plasma 
2.4.7.1 Stock preparation of seven hydroxyphenyl-γ-valerolactones 
Seven hydroxyphenyl-γ-valerolactones: 5-(3’,4’-dihydroxyphenyl)-γ-valerolactone (34DHPVL), 5-
(3’,4’,5’-trihydroxyphenyl)-γ-valerolactone (345THPVL), 5-(4’-hydroxy-3-methoxyphenyl)-γ-
valerolactone (4H3MPVL), 5-(4’-hydroxyphenyl)-γ-valerolactone-3’-O-glucuronide (4HPVL-3GlcA), 
5-(3’-hyroxyphenyl)-γ-valerolactone-4’-O-glucuronide (3HPVL-4GlcA), 5-(3’-hydroxyphenyl)-γ-
valerolactone-4’-O-sulfate sodium salt (3HPVL-4S), 5-(4’-hydroxyphenyl)-γ-valerolactone-3’-O-
sulfate sodium salt (4HPVL-3S), were resuspended in 100 % DMSO to make final stocks of 1 mg/mL, 
stored at -20 °C until use. Aliquots of all the seven HPVLs were pooled together to make a stock that 
contained each metabolite at 143 µg/mL. A standard curve was prepared from the 143 µg/mL stock 
for concentrations ranging from 195 ng/mL to 50 μg/mL in final solvent concentration of 65 % 
methanol with 35 % DMSO (v/v). 
 
2.4.7.2 Serum standard curve preparation with hydroxyphenyl-γ-valerolactones 
Triplicate serum standard curves were prepared using 50 µL volumes of mouse serum (Sigma, UK) 
spiked with 2.895 µL of pre-prepared pooled phenyl-γ-valerolactone stocks in 65 % methanol with 
35 % DMSO (v/v) (195 ng/mL to 50 μg/mL) (from section 2.4.7.1), ranging from final plasma 
concentrations of 2500 ng/mL to 0 ng/mL, using a total of ten concentrations. A 5 μL aliquot of 1 
mg/mL of the internal standard syringic acid, prepared in 100 % methanol, was spiked into the 
serum standard curve. For post-spiked plasma samples, 50 μL of plasma was processed according 
to section 2.4.7.3, and the final samples were spiked with the HPVLs and internal standard stocks 
in the same volumes and concentrations as the pre-spiked samples, in triplicate. 
All processed pre-spiked and post-spiked standards were spiked with 5 μL of 1 mg/mL 
protocatechuic acid in 100 % methanol, to act as a volume standard for the run, giving a final volume 
of 60 μL (50 + 5 + 5 μL).  
 
2.4.7.3 Hydroxyphenyl-γ-valerolactone detection in mouse plasma: plasma crash 
technique 
Plasma samples in 50 μL volumes from the C57BL/6J mice study, detailed in section 2.4.4/2.4.5, 
were spiked with 5 µL of 1 mg/mL syringic acid in 100 % methanol. Plasma was processed prior to 
UPLC-MS2 analysis as follows: 65 μL of 100 % acetonitrile was added to plasma and vortexed, 




were placed on ice for 15 mins and then centrifuged at 13,300 rpm for 15 mins at 4 °C. The 
supernatant was collected into 300 μL glass vial inserts and 5 μL of the volume standard (1 mg/mL 
protocatechuic acid in 100 % methanol), was added. All samples and standards were injected at 2 
μL with a flow rate of 0.4 mL/min into an Agilent 1200 series LC 6490 Triple Quad LC-MS mass 
spectrometer (Agilent Technologies, CA, US), using a Waters Acquity UPLC HSST3 Column (100 x 2.1 
x 1.7 μm), and with mobile phase A (0.1 % formic acid in H2O), and B (0.1 % formic acid in 
acetonitrile). The gradient was run according to Table 2.2. The retention times, parent and daughter 
ions, collision energies, polarity and cell accelerator voltage for each of the compounds investigated 
are shown in Table 2.4.  
Response areas from samples were acquired using Agilent Masshunter Quantitative Analysis 
software as supplied by the instrument manufacturer. Standard curves were plotted (Appendix 
Figure 1) for the post-processed spiked standards and these used to calculate the response factors 
for each of the compounds (Table 2.4). Recoveries of the standards from the pre-spiked to post-
spiked samples were calculated following concentration determination according to Formula 2.2. 
Recovery ranges for each compound are also displayed in Table 2.4, alongside limits of detection 









Formula 2.2: Calculation of the response factors following UPLC-MS2 
Peak area values following quantification of UPLC-MS results were subjected to this formula to obtain 
response factors and concentration values for each compound in biological samples. R: response factor for 
post-spiked standards; Ax: response area of the compound of interest; AIS: response area for the internal 
standard; Cx: concentration of the compound of interest (ng/mL); CIS: concentration of the internal standard 
(ng/mL).  
 
Table 2.2: Gradient applied throughout the UPLC-MS2 run in the Agilent 12000 series LC 6490 Triple Quad 
This gradient was used for the methods outlined in sections 2.4.7.3, 2.4.7.4 and 2.4.8.2 for plasma and urine 
processed samples. 
Time (mins) % Mobile A % Mobile B 
0.00 100 0 
0.50 100 0 
20.00 82 18 
30.00 5 95 
30.10 100 0 




2.4.7.4 Phenyl-γ-valerolactone detection in mouse plasma: cartridge filtration technique 
Standards were prepared as per section 2.4.7.2 for the pre-spiked and the post-spiked standards (n 
= 6 replicates).  
Mouse plasma samples (50 μL) volumes were spiked with 5 µL of 1 mg/mL syringic acid in 100 % 
methanol and processed as follows: STRATA-X cartridges (500 mg capacity, 6 mL maximum volume 
load, 33 μm pore size) were hydrated by loading 6 mL of 0.25 % formic acid in MeOH and drained 
under vacuum, then equilibrated with 6 mL of 0.1 % formic acid with draining, loaded with 500 µl 
of 0.1 % formic acid (without draining), sample loaded (100 μL) and a further 500 µL of 0.1 % formic 
acid loaded; the cartridge was drained  to dryness around 1 drop/second and then washed with 6 
mL of ddH2O and 6 mL of 2 % MeOH (both under vacuum) before being completely dried (30 mins 
under vacuum); the cartridge was eluted at 1 drop per second: 5 mL of 0.25 % formic acid in MeOH, 
after soaking for 10 mins 1 mL of 0.25 % formic acid in MeOH; a 5 mL of 2 % NH4OH in MeOH (pH 
10.5), after soaking for 10 mins 1 mL of 2 % NH4OH in MeOH (pH 10.5). The final 12 mL of eluted 
sample was dried to approximately 200 μL using a Genevac EZ-2 Elite centrifugal evaporator 
(Biopharma, UK). If the sample volume was significantly below the 200 μL then it was made up to 
approximately 200 μL with 0.25 % formic acid in MeOH. Samples were then centrifuged for 10 mins 
at 17,000 g to pellet any remaining debris and the supernatant placed into vials where 5 μL of 1 
mg/mL protocatechuic acid was added as a volume standard.  
Samples were run on the UPLC-MS2 exactly as described in section 2.4.7.3. The recovery values are 
displayed in Table 2.4. 
 
2.4.7.5 Serum standard curve preparation with (−)-epicatechin conjugates and 
hydroxyphenyl-γ-valerolactones 
Stock standards of five hydroxyphenyl-γ-valerolactones: 34DHPVL, 3HPVL-4S, 4HPVL-3GlcA, 3HPVL-
4GlcA, 4H3MPVL, and (−)- epicatechin were resuspended in 100 % DMSO to make final stocks of 1 
mg/mL, stored at -20 °C until use. Aliquots of all the six compounds were pooled together to make 
a stock of 167 µg/mL. A standard curve was prepared from the 167 µg/mL stock for concentrations 
ranging from 50 ng/mL to 40 μg/mL in final solvent concentration of 76 % methanol with 24 % 
DMSO (n = 3). These were prepared using 50 µL of mouse serum (Sigma, UK) spiked with 2.5 µL of 
pre-prepared pooled stock in 76 % methanol and 24 % DMSO ranging from final plasma 
concentrations of 1730 ng/mL to 0 ng/mL, using a total of nine concentrations. A 5 μL aliquot of 3 
μg/mL internal standard taxifolin (prepared in 100 % methanol), was added to the serum standard 




2.4.7.6. For post-spiked plasma samples, 50 μL of plasma was processed according to section 
2.4.7.6, and the final samples were spiked with the 76 % methanol and 24 % DMSO stocks of 
compounds as well as internal standard, in the same volumes and concentrations as the pre-spiked 
samples (n = 3). 
 
2.4.7.6 (−)-Epicatechin and conjugates detection in plasma  
Only EC gavaged mice plasma samples were monitored using this method alongside the pre-
prepared standards (section 2.4.7.5). Plasma mouse samples were spiked with 5 µL of 3 μg/mL 
taxifolin in 100 % methanol. Plasma was processed prior to UPLC-MS analysis by performing the 
following: 65 μL of 100 % acetonitrile was added to plasma and vortexed, followed by 30 μL of ice 
cold 35 % trichloroacetic acid (in water, v/v), and vortexed; samples were placed on ice for 15 mins 
and centrifuged at 13.3 rpm for 15 mins at 4 °C; the supernatant was collected into 300 μL glass vial 
inserts. 
All samples and standards were injected at 2 μL with a flow rate of 0.4 mL/min and separated with 
a Waters Acquity UPLC HSST3 Column (100 x 2.1 x 1.7 μm) on a Waters Acquity i-Class UPLC with 
Waters Xevo TQ-S micro triple quadrupole MS (Waters Ltd, Wilmslow, UK). The mobile phase A 
consisted of 0.1 % formic acid in H2O, and the mobile phase B consisted of acetonitrile with 0.1 % 
formic acid. The column was kept at a 35 °C temperature and samples kept at 10 °C during the run. 
The gradient was run according to Table 2.3. The retention times, MRM and collision energies for 
each of the compounds investigated are shown in Tables 2.5. Please note, no recovery values, LOD, 
or response factors from the standard curves are provided because no compounds were detected, 
with the exception of spiked standards, in the 24-hour post gavage plasma samples of EC-gavaged 
mice.  
Response areas from the samples were analysed using Waters MassLynx MS software as supplied 
by the instrument manufacturer. There was no standard for epicatechin sulfate or epicatechin 
glucuronide, so it was searched for based on its MRM transitions and by reference to (−)-





Table 2.3: Gradient applied throughout the UPLC-MS2 run in the Waters Acquity i-Class UPLC 
This gradient was applied to the method outlined in section 2.4.7.6. 
Time (mins) % Mobile A % Mobile B 
0 97 3 
2 97 3 
6 80 20 
10 50 50 
12 5 95 
13 5 95 
13.10 97 3 




 Table 2.4: UPLC-MS2 input and output data for compound detection in plasma and urine 
In addition to the ion-pairs and the retention times, the recovery values and response factors for each compound for the methods used have been listed. Response factors are 
calculated from the standard curves obtained from matrix-matched standards that were SPE extracted and analysed in the same way as real samples, and the recovery ranges 
are calculated from the standard curves obtained for blank matrix samples spiked pre-processing compared to those spiked post-processing. The protein-precipitation (PPT) 
method is detailed in section 2.4.7.3, solid-phase extraction (SPE) method in section 2.4.7.4, and urine method in section 2.4.8. Rows highlighted in bold were the MRM 










































4HPVL-3GlcA 383.09 207.1 80 26 4 Negative 12.65 38.899 0.527 73-108 47-61 67-94 5 
4HPVL-3GlcA 383.09 162.9 80 42 4 Negative 12.65 20.526 0.210 60 -105 48-70 70-92 15 
4HPVL-3GlcA 383.09 113 80 25 5 Negative 12.65 10.054 0.084 48-129 43-77 68-93 12 
3HPVL-4GlcA 383.09 207.1 80 26 4 Negative 11.85 30.993 0.450 64-106 47-73 71-90 5 
3HPVL-4GlcA 383.09 162.9 80 42 4 Negative 11.85 17.547 0.181 65-107 46-68 71-93 5 
3HPVL-4GlcA 383.09 113 80 25 5 Negative 11.85 9.427 0.079 65-138 43-64 66-92 7 
4HPVL-3S 287 207 80 26 5 Negative 12.43 242.61 4.911 66-99 45-97 66-89 2 
4HPVL-3S 287 163 80 26 5 Negative 12.43 458.65 2.471 63-94 45-97 70-96 3 
3HPVL-4S 287 207 80 26 5 Negative 12.11 153.15 1.543 53-106 22-30 62-90 10 
3HPVL-4S 287 163 80 26 5 Negative 12.11 83.98 0.774 55-108 22-30 63-86 6 
4H3MPVL 223.1 103 80 38 4 Positive 18.80 159.53 1.569 73-114 47-75 72-91 4 
4H3MPVL 223.1 76.9 80 62 4 Positive 18.80 87.752 1.005 69-109 47-67 74-91 15 
345THPVL 223.06 179 80 18 5 Negative 9.00 5.912 2.38 0-39 0 51-102 900 














































34DHPVL 207.06 162.8 80 18 5 Negative 13.39 104.21 2.733 53-199 0-12 87-101 12 
34DHPVL 207.06 122 80 26 5 Negative 13.39 33.912 0.955 43-109 5-11 87-101 3 
Syringic Acid 196.7 181.8 80 26 5 Negative 12.45 NA NA NA NA NA NA 
Syringic Acid 196.7 123.1 80 26 5 Negative 12.45 NA NA NA NA NA NA 
Protocatechuic 
Acid 






Table 2.5: Additional compound detection from the urine of mice by UPLC-MS2 

























465.1 289.1 80 5 18 Negative Undetectable NA NA NA 
Epicatechin 
sulfate 
369.03 289.03 80 5 15 Negative 14.76 NA NA NA 
Epicatechin 289 245 80 5 11 Negative 14.07 0.389 73-92 15 
Hippuric acid 179.84 104.9 80 5 15 Positive 9.90 0.821 80-97 0.25 
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Table 2.6: UPLC-MS2 parameters used in the analysis of (−)-epicatechin and its phase-II conjugates in mouse 
plasma samples 














Epicatechin 290.88 122.98 0.006 20 20 Positive 6.25 
Taxifolin 304.90 149.00 0.006 24 26 Positive 7.57 
34DHPVL 206.78 121.92 0.006 20 40 Negative 6.65 
3HPVL-4S 286.78 108.86 0.006 36 20 Negative 6.23 
4HPVL-3S 286.78 108.86 0.006 36 20 Negative 6.40 
Epicatechin sulfate 369.03 289.03 0.006 15 25 Negative 6.48 
3HPVL-4GlcA 382.78 207.02 0.006 20 20 Negative 5.79 
4HPVL-3GlcA 382.78 207.02 0.006 20 20 Negative 6.06 
Epicatechin 
glucuronide 
465.10 289.10 0.006 18 25 Negative 5.41 
 
 
2.4.8 UPLC-MS analysis of urine 
2.4.8.1 Stock preparation of compounds 
Five hydroxyphenyl-γ-valerolactones: 34DHPVL, 345THPVL, 4H3MPVL, 4HPVL-3GlcA, 3HPVL-4GlcA, 
as well as epicatechin and hippuric acid were resuspended in 100 % DMSO to make final stocks of 
1 mg/mL, the remaining two hydroxyphenyl-γ-valerolactones, 3HPVL-4S, and 4HPVL-3S were 
resuspended in 100 % MeOH at 1 mg/mL, and stored at -20 °C until use. Aliquots of all the seven 
hydroxyphenyl-γ-valerolactones, (−)-epicatechin and hippuric acid were pooled together to make a 
stock of 100 µg/mL at 77.7 % DMSO with 22.2 % MeOH (v/v) concentration. A standard curve was 
prepared from the 100 µg/mL stock for concentrations ranging from 195 ng/mL to 50 μg/mL in final 
solvent concentration of 38.8 % DMSO with 61.1 % MeOH. 
 
2.4.8.2 Methanol standard curve preparation for quantification of urine compounds 
Standard curves were prepared (n = 3) using 190 µL of 100 % MeOH spiked with 10 µL of pre-
prepared pooled compounds (section 2.4.8.1), ranging from final standard concentrations of 2500 
ng/mL to 0 ng/mL, using a total of ten concentrations. A 10 μL aliquot of 1 mg/mL internal standard 
taxifolin (prepared in 100 % methanol) was spiked into the MeOH standard curve. Final pre-
processed standards were therefore of 200 μL volume. Standards were then processed according 
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to the method outlined in section 2.4.8.3. For post-spiked MeOH samples, 190 μL of MeOH was 
processed according to section 2.4.8.3, and the final samples were spiked with the compound 
stocks and internal standard stocks in the same volumes and concentrations as the pre-spiked 
samples (n = 3). 
All processed pre-spiked and processed post-spiked standards were spiked with 5 μL of 1 mg/mL 
protocatechuic acid (in 100 % methanol), to act as a volume standard for the run.  
 
2.4.8.3 Hydroxyphenyl-γ-valerolactone and (−)-epicatechin conjugate 
analysis of mouse urine 
The target volume of mouse urine for analysis was 190 μL, but for collected samples of less than 
this volume, the maximum available volume was used, and the method was scaled down 
accordingly. Mouse urine samples (190 μL) were spiked with 10 µL of 1 mg/mL taxifolin (in 100 % 
methanol). Urine was processed prior to UPLC-MS2 analysis as follows: 200 μL of 5 % TCA was added 
and vortexed followed by 100 μL of DMF; the samples were vortexed and left at room temperature 
for 20 mins and vortexed again before being centrifuged (10 mins at 13,300 rpm) and spiked with 
5 μL of 1 mg/mL protocatechuic acid; these were then filtered through Whatman® 0.45 μM filter 
vials, which held a maximum capacity of 400 μL.  
Samples were then run on the UPLC-MS2 according to the exact specifications outlined in section 
2.4.7.3. There were further additional ion pairs screened for the compounds listed in Table 2.6.  
The maximum concentration run for the standard curve was lower than the maximum 
concentration detected in the samples (typically the 1-hour samples). Because of this, an additional 
standard curve was run up to 121 μg/mL for a total of eight concentrations (5-fold dilutions). 
Overall, the standard curves were linear up to 10 μg/mL and then the gradient decreased, and the 
line of best fit followed a y = x2 + x + c pattern. Therefore, for the compounds that were detected 
in the samples at concentrations much higher than 2500 ng/mL, then the response factor from the 
more concentrated standard curve was used. The response factors from both standard curves were 
almost identical for the aglycones, O-methylated and O-glucuronidated metabolites, but the O-
sulfates were different. The response factors for the 3HPVL-4S and 4HPVL-3S were 4.56 and 4.01, 
respectively, and these values were used to calculate the sample concentrations beyond 10 μg/mL. 
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2.4.9 Calculation of elimination half-lives 
Once concentrations were calculated for plasma and urine HPVL metabolites, a concentration over 
time curve was drawn for each metabolite and for the total metabolites detected (Figure’s 2.3 and 
2.4). From this, the area under the pharmacokinetic curve (A.U.C) was calculated using the standard 
integration trapezium rule formula (manually calculated in Microsoft Excel). The peak 
concentration (Cmax) and time for peak concentration (Tmax) were taken from the peak analytical 
points. Elimination half-lives (T1/2) for each compound were calculated according to Byers et al 
(2009) (320). Briefly, the elimination rate constant (k) was calculated according to Formula 2.3 a/c, 
taking the average of the k constants over the entire study length, the T1/2 was then calculated 
according to Formula 2.3 d.  
𝑎) 𝐶𝑡+1 = 𝐶𝑡  ×  𝑒
−𝑘𝑡 






𝑐)  𝑘?̅? = ∑











Formula 2.3: Elimination half-life formula 
Steps a-d were performed to calculate the elimination half-lives for all HPVL metabolites from both urine and 
plasma pharmacokinetic curves, b) is the rearrangement of the formula in a). Ct = Concentration (C) at time 
(t) after dose; Ct+1 = concentration at time (t+1) after t; k = elimination rate constant; T1/2 = elimination half-
life; N = number of HPVL concentrations recorded; x ̄= mean. 
  




2.5.1 Method selection for plasma processing 
Following processing, mouse plasma samples were separated on a Waters reverse phase C18 
Column and passed through a UPLC-MS2 to quantify the concentrations of seven HPVLs. Two 
processing steps were tested on the plasma samples; one was a PPT method (section 2.4.7.3), and 
the other was an SPE method (section 2.4.7.4). The PPT method allowed the determination of all 
seven HPVL concentrations in all the plasma samples, but with lower precision due to inconsistent 
recoveries of standards, whereas the SPE method allowed the determination of only five of the 
HPVLs (4HPVL-3GlcA, 3HPVL-4GlcA, 4HPVL-3S, 3HPVL-4S and 4H3MPVL) but with better precision, 
which reflected the more consistent recoveries of standards.  
The PPT method gave recovery ranges (“Recovery range (%) – plasma PPT method” in Table 2.4) 
that varied from 0-114 % across the different compounds. The SPE process gave much more 
consistent recoveries, except for 34DHPVL and 345THPVL, which may be as a consequence of their 
high limit of detections (LOD). However, the data obtained for mouse samples processed with the 
SPE method were considered unreliable; this is because the peak areas for the target metabolites 
in mice samples were considerably lower than the peak area obtained for the same compounds 
that had been processed using the PPT method, even though the peak areas for the internal 
standards was similar. Moreover, the greater number of replicate standards quantified from the 
SPE extraction method resulted in the UPLC-MS2 to run considerably longer than when it was run 
for the PPT extracted samples. Consequently, this caused trailing retention times and a reduced 
level of responsiveness. Furthermore, the addition of the drying step following SPE extraction 
caused further loss of the metabolites. And so, the unreliability of the SPE procedure was not 
pursued for the final quantification of the HPVL metabolites.  
 
2.5.2 HPVL metabolites peak in the plasma 1-hour following ingestion 
HPVLs and EC conjugates were quantified in plasma samples processed using the PPT methods 
described in, section 2.4.7.3 and section 2.4.7.6. EC conjugates were assessed in only the 24-hour 
post EC gavaged mouse samples, and HPVLs were quantified in all plasma samples. Figure 2.3 
displays the resulting concentrations of each HPVL up to 24-hour’s post oral gavage of 80 mg/kg 
body weight of 34DHPVL or EC, and Table 2.7 summarises the data. In total, the combined Cmax of 
HPVL metabolites in plasma was 7.18 μM (1-hour) which estimates to be a tiny 0.11 % of the 
ingested 34DHPVL dose. This was calculated from the average mass of 1.84 mg of 34DHPVL 
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provided to the mice (8.85 μmol), and the average blood total volume in the mice was 1.34 mL (58.5 
mL/kg body weight of blood (321)), consequently, the 7.18 μM of HPVL metabolites is equal to 9.62 
nmol (0.11 % of the ingested dose). The area under the pharmacokinetic plasma curve (A.U.C) for 
the total HPVL metabolites detected was 14.31 μM (Figure 2.3 H).  
There was no detection of (−)-epicatechin, epicatechin-glucuronide or epicatechin-sulfate in any of 
the 24-hour post EC gavaged mouse samples. This was as expected, as there are several published 
reports highlighting the quick metabolism and excretion of these SREMs. The only detectable 
concentrations in the EC gavaged mice were for 3HPVL-4S and 4HPVL-3S (Figure 2.3 G), however, 
the concentrations were very low (6 and 2 nM respectively).  
4HPVL-3S, 3HPVL-4S, 34DHPVL, and 4H3MPVL were detectable in the plasma of 34DHPVL-gavaged 
mice at 24-hours, but 3HPVL-4GlcA and 4HPVL-3GlcA could not be detected and 345THPVL was only 
detected in the plasma of one mouse at 24 hours post-gavage. The glucuronides were the most 
concentrated compounds found in mice plasma in the early timepoints, peaking 1-hour post gavage 
at 3.97 ± 1.41 μM and 0.70 ± 0.30 μM, for 3HPVL-4GlcA and 4HPVL-3GlcA respectively. It is possible 
that the concentrations could have been higher in the plasma prior to or soon after the 1-hour 
timepoint, however since there were blood samples collected between 0-1 or 1-2 hours, it was not 
possible to evaluate this. HPVL-O-glucuronide concentrations were drastically lower at the 2-hour 
timepoint, with estimated concentrations of 0.64 ± 0.21 μM and 0.10 ± 0.03 μM, and negligible 
concentrations after 6 hours. They also expressed quick elimination half-lives between 0.33-0.35 
hours and so this demonstrates the rapid clearance of the glucuronides from the circulation.   
HPVL-sulfates were also found at relatively high concentrations in plasma, with highest 
concentrations observed in 1-hour samples (2.26 ± 0.78 μM and 0.18 ± 0.04 μM for 4HPVL-3S and 
3HPVL-4S, respectively). Concentrations then dropped gradually from 1 to 6-hours and were still 
detectable in plasma after 24-hours (4.8 nM and 1.8 nM for 4HPVL-3S and 3HPVL-4S, respectively). 
Sulfate HPVLs appeared over a long timeframe and at high concentrations throughout; this could 
be because they are metabolised or synthesised more slowly than HPVL-glucuronides or because 
there are differences in the excretion rate. This is partly demonstrated by the longer circulation 
time of the O-sulfates, with elimination half-lives of 0.94-1.18 hours, almost 3-4 times longer than 
the glucuronides.  
34DHPVL and 4H3MPVL aglycones were detected at much lower concentrations in plasma samples 
than glucuronides and sulfates, which is consistent with efficient phase-II conjugation and rapid 
conversion of aglycones to phase-II conjugates by small intestinal enterocytes and the liver. Both 
aglycones were found at the highest concentration in 1-hour post gavaged samples (0.22 ± 0.04 μM 
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and 0.10 ± 0.02 μM for 34DHPVL and 4H3MPVL, respectively). 34DHPVL was more slowly cleared 
in the mice than 4H3MPVL, with a T1/2 of 0.66-hours and a mean concentration at 24-hours of 2 nM 
for 4H3MPVL. 
345THPVL was included in the list of targeted metabolites because it could plausibly arise from 
hydroxylation of 34DHPVL. An ion current response was observed for the 345THVL ion pair; 
however, this peak was below the estimated limit of detection for 345THPVL. No peak was observed 
in 25 % of mouse samples, and inter-mouse variance was very high, so if the observed peak was 
due to 345THPVL, then the observed concentrations were approximately 10-fold lower than for the 
34DHPVL aglycone (low nM). Overall, the evidence suggests that this is not an important metabolic 
route and possibly not a metabolic route at all.  
 
Table 2.7: 34DHPVL metabolites detected in mouse plasma 
This table summarises the results for the detection of hydroxyphenyl-γ-valerolactones in the plasma of mice 
from the pharmacokinetic study. Cmax: the maximum concentration detected at a time; Tmax: time at which the 
maximum concentration was observed; A.U.C: area under the plasma concentration over time curve 
(estimated from the graphs produced in Figure 2.3); T1/2: estimated elimination half-life.  
Epicatechin metabolites Cmax (μM) Tmax (hours) A.U.C (μM/hour) T1/2 (hours) 
34DHPVL 0.22 1 0.91 1.05 
4HPVL-3GlcA 0.70 1 0.96 0.33 
3HPVL-4GlcA 3.97 1 5.75 0.35 
4HPVL-3S 2.26 1 6.36 0.94 
3HPVL-4S 0.18 1 0.60 1.18 
345THPVL (putative) 0.03 1 0.17 1.57 
4H3MPVL 0.10 1 0.24 0.66 
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 Figure 2.3: Hydroxyphenyl-γ-valerolactone concentrations in 0-24 hour plasma samples of mice fed 
34DHPVL 
Mice were oral gavaged with 80 mg/kg body weight of 34DHPVL, and plasma concentrations for 
compounds (A) 3HPVL-4GlcA; (B) 4HPVL-3GlcA; (C) 4HPVL-3S; (D) 3HPVL-4S; (E) 34DHPVL; (F) 
4H3MPVL, were quantified over time. (G) 24-hour detection of 3HPVL-4S and 4HPVL-3S following oral 
gavage of 80 mg/kg body weight of EC. Error bars represent the standard error of the mean (SEM) for 
the line graphs and 95 % confidence interval for the dot plot graphs. 
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2.5.3 4HPVL-3S is the most concentrated urinary excreted metabolite 
following 34DHPVL ingestion 
Mouse urine samples processed and analysed according to the method detailed in section 2.4.8.3 
were used to estimate the concentrations of metabolites in urine samples collected over time 
following 34DHPVL gavage at 80 mg/kg body weight. It was not possible to collect urine samples at 
each timepoint for each mouse, and so the data presented here are for a limited number of animals 
at each timepoint and the number involved has been indicated. The data for urinary concentrations 
for each metabolite over time are shown in Figure 2.4 with a summary in Table 2.8. Data for only 
the 24-hour timepoint samples collected following EC administration are also shown.  
After dosing with 34DHPVL, HPVL-sulfates were excreted highest at 1-hour (561 μM and 132 μM, n 
= 2 for 4HPVL-3S and 3HPVL-4S, respectively) post-gavage, (Figure 2.4 C/D). These compounds were 
excreted gradually over the 24-hour time period, with concentrations still high at 24-hours (4.27 ± 
1.55 μM and 1.26 ± 0.95 μM, n = 4, mean and SD values) and T1/2 values of 3.01 and 1.18 hours, 
after a 24-hour gavage for 4HPVL-3S and 3HPVL-4S, respectively. These observations are consistent 
with a process in which 34DHPVL is rapidly conjugated to sulfated forms following ingestion, 
circulate in the plasma, and are then excreted, with excretion via the kidneys (urine) appearing to 
be the major route.  
The concentrations of HPVL-glucuronides peaked in urine samples collected 1-hour after gavage, 
reaching 94 ± 29 μM and 66 ± 63 μM for 3HPVL-4GlcA and 4HPVL-3GlcA, respectively (Figure 2.4 
A/B). Concentrations then dropped rapidly in samples after the 1-hour timepoint and were only 
0.17 ± 0.06 μM and 0.11 ± 0.03 μM at 24-hours, with T1/2 estimates of 1.22 and 0.56 hours, for 
3HPVL-4GlcA and 4HPVL-3GlcA, respectively. The glucuronide conjugates have much shorter 
elimination half-lives than the sulfate conjugates. 
The aglycones 34DHPVL and 4H3MPVL appeared to be rapidly cleared from the plasma by the 
kidneys, evidenced by the highest concentrations in urine being in the earliest 1-hour timepoint (84 
± 92 μM and 116 ± 146 μM, respectively). These aglycones possessed the shortest elimination half-
lives of all of the quantified metabolites at 0.53 and 0.36 hours, with only nanomolar concentrations 
being detected in urine 24-hours after gavage.  
Since urine was collected periodically and there was no urine collected between 6-24 hours, it is 
not possible to accurately determine the recovery of HPVL metabolites from the concentration 
ingested. However, an estimate was calculated based on the area under the urine pharmacokinetic 
curve (A.U.C) for the total HPVL metabolites over time (Figure 2.4 I) and from the amount of 
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34DHPVL ingested. There was an average mass of 1.84 mg of 34DHPVL provided to all the mice, 
which equates to an amount of 8.85 μmol. The A.U.C for total HPVL urinary metabolites was 5012 
μM/hour, and so, when making the assumption of an average urinary excretion of 0.8 mL by the 
mice over 24-hours (322) then the amount of HPVL metabolites excreted in urine is 4.01 μmol; 
accounting for an estimated recovery of 45 % of the ingested dose.  
There was a correlation between the detected concentrations in mouse urine and plasma for 
345THPVL. However, in keeping with the literature (1, 5), the concentrations of the 34DHPVL 
metabolites in urine should be far greater than the observed concentrations in plasma, this is typical 
for the rapid excretion of xenobiotics by the kidneys into urine. Because of this and the high LOD 
for 345THPVL, it is likely that the peak detected for 345THPVL could be an artefact of the analysis.  
For the majority of the pharmacokinetic time courses for the urinary excretion of the different 
34DHPVL conjugates, there was a smaller second peak, typically between 3 and 6-hours. This is the 
hallmark for enterohepatic recirculation where a fraction of the peripheral blood metabolites are 
excreted via the liver into bile, which is later emptied into the small intestine, allowing for later 
reabsorption by the intestine and further intestinal/hepatic metabolism.  
In 24-hour samples from EC-gavaged mice, there were detectable concentrations of 3HPVL-4GlcA, 
4HPVL-3GlcA, 4HPVL-3S, 3HPVL-4S, 34DHPVL and 4H3MPVL. This is different from what was 
observed for 24-hour plasma samples for which only 4HPVL-3S and 3HPVL-4S were detected (Figure 
2.4 G/H). This reflects the substantially lower concentrations of metabolites present in plasma 
when compared to urine, where the majority were below the LOD after 24-hours. The order of 
concentrations of the individual HPVL metabolites from EC-fed mice was similar to that observed 
for 34DHPVL-fed mice (sulfates > glucuronides > aglycones), showing that once HPVLs are formed 
by microbiota in the colon following EC ingestion, their metabolism for phase-II conjugation is 
similar to that for 34DHPVL when fed directly and absorbed by the small intestine.     
The 24-hour urinary concentrations for the HPVL conjugates were similar for EC-gavaged and 
34DHPVL-gavaged mice (Figure 2.4 G/H), as were the 24-hour plasma concentrations for 4HPVL-3S 
and 3HPVL-4S (section 2.5.2, Figure 2.3 G). Finally, no EC-sulfates, EC-glucuronide or EC aglycone 
were detected in 24-hour urine samples of EC-gavaged mice. This is likely due to the rapid clearance 
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Table 2.8: 34DHPVL metabolites detected in mouse urine 
This table summarises the results for the detection of hydroxyphenyl-γ-valerolactones in the urine of mice 
from the pharmacokinetic study oral gavaged with 80 mg/kg of 34DHPVL. Cmax: the maximum concentration 
detected at a time; Tmax: time at which the maximum concentration was observed; A.U.C: area under the 
urinary concentration over time curve (estimated from the graphs produced in Figure 2.4); T1/2: estimated 
elimination half-life. 
Epicatechin metabolites Cmax (μM) Tmax (hours) A.U.C (μM/hour) T1/2 (h) 
34DHPVL 84.1 1 141.8 0.53 
4HPVL-3GlcA 65.6 1 134.6 0.56 
3HPVL-4GlcA 93.8 1 492.0 1.22 
4HPVL-3S 561.0 1 3466 3.01 
3HPVL-4S 131.7 1 595.5 1.18 
345THPVL (putative) 0.03 1 0.04 0.73 
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Figure 2.4: Hydroxyphenyl-γ-valerolactone concentrations in 0-24 hour urine samples of mice fed 34DHPVL 
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Figure 2.4 (continued): Mice were orally gavaged with 80 mg/kg body weight of 34DHPVL, and urinary 
excretion concentrations for compounds (A) 3HPVL-4GlcA; (B) 4HPVL-3GlcA; (C) 4HPVL-3S; (D) 3HPVL-4S; (E) 
34DHPVL; (F) 4H3MPVL, were quantified over time. Mice oral gavaged with 80 mg/kg EC had detectable 
concentrations in 24-hour urine samples for (G) 4HPVL-3GlcA, 3HPVL-4GlcA, 34DHPVL and 4H3MPVL; and, (H) 
3HPVL-4S and 4HPVL-3S. Total hydroxyphenyl-γ-valerolactone metabolites following 34DHPVL gavage over 
time are shown in (I). Error bars represent the standard error of the mean (SEM) for the line graphs and 95 % 
confidence interval for the dot plot graphs. 




The purpose of the pharmacokinetic study was to compare the absorption and excretion profile of 
HPVLs when provided as an oral dose compared to providing its parent compound as an oral dose. 
In doing so, this study has revealed that: 
(1) There is rapid conjugation and absorption of HPVLs, that provide peak plasma concentrations 
after 1-hour. 
(2) This is followed by rapid urinary excretion of the compounds which again is highest in 1-hour 
post-gavaged samples. 
(3) HPVL metabolites are still excreted after 24-hours, although at substantially lower 
concentrations. 
(4) HPVL-O-sulfates have longer elimination half-lives than HPVL-O-glucuronides and aglycones.  
This study was novel in directly feeding a HPVL to rodents and this is therefore the first report for 
the pharmacokinetic behaviour in such instance. Consequently, there is no possibility of comparing 
the results reported here with other studies for the pharmacokinetics of HPVLs. However, the 
appearance of HPVLs following oral consumption of the flavanol EC and flavanol-rich foods and 
extracts has been reported, and these provide the backdrop to understand the novelty of this new 
data and the insights it has uniquely provided.  
 
2.6.1 There is rapid absorption and excretion of 34DHPVL and its metabolites 
Maximal plasma and urinary concentrations of all 34DHPVL metabolites occurred within 1-hour of 
34DHPVL oral gavage, showing that these compounds are rapidly absorbed, distributed, and quickly 
excreted in the urine in mice in the current study. Although timepoints prior to the 1-hour and very 
soon after this were not taken, it is likely that the maxima detection at 1-hour is true of the HPVL 
metabolites pharmacokinetic profile; this is indeed true for the pharmacokinetic profile of EC 
conjugates following EC-gavage (1, 5). When EC is directly fed to humans, there is the requirement 
for microbial catabolism of EC and EC-conjugates to HPVLs and further phase-II conjugation by the 
enterocytes/hepatocytes, consequently the Tmax times for HPVLs in the circulation are much later 
at ~6-hours (1). In contrast, this study has shown that 34DHPVL-gavage in mice causes the rapid 
absorption and production of HPVL metabolites (4HPVL-3GlcA, 3HPVL-4GlcA, 4HPVL-3S, 3HPVL-4S 
and 4H3MPVL) by phase-II conjugation from enzymes within small intestinal enterocytes and the 
liver, subsequently they appear maximally in plasma at around 5-hours earlier than when EC is 
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gavaged. In keeping with this observation, 34DHPVL metabolites are rapidly processed by the 
kidneys and excreted in urine when dosed orally (approximate Tmax of 1-hour), compared to the 
delayed detection of HPVL metabolites in urine following EC-gavage (Tmax 4-8 hours) (1).  
 
2.6.2 O-glucuronide and O-sulfate HPVL distribution in mice 
A very interesting observation was that the O-glucuronides were initially the main conjugated form 
of 34DHPVL and accounted for 62 ± 1.98 % of all the circulatory compounds screened at 1-hour; 
this was followed by the O-sulfates (34 ± 1.73 %) and then the aglycones (5 ± 0.97 %). This is 
different to that reported for humans fed (14C)-EC where 4HPVL-3S accounted for 60 % (mol %) of 
the total concentration of HPVLs in peripheral blood samples taken 6-hours post-consumption (1, 
96). In addition, 3HPVL-4S was detected in the plasma of mice fed 34DHPVL in the current study, 
whereas this compound was not detected in plasma samples from previously reported studies 
where flavanols were consumed and the HPVLs were generated by the gut microbiota (1, 5). 
Although the glucuronides accounted for the majority of total conjugated metabolites at their Cmax 
in mice, the sulfates had the highest exposure over time evidenced by the highest A.U.C values and 
the longest elimination half-lives (Tables 2.7 and 2.8). This is also reflected in a previously reported 
human study, where 4HPVL-3S was reported to account for the largest plasma and urinary A.U.C 
and had the longest elimination half-life (1). In contrast, in EC-gavaged rats, 3HPVL-4GlcA 
dominated the total urinary excretion over 4HPVL-3S (5). It is noteworthy that the elimination half-
lives of all the 34DHPVL conjugates were reported to be significantly longer in humans in 
comparison to values estimated for the mice in this study. This is consistent with humans having 
slower metabolic activity compared to mice (323, 324). This might be relevant when considering 
the length of treatments to be used when planning in-vitro experiments to determine their 
biological activities, for example cultured mammalian cell models. Regardless, this study has shown 
that the mouse model is a closer fit with what is observed in humans. This might reflect the relative 
genetic closeness of mice to humans in comparison to other animals such as rats and rabbits. 
Although, it must be taken into account that there are often large differences between mice and 
humans in terms of metabolic activity (323, 324).  
 
2.6.3 The detection of 34DHPVL at 24-hours post-gavage 
At 24-hours post 34DHPVL-gavage in mice, there were still detectable plasma concentrations of 
34DHPVL, and these were detected to be the most concentrated HPVL screened at this time-point 
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(~15 nM) with a high T1/2 of 1.05-hours. This occurred despite enterohepatic recirculation where 
further conjugation is highly likely, as evidenced by the second peak of 34DHPVL and conjugates in 
urine at 3-hours. So, despite the evidence for the rapid absorption and phase-II conjugation of 
34DHPVL, when provided orally at concentrations of 2 mg/25 g mouse, not all of it is converted to 
conjugates after 24-hours and there is a long elimination clearance of the metabolite. This 
observation cannot be explained by this study, but the persistence of 34DHPVL in 24-hour plasma 
samples of the mice appears to be a rodent phenomenon, because it has previously been reported 
that the 34DHPVL aglycone was not detectable in human plasma after EC-consumption, but it was 
detectable in the plasma of rats administrated with EGCG; first appearing at 6-hours from 
consumption and peaking later (98).  
Similarly to humans (1), the biggest A.U.C was for the HPVL-sulfates in this mouse study followed 
by the glucuronides, whilst in rats 3HPVL-4GlcA dominates over 4HPVL-3S (5). This reiterates how 
the mouse model is a better choice when trying to make biological judgements in humans, versus 
other animal models, such as rats, rabbits and amongst others, due to their greater similarity in 
genetics (325), although still vastly different in terms of metabolic activity. 
Within this mouse study there was an estimated recovery of 45.3 ± 34 % of the ingested 34DHPVL. 
This value is low compared to other studies mostly because of the short 24-hour period where 
measurements were taken. In humans and rats, there is excretion of metabolites, particularly ring-
fission metabolites (RFMs), between 48-72-hours (1, 5). There is still the detection of HPVLs after 
24-hours in both plasma and urine in this study, informing that there will be further excretion of 
the compounds beyond this. Additionally, only two biological matrix markers have been assessed 
in this study, to find a greater recovery of the compounds following ingestion there would need to 
be an assessment of faeces, red blood cells, and synovial fluid (309), where 34DHPVL has been 
shown to bind to these latter two matrices. Finally, there are also further metabolites of HPVL’s 
that have not been screened for in this study, these are namely, hydroxyphenyl valeric acids, 
hydroxyphenyl propionic acids and hydroxyphenyl benzoic acids (1, 5); thus screening for these 
additional compounds would increase the recovery of the ingested dose.




The mouse pharmacokinetic study performed in this chapter has shown that: 
(1) 34DHPVL is very rapidly absorbed (within 1-hour). 
(2) 34DHPVL is very rapidly metabolised to phase-II conjugates. 
(3) There is rapid urinary excretion of 34DHPVL and its metabolites (peak in 1-hour). The 
data also shows that O-glucuronides are the dominant early metabolic form, consistent 
with conjugation in the small intestine whereas the dominant later forms are O-sulfates, 
which is consistent with liver O-sulfation, and indeed 34DHPVL-O-glucuronides appear to 
be transformed into O-sulfates in the liver post first pass metabolism.  
(4) Finally, evidence that 34DHPVL undergoes enterohepatic circulation has been reported.  
There are several limitations from the study design that do not allow for a complete picture with 
regards to the pharmacokinetics for 34DHPVL and its metabolites. If this study were to be repeated: 
(1) More mice would have been used to decrease the error surrounding the observed 
concentrations at each timepoint, in addition to the use of both male and female mice to 
observe differences in HPVL pharmacokinetics between the sexes. 
(2) Samples would have been taken at several additional earlier timepoints following oral 
gavage to allow a more accurate estimation of the Tmax and Cmax in particular (e.g. 15, 30, 
45, 60 and 90 mins). 
(3) Metabolic organs would have been harvested to allow determination of the 
concentrations in them at each timepoint. 
(4) Measurements of the concentrations of 34DHPVL metabolites would have been 
performed in other biological samples such as faeces, red blood cells, and the gut 
(duodenum, jejunum, ileum, cecum and colon), to provide a more complete picture of HPVL 
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Chapter 3: A dietary intervention study to explore the 
effects of 3’,4’-dihydroxyphenyl-γ-valerolactone and (−)-
epicatechin on insulin resistance in high fat diet fed mice 
3.1 Abstract 
Background: There are numerous reports showing that (−)-epicatechin (EC) consumption has 
beneficial effects on health and in particular biomarkers of type-2 diabetes. Such evidence includes 
the protection against hepatic steatosis and insulin resistance in high fat diet fed mouse models 
supplemented with EC. However, since a substantial proportion of ingested EC is converted to 
hydroxyphenyl-γ-valerolactones (HPVL) by the gut microbiota, and these HPVLs are efficiently 
absorbed and account for about one third of EC metabolites that reach the peripheral circulation, 
it is not clear if the effects of consuming EC are caused by EC and its phase-II metabolites per se, or 
by HPVLs, or a combination of both.  
Aim: The purpose of this study was, for the first time, to directly compare the effects of EC and its 
microbial metabolite 34DHPVL on insulin resistance in a high-fat diet fed mouse model to produce 
metabolic changes causing insulin resistance. 
Methods: A total of eighty C57BL/6J mice were fed six different diets containing 20 mg/kg body 
weight of EC or 34DHPVL or no supplement into either a low fat 10 % kcal (LF) or high fat 60 % kcal 
(HF) base diet for 15-weeks. Plasma insulin and glucose levels were recorded after 13-weeks of 
dietary intervention via a fasted glucose tolerance test (GTT).  
Results: The HF diet significantly increased body weight in mice by 56 ± 8.5 % (p < 0.0001) and 
impaired insulin sensitivity when compared to the LF diet (79 ± 5.1 % higher glucose A.U.C, p < 0.05). 
The supplementation of EC into the HF diet (HF+EC) caused a significant reduction in blood glucose 
concentrations by 26 ± 3.8 % at 2-hours after intraperitoneal glucose injection during the GTT (p = 
0.007) and significantly reduced body weight gain in the mice by 12 ± 5.8 % (p = 0.03). Although EC 
supplementation lowered fasting plasma insulin in HF diet fed mice and consequently almost 
halved the HOMA-IR, the glucose A.U.C was not significantly different to HF fed mice (77.4 mg/dL 
versus 82.5 mg/dL, p = 0.32) and the absolute HOMA-IR still indicated the mice were insulin 
resistant. Interestingly, there was no difference in epididymal fat mass between EC supplemented 
and non-supplemented mice on HF diets. In contrast, 34DHPVL supplemented into HF diet fed mice 
did not prevent body weight gain and increased the fasting insulin concentrations in comparison to 




0.08). Remarkably, 34DHPVL supplementation did reduce the glucose A.U.C but not significantly (p 
= 0.12). Additionally, 34DHPVL supplementation increased the dietary intake in mice with 
borderline significance to the non-supplemented HF diet fed mice (p = 0.07).  
Conclusion: EC significantly lowered plasma glucose and protected against HF diet induced weight 
gain compared to non-supplemented HF diet fed mice. On the other hand, 34DHPVL was not able 
to protect against body weight gain, and instead raised plasma insulin concentrations compared to 
non-supplemented HF diet fed mice, which is suggestive of impaired hepatic insulin clearance. 
Regardless, the reduced blood glucose A.U.C in 34DHPVL supplemented HF diet fed mice showed a 
response to the raised insulin which was indicative of an improved insulin sensitivity compared to 
non-supplemented mice. Because this is the first study of its kind to feed HPVLs over a long 
intervention period to mice, there is a requirement for further research in-order to understand the 
mechanisms underlying HPVL’s actions, nonetheless, this study has proved to be hypothesis 





Overweight and obesity is a worldwide health concern and it is predicted to affect 18 % of men and 
21 % of women at a global level by 2025 (326) and 8 % of the UK by 2035 (327). Obesity increases 
the prevalence for cardiovascular disease, cancer risk, mobility problems, osteoarthritis, mental 
illnesses, and type-2 diabetes (328-333). Lifestyle factors can influence the development of these 
conditions and diet is a major influencing factor that can drive or mitigate against the development 
of type-2 diabetes. Type-2 diabetes is a reversible condition and dietary polyphenols, in particular 
flavanols, have been shown to provide protection against insulin resistance (334-337). In chapter 
1, the pathogenesis of insulin resistance and the current evidence surrounding the actions of the 
flavanol EC and its actions in-vitro and in-vivo on insulin resistance were discussed in some detail, 
and only a brief re-visit will be provided here. The review of the literature on HPVLs was discussed 
extensively in chapter 1, but because there are no reported effects of HPVLs on insulin resistance, 
it can only be assumed that they will contribute to the protective effects seen by EC against insulin 
resistance.   
 
3.2.1 The actions of (−)-epicatechin in the protection against insulin 
resistance 
EC constitutes around 37 % of flavanols in cocoa products (25, 26) and ~7 % in green tea (29, 30). 
Estimated consumption of flavonoids is around 400 mg/day, of which an estimated 25 mg/day is 
attributed to EC, with growing evidence for flavonoids role, and more particularly ECs role, in 
preventing the onset of insulin resistance (301-305). In high fat diet fed mouse models, the 
consumption of EC at doses of 1-200 mg/kg body weight has been shown to significantly mitigate 
body weight gain and insulin resistance that are induced by consumption of the high fat diets (127, 
129, 130, 224, 227). Blood glucose and insulin have been primarily recorded through performing 
GTT’s in the fasted state, and later allows for the calculation of the HOMA-IR and the area under 
the concentration over time curves, providing clear metrics to quantify the level of insulin 
resistance. Rat models have also been used and the reported results mirror the effects of EC for 
improving insulin sensitivity (226, 338).   
In a human intervention study, EC consumption of 100 mg/day for 4-weeks by overweight and 
normal weight subjects caused a reduction in their HOMA-IR and concomitantly an improvement 
in their insulin sensitivity when compared to placebo treated controls (233). Meanwhile, one-time 




towards sustained fat oxidation by EC post prandially, but the effects were seen to be greater in 
overweight versus normal weight subjects (234).  
Investigative studies have been performed to identify the mechanistic actions of EC. These have 
been accomplished through the analysis of protein/mRNA expression in the liver and adipose 
tissues from rodent models and from in-vitro cell culture models in HepG2 (liver), 3T3-L1 (adipose) 
and INS-1E (β islet) cells. EC has been shown to negate the redox potential in cells, largely through 
preventing the activation of c-Jun N-terminal kinase 1/2 (JNK) or of the inhibitor nuclear factor κB 
(IκB) kinase (IKK) (129, 338) which are increased during inflammation, subsequently preventing 
redox induced phosphorylation of IRS-1 and so preventing inhibition of the insulin signalling 
pathway (339, 340). Further, EC has been shown to interact with protein kinase C which also 
exhibits redox sensitivity and further phosphorylates IRS-1, but EC has been demonstrated to 
prevent this (338).  
Inflammation is also a big driver for the development of insulin resistance, largely through the 
activation of nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB). EC has been 
demonstrated to inhibit NF-κB activation in metabolic tissues, and consequently caused a reduction 
in the inflammatory markers TNF-α and monocyte chemo-attractant protein-1 (MCP-1) (229, 338). 
Other mechanisms by which EC may impact upon insulin resistance is through the modulation of 
intestinal permeability via the prevention of high fat diet-induced paracellular transport and 
endotoxemia which could in part contribute to the improvement of insulin sensitivity (130); and by 
EC directly targeting the stimulation of glucose regulating proteins via an increase in the levels and 
activation of insulin signalling AMPK, IR and IRS-1 (129, 285, 341) and decreasing the levels of the 
gluconeogenic enzyme PEPCK (341). Finally, EC treatment with INS-1E cells enhanced insulin 
secretion through a CaMKII dependent mechanism (293).  
Overall, the existing published evidence supports the beneficial effects of EC on insulin resistance 
is strong and that is the basis of the research described in this chapter which seeks, for the first 
time, to investigate the potential role of gut microbiota-derived metabolites of EC in mitigating 




3.3 Aims and approach 
HPVLs are the most concentrated group of colonic metabolites generated by EC metabolism that 
enter the circulatory system. Because of our lack of understanding surrounding what the bioactive 
metabolites from EC are with regards to disease protection, and specifically for mitigating the onset 
of type-2 diabetes, it is necessary to investigate this using a targeted approach. The overall objective 
approached was to directly compare the effects of EC with its main microbial metabolite, 34DHPVL, 
on insulin resistance in a high-fat diet fed mouse model of type-2 diabetes. The key aspects of the 
study design were to:  
(1) Induce insulin resistance in mice by feeding a 60 % kcal HF diet from fat and comparing 
against a control 10 % kcal LF diet from fat over a course of 15-weeks.  
(2) Measure differences in body weight and insulin resistance caused by supplementation 
of the diet with 20 mg/kg body weight of EC in mice. 
(3) Determine the effects of supplementation of the diets with 20 mg/kg body weight of 
34DHPVL on body weight and insulin resistance and compare the effects with EC.  
The resulting data was used to address the following questions: 1) does EC dietary supplementation 
significantly mitigate against HF diet induced insulin resistance and body weight gain? 2) Does direct 
dietary supplementation with the microbial metabolite 34DHPVL significantly improve insulin 
resistance and body weight gain induced by the HF diet? 3) Does dietary supplementation with EC 
or 34DHPVL improve the glycaemic index when supplied in the LF (high carbohydrate) diet and 
compared to the LF treatment group? The following linked hypotheses were addressed by this 
research:  
(1) Both EC and 34DHPVL significantly mitigates HF diet induced body weight gain in mice.  





3.4.1 Synthesis of 3’,4’-dihydroxyphenyl-γ-valerolactone  
34DHPVL was synthesised by an in house synthetic organic chemist (Dr Paul Needs, Quadram 
Institute Bioscience, UK) using a modified version of that published by Chang et al (300) (Figure 3.1). 
Full details can be found in Hollands et al (2020) (2).  
 
 
3.4.2 Preparation of mouse pellets 
(−)-Epicatechin was purchased from Toronto Chemicals (Ontario, Canada) and 34DHPVL was 
synthesised in house as previously described (see section 3.4.1). The diets were prepared with help 
from Research Diet Inc (New Jersey, USA) according to the formulations described in Table 3.1. 
Formulations were such that low-fat diets contained 10 % kcal energy from fat (fat: lard and 
soybean oil) (Research Diets D12450 J) and high-fat diets contained 60 % kcal energy from fat, an 
increase in the saturated fat from lard (Research Diets D12492). The amount of compound required 
was calculated based on the estimated average daily food consumption of 3.5 g per mouse and to 
Figure 3.1: Synthetic steps to produce 5-(3’,4’-dihydroxyphenyl)-γ-valerolactone 
Initially, 2-triisopropylsilyloxyfuran was prepared, with high yields from purification and distillation. The 
intermediate 2-[(3,4-dibenzyloxyphenyl)-triisopropylsilyloxy-methyl]-2H-furan-5-one was isolated as a 
diastereomeric mixture and purified before conversion to 5-(3’,4’-dihydroxyphenyl)-γ-valerolactone via 5-
[(3,4-dibenzyloxyphenyl)methylene]furan-2-one. The above image has been edited from that published by 
Hollands et al (2020) (2) with permission. All synthetic steps were performed by Dr Paul Needs, Quadram 




contain 20 mg/kg body weight of either EC or 34DHPVL. In total this accounted to 200 mg 
compound/kg diet when using Formula 3.1. Please see Table 3.1 for the complete ingredient list for 
each of the six different diets. Pellets were slow dried during formulation to reduce the risk of 
compound breakdown and were then sealed in airtight bags and irradiated for sterility at 10-20 
kGy.  
 
Table 3.1: Dietary constituents of mouse pellets 
This table has been taken directly from the pellet manufacturer Research Diets (US). 
Product LF HF 
LF + 200 
mg/kg diet 
34DHPVL 
HF + 200 mg/kg 
diet 34DHPVL 
LF + 200 
mg/kg diet EC 
HF + 200 
mg/kg diet 
EC 
 D12450 J D12492 Formula 1 Formula 2 Formula 3 Formula 4 
% g kcal g kcal g kcal g kcal g kcal g kcal 
Protein 19 20 26 20 19 20 26 20 19 20 26 20 
Carbohydrate 67 70 26 20 67 70 26 20 67 70 26 20 
Fat 4 10 35 60 4 10 35 60 4 10 35 60 
Total  100  100  100  100  100  100 
kcal/gm 3.8  5.2  3.8  5.2  3.8  5.2  
 
Ingredient g kcal g kcal g kcal g kcal g kcal g kcal 
Casein 200 800 200 800 200 800 200 800 200 800 200 800 







0 0 506.2 
202
5 
0 0 506.2 2025 0 0 
Maltodextrin 
10 
125 500 125 00 125 500 125 500 125 500 125 500 
Sucrose 68.8 275 
68.
8 





Cellulose 50 0 50 0 50 0 50 0 50 0 50 0 
 
Soybean Oil 25 225 25 225 25 225 25 225 25 225 25 225 










Table 3.1: Dietary constituents of mouse pellets (continued) 
Product LF HF 
LF + 200 
mg/kg diet 
34DHPVL 
HF + 200 
mg/kg diet 
34DHPVL 
LF + 200 
mg/kg diet EC 
HF + 200 
mg/kg diet 
EC 
 D12450 J D12492 Formula 1 Formula 2 Formula 3 Formula 4 
% g kcal g kcal g kcal g kcal g kcal g kcal 
DiCalcium 
Phosphate 
13 0 13 0 13 0 13 0 13 0 13 0 
Calcium 
Carbonate 
5.5 0 5.5 0 5.5 0 5.5 0 5.5 0 5.5 0 
Potassium 











10 40 10 40 10 40 10 40 10 40 10 40 
Choline 
Bitartrate 
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34DHPVL 0 0 0 0 0.212 0 0.155 0 0 0 0 0 
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Formula 3.1: Formula to calculate the required pellet concentrations of EC or 34DHPVL 
DD: Diet dose; SD: Single daily dose; BW: Body weight; FI: Daily food intake. For this study, values had the 
following input: SD = 20 mg compound/kg body weight; BW = 35 g; FI= 3.5 g diet/day. Resulting in DD = 200 
mg compound/kg diet. 
 
3.4.3 Power calculation  
Cremonini et al (127) have reported a mouse dietary intervention study feeding C57BL/6J mice EC 
at 20 mg/kg body weight in combination with a low-fat (10 % kcal) or high-fat (60 % kcal) diet for 
15-weeks (N = 10). They reported that EC supplemented into HF diet fed mice improved insulin 
sensitivity (measured by a glucose tolerance test) compared to non-supplemented controls, and 
this did so with a power of 50 %. This study was therefore used as a backbone to perform a power 
calculation to identify the numbers of mice required in the current study presented in this chapter.  
Power calculations were performed using R Studio (version 3.6.1) with an effect size of 0.9829, a p-
value of 0.05 and a power of 60 %. This computed a minimum mouse number of 12 mice per group. 
However, the batch differences in the mice arrivals meant there were uneven housing numbers of 
2, 3 or 5 mice per cage with a total of 12-14 mice per group (specified in section 3.4.4).  
 
3.4.4 Study design  
All experiments described here were performed in compliance with the European Union regulations 
concerning the protection of experimental animals and with the UK Home Office Animals (Scientific 
Procedures) Act of 1986 under personal license I39D37621 and project license 70/8710.   
Eighty healthy C57BL/6J male mice, aged 6-weeks, were purchased from Charles River, UK, and 
batches delivered every two weeks for a total of seven batches. They were acclimatised on chow 
diet RM3 (SDS Special diet services, UK) as supplied by the housing facility for 2-weeks. At 8-weeks 
of age, all mice were placed on a low-fat diet (10 % kcal) (LF) for 2-weeks. At 10-weeks of age, all 
mice were placed onto their respective intervention diets for 15-weeks: LF (14 mice), LF 
supplemented with 20 mg/kg body weight EC (LF+EC) (13 mice), LF supplemented with 20 mg/kg 
body weight 34DHPVL (LF+34DHPVL) (13 mice), high-fat (60 % kcal) (HF) (14 mice), HF 
supplemented with 20 mg/kg body weight EC (HF+EC) (12 mice) or HF supplemented with 20 mg/kg 
body weight 34DHPVL (HF+34DHPVL) (14 mice), see Table 3.1 for formulations. Body weight and 




Housing conditions consisted of between 2, 3 or 5 mice per cage and were kept in ventilation at 22 
± 2 °C with 55 ± 5 % humidity and 12-hour light-dark cycles. Mice cages were checked daily, and 
bedding and water was changed weekly by housing facility staff. Pellets were kept in the cage 
hoppers and freshly supplied every 2-3 days with continuous monitoring of cage consumption by 
weighing the amount consumed and subtracting this from the amount provided. All procedures 
throughout the study were performed in ventilated cabinets.  
 
3.4.5 Glucose tolerance test and plasma glucose and insulin recording 
During the 13th week of the intervention, mice were fasted for 16-hours overnight. Tails were locally 
anaesthetised using a lidocaine spray (Intubeaze® spray; Chapelfield Veterinary Partnership, UK) 
before bloodletting. An approximate 3 mm of tail length was cut and removed and allowed for 
blood sampling. Prior to glucose injection (0 mins), blood was collected into Microvette 200 μL EDTA 
blood collection tubes (Sarstedt, Germany, cat: 20.1288.100) and blood glucose concentration was 
recorded using a glucometer (Alphatrak 2 Starter Kit, Animed Direct, UK, cat: 15089). A 20 % D-
glucose (Sigma, UK, cat: G8270) solution was prepared with PBS, and filtered (0.22 μm) on the same 
day as use. The glucose tolerance test (GTT) was then performed by intraperitoneally injecting the 
mice with the prepared glucose at 2 g /kg body weight, calculated as per Formula 3.2: 
 
𝜇𝐿 of 20 % solution to inject =  10 × 𝐵𝑜𝑑𝑦 𝑊𝑒𝑖𝑔ℎ𝑡 (𝑔) 
Formula 3.2: Calculating the volume of 20 % glucose solution to inject into mice 
 
Glucose was administered via a 27G ½” BD Precision Glide syringe needle (Sigma, UK, cat:Z192384). 
Blood was then drawn by stroking the tail in a downwards direction and blood glucose was recorded 
at 15, 30, 60 and 120-mins post-injection, and blood was collected. Collected blood samples were 
centrifuged at 2000 g for 15 mins at 4 °C to collect the serum and immediately stored at -80 °C until 
use. 
For intraperitoneal injection, mice were held via a tight scruff and turned onto their backs with head 
angling towards the ground at around a 60° angle. Their hind limbs would splay out, leaving enough 
room to inject into the intraperitoneal sack. Prior to needle removal, a light twist was performed to 




To record plasma insulin from the GTT, an Insulin ELISA (Crystal Chem, Netherlands, cat:90080) was 
performed as per the manufacturer’s protocol. Insulin concentrations in ng/mL were converted to 
mIU/mL (milli insulin units per millilitre) by using Formula 3.3 (342). The homeostatic model of 
insulin resistance (HOMA-IR) was later calculated using Formula 3.4 according to Matthews et al 










































) × 𝐺0 (𝑚𝑀)
22.5
 
Formula 3.4: HOMA-IR formula 













Formula 3.5:QUICKI formula 
I0: is fasting plasma insulin, G0: is fasting plasma glucose (344). 
 
3.4.6 Terminal anaesthesia and tissue harvest 
Mice were sacrificed by cardiac puncture and PBS perfusion at 15-weeks into the intervention. This 
was performed by the described procedures in chapter 2, section 2.4.5 without urine collection. All 
blood collections were centrifuged at 2,000 g for 15 mins at 4 °C to collect the serum and stored at 




Tissues were harvested immediately after cardiac puncture as per Table 3.2, these included: liver, 
brain, prostate, duodenum, jejunum, ileum, colon, aorta, epididymal fat, inguinal fat, and brown 
adipose tissue. 
 
Table 3.2: Tissues harvested from C57BL/6J mice and their storage conditions 
Tissue Storage 
Liver • RNA later and stored at -40 °C 
• Snap frozen in liquid nitrogen and stored at -80 °C 
• Formalin 24-48 hours, 50 % ethanol for up to 2-weeks, embedded in paraffin and stored at 4 
°C 
• Formalin 24-48 hours, 15 % sucrose until sunken, 30 % sucrose until sunken, OCT embedded, 
stored at -80 °C 
Aorta • RNA later and stored at -40 °C 
• Formalin 24-48 hours, 70 % ethanol for up to 2-weeks, embedded in paraffin and stored at 4 
°C 
• OCT embedded, stored at -80 °C 
Inguinal Fat • RNA later and stored at -40 °C 
• Formalin 24-48 hours, 70 % ethanol for up to 2-weeks, embedded in paraffin and stored at 4 
°C 
• Snap frozen in liquid nitrogen and stored at -80 °C 
Epididymal Fat • RNA later and stored at -40 °C 
• Formalin 24 - 48 hours, 70 % ethanol for up to 2 weeks, embedded in paraffin and stored at 4 
°C 
• Snap frozen in liquid nitrogen and stored at -80 °C 




• RNA later and stored at -40 °C 
• Snap frozen in liquid nitrogen and stored at -80 °C 
Brain • Snap frozen in liquid nitrogen and stored at -80 °C 
Duodenum • RNA later and stored at -40 °C 
• Snap frozen in liquid nitrogen and stored at -80 °C 
• Formalin 24-48 hours, 50 % ethanol for up to 2-weeks, embedded in paraffin and stored at 4 
°C 
• Formalin 24-48 hours, 15 % sucrose until sunken, 30 % sucrose until sunken, OCT embedded, 
stored at -80 °C 
Jejunum • RNA later and stored at -40 °C 
• Snap frozen in liquid nitrogen and stored at -80 °C 
• Formalin 24-48 hours, 50 % ethanol for up to 2-weeks, embedded in paraffin and stored at 4 
°C 
• Formalin 24-48 hours, 15 % sucrose until sunken, 30 % sucrose until sunken, OCT embedded, 




Table 3.2: Tissues harvested from C57BL/6J mice and their storage conditions (continued) 
Tissue Storage 
Ileum • RNA later and stored at -40 °C 
• Snap frozen in liquid nitrogen and stored at -80 °C 
• Formalin 24-48 hours, 50 % ethanol for up to 2-weeks, embedded in paraffin and stored at 4 
°C 
• Formalin 24-48 hours, 15 % sucrose until sunken, 30 % sucrose until sunken, OCT embedded, 
stored at -80 °C 
Colon • RNA later and stored at -40 °C 
• Snap frozen in liquid nitrogen and stored at -80 °C 
 
 
3.4.7 Statistical Calculations 
All statistical calculations were performed in R Studio, version 3.6.1. Linear mixed models were used 
through packages “lme4” (345) and “nlme” (346) with cage effects introduced as a random variable. 
Once a linear model was designed, residual variances were checked using “plot(linearmodel)”, and 
checked for group residual variances by adding the diet (treatment) as an aesthetic:  
data$residuals, <- resid(linearmodel)                                                                                                 
ggplot(data , aes(y=residuals, x=treatment)) + geom_point() 
Normality of the residuals was determined using “qqnorm(resid(linearmodel))”. Only once the 
linear model assumptions were met (normally distributed residuals, equal variance distribution 
across all groups) was then “lme4::lmer” applied. If residuals were normally distributed but distinct 
differences across group residuals occurred, then “nlme::lme” was used to allow for a grouping 
factor for unequal residual variance, “weights=varIdent(form=~1|HFvsLF)”. If, however, none of the 
above were met and grouping for unequal variance did not improve the residual scatter, then the 
data was transformed as specified in Table 3.3 and applied to the same methods. Statistically 
significant p-values were obtained through default methods ‘Sattherthwaite’, however ‘Kenward-
Roger’ was also examined to determine if values were distinctly different, this was not the case for 





Table 3.3: Transformations made on the data for statistical analysis and the linear model R package used 
Mouse Measurement Transformation R package used 
Carbohydrate consumption Log10 lmer 
Fat consumption Log10 lmer 
FER Log10 nlme 
Body weight N/A nlme 
Liver weight N/A nlme 
Epididymal weight N/A nlme 
Glucose data N/A nlme 
Insulin data N/A nlme 









3.5.1 (−)-Epicatechin but not 3’,4’-dihydroxyphenyl-γ-valerolactone 
supplementation inhibited high-fat diet induced body weight gain in mice 
Body weight was continuously monitored throughout the 15-week dietary intervention study to 
determine whether the different diets influenced body weight gain. Table 3.4 displays the final 
weights for each dietary group and Figure 3.2 shows the overall change in body weights throughout 
the intervention period. Before the mice commenced the intervention, they weighed an average of 
24.62 ± 1.32 g, this was regardless of the different batch arrivals of mice over several weeks. At the 
end of the 15-week intervention, all mice on diets of LF, LF+EC and LF+34DHPVL had consistent 
body weights within 1-2 g of each other, and thus the supplementation of EC or 34DHPVL into low 
calorie diets did not influence changes in body weight between groups. 
For LF diet fed mice, at the end of the study they had gained 5.78 ± 1.43 g in weight from when they 
commenced the study, whereas HF diet fed mice gained 23.4 ± 3.59 g in weight (Figure 3.2 B). For 
the mice on HF diets supplemented with or without compound, they weighed significantly more 
than all LF dietary intervention fed mice (p < 0.0001), gaining an average of 0.176-0.223 g in body 
weight per day when compared to LF intervention fed mice (0.049-0.055 g body weight gain per 
day) at the end of the study. HF diet fed mice supplemented with EC weighed significantly less than 
HF diet fed mice (43.18 ± 6.59 g versus 47.92 ± 3.80 g, p = 0.028, respectively), showing that an 
effect of EC supplementation was bioprotective against high-fat diet induced body weight gain. In 
contrast, 34DHPVL supplemented into HF diet fed mice did not affect body weight gain when 
compared to non-supplemented controls (46.43 ± 1.94 g), and so, HPVLs did not contribute to the 
protective effects seen by EC consumption on body weight.  
Figure 3.2: Mouse body weight data 
A) Body weights of each dietary intervention group over the 15-week intervention; B) Body weight gain in 
mice over 15-weeks of dietary intervention, each point represents an individual mouse. All errors bars 
represent standard error. Significance ***p < 0.001, ****p < 0.0001 compared to LF diet.  + p < 0.05 




Table 3.4: Mouse weights and dietary consumption data 
Unless otherwise specified, all weights presented are final values at the end of the 15-week intervention. Food 
intake and food efficiency ratio (FER) are calculated as average intakes over the entire 15-weeks. All errors 
represent standard deviation. Significance *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 compared to 
LF diet.  + p < 0.05, ++++ p < 0.0001 compared to their respective controls (HF with supplements are compared 
to HF, LF with supplements are compared to LF). 
 
LF LF+EC LF+34DHPVL HF HF+EC HF+34DHPVL 
Initial body 
weight (g) (week 
0) 
24.8 ± 1.07 24.4 ± 1.37 24.7 ± 1.68 24.5 ± 1.04 24.7 ± 1.73 24.6 ± 1.54 
Final body weight 
(g) 
30.7 ± 1.20 29.5 ± 1.83 30.2 ± 2.48 
47.9 ± 3.80 
**** 
42.4 ± 6.59 




0.06 ± 0.01 0.05 ± 0.01 0.05 ± 0.02 
0.22 ± 0.03 
**** 
0.18 ± 0.05 
****+ 
0.21 ± 0.06**** 
Food intake 
(g/mouse/day) 
3.10 ± 0.21 3.13 ± 0.07 2.86 ± 0.28++++ 
2.67 ± 0.16 
**** 2.60 ± 0.13




11.8 ± 0.47 11.8 ± 0.77 
10.5 ± 0.76 
++++ 
13.9 ± 0.83 
**** 
13.7 ± 0.69 
**** 
14.4 ± 0.89 
+**** 
EC or 34DHPVL 
consumption 
(mg/mouse/day) 
- 0.62 ± 0.04 0.55 ± 0.04 - 0.52 ± 0.03 0.55 ± 0.03 
FER 1.75 ± 0.22 1.56 ± 0.22 1.87 ± 0.25 
8.06 ± 1.06 
**** 6.15 ± 1.36
**** 7.31 ± 2.44**** 
Liver weight (g) 1.26 ± 0.24 1.21 ± 0.20 1.17 ± 0.19 
1.79 ± 0.39 
** 1.57 ± 0.35 1.93 ± 0.64
*** 
Liver weight to 
body weight ratio 
0.04 ± 0.01 0.04 ± 0.01 0.04 ± 0.01 0.04 ± 0.01 0.03 ± 0.01 0.04 ± 0.01 
Epididymal 
weight (g) 
0.74 ± 0.30 0.54 ± 0.12 0.70 ± 0.31 
2.60 ± 0.39 
**** 
2.39 ± 0.81**** 2.18 ± 0.66**** 
Epididymal 
weight to body 
weight ratio 
0.02 ± 0.01 0.02 ± 0.00 0.02 ± 0.01 
0.06 ± 0.01 
**** 0.06 ± 0.02
*** 0.05 ± 0.01** 
 
 
3.5.2 High-fat consumption caused significant weight increases in the liver 
and epididymal adipose tissues compared to the low-fat treatment group  
At the point of sacrifice, livers and epididymal fat mass from the mice were weighed. This helped 
to identify whether the different interventions caused weight changes in these internal organs and 
whether these organs were responsible for the differences seen in final body weights.  
For HF diet fed mice, their livers weighed an average of 1.79 ± 0.39 g, and this was significantly 




EC was supplied into the HF diet (1.57 ± 0.35 g), whereas liver weight gain was higher when 
34DHPVL was supplied into the HF diet (1.93 ± 0.64 g), but the differences by either supplement 
were not significant (Figure 3.3 A, Table 3.4). For EC supplemented into HF diet fed mice and 
compared to LF non-supplemented mice, there was borderline significance between their liver 
weights (p = 0.0786). Therefore, EC supplementation does appear to have a modest effect in 
inhibiting liver weight gain by 12 % from fat.  
Liver to body weight ratio was also calculated to understand whether liver weight gain in HF diet 
fed mice occurred irrespective of body weight gain. However, the consistent mean data values 
across all dietary interventions (Figure 3.3 B) suggests that liver weight gain occurred because of 
body weight gain, i.e. EC mitigated liver weight gain in HF diet fed mice when compared to HF 
controls because they had a reduction in body weight. 
Surprisingly, EC supplementation into the HF diet caused no significant reduction in epididymal 
adipose weight, when compared to the non-supplemented diet (2.39 ± 0.81 g versus 2.60 ± 0.39 g, 
p = 0.29), (Figure 3.3 C). The same was true for 34DHPVL supplemented into HF diet fed mice, 
although the mean was lower compared to the HF diet fed mice, the high variance likely prevented 
a significant effect from being detected (2.18 ± 0.66 g, p = 0.16). Furthermore, for all HF intervention 
fed mice, their epididymal mass to body weight ratio was significantly higher than the LF fed mice 
(Figure 3.3 D). This suggests that all HF fed mice stored the extra calories they consumed as white 
adipose tissue.  
Regression analyses were performed to determine whether a correlation existed between liver 
weight or epididymal weight to body weight (Figures 3.3 E/F) to identify whether body weight 
caused an increase in weight of these tissues. The results highlight a strong positive correlation for 
both liver weight (p < 0.0001, R2 = 0.64) and epididymal weight (p = 0.0001, R2 = 0.74) to body 
weight.  
Finally, changes in the weights of the livers of LF diet fed mice supplemented with 34DHPVL or EC 





Figure 3.3: Epididymal adipose and liver tissue weights from mice 
All weights were recorded at the point of sacrifice. A) Final liver weights; B) Liver weight to body weight ratio; 
C) Epididymal adipose tissue weight; D) Epididymal adipose tissue weight to body weight ratio; E) Regression 
analysis for liver weight and body weight; F) Regression analysis for epididymal weight and body weight. Each 
point represents an individual mouse on that respective diet. Bars represent 95 % confidence intervals with 




3.5.3 Mice on low-fat diets consumed more food compared to those on high-
fat diets 
Cage food consumption was monitored throughout the duration of the intervention study. It was 
anticipated that this data would be useful in the interpretation of differences between diets in the 
weight gain observed, i.e. were differences in weight gain correlated with the rates of food 
consumption.  
For LF diet fed mice, food consumption was higher by 0.24-0.54 g/mouse/day than mice on the HF 
fed diet (3.10 ± 0.21 g/mouse/day versus 2.67 ± 0.16 g/mouse/day, p < 0.0001, respectively) (Table 
3.4), which suggests that satiety was reached earlier on from the HF diet. The same was true for 
mice on LF diets supplemented with EC but not for those supplemented with 34DHPVL where their 
food intake was reduced (2.86 ± 0.28, p < 0.0001) by an average of 0.26 g/mouse/day when 
compared to LF diet only fed mice. An assumption made to understand this could be that 34DHPVL 
influenced the palatability of the LF diet (possibly bitterness), or because it caused satiety to be 
reached earlier. In contrast, 34DHPVL supplemented into the HF diet caused mice to consume more 
food than those on the non-supplemented diet, but with borderline significance (p = 0.065). It is 
possible that the greater lard content of the HF diet compared to the LF diet overcame the potential 
palatability issue with 34DHPVL (similar to the situation with chocolate where the fat and sugar 
mask the bitterness of the cocoa polyphenols). However, because of the differences in dietary 
consumption across the groups, the mass of polyphenol consumption was different in all 
supplemented groups, refer to Table 3.4 for values.  
Figure 3.4 A shows a graph of the nutritional intake following each dietary intervention. For all HF 
dietary interventions, the mice consumed significantly more protein (p < 0.0001), more calories (p 
< 0.0001), more fat (p < 0.0001) and less carbohydrates (p < 0.0001), compared to LF diet fed mice. 
34DHPVL supplemented into the HF diet caused a significant increase in calorie and protein intake 
compared to non-supplemented mice, which is due to the greater food consumption observed for 
mice in this group. However, because mice on the diet of 34DHPVL supplied in combination with 
the LF diet consumed less food compared to the LF control, this was also accompanied by a 
significant reduction in their calorie (p < 0.0001), protein (p = 0.0002), carbohydrate (p < 0.0001) 
and fat (p < 0.0001) intake, nevertheless this caused the consumption in the amount of 34DHPVL 
to be equal in both the LF and HF supplemented diets (0.55 ± 0.04 mg). 
The average daily consumption of EC and 34DHPVL in mice was between 0.52-0.62 mg/day, which 
when converting to a human equivalent dose using the reverse of Formula 2.1 in chapter 2, section 




(for 70 kg person body weight). Humans in Europe consume an average daily EC dose of 24 mg/day 
(306), but there is large interindividual and intercountry variation where doses are shown to exceed 
100 mg/day as discussed by Vogiatzoglou et al (306). The amount consumed by mice in this study 
therefore reflects a physiological amount consumed in humans, especially those consuming a 
variety of food sources high in polyphenols. 
To determine how efficient the mice were at converting their food intake into body weight, a feed 






Formula 3.6: Feed efficiency ratio calculation 
 
The results showed that all HF dietary intervention fed mice had a significantly higher FER when 
compared to LF fed mice (Figure 3.4 B, Table 3.4), and so smaller quantities of food intake resulted 
in greater mass gain. Furthermore, the addition of either EC or 34DHPVL into either HF or LF diets 





Figure 3.4: Mice dietary consumption data 
A) Average dietary intake for all groups over the 15-week intervention. Values were calculated from the 
nutritional information of the food pellets; error bars represent standard error. B) Feed efficiency ratio dot plot, 
each point represents the average of a cage in the respective dietary group. Bars represent 95 % confidence 
interval with mean. Significance **** p < 0.0001 compared to LF diet. + p < 0.05, +++ p < 0.001, ++++ p < 0.0001 
compared to their respective controls (HF with supplements are compared to HF, LF with supplements are 




3.5.4 (−)-Epicatechin but not 34DHPVL supplementation of high-fat diet fed 
mice caused an improvement in insulin sensitivity compared to high-fat 
controls 
Glucose tolerance tests (GTT) were performed in week-13 of the intervention by supplying a 2 g/kg 
body weight bolus glucose dose to the mice and measuring their blood glucose and insulin levels 
over time; if they re-established baseline blood glucose levels within 2-hours, then this was 
indicative of a good response to insulin. The test provided a measure for insulin resistance, where 
the HOMA-IR and QUICKI was calculated. This test allowed for the identification of whether EC or 
34DHPVL protected against HF diet induced insulin resistance.  
Initial results demonstrated that mice on all LF dietary interventions responded quicker in returning 
their glucose levels than all mice on HF dietary interventions, Figure 3.5 A. Despite all mice having 
received the same dose of glucose at 2 g/kg body weight, the mice on all LF dietary interventions 
achieved a lower glucose Cmax (maximum concentration) than all mice on the HF dietary 
interventions, (Table 3.5). This indicated that all LF diet fed mice were receptive to the low 
concentration of insulin released (Figure 3.6 A) to prevent rises in blood glucose. Blood glucose 
levels in all LF dietary intervention treatment groups rapidly declined between 30-60 mins post-
injection, and so they responded quickly in returning glucose homeostasis.  
The supplementation of 20 mg/kg body weight EC into LF diet fed mice caused a significant 
reduction in the glucose area under the curve (A.U.C) when compared to the non-supplemented 
group (1824 ± 24 mmol/L versus to 2221 ± 394 mmol/L, p = 0.028, respectively) (Figure 3.5 B); but, 
they did not release more insulin to cause this effect, and were thus insulin sensitive.  
In contrast, all HF diet fed mice exhibited significantly higher baseline glucose levels (67 ± 3 % more) 
when compared to the LF mice (p ≤ 0.006). Therefore, because they also exhibited significantly 
higher levels of blood insulin (p ≤ 0.002) (Figure 3.6 A), they were unable to respond to insulin in 
lowering blood glucose, which is a clear sign of insulin resistance. Immediately following the glucose 
injection in all HF intervention treatment groups, was a sharp rise in blood glucose where they had 
6.32-9.24 mmol/L higher glucose concentrations at the Cmax compared to LF diet fed mice. Blood 
glucose levels only started to decline in all HF treatment groups at 60 mins post-injection, which 
was significantly delayed compared to LF diet fed mice. At 120 mins following the glucose dose, HF 
diet fed mice reduced their blood glucose levels by only 14  ± 7 % (a drop in 4.92 mmol/L) from their 




dietary fed mice. Thus, HF diet fed mice struggled to restore baseline blood glucose levels, and as a 
consequence of this there was a 73 % higher glucose A.U.C compared to LF diet fed mice. 
The addition of EC or 34DHPVL into the HF diet was associated with an improvement in the lowering 
of blood glucose compared to non-supplemented mice. All HF diet fed mice expressed similar 
baseline glucose levels, but, only EC supplemented into HF diet fed mice had significantly lower 
glucose levels from their Cmax (a reduction by 12.13 mmol/L) by the end of the test, when compared 
to HF diet fed mice. Additionally, this group also exhibited lower levels of blood insulin, which 
confirms that EC supplied in combination with the HF diet increased insulin sensitivity and 
ameliorated HF diet induced insulin resistance. Surprisingly, 34DHPVL supplied in combination with 
the HF diet caused mice to exhibit lower glucose concentrations throughout the GTT (borderline 
significance at 120 mins, p = 0.0609) in comparison to HF diet fed mice. This could be due to their 
significantly higher blood insulin levels observed throughout the test, i.e. even though high plasma 
insulin suggests they are insulin resistant, the fact that insulin levels are so high might mean that 
there is still an insulin response. Despite these results, there were no differences between the 
glucose A.U.C concentrations over time between HF fed mice with or without compound 
supplementation.  
Furthermore, LF dietary fed mice supplemented with 34DHPVL also displayed lower glucose levels 
during the test than LF fed mice, and they expressed significantly higher baseline insulin levels. 
Therefore, the addition of 34DHPVL into low-fat or high-fat diets seemed to initiate similar effects. 
To identify whether blood glucose levels correlated with mice body weight, a regression analysis 
was performed using individual mouse blood glucose A.U.C values and their respective body 
weights at week-13 of the intervention (Figure 3.5 B). The results showed a strong positive 
correlation between the two variables, p = 0.0191, R2 = 0.67, i.e. an increase in body weight was 
strongly associated with an increase in blood glucose concentrations, such that heavier mice 











Table 3.5: Glucose and insulin values following GTT 
GTT was performed at week-13 of the dietary intervention study and insulin and glucose concentrations were 
recorded throughout the 120-minute experiment. Please refer to Figure 3. 5, Figure 3. 6 and Figure 3. 7 for the 
graphical illustrations. All values illustrated are means with standard deviation. Cmax: maximum concentration; 
Tmax: time to reach maximum concentration; A.U.C: area under curve values from the figures. Significance 
**** p < 0.0001 compared to LF diet. + p < 0.05, ++ p < 0.01 compared to their respective controls (HF with 
supplements are compared to HF, LF with supplements are compared to LF). 
 LF LF+EC LF+34DHPVL HF HF+EC HF+34DHPVL 
Glucose A.U.C 
(mmol/L) 
2221 ± 394 1824 ± 249+ 2029 ± 273 
3681 ± 419 
**** 
3635 ± 621 
**** 




26.9 21.3 23.0 36.1 35.2 33.2 
Glucose Tmax 
(mins) 
30 30 30 60 60 60 
Insulin A.U.C 
(ng/ml) 
24.4 ± 16.9 20.7 ± 5.07 32.2 ± 11.1 85.2 ± 31.8** 77.4 ± 36.9* 




0.26 0.21 0.30 1.07 0.82 1.60 
Insulin Tmax 
(mins) 
30 15 15 120 120 120 
HOMA-IR 0.58 ± 0.21 0.90 ± 0.20 2.30 ± 0.49 
12.2 ± 1.90 
**** 
6.74 ± 1.76** 
21.8 ± 3.61 
**** 
QUICKI 0.40 ± 0.07 0.44 ± 0.04 0.35 ± 0.01 0.28 ± 0.01*** 0.32 ± 0.02* 








3.5.5 Mice on diets supplemented with 3’,4’-dihydroxyphenyl-γ-
valerolactone exhibited significantly higher baseline insulin levels 
Insulin concentrations during the GTT were determined using an insulin ELISA kit and from the 
plasma samples harvested from the mice at recorded times.  
Before the test, baseline blood levels for mice on diets of EC in combination with LF, and LF, were 
at expected physiological levels, and slowly increased by 15-30 mins post-injection and declined 
Figure 3.5: Glucose data from the GTT 
GTT was performed in week-13 of the dietary intervention A) Glucose concentrations in plasma recorded for 120 
mins after the glucose injection. Statistical p-values for each comparison at specific time-points are displayed in 
the table beneath the graph: red values are statistically significant, green values are borderline significant, black 
values are of no significance; B) Regression line for glucose area under curve values against body weight, each 
point represents an individual mouse and the grey shading is the 95 % pointwise confidence interval; C) Area 
under curve (A.U.C) values from graph A for each dietary group. All graphical error bars represent standard error. 
Significance **** p < 0.0001 compared to LF diet. + p < 0.05, compared to their respective controls (HF with 




almost immediately back to baseline by 120 mins (Figure 3.6 A). This small change in insulin 
response reflects the high level of sensitivity of their insulin receptors to stimulate glucose uptake 
and induce glycogenesis.  
The baseline insulin levels for 34DHPVL supplemented LF diet fed mice were significantly higher by 
400 ± 500 % ( p = 0.002) than LF diet fed mice, and in addition, they expressed modest changes in 
their insulin levels after injection. It is possible that the mice fed the 34DHPVL supplemented LF diet 
exhibited more insulin to compensate for the high blood glucose levels that arose after food 
consumption, although this is unlikely because it was a fasted test. In contrast, EC supplemented LF 
diet fed mice did not exhibit alterations in insulin levels throughout the test, when compared to LF 
only fed mice, but they did respond better in restoring their glucose levels by the end of the GTT.  
All HF diet fed mice consistently exhibited much higher insulin levels at baseline and throughout 
the GTT. There was also a clear time lag of 60 mins for the mice to respond to the glucose and raise 
their insulin levels, consequently, the rise in insulin was not sufficient to restore baseline glucose 
levels by the end of the 2-hours. Overall, HF intervention fed mice expressed a total rise in insulin 
of 0.5 ± 0.16 ng/ml compared to the 0.2 ± 0.3 ng/ml rise from LF intervention fed mice. These results 
show that all the HF diet fed mice are insulin resistant, presumably because the pancreatic β-cells 
are overworked to produce insulin in order to restore glucose levels, or because 34DHPVL inhibits 
a regulator of insulin, but because the insulin receptors were desensitised, there was a reduced 
efficiency to restore blood glucose. 
The supplementation of EC in the HF diet of mice lowered baseline insulin levels (p = 0.18) and they 
responded more efficiently in lowering blood glucose levels by the end of the test compared to HF 
controls. Baseline insulin levels in 34DHPVL supplemented HF diet fed mice were significantly higher 
than the HF control (1.17 ± 0.68 ng/ml compared to 0.65 ± 0.31 ng/ml, p = 0.008, respectively), and 
this was despite an almost identical starting glucose concentration. The overall pattern in response 
to the glucose injection was very similar for 34DHPVL supplemented into HF diet fed mice and HF 
fed mice, where there was a total increase of 0.45 ng/ml insulin in both groups. However, because 
the experiment was stopped after 2-hours, it was not possible to determine where the end-point 
insulin Cmax levels were.  
To identify whether there was a correlation between insulin levels and body weight, a regression 
analysis was performed using the insulin A.U.C values for each mouse and their respective body 
weights at 13-weeks into the intervention (Figure 3.6 B). This showed there was a strong positive 




with higher blood insulin concentrations. The positive correlations for both glucose and insulin to 




Figure 3.6: Insulin data from the GTT 
GTT was performed during week-13 of the dietary intervention and insulin levels were recorded throughout. A) 
Insulin concentrations in plasma up to 120 mins after the glucose injection. Statistical p-values for each 
comparison and time point are displayed in the table beneath the graph: red values are statistically significant, 
green values are borderline significant, black values are of no significance; B) Regression line for insulin area 
under curve values against body weight, each point represents an individual mouse and the grey shading is the 
95 % pointwise confidence interval; C) Area under curve (A.U.C) values from graph A for each dietary group. All 
graphical error bars represent standard error. Significance * p < 0.05, ** p < 0.01, **** p < 0.0001 compared to 
LF diet. ++ p < 0.01, compared to their respective controls (with supplements are compared to HF, LF with 




3.5.6 (−)-Epicatechin supplemented high-fat diets caused an improvement in 
insulin sensitivity compared to high-fat diet fed mice 
The homeostatic model assessment of insulin resistance (HOMA-IR) is a model derived by 
Matthews et al (1985) (343) that has been approved to quantify the levels of insulin resistance; 
where scores lower than 2.5 are indicative of a ‘normal’ insulin response to glucose. Conversely, 
the quantitative insulin sensitivity check index (QUICKI) is a method to quantify insulin sensitivity 
as opposed to insulin resistance (344); where indexes > 0.382 classify non-obese subjects, ~ 0.331 
classifies obese subjects and < 0.304 classifies diabetic subjects (344). Blood insulin and glucose 
concentrations from the GTT were applied to these checks as per Formulas’ 3.3 and 3.4 in the 
methods section.  
Mice fed the EC supplemented LF diet or the non-supplemented LF control diet had HOMA-IR scores 
< 1.0 and QUICKI scores > 0.38 (Table 3.5, Figure 3.7), which are optimal scores that suggest a 
normal sensitivity to insulin. In contrast, mice fed the 34DHPVL supplemented LF diet exhibited 
early signs of insulin resistance, evidenced by a HOMA-IR between 1.9-2.9 (p for difference = 0.062, 
and QUICKI 0.29-0.43, p = 0.10) when compared to LF diet fed mice; this is mostly due to their 
higher blood insulin levels.  
Moreover, for mice on all HF interventions, they expressed a HOMA-IR > 2.9 and a QUICKI = 0.27, 
which was significantly higher when compared to LF diet fed mice (p ≤ 0.0002). Consequently, all 
HF diet fed mice exhibited insulin resistance. However, EC supplemented into the HF diet and 
compared to HF diet fed mice caused a reduction in the mean HOMA-IR score (6.74 ± 6.11 
compared to 12.23 ± 7.12, p = 0.072, respectively) (Figure 3.7). The large variance seen in the scores 
in this dietary group shows that the protection against insulin resistance afforded by consuming EC 
was greater in some mice more than others.  
The opposite of this was true for mice fed the 34DHPVL supplemented HF diet, which exhibited a 
HOMA-IR of 21.76 ± 13.52, and a mean QUICKI score of 0.27 (borderline significant compared to 
the HF only intervention group, p = 0.078). This would suggest that this group of mice were more 
insulin resistant. 
This study has provided novel data to show that 34DHPVL can promote higher blood insulin levels 
in both low and high calorie diets. Meanwhile, it has reinforced the existing published evidence 






Figure 3.7: Insulin resistance data 
Glucose and insulin concentrations from the GTT for each mouse were used to calculate: A) HOMA-IR 
(Formula 3.3) and B) QUICKI (Formula 3.4). Each point represents an individual mouse. Bars represent 95 % 





This research study was performed to investigate whether 34DHPVL could protect against high fat 
diet induced insulin resistance, and as such, whether HPVLs were the causative agents for the 
changes that ultimately manifest as improved sensitivity to insulin by EC consumption in high-fat 
diets. Subsequently, this work has shown that: 
(1) EC slowed the progression of insulin resistance in HF diet fed mice. 
(2) 34DHPVL supplementation of both HF and LF diets caused an increase in fasting baseline 
blood insulin levels when compared to their non-supplemented controls. 
(3) 34DHPVL supplementation of both HF and LF diets caused a better response to glucose 
challenge in lowering blood glucose when compared to their non-supplemented controls.  
(4) EC mitigated weight gain when supplemented into HF diet fed mice, whilst 34DHPVL did 
not. 
(5) Mice on LF diets consumed more food but less calories than mice on HF diets. 
(6) 34DHPVL affected the daily amount of food consumed in both HF and LF dietary fed 
mice. 
This is the first report describing how HPVLs, when provided directly in the feed of mice, induces 
the effects observed with relation to insulin resistance. As a result, this discussion will be largely 
focussing on how EC influences insulin resistance in mice, which can also drive hypothesised 
mechanisms for how 34DHPVL exerts the effects seen in the mice in this study, and more specifically 
how it could raise fasting insulin concentrations.  
 
3.6.1 How might 3’,4’-dihydroxyphenyl-γ-valerolactone raise baseline insulin 
concentrations? 
EC has been previously reported to protect against insulin resistance in HF diet fed mice/rat models 
and to mitigate the onset of weight gain (127, 129, 130, 224, 226, 227). However, due to the 
negligible concentrations of unmetabolized parent EC that enters a human’s circulatory system 
(347, 348) and the understanding that unmetabolized parent EC does not circulate in rodents (1, 
5), it is necessary to identify what the active EC metabolite(s) are. Because one third of EC 




the main objectives of this research was to investigate whether or not HPVLs are bioactive 
metabolites of EC.  
The prolonged consumption of a HF diet over time can cause obesity and insulin resistance, both 
hallmarks of metabolic syndrome (MetS) (349-352). MetS increases the incidence of metabolic 
associated fatty liver disease (MAFLD), itself caused by a series of inflammatory events that lead to 
dysregulation of liver functions and glucose metabolism (350). The study presented in this chapter 
reports a potential protective effect of HPVLs against HF diet induced insulin resistance, however, 
the results are inconclusive. HPVLs supplemented into the LF and HF diets caused lower glucose 
levels following a glucose challenge compared to their respective controls, however, the results 
were not statistically significant. These data suggests that HPVLs may be partly responsible for the 
beneficial effects of EC consumption on HF diet induced insulin resistance, but additional research, 
for example a more powerful study with greater numbers of mice than the one described here, and 
testing of more biological markers is necessary to generate further evidence to address this 
question. The HPVL fed mice also had much higher insulin concentrations than HF diet fed mice, 
consequently, the insulin sensitivity calculations provided poorer scores (HOMA-IR and QUICKI), 
which would normally be regarded as a sign of insulin resistance despite exhibiting lower glucose 
levels than their controls. Normally, a higher fasting insulin concentration implies that the β-cells 
are continually stimulated to secrete insulin and keep glucose levels down, but the responsiveness 
of the mice to the insulin in reducing glucose suggests that this might not necessarily be the case 
here. If the high insulin levels occurred because of impaired hepatic insulin clearance rather than 
hypersecretion by the pancreas, then this could favour the protection against insulin resistance. 
But, because this is the first study to provide 34DHPVL into the feed of mice and investigate insulin 
resistant effects, it has therefore proved to be hypothesis generating. 
There are several plasma markers that could have been assessed in this study to provide more 
information to explain the actions of 34DHPVL on raising fasting insulin concentrations, such as C-
peptides (hepatic insulin clearance marker), leptin (a marker that reduces gluconeogenesis and 
favours glucose uptake), and creatinine (kidney functions for urinary excretions), but aspartate 
transaminase/alanine transaminase (AST/ALT) levels are reviewed in chapter 4 with histology of the 
liver. However, because these effects were not anticipated, further plasma marker analysis was not 
performed. Because of this, a discussion of the current evidence that reports similar effects to those 
seen in this study will be considered.   
Following a randomised control study in humans of different ethnicities, it was reported that non-




Mexican American’s, despite no signs of diabetes and no family history of diabetes (353). But, by 
assessing plasma insulin and C-peptide concentrations, they could determine that the higher insulin 
concentrations were most likely due to insufficient insulin clearance via the liver because there was 
a correlation for high insulin to low C-peptide levels. Meanwhile in White and Mexican individual’s 
they expressed low insulin with high C-peptide levels. C-peptides and insulin are released from 
pancreatic β-cells at the same time in equimolar amounts (354), but C-peptides are metabolised by 
the kidneys whereas insulin is metabolised by the liver (355). Because of this, the low level detection 
of C-peptides and the high level detection of insulin implies that there was an impaired hepatic 
insulin clearance in non-Hispanic blacks (353). This study’s findings were also supported by Rossell 
et al (1983) (355) in obese subjects, where only obese individuals suffered from hyperinsulinemia 
and low C-peptide levels, and so expressed a low clearance of insulin by the liver. The rationale for 
this effect was suggested to be because when “the portal insulin concentration increases, the liver 
is incapable of increasing its capacity to remove insulin” (355). An even earlier study found similar 
findings for hyperinsulinemia accompanying low C-peptide levels in patients who suffered from 
liver cirrhosis, where their livers were so badly damaged that they encountered insufficient insulin 
clearance (354). And, when these patients blood glucose levels were examined, only cirrhotic 
subjects displayed significantly elevated blood glucose levels, however, the glucose levels and 
concentration of insulin secreted did not differ between the hyperinsulinemic and 
normoinsulinemic subjects (354). Furthermore, the effect of weight loss has been shown to 
increase hepatic insulin clearance and restore insulin sensitivity (356), and so demonstrating that 
these effects can be reversed. But, because C-peptide levels were not recorded in this current study, 
it is only a suggestion that 34DHPVL may impair insulin clearance, but it would support the evidence 
for the lower blood glucose and the higher insulin levels seen in the mice when compared to 
controls.  
If insulin clearance is impaired following 34DHPVL supplementation into the diet, then it could be 
eliciting actions through several processes. The impairment of insulin clearance can cause hepatic 
steatosis because chronic hyperinsulinemia can stimulate hepatic de novo lipogenesis (357-360), 
and therefore, the impairment of insulin clearance could be the link between hepatic insulin 
resistance and steatosis. High circulatory insulin concentrations can also cause the desensitisation 
and lysosomal degradation of the insulin receptor (361) via inactivating or deleting the glycoprotein 
‘carcinoembryonic antigen-related cell adhesion molecule 1’ (CEACAM1), that has a central role to 
promote hepatic insulin clearance (362). Chapter 5 discusses in detail the CEACAM1 gene 
expression changes by the dietary interventions. To summarise, there were marginal reductions in 




in its expression for EC supplemented into HF diet fed mice when compared to HF controls. 
Therefore, this data somewhat supports the notion that 34DHPVL impairs hepatic insulin clearance.  
In this current study, 34DHPVL supplemented into high fat diet fed mice expressed lower glucose 
levels throughout the GTT than their non-supplemented controls. This suggests a pre-diabetic state 
in this group of mice because they were still responsive to the rise in insulin by lowering their blood 
glucose, and they did so more rapidly than HF only fed mice. Because of this, it is hypothesised that 
34DHPVL supplemented into the diet of mice caused an impairment in insulin clearance through 
the inactivation or desensitisation of the CEACAM1 receptor, rather than the hypersecretion of 
insulin. This effect over time would cause insulin resistance and type-2 diabetes, which was seen 
by the poorer response of the mice to lower blood glucose than LF diet fed mice (363). Finally, 
because impaired insulin clearance is also inversely correlated with liver lipid accumulation (364), 
this could help to explain why 34DHPVL supplemented into HF diet fed mice expressed higher liver 
lipids (as discussed in chapter 4 of this thesis).  
 
3.6.2 Mechanistic insights of how the consumption of (−)-epicatechin can 
cause improvements in insulin sensitivity 
The results presented in this chapter report a protective effect of EC against HF diet induced body 
weight gain and insulin resistance in mice. EC supplied in combination with the HF diet improved 
the response to insulin-induced glucose reduction compared to HF diet fed mice which was 
evidenced by lower insulin levels and an overall improvement in their insulin resistance/sensitivity 
scores (HOMA-IR and QUICKI). These findings reinforce the literature which report protective 
effects of EC against HF diet induced insulin resistance and body weight gain, and in the following 
sections these shall be discussed to establish what is known about how EC induces these positive 
changes.  
In 2019, Cremonini et al (128) reviewed ECs role in the mitigation of insulin resistance, specifically 
focussing on how EC inhibits the production of oxidants through NADPH oxidase and NF-κB, JNK, 
IKK and protein kinase C (PKC) signalling pathways. As highlighted in chapter 1 of this thesis, the 
activation of these pathways causes the phosphorylation of serine residues on IRS-1 receptors, and 
subsequently desensitises these receptors to insulin over time (153-158). Cocoa products which are 
rich in EC and other flavanols have been shown to decrease the phosphorylation of serine on IRS-1 
in Zucker-diabetic fatty rats (199) and in HF diet fed mice that had been supplemented with EC, and 




proteins Akt and ERK1/2 in the liver and adipose tissue (127). Similar findings were confirmed 
following the incubation of EC with HepG2 cells, which restored insulin sensitivity via preventing 
palmitate induced activation of NADPH oxidase, and by reducing IR phosphorylation in mice (129). 
Furthermore, EC has been reported to lower the oxidation of lipids or proteins in the liver (129, 
229), adipose tissue (229) and intestines (130). These are all putative mechanisms for how EC 
supplementation could improve insulin sensitivity in mice in this current study. 
EC has been well documented to mitigate the inflammatory events caused by HF diet consumption, 
particularly in the liver and adipose tissue (224, 225), which can subsequently affect glucose 
metabolism and insulin sensitivity (127). One explanation to describe this effect could be because 
EC is reported to protect the tight junction barrier integrity of the small intestines in mice (130), 
and subsequently protected against HF diet induced intestinal inflammation which would otherwise 
cause a ‘leakier’ gut and allow for paracellular transport of bacterial and dietary antigens. 
Consequently, EC ameliorated inflammatory mediated NAFLD and insulin resistance (232, 365-367). 
It is thought that EC and other polyphenols protect the intestinal barrier by preventing HF diet 
induced gut microbiome dysbiosis (368). This could be a mechanism of action for the effects seen 
by EC in this current study, but experimental validation would be required to prove this. 
Furthermore, another explanation for the effects seen by EC in combination with the HF diet in this 
this chapter could be because of enhanced mitochondrial biogenesis. It has been previously 
reported that EC regulates redox potential and the phosphorylation of IR/IRS-1 whilst preserving 
mitochondrial biogenesis (227, 230). This is relevant because pancreatic β-cells regulate insulin 
secretion mostly through their mitochondria, and mitochondrial dysfunction contributes to insulin 
resistance (369, 370). EC has been shown to increase the protein levels of mitochondrial related 
biogenesis genes: proliferator-activated receptor gamma coactivator-1-alpha (PGC1α), 
mitochondrial transcription factor A (TFAM), sirtuin-1 (SIRT1), sirtuin-3 (SIRT3), and uncoupling 
protein 1 (UCP1) in adipose tissue and skeletal muscle of mice on HF diets and compared to HF 
treatments (230). These effects were also confirmed following the isolation and culture of obese 
participants adipose tissue with EC (230). 
In summary, these studies highlight that EC could act to improve insulin sensitivity and mitigate 
insulin resistance effects by improving mitochondrial function, enhancing mitochondrial biogenesis, 
deactivation of inflammatory signalling, reductions in ROS production, and by interfering with 
serine phosphorylation on IR/IRS-1 receptors. Although these markers were not assessed in this 




the response of circulating insulin to lower blood glucose, but because no studies have addressed 
this question, further studies are required to explore this gap in the literature.  
 
3.6.3 The consumption of high-fat diets caused an increase in body weight 
gain and a reduction in the mass of food consumed compared to low-fat diet 
fed mice 
Consistent with the literature, this investigation has confirmed that a 60 % kcal from fat in HF diet 
fed mice can induce a significant increase in body weight, along with the weights of liver and 
epididymal adipose tissue and the epididymal to body weight ratio throughout the 15-week 
intervention (371-373). However, the liver to body weight ratio did not alter between the six dietary 
intervention groups, which has also been confirmed by Sano et al (224), and so the increase in liver 
weight was because of rises in body weight. This chapter also reports a significantly higher 
epididymal adipose weight to body weight ratio in in all HF intervention fed mice than LF 
intervention fed mice which implies that the excess calorie consumption was stored as white 
adipose tissue, as has been previously reported (374).  
This chapter also reports a significant decrease in the mass of food consumed by mice on the HF 
diet when compared to the LF diet. This is due to the greater calorie intake, where HF diet fed mice 
consumed 5.2 kcal/g compared to 3.8 kcal/g from the LF diet. Mice will only consume the energy 
that they require, and so to ensure that mice put on weight and become fatter, the diet needs to 
be modified for where the main source of calories comes from (375). To explain this, the 
consumption of high calories from fat can suppress the oxidative capacity of the mitochondria in 
the liver and skeletal muscle (376, 377), and consequently this slows down metabolism and causes 
greater weight gain. In addition, studies have also shown that mice fed HF diets express high 
circulatory leptin levels (378); a hormone that regulates appetite and is associated with decreased 
food consumption (379). Although leptin levels were not recorded in this current study, there is 
enough evidence in the literature to suggest that the decreased appetite in HF diet fed mice is 
because of high circulatory leptin levels, which is an active attempt to control excess weight gain in 
mice (228, 378, 380). Furthermore, this current study shows an increase in the daily average food 
intake in mice on diets of 34DHPVL supplied in combination with HF and compared to the HF only 
treatment group. This could be because the mice developed an insensitivity to leptin which is 
reported to occur by HF diet consumption. For example, Lin et al (2000) (378) reported that HF diet 




leptin to slow down dietary consumption of the excess calories, and after 19-weeks, they developed 
leptin resistance, and thus caused an increase in dietary consumption and more dramatic weight 
gain (378). In this current study, the supplementation of 34DHPVL into the HF diet could somehow 
be exacerbating the effects of leptin resistance. Unfortunately, leptin levels were not recorded 
throughout this intervention study to understand whether this was an underlying mechanism.  
Finally, the amount of polyphenols consumed by mice in this study is representative of a 
physiological dose consumed in humans, particularly those with high polyphenol diets, and thus the 
physiological and phenotypical effects seen in mice here could be good predictors for those in 
humans.  
 
3.6.4 The mechanistic effects of (−)-epicatechin, but not 3’,4’-
dihydroxyphenyl-γ-valerolactone, in ameliorating high-fat diet induced body 
weight gain in mice 
In this current study, the supplementation of EC at 20 mg/kg body weight significantly mitigated HF 
diet induced weight gain in mice. This finding has been reinforced by Sano et al (224) and Cremonini 
et al (127, 130) where the effects on inhibiting body weight gain were seen at supplied 
concentrations of EC at 200 mg/kg body weight (224) and at 20 mg/kg body weight (127, 130). And 
so, the consumption of EC at physiological concentrations are sufficient to induce obesity protective 
effects. 
The metabolic actions underlying how EC prevents body weight gain has been scarcely explored. 
However, it could act by influencing mitochondrial biogenesis, and by stimulating a brown adipose 
tissue (BAT) phenotype in white adipose tissue (WAT), as has been shown previously (230). They 
reported that the BAT phenotype was induced following an increase in mitochondrial density, which 
subsequently drove the transcription of thermogenic genes and raised fatty acid β-oxidation (230).  
The main flavanol researched for its disease protective effects is EGCG, especially with regards to 
the prevention of weight gain from high calorie consumption/cell culture environments (368, 381-
383). Thus, it is assumed that EC has similar effects to EGCG but of lower potency, as it is known 
that its lack of gallate reduces its bioactivity in comparison to EGC, ECG and EGCG (381, 384, 385). 
To demonstrate the anti-weight gain effects from these compounds, the in-vitro culture of 3T3-L1 
mouse pre-adipocyte cell lines with EC, EGC, and EGCG (100-400 μM), showed that all three 
compounds induced apoptosis in pre-adipocytes and increased the levels of caspase-3 activity, an 




to then activate caspase-3 (390, 391). Moreover, EGCG has been shown to phosphorylate (activate) 
AMPK and its downstream substrates in 3T3-L1 cells through the increase in ROS, resulting in the 
mitigation of adipocyte differentiation (385) in male Wistar rats (392), male Sprague Dawley rats 
(393), and female C57BL/6J mice (394). The downstream effects from activated AMPK are to 
suppress the stimulation of peroxisome proliferator activator receptor-γ (PPARγ) and 
CCAAT/enhancer binding protein α (C/EBPα), both regulators of adipocyte differentiation (386), 
and the transcription factor SREBP-1c that enhances lipogenesis and adipogenesis (387). Lu et al 
(2012) (395) has also reported the anti-obesogenic effects of green tea polyphenols, rich in EGCG, 
via the reversal of 11/12 obesity regulated gene expressions in Virgin Sprague Dawley female rats, 
in support with other studies (396-398). These actions therefore caused an increased energy 
expenditure in the rats through the activation of genes such as Adcyap1r1 and Adrb1, and thus 
increased the rate of lipolysis and a reduction of body fat (398). It is therefore highly plausible that 
EC in this current study could be inducing these same actions in mice.  
By observing the weight gain in mice on all six dietary interventions in this current study, it has 
allowed for conclusion on whether both EC and 34DHPVL can prevent high fat diet induced weight 
gain. Taken together, these observations support the notion that EC metabolites (SREMs) and not 
the respective microbiota derived HPVLs, are the causative agents that cause the reduced weight 
gain in HF diet fed mice. There is sufficient evidence from published reports to suggest how EC may 
induce anti-obesogenic effects, and so, both EC and 34DHPVL influenced different pathways and 





The dietary intervention mouse study performed in this chapter has formed the foundations for 
this thesis and upcoming chapters with a primary aim to determine whether 34DHPVL was 
responsible for mitigating insulin resistance effects in high fat diet fed mice, using EC as a positive 
control. The results of this investigation have resulted in the following hypotheses and conclusions 
in this chapter:  
(1) EC reduced weight gain and insulin resistance effects from high fat diet fed mice most 
likely by mechanisms reported previously in the literature.  
(2) 34DHPVL supplementation increased food consumption in high fat diet fed mice 
possibly by increasing circulatory leptin concentrations and desensitising cells to leptin. 
(3) The consumption of both EC and 34DHPVL in mice represent physiological dose 
consumption in humans, and so the effects seen in mice could be predictive for those in 
humans.  
(4) 34DHPVL supplementation in mice induced hyperinsulinemia through a hypothesised 
process of decreased insulin clearance by the liver, which in return induced pre-diabetes, 
seen by impaired glucose metabolism.   
Overall, this study provides evidence to suggest that HPVLs could be partly responsible for 
improving insulin sensitive effects following EC consumption. The study’s experimental limitations 
demonstrate that more research is required to prove the above generated hypotheses. These 
include recording circulatory leptin and C-peptide levels throughout the entire duration of the 
intervention, in addition to performing more targeted experiments on insulin sensitive tissues 
(skeletal muscle, pancreas and liver) to assess the protein concentrations and activity levels of 







EXPLORING THE BIOLOGICAL CHANGES INDUCED BY (−)-
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Chapter 4: Exploring the biological changes induced by (−)-
epicatechin and 3’,4’-dihydroxyphenyl-γ-valerolactone 
when supplemented into high-fat and low-fat diet fed mice 
4.1 Abstract 
Background: Metabolic associated fatty liver disease (MAFLD, formerly known as non-alcoholic 
fatty liver disease) arises following the continued consumption of high calorie diets which causes 
its hallmark features for liver steatosis, hepatic insulin resistance and hepatic damage/fibrosis. But 
there are several studies that report the protection against MAFLD and more specifically hepatic 
lipid accumulation in high-fat (HF) diet fed rodents that have been supplemented with (−)-
epicatechin (EC). The current evidence for this indicates a reduction in hepatic de novo lipogenesis 
(DNL) processes. But there is no evidence to suggest whether hydroxyphenyl-γ-valerolactones 
(HPVLs), which are the most abundant circulatory metabolites of (−)-epicatechin (EC), mediate 
these effects from EC consumption. Therefore, the livers from the mouse intervention study 
(chapter 3) were processed to explore the physiological and phenotypical markers for lipids, 
fibrosis, and inflammation, in order to assess whether consumption of EC or 34DHPVL caused 
significant changes in this metabolic organ. 
Aim: To quantify the effects of 20 mg/kg body weight consumption of EC and 34DHPVL on liver 
lipids, and biomarkers of fibrosis and inflammation, and plasma lipids and liver damage markers, 
when supplemented into low-fat (LF) and HF diets of mice. 
Methods: Livers were harvested at the end of the intervention study (chapter 3) and processed as 
follows: paraffin embedded liver sections were stained for hematoxylin and eosin (H&E), Sirius red, 
and CD11B to observe the level of steatosis, fibrosis, and inflammation, respectively; cryopreserved 
liver sections were stained using LipidToxTM to observe liver lipids; and cryopreserved liver lobes 
were subjected to the Bligh and Dyers method for lipid extraction and quantification. Finally, an 
alpha amylase enzyme assay was performed using the PAHBAH method to quantify release of 
maltose from corn starch alone or when incubated in the presence of the α-amylase inhibitor 
acarbose, or with EGCG or 34DHPVL to determine whether 34DHPVL could inhibit enzyme activity.  
Results: Mice on the HF and HF+34DHPVL interventions exhibited a 2-fold increase in hepatic lipids 
when compared to the LF diet (p < 0.01), whilst the mice on the HF+EC diet exhibited a 33 ± 3 % 
reduction in liver lipids than the HF controls (not significant). Furthermore, all HF intervention fed 




lipoproteins (HDL) and HDL3 levels in plasma when compared to LF diet fed mice (p < 0.05). But 
there were no significant changes observed in plasma lipids following the supplementation of EC or 
34DHPVL into HF diets of mice and compared to non-supplemented HF controls. No significant 
differences were detected in the levels of liver fibrosis between any of the HF and LF intervention 
fed mice, despite several mice exhibiting severe liver damage on the LF intervention, as determined 
by Sirius red staining. Finally, the activity of alpha amylase on starch was not inhibited by 34DHPVL, 
but the well-known inhibitor acarbose almost completely inhibited α-amylase activity. 
Conclusion: In line with previous studies, EC was able to mitigate the accumulation of liver lipids in 
mice fed HF diets. In contrast with the literature, EC supplementation into HF diet fed mice was not 
successful in lowering serum lipids when compared to non-supplemented mice. This indicates that 
EC caused a reduction in hepatic DNL but had no effect on circulatory lipid clearance. Moreover, 
there was no evidence to indicate that 34DHPVL protected against hepatic lipid accumulation in 
high fat diet fed mice. Furthermore, both the HF and LF (LF was also high in complex carbohydrates) 
diets induced liver damage, which was most likely to have occurred via the activation of 
inflammatory signalling pathways, that high-fat and high-carbohydrate diets are known to 
stimulate. Finally, because 34DHPVL was not successful in inhibiting alpha amylase activity, this was 
evidence to suggest that it does not affect the digestion of starch and consequently it was not a 
mechanism for its glucose lowering effects seen in mice. Overall, EC provided a level of protection 
against hepatic lipid accumulation but not against liver damage or inflammation, whereas, 34DHPVL 





The dietary intervention study that was performed in chapter 3 has provided evidence for the 
protective effects against insulin resistance from EC or 34DHPVL supplemented HF diet fed mice, 
and these effects also indicate towards the protection against MAFLD. This chapter is purposed to 
investigate the physiological changes that are induced by MAFLD and whether EC or 34DHPVL 
influence these. Before this can be discussed, it is essential to understand the relevance and 
mechanisms of DNL and lipolysis, and so this shall be explained in this introduction.  
 
4.2.1 Regulation of fatty acids 
The ingestion of high calorie diets in the form of saturated fats can prove detrimental to health in 
the long-term, contributing to obesity, cardiovascular disease (CVD), metabolic syndrome, insulin 
resistance and metabolic associated fatty liver disease (MAFLD) (399). Controlling fat intake, as well 
as understanding its metabolism and oxidation, can assist in the prevention of disease. Moreover, 
other dietary components, especially polyphenols, have been shown to modulate lipid metabolism 
(400-405) such as by slowing down the rate of fat oxidation (129, 130, 229), and so, this highlights 
the benefits of dietary control.  
 
4.2.1.1 Lipolysis 
After food ingestion, the mouth, stomach, and pancreas secrete lipase enzymes to hydrolyse the 
primary ester bonds of short-chain triglycerides. But, most of the breakdown of triglycerides occurs 
in the small intestine where around 50-70 % of fatty acids are formed as a result (406). Due to the 
hydrophilic nature of short and medium chained fatty acids, they can be passively absorbed through 
the stomach and transported to the liver via the portal vein (407). On the other hand, long chain 
fatty acids are hydrophobic and form lipid droplets in the form of micelles that are later absorbed 
through enterocytes into the lymphatic system and eventually transported into the circulation. 
Moreover, dietary phospholipids continue into the jejunum for continued hydrolysis (407).  
In adipose tissue, the enzymes adipose triglyceride lipase (ATGL) and hormone-sensitive lipase 
(HSL) are responsible for more than 90 % of triglyceride hydrolysis, however, in the liver, ATGL is 
responsible for less than 50 % of their hydrolysis (408). These enzymes are activated by PPARγ 
agonists, glucocorticoids and by fasting, whereas insulin decreases their expression levels. The rise 
in ATGL transcriptomic mRNA levels is initiated by SIRT1-mediated deacetylation of FOXO1, but the 




by AMP-activated protein kinase (AMPK) once it has been activated by phosphorylation of a serine 
residue, cryptically, AMPK has also been shown to inhibit lipolysis (408). An alternative activation 
approach of ATGL occurs from the β-adrenergic stimulation of perilipin-1 (PLIN-1), subsequently 
causing the release of comparative gene identification-58 (CGI-58), that binds to and activates ATGL 
(Figure 4.1) (409). Meanwhile, the actions of HSL are to hydrolyse diacylglycerols, whilst 
monoacylglycerol lipase (MGL) hydrolyse monoacylglycerols, and both contribute to around 10 % 
of triglyceride breakdown (410). HSL is activated once it is phosphorylated by PKA and AMPK and 
fully activated by the binding of phosphorylated PLIN-1.  
For non-adipose tissue lipolysis, the mechanism for activation is very similar to that mentioned 
previously for PLIN-1 activation, but instead for the protein perilipin-5, which recruits both ATGL 
and CGI-58 for complete ATGL activation (Figure 4.1) (408). The liver also produces autophagy-
related protein 7 (Atg7), an autolipophagosome, that consumes cytoplasmic lipid droplets and fuses 
with lysosomes for their degradation (408). However, chronic fat feeding impairs this process and 
ultimately causes lipid accumulation in the liver, which is a precursor for the development of 
MAFLD. In contrast, even under normal fasting conditions, autophagy has been shown to promote 
lipid accumulation, thus playing pleiotropic roles. Finally, the liver protein PNPLA3 (patatin-like 
phospholipase domain-containing protein 3), also known as adiponutrin, expresses high homology 
to ATGL and has been shown to act as a triglyceride hydrolase, however, its exact role remains 
unclear because it has also been reported to activate genes involved in lipid production (408).  
In contrast to lipolysis processes, insulin promotes lipid storage in the liver by “increasing de novo 
lipogenesis (DNL), suppressing fatty acid oxidation, and promoting triglyceride esterification”(411). 
In normal circumstances, the liver will contribute to around 10-37.5 % of fatty acids produced by 
DNL processes in the postprandial period (399). Insulin also reduces the rate of lipolysis through 
transcriptional downregulation of ATGL and HSL and via Akt induced phosphorylation of 
phosphodiesterase 3B (PDE3B) isoforms that prevents phosphorylation of HSL and PLIN-1 (408). 
Furthermore, insulin can activate lipoprotein lipase (LPL) on the capillary endothelium of 
adipocytes, and so, this causes the hydrolysis of triglycerides in chylomicrons and very-low density 
lipoproteins (vLDL) found in the circulation system (412). Once diacyglycerols are formed they can 
act as second messengers and activate protein kinase-C (PKC), which in turn can phosphorylate the 
insulin receptor substrate-1 (IRS-1), and over-time this can cause IR desensitisation in the liver and 






Fatty acid synthesis is an integral process to allow for fat storage, brain myelination and for the 
survival of cells because they are incorporated into membrane tissue formations (413). Lipogenesis 
involves the formation of fatty acids as well as triglycerides by the liver and adipose tissue, and is 
otherwise known more commonly by DNL (414). To stimulate DNL, consuming high carbohydrate 
diets causes a rise in plasma glucose levels, whereas continuous HF consumption causes the onset 
of insulin resistance, both of which contribute to DNL activation. High circulatory glucose levels 
activate lipogenic genes by two mechanisms (1) raising circulatory insulin concentrations, which 
has been discussed previously to stimulate DNL, and (2) converting glucose to acetyl-CoA, which 
enters a series of enzymatic reactions to produce triglycerides.  
 
 
To describe the production of triglycerides from acetyl-CoA, firstly it is converted to malonyl-CoA 
by acetyl-CoA carboxylase (ACC), itself activated by protein phosphatase 2a (PP2a)-mediated 
Figure 4.1: Lipolysis during fasting in adipose and oxidative tissues 
In adipose tissue, β-adrenergic stimulation of lipolysis activates the three enzymes ‘adipose triglyceride 
lipase’ (ATGL), ‘hormone-sensitive lipase’ (HSL) and ‘monoacylglycerol lipase (MGL). ATGL cleaves the first 
ester bond in triacylglycerols (TG), HSL hydrolyses diacylglycerols (DGs), and MGL hydrolyses MGs. For full 
activation of ATGL, ‘comparative gene identification-58’ (CGI-58) binds to it, whereas HSL is phosphorylated 
by ‘protein kinase A’ (PKA) or by ‘adenosine monophosphate-activated protein kinase’ (AMPK) and recruits 
phosphorylated perilipin (PLIN)-1 for activation. In oxidative tissues, PLIN-5 is present instead of PLIN-1 and 




dephosphorylation (415). Fatty acid synthase then acts on malonyl-CoA to elongate the chain by 
two carbons at a time to a carbon-16 chained molecule, and is finally released as palmitate (416) 
(Figure 4.2). Moreover, the production of malonyl-CoA from acetyl-CoA can inhibit carnitine 
palmitoyltransferase (CPT-1) on the mitochondria and thus control the rate of fatty acid entry, as 
such, high malonyl-CoA levels, as supplied by high carbohydrate diets, can suppress mitochondrial 
fatty acid oxidation and increase triglyceride formation. The reverse of the above process is 
mediated by AMPK that can phosphorylate and inhibit ACC and activate malonyl-CoA decarboxylase 
(MCD) which decarboxylates malonyl-CoA to acetyl-CoA (416).  
Enzymes involved in fatty acid biosynthesis are mostly regulated by the transcription factors ‘sterol 
regulatory element binding protein-1c’ (SREBP-1c) and carbohydrate response element binding-
protein (ChREBP). Fatty acyl-CoA, derived from fatty acids, can enter the mitochondria for β-
oxidation via the actions of CPT-1. Alternatively, acyl-CoA is used as a substrate for glycerol 
phosphate acyltransferase (GPAT1), an enzyme that mostly resides in the outer mitochondrial 
membrane, and has high activity in the liver and adipose tissues to stimulate the production of 
phospholipids (417) (Figure 4.2). During the consumption of high carbohydrate diets, hepatic Gpat1 
transcription levels are drastically increased by SREBP-1c. In contrast, the consumption of high fat 
diets reduces the rate of fatty acid biosynthesis by lowering hepatic Gpat1 levels (416).  
Lipogenesis is also promoted by insulin via the stimulation of SREBP-1c synthesis, subsequently 
inducing DNL (411). However, in the case of insulin resistance, more triglycerides are secreted into 
the circulatory system and their metabolism is reduced, causing an impaired clearance of lipids 
(411).  
 
4.2.2 The effects of flavanols on lipogenesis and lipolysis 
As discussed in chapter 3 (section 3.5.1), flavanols have been reported to prevent body weight gain 
in mammals from high fat diets through several processes, which are summarised here.  
In-vitro experiments on HepG2 cells have shown that green tea polyphenols (GTP) comprising of 68 
% EGCG, 19 % EC, 7 % EGC, and 1 % ECG, in the presence of glucose and insulin can increase the 
rate of glycogen synthesis in a dose dependent manner, when compared to the actions of insulin 
alone (400). Evidence suggests that this occurred by the increase in the phosphorylation levels of 
glycogen synthase kinase-3β and glycogen synthase. But also, when the cells were incubated with 




(phosphorylated) ACC. Thus, GTP have been revealed to regulate glycogen synthesis and lipogenesis 
enzymes.  
In a further study, GTP were reported to decrease the adipose tissue expression of SREBP-1c, FASN 
(fatty acid synthase), SCD-1 (stearoyl-CoA desaturase) and HSL to levels similar to those in lean 
mice, whereas their levels were significantly overexpressed in obese mice (401). These gene 
changes were not also observed in the mice livers of the same study despite GTP supplementation 
causing a reduction in steatosis levels (401), and so the effects of GTP were targeted to decrease 
only adipose tissue lipogenesis processes. Because of this, it was likely that steatosis was decreased 
because there was less availability of adipose-derived fatty acids that are otherwise processed by 
the liver (401). Similarly, Wolfram et al (2005) confirmed these results in EGCG supplemented diet 
fed C57BL/6J mice, for all listed genes (402). Furthermore, they reported a reduction in gene 
expression for GPAT and LPL but an increase for the fatty acid β-oxidation gene CPT-1. A different 
study demonstrated that rats supplied with GTP in HF diets caused an increase in AMPK activation 
and a decrease in active ACC (403). To add to this, it is common that inflammatory marker 
expressions, such as TNF-α, in the circulation and adipose tissues can stimulate lipogenesis, but GTP 
supplemented into HF diet fed mice have been shown to reduce these (401, 403). 
To focus more specifically on EC, Cheng et al (2017) investigated the actions of EC at concentrations 
of 10, 20, and 40 mg/kg body weight consumption in Sprague-Dawley rats on HF diets (404). In 
doing so, they found that EC at 20 and 40 mg/kg body weight supplementation was able to reduce 
the expression of SREBP-1c and INSIG1, a gene that regulates lipogenesis in the endoplasmic 
reticulum. In comparison, for Zucker diabetic fatty rats that were fed a 10 % cocoa diet rich in EC, 
they expressed lower levels of the proteins SREBP-1c, FASN, and anti-fibrogenic PPARα, in the liver 
(405). These findings were also reciprocated in the same study for hepatic HepG2 cells that were 
cultured under a high glucose environment, and their culture with EC (3 mM) also caused higher 
phosphorylated (active) levels of AMPK (405). Finally, EC cultured onto HepG2 cells has been shown 
to reduce the protein expressions of FASN, ACC, ACLY (ATP-citrate synthase) and CPT-1, ultimately 
reducing DNL processes (418).  
Overall, there is evidence to imply that EC has an influence on the reduction of DNL processes, 





Figure 4.2: Fatty acid and phospholipid biosynthesis 
The consumption of glucose or high carbohydrate diets raises blood glucose levels and initiates the biosynthesis 
of fatty acids and phospholipids in both the liver and adipose tissue. After glycolysis, pyruvate undergoes an 
enzymatic reaction into acetyl-CoA. Acetyl-CoA is then a substrate for acetyl-CoA carboxylase (ACC) and 
transformed into malonyl-CoA. Malonyl-CoA can then either be de-carboxylated to acetyl-CoA by malonyl-CoA 
decarboxylase (MCD) or transformed into fatty acids by fatty acid synthase. Malonyl-CoA also inhibits carnitine 
palmitoyltransferase-I (CTP-1), a mitochondrial enzyme responsible for producing acyl-carnitines and 
subsequently β-oxidation. A series of further enzymes are then involved to convert fatty acyl-CoA into 
triacyglycerols and diacylglycerols. Phosphatidic acid and diacylglycerols can also be re-directed to form 
phospholipids, glycerophospholipids and lysophospholipids. AMP-activated protein kinase (AMPK) can inhibit the 
action of ACC through phosphorylation, whilst protein phosphatase 2a (PP2a) activates ACC via 
dephosphorylation. AMPK can also activate MCD through phosphorylation, thereby lowering malonyl-CoA stores. 
Insulin can activate pathways that inhibits AMPK activity and increase PP2a activity, thus increasing the 






Following the main dietary intervention study outlined in chapter 3, the purpose of this chapter 
was to investigate other biological changes induced by the HF diet in mice liver tissue and plasma 
markers, and to determine whether EC or 34DHPVL can influence these. As such, the aim of this 
chapter was to provide quantifiable measures for how the HF diet with or without EC or 34DHPVL 
supplementation alters biological markers. To achieve this, the following were achieved: 
(1) Quantify liver lipids following the Bligh and Dyer’s extraction protocol.  
(2) Quantify plasma lipid concentrations using clinical chemistry.  
(3) View the scale of liver inflammation via CD11B immunostaining.  
(4) Assess liver damage in mice via hepatic tissue staining and pixel quantification for the 
fibrosis marker, Sirius red, and from analysing plasma markers for liver damage.  
(5) Identify whether 34DHPVL can inhibit the digestion of starch by alpha amylase.  
The data produced was used to address the following questions: (1) Can EC and 34DHPVL mitigate 
the accumulation of liver lipids in HF diet fed mice? (2) Will EC and 34DHPVL reduce the levels of 
circulatory lipids in HF intervention fed mice? (3) Does EC and 34DHPVL mitigate the onset of liver 
damage from LF and HF diets? (4) Is 34DHPVL capable of inhibiting alpha amylase activity on starch 
digestion and therefore lower blood glucose levels in mice? A number of hypotheses were tested, 
as follows: 
(1) EC and 34DHPVL will counteract against HF diet induced liver steatosis. 
(2) EC and 34DHPVL will counteract against HF diet induced rises in plasma lipids. 
(3) EC and 34DHPVL will mitigate HF or high-complex-carbohydrate (in LF diet) diet induced 
hepatic damage. 
(4) 34DHPVL will inhibit alpha amylase activity on starch digestion and subsequently 





4.4.1 Materials & solutions 
Neo-mount® anhydrous mounting medium (1090160100), Sirius red (365548), coverslips 
(Z692263), paraffin wax (Paraplast®, cat: P3558), A-amylase type I-a PMSF treated from porc 
(A4268-25MG), starch from corn (S4180-500G), p-hydroxybenzoic acid hydrazide (H9882-25G) 
(PAHBAH), D-(+)-maltose monohydrate from potato (M5885-100G), hematoxylin harris, eosin, 
trisodium citrate dehydrate, citric acid pellets, triton-x 100, bovine serum albumin (BSA), goat 
serum, tris, hydrogen peroxide, tween-20, (−)-epigallocatechin gallate (EGCG) (E4143), acarbose 
(A8980), hydrochloric acid (HCL) and sodium chloride were purchased from Sigma Aldrich, UK. Fast 
Green FCF (F7252) was purchased from Merck. Primary CD11B antibody rabbit (ab133357) was 
purchased from Abcam, UK. OCT (AGR1180) and Histo-Clear II (AGR1353), were purchased from 
Agar Scientific, UK. HCS LipidTOX™ green neutral lipid stain (H34475), methanol-free formaldehyde 
ampules (11586711), DAPI (D1306), and superfrost plus microscope slides (12628026), were 
purchased from ThermoFisher Scientific, UK. Histo-Clear I (HS-200) was purchased from the 
LabShop, UK. Triglyceride Liquicolor Mono Assay Kit was purchased from Human Gmbh, Germany. 
Dako antibody diluent buffer (s0809), Dako En Vision secondary anti-rabbit antibody (K4003), and 
Dako DAB+ Substrate Chromogen System (GV825) were purchased from Agilent technologies, UK. 
3’,4’-dihydroxyhydroxyphenyl-γ-valerolactone (34DHPVL) was prepared as previously described in 
section 3.4.1.  
Tris buffer solution (TBS) was made to a 20X stock by dissolving 175.2 g NaCl and 24.28 g Tris in 
water and adjusted to pH 8.0 with HCL. TBS-Tween (TBS-T) was then made using 949 mL water, 250 
mL 20X TBS and 1ml Tween-20. Citrate buffer solution pH 6.0 was made using two pre-made 
solutions citrate A and citrate B, prepared as follows: citrate A: 10.5 g of citric acid in 500 mL distilled 
water; citrate B: 14.7 g of trisodium citrate dehydrate in 500 mL distilled water. The final citrate 
buffer was then made by mixing 18 mL of citrate A with 82 mL of citrate B and brought to a final 
volume of 1 L with distilled water. 
 
4.4.2 Hematoxylin and eosin (H&E) staining of liver sections 
Paraffin embedded liver sections (from the mice dietary intervention study as described in chapter 
3) were cut to 5 μm using the Leica Biosystems HistoCore BIOCUT (RM2235, UK) onto superfrost 
plus slides. Sections were: de-paraffinized in Histo-Clear I for 5 mins, and for 5 mins in Histo-Clear 




water; incubated for 5 mins in Harris’s hematoxylin, and rinsed for 5 mins in running water; 
incubated for 15 secs in 1 % acid solution (1 % hydrochloric acid in 70 % ethanol) and rinsed with 
water; immersed in 0.1 % sodium bicarbonate (in water) for 1 min, and rinsed for 5 mins under 
running water; and counterstained for 30 secs in eosin. Sections were finally dehydrated for 2 mins 
in 70 % ethanol, 2 mins 80 % ethanol, 2 mins 100 % ethanol, 5 mins Histo-Clear I, and 5 mins Histo-
Clear II, and then mounted in Neo-Mount and covered with coverslips.  
 
4.4.3 Sirius red staining of liver sections 
Paraffin embedded liver sections were cut to 5 μm using the microtome, onto Superfrost Plus slides. 
Sections were: de-paraffinized in Histo-Clear I for two changes of 10 mins; hydrated for 2 mins in 
100 % ethanol, 2 mins in 80 % ethanol, 2 mins in 70 % ethanol, and 5 mins in water; incubated in 
0.01 % Fast Green FCF solution in picric aqueous solution for 15 mins; incubated in 0.04 % Fast 
green FCF/0.1 % Sirius red in saturated picric aqueous solution for 15 mins. Sections were finally 
dehydrated in 100 % ethanol for 5 mins and incubated in Histo-Clear I for 10 mins and then mounted 
in Neo-Mount and covered with coverslips.  
 
4.4.4 LipidTOXTM staining of liver sections  
OCT embedded liver sections were cut to 5 μm using the Thermo Scientific Microm HM560 Cryostat 
(UK) onto Superfrost Plus slides. Sections were then: immersed in 4 % methanol free formaldehyde 
for 15 mins, removed and evaporated for 20 mins at room temperature; rinsed in 1X PBS twice for 
5 mins each; incubated in DAPI (1:1000 in PBS) at room temperature for 1 min; washed in PBS thrice 
for 8 mins each; and incubated in HCS LipidTOX™ Green Neutral Lipid stain (1:1000 in PBS) at room 
temperature for 69 mins. Sections were finally mounted in Aqueous Vectamount® for 24-hours at 
room temperature in the dark. Coverslips were then secured, and the slides were kept at 4 °C.  
 
4.4.5 Staining of liver sections for the inflammatory marker, CD11B  
Paraffin mounted liver sections on Superfrost Plus slides were: deparaffinised and rehydrated as 
per section 4.4.2; blocked with 3 % H2O2 in methanol (v/v) at room temperature for 10 mins and 
rinsed in water; unmasked (antigen retrieval) by boiling for 20 mins in a microwave in Citrate buffer 
(pH 6.0) and cooled for 20 mins; washed in TBS-T for three sets of 5 mins; blocked in 50 μL of 




room temperature; drained and incubated with primary antibody (1:3000 dilution of CD11B anti-
rabbit in Dako antibody diluent buffer) overnight at 4 °C; washed in TBS-T for three sets of 5 mins; 
incubated in Dako En Vision secondary anti-rabbit antibody for 30 mins at room temperature; 
washed in TBS-T for three sets of 5 mins; developed in Dako DAB+ Substrate Chromogen System 
until CD11B staining was visible (~30 secs); and the reaction was stopped by placing the slides in 
water, and counterstained by using the reverse protocol of the H&E staining as described in section 
4.4.2, (starting with the hematoxylin step and ending with histoclear). The slides were finally 
mounted using NeoMount and covered with coverslips.  
 
4.4.6 Imaging the stained liver sections 
Hematoxylin and eosin (H&E), Sirius red, and CD11B stained sections were imaged at 4X, 10X an 
20X magnification on Olympus BX60 microscope (Olympus) on brightfield mode using a Progress 
C10 plus camera (2080x1542 HQ, Jenoptik, Germany). LipidTOX stained sections were imaged on 
the Zeiss Axio Imager 2 microscope (using camera adaptors 60C 1” 1.0x and 60NC 2/3” 0.63x) 
(Germany) at 358 nm for DAPI and 488 nm for LipidTOX (green). A total of six images were taken 
for each Sirius red stained section, and two to three images for the LipidTox and CD11B stained 
sections. 
 
4.4.7 Pixel quantification of imaged liver sections in Fiji  
Fiji (419), the image processing package in ImageJ (NIH) was used to quantify pixel intensity for 
images taken from liver sections stained for Sirius red and LipidTOX. Sirius red pixel intensity was 
quantified according to documentation on the ImageJ website (420). LipidTOX pixel intensity was 
quantified according to a method devised by Dr Paul Thomas at the University of East Anglia 
(Manager of the Henry Wellcome Laboratory for Cell Imaging, UK). Macro plugins were then 
designed and installed into Fiji software to ensure equal analysis of all the sections. 
An average of all the pixel intensities were taken from each section imaged in replicate. An average 
was then obtained for each dietary intervention group.  
 
4.4.8 Triglyceride extraction from C57BL/6J liver samples 
Snap frozen liver samples were processed into a homogenous powder using a pestle and mortar 




follows. Crushed 30 mg liver samples were homogenised in 200 μL chloroform and 400 μL methanol 
using the Precellys 24 Lysis and Homogeniser at 6000 rpm for 30 secs (Bertin Technologies, France). 
A further 200 μL of chloroform was added and samples homogenised again. Samples were 
transferred to new 1.5 mL centrifuge tubes and centrifuged for 10 mins at 4,300 g. The lower layer 
containing the lipids was transferred into a new 1.5 mL centrifuge tube and the chloroform was 
evaporated overnight in a fume cupboard. Lipids were then dissolved in 700 μL of 2 % Triton-X-100 
in PBS. Samples were then vortexed until lipids were completely dissolved. After this, 2.5 μL of the 
dissolved liver lipid samples were loaded onto 96 well plates in triplicates and 250 μL of reagent 
from Triglyceride Liquicolor Mono Assay Kit was added and the plate incubated for 5 mins at 37 °C. 
A triglyceride standard curve was prepared according to the kit’s protocol. The plate was then read 
on the FLUOstar Optima Microplate Reader (BMG Labtech, Germany) at 500 nm. Mice liver lipids 
were quantified according to the standard curve and the kit’s protocol, values were then converted 
to obtain mg of lipid mass per mg of liver mass.  
 
4.4.9 Quantification of various plasma biomarkers (RANDOX) 
Clinical chemistry analyser kits from RANDOX Daytona plus (UK) for total cholesterol (CH 8310), 
high-density lipoproteins (CH 8311), high-density lipoprotein-3 (CH 10165), triglycerides (TR 8332), 
aspartate transaminases (AS 8306), and alanine transaminases (AL 8304) were performed on mouse 
plasma according to the manufacturer’s instructions. 
Low-density lipoprotein concentrations were calculated using the Friedewald formula (Formula 
4.1). 
 
𝐿𝐷𝐿 = 𝐶𝐻𝑂 −
𝑇𝑅𝐼𝐺
2.18
− 𝐻𝐷𝐿  
Formula 4.1: Friedewald formula to calculate LDL concentration 
LDL: low-density lipoproteins; CHO: cholesterol; TRIG: triglycerides; HDL: high-density lipoproteins. All units 
were in mmol/L (422). 
 
4.4.10 α-amylase enzyme activity 
Starch from corn was prepared in PBS buffer to 5 mg/mL and cooked at 90 °C for 20 mins. Aliquots 
of 5 mLs were then incubated at 37 °C. A 1:1000 dilution of α-amylase was prepared in PBS and 100 
μL of this added to 5 mL of 5 mg/ml gelatinised corn starch. At 0, 3, 6, 9 and 12 mins after the 




100 μL of 0.3 M Na2CO3 solution to stop the reaction. This mix was then centrifuged at 15,000 g for 
5 mins at room temperature. The initial reaction velocity was determined using the PAHBAH 
method described by Sun et al (2016) (423). Briefly, the supernatant was diluted by 4-fold in PBS 
and 100 μL placed into separate 1.5 mL centrifuge tubes. A 5 % (w/v) final working PAHBAH reagent 
was prepared in a 1:9 volume of 0.5 M HCl:0.5 M NaOH solution (method with modifications from 
Lever, 1973 (424)). A 1 mL of PAHBAH reagent was added to duplicate samples (100 µL) and boiled 
at 99 °C for 5 mins and absorbance measured in a 96-well plate at 380 nm in a FLUOstar Optima 
Microplate Reader (BMG Labtech). Although 405 nm is the optimum absorbance for the assay, the 
closest available working filter was 380 nm, accounting for around 80 % of the absorbance value to 
be captured. Maltose (100 μL) was used as the standard curve at 0.01-1.0 mM in PBS. Absorbance 
readings acquired were converted to the concentrations of the reduced sugar. Initial reaction 
velocity and therefore enzyme activity was calculated from the reducing sugar concentration in the 
reaction solution against time. Α-amylase enzyme activity was determined to be 5.2 kU/mL. 
 
4.4.11 Starch digestion kinetics 
Once the enzyme activity was determined (section 4.4.10), assessment for the most optimal 
enzyme concentration was acquired. To achieve this, firstly, α-amylase at 2.5, 5.0, 12.5, and 25 
U/mL was prepared from stock solution of 5.2 kU/mL in PBS. Secondly, 50 μL of PBS was incubated 
for 5 mins at 37 °C with 50 μL of α-amylase pre-prepared stocks, the 100 μL was then added to 5 
mL of 5 mg/mL corn starch solution as previously described to make final enzyme reaction 
concentrations of 0.05, 0.10, 0.25 and 0.30 U/mL. Aliquots of 100 μL reaction solution was 
withdrawn at 0, 3, 6, 9 and 12 mins. The rest of the protocol described in section 4.4.10 was then 
performed to calculate the initial rates of the reactions. The reaction that provided a complete 
linear production of maltose within the 12 mins was selected for future inhibition assays; this was 
0.05 U/mL. 
 
4.4.12 Inhibition assays of α-amylase by EGCG and 34DHPVL 
As described in section 4.4.10, corn starch was prepared. After that, 50 μL of α-amylase at 5 U/mL 
was pre-incubated for 5 mins with 50 μL of: PBS, or 15 mM EGCG, or 100 mM 34DHPVL, or 200 μM 
acarbose, at 37 °C. Once warmed, 100 μL of the enzyme with PBS/compound was added to the 5 
mL of 5 mg/mL starch to make 0.05 U/mL α-amylase and 150 μM EGCG and 1mM 34DHPVL. The 




4.4.13 Statistical Calculations 
All statistical analyses were performed as described in section 3.4.7. Datasets with unequal variance 
were transformed according to Table 4.1 prior to statistical analysis and analysed using the linear 
model method as listed in the Table 4.1.  
 
Table 4.1: Transformations made on the data for statistical analysis and the linear model R package used 
Mouse Measurement Transformation R Package used 
Sirius red pixels Log10 nlme 
LipidTox pixels Log10 lmer 








Liver lipids in whole liver 




Plasma aspartate transaminases Log10 nlme 
Plasma alanine transaminases Log10 nlme 
Plasma triglyceride N/A lmer 
Plasma triglyceride/HDL ratio N/A lmer 
Plasma LDL N/A nlme 
Plasma HDL N/A lmer 
Plasma HDL3 N/A lmer 





4.5.1 H&E and CD11B staining revealed hepatic liver damage and 
inflammation by all diets 
Liver sections from the mice dietary intervention study (as described in section 3.4.4) were stained 
using H&E to assess the general physiology of the tissue for steatosis, and fibrosis, which are known 
precursors for the onset of MAFLD and non-alcoholic steatohepatitis (NASH). The hematoxylin dye 
stains the nuclei a bluish dark purple colour, whilst eosin counterstains the remaining tissue to 
become pink, and hence allowing for the recognition of hepatic cellular structures, damage, and 
nuclei displacement. Non-stained areas that appeared white were lipids, where large fat droplets 
can be defined as microvesicular or macrovesicular steatosis; the former of the two involves small 
fat droplets that do not displace the nuclei, whilst the latter displaces the cell nuclei to the cell 
periphery because of its large size. In a separate immunostaining procedure, liver sections were 
also assessed for the infiltration of inflammatory leukocytes using a CD11B antibody with 
hematoxylin as the counterstain. 
Healthy functioning livers are defined by the lack of exhibitions for: visible fat deposits, bridging of 
cellular structures, inflammatory cell accumulation, and lots of mitotic cells (425). It was apparent 
that a large majority (N = 9) of the mice on all LF dietary interventions (i.e. with or without 
compound) had ‘healthy’ liver physiologies (Figure 4.6). Conversely, a total of three mice from the 
LF diet (Figure 4.3), three mice from the 34DHPVL supplemented LF diet (Figure 4.5) and two mice 
from the EC supplemented diet LF diet (Figure 4.4) exhibited severe liver inflammation, steatosis, 
fibrosis and hyperplasic cells. The fibrosis was later confirmed by Sirius red staining (described in 
section 4.5.2) where these same samples exhibited high collagen levels that appeared in a bridging 
fashion. CD11B staining confirmed inflammatory cell accumulation in some of the mice on LF 
intervention livers with or without compound supplementation, and these appeared as dark brown 
spots on a lighter brown background (Figure 4.8). The liver sections that displayed high 
inflammatory infiltrates from all LF intervention fed mice were confirmed to be the same mouse 
livers that exhibited a fibrotic phenotype.  
The mice on HF diets presented with extreme hepatic steatosis, and only showed signs of 
improvement following the addition of EC into the diet (Figure 4.7), this was confirmed visually by 
H&E and LipidTOX staining, and was quantified by lipid extraction (discussed later in section 4.5.3). 
There were signs of a reduction in inflammatory infiltrates in the livers of mice on all the HF dietary 
interventions when compared to those on all LF dietary interventions, as determined visually by 




were also high in carbohydrates and very low in fibre) caused liver damage and inflammation, that 
could be greater than those exhibited from the HF diets. However, only once the liver damage 
markers in plasma for AST and ALT were assessed (discussed later in section 4.5.2), there were no 
significant differences between any of the treatments (Figure 4.13).  
 
 
Figure 4.3: Hematoxylin and eosin stains of hepatic sections from LF fed mice that present signs of 
fibrosis 
A/C/E 4x magnification. B/D/F 10x magnification of sections from A/C/E. Yellow arrows point towards an 
area of inflammation, green arrows point towards a fat droplet. Each row represents a section obtained 





Figure 4.4: Hematoxylin and eosin stains of hepatic sections from LF+EC fed mice that show signs of 
fibrosis 
B/D 10x magnification of sections from A/C. Yellow arrows point towards an area of inflammation, green 





Figure 4.5: Hematoxylin and eosin stains of hepatic sections from LF+34DHPVL fed mice that show signs 
of fibrosis 
A/C/E 4x magnification. B/D/F 10x magnification of sections from A/C/E. Yellow arrows point towards an 
area of inflammation, green arrows point towards a fat droplet. Each row represents a section obtained 





Figure 4.6: Hematoxylin and eosin stains of hepatic sections from LF intervention fed mice that exhibited 'normal' physiology 
All sections presented are of 10x magnification. A-D sections were taken from LF fed mice, E-H sections were taken from LF+EC fed mice, I-L sections were taken from 





Figure 4.7: Hematoxylin and eosin stains of hepatic sections from HF intervention fed mice 
All sections presented are of 10x magnification. A-E sections were taken from HF fed mice, F-I sections were taken from HF+EC fed mice, K-N sections were taken from 
HF+34DHPVL fed mice. Each image was obtained from a different mouse liver section. Arrows in images A and N: Black arrows point to zones of macrovesicular fat, 





Figure 4.8: CD11B immunostains of hepatic sections from all LF intervention fed mice 
All sections presented are of 20x magnification. A-D sections were taken from LF fed mice, E-H sections were taken from LF+EC fed mice, I-L sections were taken from 
LF+34DHPVL fed mice. Each image was obtained from a different mouse liver section. Positive CD11B cells are represented by dark brown areas that some black 





Figure 4.9: CD11B immunostains of hepatic sections from all HF intervention fed mice 
All sections presented are of 20x magnification. A-D sections were taken from HF fed mice, E-H sections were taken from HF+EC fed mice, I-L sections were taken 
from HF+34DHPVL fed mice. Each image was obtained from a different mouse liver section. Positive CD11B cells are represented by dark brown areas that some 





Figure 4.10: Sirius red stains of hepatic sections from all LF intervention fed mice that exhibited no signs of fibrosis 
All images presented are of 4x magnification. Sirius red stain binds to tissue collagen and appears red. Sections were counterstained in Fast Green FCF solution and 
stained the rest of the tissue green. All sections presented do not show signs of fibrosis, but there can be collagen seen around the portal veins, which is normal. A-D 
sections were taken from LF fed mice, E-H sections were taken from LF+EC fed mice, I-L sections were taken from LF+34DHPVL fed mice. Each image was obtained from 






Figure 4.11: Sirius red stains of hepatic sections from all HF intervention fed mice that exhibited no signs of fibrosis 
All images presented are of 4x magnification. Sirius red stain binds to tissue collagen and appears red. Sections were counterstained in Fast Green FCF solution and stained 
the rest of the tissue green. All sections presented do not show signs of fibrosis, but there can be collagen seen around the portal veins, which is normal. A-D sections were 







Figure 4.12: Sirius red stains of hepatic sections from all LF intervention fed mice that presented clear signs of fibrosis 
All images presented are of 4x magnification. Sirius red stain binds to tissue collagen and appears red. Sections were counterstained in Fast Green FCF solution and stained 
the rest of the tissue green. All sections presented show clear signs of fibrosis, which represents a build-up of collagen. Collagen also appeared in a bridging fashion across 
some of the tissues, which is indicative of severe liver damage. A-D sections were taken from HF fed mice, E-H sections were taken from HF+EC fed mice, I-L sections were 




4.5.2 The levels of liver fibrosis appeared to be no different across all dietary 
intervention fed mice  
Mice livers from the dietary intervention study were harvested and stained for Sirius red. Sirius red 
is a dye that binds to collagen, and thus allows for the interpretation for healthy or diseased state 
livers. A high accumulation of collagen in hepatic tissue can be indicative of fibrosis and a precursor 
to cancer. Generally, fibrotic livers have approximately four to six times more extracellular matrix 
than normal (26-28).  
Overall, most of the mice did not experience high levels of collagen in their livers (Figure 4.10/11), 
however, there were noticeably three LF intervention fed mice that exhibited high collagen levels, 
alongside three EC supplemented LF fed mice and two 34DHPVL supplemented LF fed mice (Figure 
4.12), this was illustrated by the ≥ 9-fold, ≥ 5-fold and ≥ 10-fold greater pixel intensities than the 
remaining mice in their group, respectively. These datasets represent 23 % of the total mice sample 
size on LF diets with or without supplementation, but were also confirmed outliers from the 
remaining data for pixel intensity values, however, it does not seem sensible to remove these 
datasets because they occupy almost a quarter of the LF sample size. Because of the high pixel 
intensities in these samples and the severe bridging fashion of the collagen, it demonstrates that 
these particular mice suffered from severe hepatic perisinusoidal and portal/periportal fibrosis, 
that ultimately could have led to hepatocellular carcinoma. Generally, this implies that the LF high 
carbohydrate low fibre diet was capable of inducing liver damage, and if the intervention was 
performed over a longer timeframe, it is very likely that more mice would have exhibited a similar 
phenotype.  
In contrast to the LF diet, HF diet fed mice exhibited uniform Sirius red pixilation in all three dietary 
groups, except for one mouse on the EC supplemented diet (Figures 4.11, and 4.13 A/B). Yet despite 
the large differences in the mean values between LF fed and HF fed mice, there were no statistical 
significances between any of the treatment groups, even following the removal of outliers. This 
indicates that both the LF and HF diets contributed to hepatic collagen accumulation, and 
thenceforth a scale of liver damage.  
To reinforce the quantified pixilation values from Sirius red staining, mice plasma was assessed for 
ALT and AST levels, which are markers that directly correlate to the scale of liver damage. There 
were several mice that exhibited extreme values for AST and ALT (Figure 4.13 C/D), and these 
mirrored the same mice that exhibited signs of severe fibrosis. Despite this, there was no statistical 
significance in AST and ALT levels between any of the dietary intervention groups, even once the 




conjunction with extreme values for liver damage markers, it is not sensible to exclude these 
extreme datapoints from the sample size for analysis.  
Published studies report reference ranges for AST and ALT to provide a scale on the level of liver 
damage present, however, these values are very much laboratory dependent (426). As such, a 
normal AST reference range can lay anywhere within 0-79 U/L, whilst for ALT it can be between 0-
65 U/L, and a healthy AST/ALT ratio is around 0.8. In MAFLD, AST can be 2-5 times elevated where 
the AST/ALT ratio is normally 1.0 or more (427-430). As seen in Table 4.2, all dietary intervention 
groups exhibited an abnormal AST/ALT ratio that exceeded 1.0, where LF and LF+34DHPVL 
appeared to be the worst affected. These scores therefore suggest that all dietary groups displayed 
signs of MAFLD and consequently liver damage. But, because there were no significant changes 
seen by supplementing EC or 34DHPVL into either HF or LF dietary fed mice for the AST/ALT ratio, 
this indicates that they did not exert a protective effect against HF or LF high carbohydrate induced 
liver damage. A regression analysis was also performed for the Log10 AST or Log10 ALT to body weight 
ratio, but no correlation was found (data not shown), and so there was no link towards hepatic liver 
damage and body weight.  
 
Table 4.2: Values for liver damage markers in mice from the dietary intervention study 
Sirius red values were obtained from the quantification of red pixels in Fiji software and represent the levels 
of collagen in the sections. AST: aspartate transaminase. ALT: alanine transaminase. Both AST and ALT were 
recorded in U/L and are both detected in the plasma of mice and represent the level of liver damage. Values 
are represented as means of the whole group sample sizes with standard deviation. 
 LF LF+EC LF+34DHPVL HF HF+EC HF+34DHPVL 
Sirius red 
pixels 
2.50 x 107± 
4.02 x 107 
2.06 x 107± 
3.12 x 107 
1.98 x 107± 
3.02 x 107 
8.96x 106± 
7.24 x 106 
1.20 x 107± 
1.04x 107 
1.45 x 107± 
1.05 x 107 
Sirius red 
Log10 pixels 
7.00 ± 0.56 6.97 ± 0.55 6.91 ± 0.64 6.75 ± 0.47 6.95 ± 0.34 6.99 ± 0.36 
AST (IU/L) 372 ± 309 370 ± 330 828 ± 1246 206 ± 65.0 191 ± 88.2 190 ± 68.4 
ALT (IU/L) 154 ± 173 179 ± 175 648 ± 1508 87.8 ± 39.6 74.2 ± 44.4 87.9 ± 57.9 
AST/ALT 
Ratio 3.34 ± 1.23 2.49 ± 0.88 4.33 ± 3.14 2.67 ± 1.04 3.02 ± 1.60 2.71 ± 1.19 
Log10 AST 2.43 ± 0.38 2.42 ± 0.39 2.50 ± 0.63 2.29 ± 0.14 2.23 ± 0.22 2.25 ± 0.15 






Finally, regression analyses were performed to identify whether there was a correlation for AST or 
ALT levels (Log10) to the levels of red pixels detected from Sirius red staining (Log10) (Figure 4.13 
E/F). There was a positive linear relationship between these variables, but because of the high 
variance, the R2 values were low and there was not a significant association found (Log10 Sirius to 
Log10 ALT, p = 0.974, Log10 Sirius to Log10 AST, p = 0.139). Correlations for AST/ALT were also 





Figure 4.13: Data extracted for hepatic Sirius red and plasma liver damage markers 
A) Log10 of Sirius red pixels from hepatic sections, dot plot chart; B) Raw Sirius red pixel values from hepatic 
sections, dot plot chart; C) Log10 AST values recorded from the plasma of mice, dot plot; D) Log10 ALT values 
recorded from the plasma of mice, dot plot; E) Regression graph for Log10 AST against Log10 Sirius red pixels; F) 
Regression graph for Log10 ALT against Log10 Sirius red pixels. Each point represents an individual mouse on that 
respective diet. Bars represent 95 % confidence intervals with mean. Sirius red values are obtained from the 




4.5.3 (−)-Epicatechin, but not 3’,4’-dihydroxyhydroxyphenyl-γ-valerolactone, 
reduced hepatic steatosis in high-fat diet fed mice  
Mice livers were processed for visual assessment of lipids and processed for lipid quantification. 
Firstly, snap frozen livers were sectioned and stained for LipidTOXTM, a green fluorescent dye that 
targets lipids, and the pixel intensity was quantified using image processing software Fiji. Secondly, 
30 mg portions of snap frozen liver lobes were processed using the Bligh and Dyer (421) method to 
extract lipids which were later quantified using a Triglyceride Liquicolor Mono assay kit. These 
allowed for identification of whether EC or 34DHPVL were able to protect against HF diet induced 
steatosis.  
Lipids were quantified from livers and are presented as the mass of lipids (mg) per g of liver tissue. 
For all LF dietary intervention fed mice there were no significant changes observed following the 
supplementation of EC or 34DHPVL into the diets of mice (Figure 4.14 C/D and Table 4.3). However, 
EC supplemented into HF diet fed mice and compared to HF fed mice caused a reduction in liver 
lipids by ~0.018 mg (p = 0.11) but did not reach statistical significance. However, significant 
increases in liver lipids were observed for 34DHPVL supplemented into HF diet fed and HF fed mice 
compared to LF fed mice (p = 0.006 and p = 0.0035, respectively). Moreover, EC supplemented into 
HF diet fed mice exhibited no significant changes in liver lipid levels to LF diet fed mice, and thus EC 
protected against lipid accumulation (p = 0.20). The individual mouse liver lipid levels for both the 
EC and 34DHPVL supplemented into HF diet fed mice were at both high and low levels, and so, this 
high variation demonstrates a strong or weak response of the mice to the diets with regards to lipid 
accumulation. 
Although the fluorescent staining of lipids cannot be used to quantify mass, it does allow for the 
visual assessment of lipid coverage in the tissue, and the pixel intensities can be used as a semi-
quantitative measure (Appendix Figures 3-6). The effects observed for LipidTOX pixel intensities 
were comparable to the effects seen for liver lipids and also reinforce the data where statistically 
significant changes were observed (Figure 4.14 A/B and Table 4.3).  
To determine whether there was a correlation between body weight and liver lipid mass, a plot of 
these two variables was created to identify whether there was a trend in the data (Figure 4.14 E). 
There was no effect between the two variables up to a body weight of 45 g, however at ≥ 45 g there 
was a clear positive correlation (R2 = 0.56, p = 0.0002, Figure 4.14 F). Because of this, it appears the 
mice were able to metabolise the lipids efficiently from the HF diet up to 45 g in body weight, but 
beyond this, they were unable to metabolise the excess lipids and subsequently stored them as fat 




Finally, because 34DHPVL supplemented into HF diet fed mice exhibited high levels of liver lipids 
and significantly higher circulatory insulin levels when compared to all other diet fed mice, a 
regression analysis was performed on all datasets to identify whether there was a correlation 
between the two (Figure 4.14 G). There was a strong positive correlation between the two variables 
(p < 0.0001, R2 = 0.65) which shows that with rising blood insulin levels there was greater hepatic 
lipid storage.  
 
Table 4.3: Values for liver lipids in mice from the dietary intervention study 
LipidTox values were obtained from the quantification of green pixels in Fiji software and represent the levels 
of lipids in the sections. Lipid mass values were obtained from the extraction of lipids from the livers of mice. 
Values are represented as means of the whole sample sizes with standard deviation. Significance *p < 0.05, 
**p < 0.01 compared to LF diet. 
 LF LF+EC LF+34DHPVL HF HF+EC HF+34DHPVL 
LipidTox pixels 
1.64 x 104 ± 
2.55 x 104 
1.75 x 104 ± 
4.00 x 104 
3.97 x 103 ± 
7.11 x 103 
8.11 x 104± 
7.19 x 104 * 
2.00 x 104 ± 
2.93 x 104 
2.01 x 105 ± 
3.08 x 105 * 
Log10 LipidTox 
pixels 
3.64 ± 0.79 3.24 ± 1.15 2.99 ± 0.77 4.51 ± 0.97* 3.78 ± 0.74 4.49 ± 1.17* 
Lipid mass (mg 
per g liver) 
25.7 ± 3.23 23.4 ± 5.13 23.2 ± 5.24 55.2 ± 23.7** 36.9 ± 22.0 63.9 ± 34.8** 
Lipid mass (mg) 
in whole liver 
32.2 ± 6.54 29.0 ± 5.75 27.7 ± 9.79 106 ± 65.7** 66.6 ± 61.5* 141 ± 120*** 
Lipid mass in 
whole liver to 
body weight 
ratio 
0.001 ± 0.002 0.001 ± 0.000 0.001 ± 0.000 
0.002 ± 0.001 
* 
0.001 ± 0.001 




To conclude, all LF intervention fed mice accumulated minimal liver lipids, however, for HF 
intervention fed mice, only once they’d exceeded 45 g in body weight did their livers store the 
excess fat. Finally, only EC supplementation in HF diet fed mice caused changes in liver lipids to 
protect against hepatic steatosis, and this was almost effective enough to reduce levels down to 










Figure 4.14: (continued) A) Log10 of LipidTox green pixels of hepatic sections, dot plot chart; B) Raw LipidTox 
pixel values from hepatic sections, dot plot chart; C) Mass of lipids present per mg liver tissue, dot plot; D) 
Mass of lipids in the whole liver tissue of each mouse and then divided by their own body weight, dot plot; E) 
Correlation graph for lipid mass per mg liver weight against body weight of the mice; there was a stationary 
phase up to ~45 g body weight followed by a positive correlation after this; F) Regression graph for the mass 
of lipids per mg liver weight against the body weight of the mice that weighed ≥ 45 g. Each point represents 
an individual mouse on their respective diet. Bars represent 95 % confidence intervals with mean. LipidTox 
values are obtained from the quantification of green pixels in Fiji, ImageJ software. Significance *p < 0.05, **p 
< 0.01 compared to LF diet fed mice. 
 
4.5.4 Mice on high-fat interventions exhibited significantly more lipids in 
their circulation than low-fat fed mice  
At the point of sacrifice, blood was harvested from the mice and subjected to assays on the RANDOX 
Daytona+ instrument to measure the levels of  cholesterol (CHO), high density lipoprotein (HDL), 
low density lipoprotein (LDL), high density lipoprotein-3 (HDL3) and triglycerides (TRIG). Thus, this 
provided quantitative data to identify whether EC or 34DHPVL could mitigate HF-diet induced rises 
in blood lipids.  
 
Table 4.4: Mice plasma lipid levels 
All plasma lipid values were from week-15 of the dietary intervention study and obtained by following assays 
according to RANDOX Laboratories. LDL: low-density lipoproteins; HDL: high-density lipoproteins. Values are 
presented as means of the group sample sizes with standard deviation. Significance *p < 0.05, ***p < 0.001, 
****p< 0.0001 compared to LF diet fed mice. 
 LF LF+EC LF+34DHPVL HF HF+EC HF+34DHPVL 
LDL (mg/dL) 21.4 ± 8.68 23.6 ± 14.5 26.4 ± 12.2 81.5 ± 17.2**** 69.8 ± 32.2**** 74.9 ± 29.5**** 
Cholesterol 
(mg/dL) 
86.4 ± 39.7 78.2 ± 31.58 86.5 ± 37.0 189 ± 26.3**** 168 ± 32.2**** 166 ± 39.0**** 
Triglyceride 
(mg/dL) 
82.3 ± 50.5 60.5 ± 27.1 75.5 ± 30.8 97.2 ± 31.2 1060 ± 56.6 94.8 ± 49.8 
HDL 
(mg/dL) 
55.3 ± 23.20 42.5 ± 19.2 54.6 ± 17.5 88.5 ± 10.3**** 76.3 ± 9.23* 88.3 ± 15.9*** 
HDL3 
(mg/dL) 
15.8 ± 5.09 13.9 ± 4.96 14.4 ± 5.94 21.0 ± 3.04* 22.1 ± 3.99*** 21.8 ± 5.53*** 
Triglyceride
/HDL ratio 
0.66 ± 0.25 0.68 ± 0.28 0.62 ± 0.17 0.49 ± 0.16 0.61 ± 0.33 0.49 ± 0.20 
 
 
It was evident that a 60 % kcal HF diet caused significant rises in circulatory lipids: CHO (p < 0.0001), 




4.15, Table 4.4). This occurred because the HF diet fed mice had a significantly higher intake of 
calories and fats compared to LF dietary fed mice (Section 3.5.3, Figure 3.4).  
On the other hand, triglyceride blood levels were not significantly affected by any of the diets, as 
illustrated by the overlapping confidence intervals in Figure 4.15 E/F. This is interesting because HF 
diet consumption is commonly known to raise blood triglycerides that are associated with an 
increased cardiometabolic risk (431). The TRIG/HDL ratio was performed (Figure 4.15 F) because it 
is supposed to provide a better scale to measure cardiometabolic risk (432). High ratios are 
indicative of smaller and denser LDL particles (very low-density LDL (vLDL)) that directly correlate 
towards a risk of atherosclerosis (431) and potential insulin resistance (433-435), this is because, 
the smaller size of vLDLs are considered to be easier to oxidise. In humans, a ratio ≥ 2.5 in women 
or ≥ 3.5 in men signifies insulin resistance (435), but it is uncertain if these ratios are unanimous in 
mice. However, despite insulin resistance having been confirmed from HF diet consumption in mice 
from this study (chapter 3), their TRIG/HDL ratios  average < 0.70, and thus this confirms that the 
human ratios are very different to the mice ratios for concluding insulin resistance. Moreover, for 
all HF dietary intervention fed mice, their TRIG/HDL averages were lower than all LF diet fed mice 
(not significant) and so the mice in this study do not support the more generalised associations that 
have been published.  
Plasma lipids were also correlated to body weight (Appendix Figure 7) where LDL (p = 0.01, R2 = 
0.65), HDL3 (p = 0.04, R2 = 0.17), and cholesterol (p < 0.01, R2 = 0.68) showed significant positive 
associations to body weight, whereas HDL (p = 0.19, R2 = 0.49), and triglycerides (p = 0.08, R2 = 




4.5.5 α-amylase activity on starch digestion was not inhibited by 3’,4’-
dihydroxyphenyl-γ-valerolactone 
Polyphenols have been reported to inhibit the enzymatic activity of α-amylase (436), which is an 
enzyme secreted in saliva and in pancreatic juices following the consumption of food, to digest 
starch. Because of this, polyphenols could lower the Cmax of blood glucose after food ingestion and 
Figure 4.15: Concentrations of plasma lipids in mice from the dietary intervention 
A) Cholesterol concentrations, dot plot chart; B) Low-density lipoprotein concentrations (LDL), dot plot chart; 
C) High-density lipoprotein concentrations (HDL), dot plot; D) HDL3 concentrations, dot plot; E) Triglyceride 
concentrations, dot plot chart; F) Triglycerides to HDL ratio, dot plot chart. Each point represents an individual 
mouse on that respective diet. Bars represent 95 % confidence intervals with mean. Significance *p < 0.05, 






may perhaps be an underlying action for their effects on hindering the development of insulin 
resistance. To determine whether 34DHPVL was capable of enzyme inhibition, it was investigated 
following its incubation with alpha amylase on starch digestion. Positive enzyme inhibitory controls 
were also performed using EGCG (reported to inhibit α-amylase) and acarbose (a known α-amylase 
inhibitor). 
Firstly, the enzyme activity of α-amylase was determined to be 5.2 kU/mL, (data not shown). For 
the reaction, starch was used at 5 mg/mL, and the optimal final reaction concentration of α-amylase 
was confirmed to be 0.05 U/mL, which was the concentration that caused a linear production of 
maltose over 12-mins (Figure 4.16 A). Although there are published studies that report the 
inhibition of α-amylase with EGCG at ≥ 100 μM concentrations (243, 437), this could not be 
reproduced in this study, and the rate of enzyme activity was not lowered by the presence of EGCG 
(Figure 4.16 B). Because of this, the purity of EGCG was checked using high-performance liquid 
chromatography mass spectrometry (HPLC-MS), but this confirmed one clear peak for EGCG at a 
mass of 459 on the LC and diode array (U.V). In contrast, 10 μM acarbose completely inhibited α-
amylase activity (Figure 4.16 B). 
The concentration selected for 34DHPVL was based on the pellet concentration provided to the 
mice (200 mg/kg) and from the assumption that density was 1 kg/m3, subsequently equating to 0.2 
g/L of 34DHPVL (0.96 mM). For convenience this was rounded up to 1 mM which was used in the 
assay. During the assay, the rate of starch degradation in the presence of α-amylase was 161 ± 9.08 
μM/min maltose production (Figure 4.16 C), whilst in the presence of 34DHPVL this became 129 ± 
0.59 μM/min maltose production, and although this was lower it was not significantly different (p 
= 0.18, unpaired two sample t-test). Therefore, 1 mM 34DHPVL did not inhibit α-amylase activity 
when supplied at 0.05 U/mL on 5 mg/mL corn starch. In addition, a separate assay that used 2 μM 
acarbose was added to the enzyme-starch reaction, and proved to cause incomplete inhibition of 
α-amylase, and significantly lowered its activity to 46 ± 8.50 μM/min maltose production, which 





Figure 4.16: Starch digestion assays using alpha amylase 
A) Maltose production data from alpha amylase activity at 0.05, 0.10, 0.25 and 0.30 U/mL on 5 mg/mL 
corn starch over 12 mins. B) Inhibitory assay using either 150 μM EGCG or 10 μM acarbose on the activity 
of 0.05 U/mL alpha amylase on 5 mg/mL starch over 12 mins. C) Inhibitory assay using either 1 mM 





To investigate whether EC or 34DHPVL protected against HF diet induced steatosis and raised 
circulatory lipids, several liver histology stains, and plasma assays were performed. A final enzyme 
assay was performed to investigate whether 34DHPVL could prevent rises in blood glucose levels 
via the inhibition of alpha amylase activity on starch digestion. The results from these experiments 
have shown the following: 
(1) 34DHPVL supplemented into HF diet fed mice, and HF diet fed mice exhibited 
significantly greater levels of hepatic steatosis when compared to LF diet fed mice.  
(2) EC but not 34DHPVL mitigated HF diet induced liver lipid accumulation. 
(3) A HF diet caused a significant rise in plasma LDL, cholesterol, HDL and HDL3 
concentrations in mice compared to LF diet fed mice.  
(4) The addition of EC or 34DHPVL into the HF diet did not affect plasma lipid levels, when 
compared to HF diet fed mice. 
(5) There were uniform levels of liver damage encountered in all mice dietary treatment 
groups, but there were approximately 20 % of mice from all LF interventions that exhibited 
severe damage.  
(6) 1 mM of 34DHPVL did not inhibit the activity of 0.05 U/mL of α-amylase on starch 
digestion.  
 
4.6.1 Hydroxyphenyl-γ-valerolactones do not contribute to the effects seen 
from EC consumption for mitigating high-fat diet induced hepatic steatosis  
It is well reported that HF diets will increase hepatic steatosis from long-term consumption, and 
this was clearly observed in the mice in this current study (438). It was also observed that EC 
lowered the levels of hepatic lipids when supplemented into HF diets by approximately 33 %, but 
this did not reach statistical significance. However, this does suggest that EC protected against HF 
diet induced liver lipid accumulation, which could occur by EC influencing hepatic de novo 
lipogenesis (DNL). To investigate this, hepatic gene expressions were assessed following RNA-
sequencing of the tissue, as described and discussed in chapter 5 section 5.6.2, and there was 
sufficient gene expression and pathway changes for the lowering of hepatic DNL when compared 




extract supplementation into the diets of diabetic rats or as treatments on hepatic cell lines (199, 
285, 338, 341, 405, 439, 440). This will be revisited in chapter 5.  
In contrast, the addition of 34DHVL into the HF diets of mice was not protective against hepatic 
lipid accumulation and instead caused ~15 % increase in liver lipids, albeit not significant. Instead 
of lowering hepatic gene expression for DNL, 34DHPVL increased hepatic gene expression for DNL 
on the HF diet only (chapter 5, section 5.5.8), which would explain the marginally increased liver 
lipids in the mice. Therefore, HPVL derived metabolites from EC consumption do contribute to 
mitigating hepatic steatosis. Additionally, there was a large variance in the hepatic lipid content for 
the mice fed HF diets supplemented with 34DHPVL, and the variance was greater than those on the 
HF diet. Accompanying the high liver lipid contents was a positive association for high insulin 
circulatory levels, which, when assessing Figure 4.14 G, the extreme levels only applied to mice on 
34DHPVL supplemented into HF diets. To explain this, studies have found that obese 
hyperinsulinemic subjects expressed a significantly higher level of DNL in their livers than obese 
normoinsulinemic subjects, and because of this they were converting carbohydrates to fats even 
when there was a small dietary contribution of carbohydrates (438). The exact mechanisms that 
underlie this are not currently well-understood, however, there are the following hypotheses; (1) 
because insulin resistance causes a reduced glucose uptake by extrahepatic tissues, this could cause 
more carbohydrates to be directed to the liver for metabolism; (2) hyperinsulinemia can induce 
hepatic DNL processes in obese subjects, and as a consequence their livers would take up more 
glucose from carbohydrate stores and convert them into fat in an attempt to control blood glucose 
(438). And so, because there were two clear groups for the mice on the HF diets supplemented with 
34DHPVL for low liver fat/blood insulin and for high liver fat/blood insulin, this could be explained 
by the hyperinsulinemic effects for raising hepatic DNL processes.   
 
4.6.2 Serum lipids were not affected by the presence of polyphenol 
supplementation  
The addition of EC or 34DHPVL into either the LF or HF diet did not influence the levels of serum 
lipids levels for LDL, cholesterol, triglycerides, HDL or HDL3. This corroborates a study performed 
by Hollands et al (2018) where healthy men and women consumed either 70 mg of monomeric 
flavanols with 65 mg of procyanidins or 140 mg of monomeric flavanols with 130 mg of procyanidins 
for four weeks, however, neither of these doses altered the levels of plasma lipids for HDL, LDL, 
cholesterol or triglycerides when compared to placebo treatments (441). Similarly, no changes in 




EC consumption for two weeks (442). In contrast to this, EC (5 mg/kg/day) supplied to 
spontaneously hypertensive rats on HF HC diets for 20-weeks significantly lowered serum LDL and 
triglyceride levels but not HDL levels compared to the HF HC diet alone (443). In addition, the supply 
of green tea extracts (delivering 1315 mg catechins) to post-menopausal women for 12-months 
caused a reduction in serum total cholesterol, and LDL levels, but there were no changes in HDL 
levels and there was an increase in triglyceride levels compared to the placebo group (444). The 
effects observed were also greater in those with higher baseline serum total cholesterol levels.  
It therefore seems that the model used and the length of dietary intervention with catechin 
supplementation in either humans or rodents influences whether there are observable changes in 
plasma lipids.  
 
4.6.3 How high-fat diet fed mice exhibit higher circulatory HDL levels than LF 
diet fed mice  
It has been observed in this current study that HF diet fed mice exhibited significantly higher levels 
of liver lipids and plasma HDL levels than LF diet fed mice. However, because there were big 
differences between the carbohydrate and fat content for both the HF and LF diets and there was 
not an intervention group that received a standard caloric diet for carbohydrate and fat content, 
this limits the analysis to understand whether the LF mice also exhibited higher circulatory and liver 
lipid levels than would normally be expected. Nonetheless, there is sufficient evidence in the 
literature to suggest that the activation of de novo lipogenesis (DNL) in the liver is responsible for 
hepatic fat accumulation and higher levels of circulatory lipids from both HF and HC fed diets. 
Plasma LDL levels are positively associated with atherogenic risk (445), whereas HDL levels are 
inversely associated with atherogenic risk and it is well reported that high-fat diets will increase 
atherogenic risk, although paradoxically with rises in the levels of HDLs (446), and also with rises in 
total cholesterol levels. In contrast, LF diets can reduce the total cholesterol levels, with reductions 
in both the levels of harmful LDL and ‘healthy’ HDL. In addition, LF HC diets that possess 60 % kcal 
or more total energy as carbohydrates, can cause an elevation in the levels of plasma triglycerides 
and a reduction in the levels of HDLs in mammals compared to lower carbohydrate diets (447-454). 
Although it is well documented that HDL is associated with a decrease in atherogenic risk (455), 
there are contrasting studies that do not support this (453, 456). For example, some human clinical 
trial studies have reported positive atherogenic outcomes in patients despite a decrease in their 




are better to measure CVD risk (458, 459). HF diet consumption has also been shown to raise 
circulatory HDL levels (204, 460-468) largely because of the onset of insulin resistance which has 
been demonstrated to increase lipoprotein lipase activity in adipose tissue, and subsequently raise 
circulatory free fatty acids (FFAs). The liver then receives these FFAs and directs them to DNL 
processes in the liver, causing steatosis and rises in circulatory lipids (464, 469-472). This 
phenomenon also explains in this current study why liver lipid mass was not positively associated 
with body weight until > 45g, because this was the point at which insulin resistance effects were 
mostly recorded, as demonstrated by the positive correlation for liver lipids and circulatory insulin 
levels.  
The lack of a standard diet control group in this study prevented the identification for whether the 
LF HC diet caused HDL levels to decrease from baseline, or whether the HF diet caused HDL levels 
to increase from baseline, or whether the two occurred side by side. To have overcame this issue, 
it would have been necessary to measure the HDL levels in the blood of mice before they 
commenced the intervention study, and thus this would have provided baseline readings. 
Regardless, the HF dietary intervention caused higher circulatory HDL levels than the LF diet in mice. 
 
4.6.4 There were no phenotypical changes observed for liver damage in mice 
supplemented with polyphenols 
Liver fibrosis occurs when the liver parenchyma is destroyed and is later replaced by scar tissue 
(473). Scar tissue is an over-deposition of extracellular matrix (ECM), which impairs the functions 
of hepatocytes and affects hepatic blood flow. This process is driven by hepatic inflammation, which 
itself is stimulated from the continued consumption of HF and/or HC diets (474). The main signalling 
pathways activated during the onset of fibrosis include the JAK-STAT, Smad, ERK and NF-κB 
pathways, and they cause an increase in the production of inflammatory cytokines, particularly 
transforming growth factor-β (TGF-β) which is the most potent fibrogenic cytokine, and they 
activate transcriptional genes involved in extracellular matrix deposition (474, 475).  
This dietary intervention study has revealed non-significant effects on liver damage from HF or LF 
dietary consumption in mice and there were no phenotypical differences observed following the 
supplementation of EC or 34DHPVL, and there were no changes in plasma transaminase levels, 
which provide a measurement of liver damage. Although there were no phenotypical differences 
observed, there were gene expression changes recorded in favour of lowering hepatic fibrosis by 




study continued for longer, then phenotypical changes may have been observed for collagen 
deposition in the livers of mice as well as for changes in serum transaminases. There are several 
reports that have published the beneficial effects of EC (20-40 mg/kg) (476), EGCG (50 mg/kg) (477) 
and green tea extracts (1-2 %; 300 mg/kg) (478, 479) on the protection against liver damage in 
different rodent models (monocrotaline induced hepatic sinusoidal obstruction syndrome in mice; 
ob/ob mice; choline deficient diet in Wistar rats; high-fat diet fed Sprague-Dawley rats), and 
following high doses (200 mg) of catechin consumption in humans with MAFLD which significantly 
lowered serum ALT levels (480). 
 
4.6.5 How high-fat and low-fat high-carbohydrate diets cause inflammatory 
induced liver fibrosis  
Despite a lack of significant changes observed for serum transaminases and collagen deposition in 
the livers of mice for HF and LF diet fed mice, there were still 23 % of all LF treatment groups that 
exhibited severe signs of liver damage, which is partly because the diet had 70 % kcal content 
attributed to complex carbohydrates, and no dietary fibre. Subsequently this can cause an induction 
of liver damage within these mice, as evidenced by published reports that compare low 
carbohydrate (LC) and HC diets (481-484). Accompanying the 23 % increase in liver damage markers 
for LF HC mice in this study were also changes in hepatic gene expressions for an induction of 
fibrogenic genes when compared to HF treatment groups, as discussed later in chapter 5. To briefly 
elude to this here, the LF diet caused an induction in the transcriptomic profile for the production 
of collagen and other ECM proteins and various pro-fibrogenic genes. And so, had the study 
continued for a longer time-period, there may be more measurable effects seen in the levels of 
hepatic damage between the mice.  
There are several studies that have reported the development of liver fibrosis and inflammation by 
LF HC and HF diets in mice (460, 472, 481, 483) and in humans (482, 485). But it should be clarified 
that the effects of the high carbohydrate diets are drastically exacerbated when the diet is lacking 
in dietary fibre, which the LF diet in this current study was, or is provided as simple rather than 
complex carbohydrates. A lack of dietary fibre can cause gut microbiota dysbiosis and in turn can 
increase gut ‘leakiness’ and stimulate inflammation that can cause liver damage (486-488), and the 
HC diet can increase hepatic DNL which is closely linked to the development of liver fibrosis (484). 
Solga et al reported that when humans consumed a HC diet (> 54 % kcal energy) versus those who 
consumed either a LC (32 % kcal energy) or HF diet, they experienced significantly higher odds of 




(with fibre, 18 % kcal fat, 58 % kcal carbohydrate – corn starch), HC diets (no fibre, 11 % kcal fat, 73 
% kcal carbohydrate – 12 % corn starch, 61 % sucrose) or HF diets (no fibre, 58 % kcal fat, 25 % kcal 
carbohydrate) for 12 or 18 months, they all experienced very similar levels of hepatic steatosis, 
fibrosis and inflammation, as well as signs of hepatic tumour growth in all treatment groups (460). 
However, it was only the standard diet fed mice that exhibited significantly lower levels of fibrosis 
at both 12 and 18 months, and lower inflammatory accumulation at 18 months, when compared to 
the HF mice. Furthermore, plasma AST and ALT levels were significantly higher in mice on the LF HC 
diet after 18 months with clear elevations seen after 12-months, when compared to HF diet fed 
mice. Similarly, the standard diet fed mice showed higher levels of AST than HF diet fed mice after 
18 months. This evidence supports the notion that HC diets in the form of starch or 
monosaccharides will induce greater liver damage over-time, more so than from HF dietary 
consumption over the same timeframe. However, had the diets been supplemented with fibre, this 
could have mitigated fibrosis development and hepatic DNL (489-492). To link this to the results 
presented in this chapter, because Tessitore et al (460) fed the LF intervention mice a lower 
carbohydrate content than the LF diet fed mice in this current study, it can be assumed that had 
the study length continued for at least 12-months or more in this current study, the LF diet fed mice 
would have experienced significantly higher levels of liver damage than the HF diet fed mice.  
 
4.6.6 The actions of α-amylase in raising blood glucose levels from starch 
ingestion 
An enzyme assay was performed to investigate whether 34DHPVL was able to inhibit the actions of 
α-amylase on starch digestion. Following food ingestion, α-amylase is produced by the salivary 
glands and is secreted into the upper intestinal tract in pancreatic juices, and acts to digest starch 
into maltose, and is later digested by further enzymes into monosaccharides (493). The rapid 
digestion of starch can cause a large glucose load in the circulation over a short-period of time, 
which, if this happens regularly can raise the risk of developing insulin resistance (494). When the 
actions of α-amylase are inhibited, it causes a more controlled release of glucose into the blood, 
and can consequently mitigate against insulin resistance effects (494). 
It is well documented that flavanols can inhibit α-amylase’s enzyme activity (436, 495-497), and EC 
does so at high concentrations (243). Because of this, EC could mitigate the development of insulin 
resistance via this mechanism. In chapter 3 of this thesis, it has been reported that EC lowered the 
overall glucose A.U.C values when supplemented into LF diet fed mice and compared to LF diet fed 




such, α-amylase inhibition is not a mechanism of action from EC or 34DHPVL in lowering blood 
glucose levels in HF diet fed mice. In addition, the presence of 34DHPVL into the LF diet caused a 
reduction in the glucose A.U.C of mice than in its absence, and so 34DHPVL was investigated to 
identify whether it could inhibit α-amylase activity.  
Corn starch was used in the reaction because this was formulated into the LF diet pellets. To this, 
either EGCG, acarbose or 34DHPVL was incubated in the presence of α-amylase, to record the rate 
of starch digestion over time. In previous studies, EGCG has been reported to inhibit α-amylase at 
relatively low concentrations, with reported IC50 values of 2 μM, 260 μM, 400 μM and a high 1 mM 
(126, 243, 437, 498, 499) in-vitro. The IC50 values were very much dependent on the concentration 
of starch and enzymes used in addition to the type of reaction performed. EGCG has also been 
assessed for its enzyme inhibiting ability in-vivo in healthy and streptozocin (STZ) injected HF 
diabetic induced mice (126). It was reported that an oral gavage of 300 mg/kg body weight of EGCG 
with starch in healthy mice significantly delayed the rise in blood glucose levels compared to the 
starch group. Similarly, in STZ HF diabetic mice, administration of EGCG (300 mg/kg body weight) 
for three weeks significantly lowered postprandial blood glucose levels and protected against 
glucose rises following a glucose tolerance test when compared to diabetic mice (126). Forester et 
al (2012) reported similar effects following corn starch gavage with or without 100 mg/kg body 
weight of EGCG in CF-1 mice, and reported protective effects of EGCG against rises in postprandial 
blood glucose levels by the starch (437). 
Despite these positive effects observed for EGCG in inhibiting alpha amylase activity in-vitro and 
mitigating glucose rises from starch in-vivo, in this current study, EGCG did not inhibit the activity 
of α-amylase. This could have been due to the type of starch used because most studies perform 
the reaction using maize or potato starch and show inhibitory effects from EGCG on α-amylase in 
their assays. In the current study, the incubation of 34DHPVL at the same concentration supplied 
in the pellets (1 mM), was not effective in inhibiting α-amylase activity. As such, 34DHPVL was not 
responsible for preventing the breakdown of starch via α-amylase in LF diet fed mice. 
EC was not measured in the starch digestion assays because it is reported to inhibit α-amylase at 
very high concentrations with a small efficacy (243). On the other hand, acarbose was used as a 






This chapter aimed to investigate the biological effects of supplying EC and 34DHPVL into the diets 
of mice and whether they could improve the hepatic physiology for fibrosis and steatosis. In 
addition, alpha amylase activity was investigated to highlight whether 34DHPVL could inhibit the 
digestion of starch. All these examinations were performed to understand how EC could mitigate 
HF diet induced insulin resistance, and to understand the contribution of 34DHPVL. As such, the 
following conclusions were drawn: 
(1) All HF treatment groups exhibited significantly higher levels of hepatic lipids than the LF 
treatment groups after 45 g in body weight, which was also the point where greater insulin 
resistance was recorded and therefore a greater level of hepatic de novo lipogenesis. 
(2) EC, but not 34DHPVL, protected against HF diet induced hepatic steatosis because of 
the lower plasma insulin levels and consequently lowered DNL activation. 
(3) The LF HC diet induced an equal level of liver damage and hepatic fibrosis when 
compared to the HF treatment groups, however there were several LF treated mice that 
exhibited severe signs of fibrosis, which was most likely caused by the high-carbohydrate 
low-fibre content. 
(4) Neither EC nor 34DHPVL mitigated the onset of liver damage/fibrosis when 
supplemented into LF or HF diet fed mice. 
(5) All HF treatment groups with or without polyphenol supplementation exhibited 
significantly higher levels of plasma cholesterol, LDL and HDL, compared to LF diet fed mice, 
most likely because of higher lipolysis activity in the adipose tissue. 
(6) 34DHPVL was not capable of inhibiting the activity of alpha amylase on starch digestion 
and was thus not responsible for the reduced glucose A.U.C when supplemented into and 
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Chapter 5: Effects of (−)-epicatechin and 3’,4’-
dihydroxyphenyl-γ-valerolactone on hepatic gene 
expression in low-fat and high-fat diet fed mice 
5.1 Abstract 
Background: In the previous chapters it was reported that 34DHPVL had a modest, non-significant 
effect on the glucose response, caused substantial increases in plasma insulin concentrations and 
increased liver lipid accumulation in liver tissues of high fat (HF) diet fed mice. In order to further 
assess the effects of 34DHPVL dietary supplementation, a genome wide transcriptomic analysis was 
undertaken using mouse liver tissue which was exposed to high concentrations of 34DHPVL via the 
hepatic portal vein, and compared to the non-supplemented HF diet and EC supplemented diet fed 
mice.  
Aim: To identify the hepatic transcriptional pathways that support the actions of 34DHPVL on 
glucose and insulin changes observed, and to identify whether EC exerts a similar response in the 
gene changes of mice fed high-fat (HF) or low-fat (LF) diets.  
Methods: RNA extracts prepared from mice liver tissue was sent for Illumina NovaSeq RNA-
Sequencing and the data were analysed in R studio using the DESeq2 package for comparisons 
against control treatments (high-fat: HF or low-fat: LF) for polyphenol treatments (EC or 34DHPVL) 
to obtain differential gene expression (DGE) data. Ranked Log2 fold-change files were then analysed 
using gene set enrichment analysis software (Broad Institute) for KEGG and REACTOME pathway 
analyses.  
Results: Large DGE changes were found for the HF versus LF diets (q-value = 0.05, upregulated = 
732, downregulated = 713 genes) with a total of 48 significantly enriched KEGG pathways (FDR q-
value = 0.25). There were significant changes induced by EC on the HF diet (q-value ≤ 0.05, 
upregulated = 68, downregulated = 7 genes) with a total of 49 significantly enriched KEGG pathways 
(FDR q-value ≤ 0.25). In contrast, 34DHPVL did not induce significant gene expression changes (q-
value ≤ 0.05, upregulated = 2, downregulated = 4 genes) and only significantly altered 2 KEGG 
pathways (FDR q-value ≤ 0.25). There were very few differences between EC and 34DHPVL 
supplemented LF diets and the non-supplemented LF diet, although there were 58-61 significantly 




Conclusion: HF diet caused significant increases in genes involved in pathways for: gluconeogenesis, 
ribosome, starch and sucrose metabolism, amino acid metabolism and fatty acid metabolic 
pathways, when compared to the LF treatment, whereas they exhibited a significant reduction in 
genes involved in de novo lipogenesis and fibrosis. The supplementation of EC in the HF diet 
significantly reversed all these changes, meanwhile the addition of 34DHPVL also reversed these 
pathway expressions but not significantly. These data suggest that EC protected against MAFLD and 
insulin resistance by reducing the expression of genes in pathways involved in the mitigation of 
insulin resistance, and by increasing the transcription of genes involved in the insulin signalling 
pathway. Further research and a bigger sample size would be required to conclude whether 





It is well established that HF diets induce gene expression and metabolic pathway changes 
associated with the development of metabolic associated fatty liver disease (MAFLD) (formerly 
known as non-alcoholic fatty liver disease, NAFLD) in rodents. In this introduction, the current state 
of the art on the effects of HF diets on gene expression profiles and metabolic pathways will be 
presented, followed by what is known about the effects of EC and 34DHPVL on biomarkers of 
metabolic syndrome induced by HF diets.  
 
5.2.1 Typical gene expression changes induced by high-fat diets in the livers 
of mammals 
In order to understand how to treat MAFLD and hepatic insulin resistance induced by long-term 
consumption of HF diets, it is important to understand how such diets can cause changes in gene 
expression and metabolic disruption in the liver. This not only allows a better understanding of liver 
disease pathogenesis but also highlights possible targets for preventing or treating disease.  
Wang et al (2016) assessed gene expression data from the livers of participants who were obese or 
exhibited MAFLD or NASH (non-alcoholic steatohepatitis) phenotypes, as well as ‘normal’ control 
samples (500). In doing so they found some common changes in the expression of genes and 
pathways that were linked to all three groups where the expression of gene changes were more 
drastic with progressing disease severity. To summarise their findings compared to control samples, 
obese livers had 505 differentially expressed genes (DEGs), MAFLD livers had 814 DEGs and NASH 
livers had 783 DEGs (using p-value < 0.01). Of these, there were 27 significantly enriched pathways 
that were common to all three groups (using p-value < 0.1), as shown in Table 5.1. The most highly 
enriched pathways for all three disease phenotypes were for ribosome, ubiquitin mediated 
proteolysis and focal adhesion and are thus important for the development of MAFLD and NASH.  
Similarly, another study investigated hepatic gene expression profiles from the livers of patients 
that expressed mild MAFLD (very minor fibrosis signs) and those with severe MAFLD (high fibrosis 
signs) (501). They found a 64 gene expression profile to be consistently associated with MAFLD, 
these were shown to be involved in cell adhesion and migration (focal adhesion), extracellular 
matrix (ECM) organisation, fatty acid metabolism, amino acid metabolism, and signal transduction 
pathways linked to fibrosis (PDGF, IGFBP) (using p-value < 0.05) (501). Furthermore, Huang et al 
(2018) assessed 3 Gene Expression Omnibus (GEO) datasets that contained data for human livers 




they reported that the GO ontology pathways and KEGG pathways listed in Table 5.2 were most 
commonly found in MAFLD when compared to non-diseased controls for all 3 omnibus datasets 
(using p-value < 0.05) (although they did not report the direction of change). Very similar findings 
were also reported by Ryaboshapkina and Hammar (2018) who also assessed the GEO database, 
but this time they analysed 7 studies (503), and by Li et al (2018) for 2 GEO databases. All these 
datasets have highlighted how MAFLD affects hepatic transcription and subsequent metabolic 
processes, showing how severe impairments in ‘normal’ signalling processes induces the disease.  
 
Table 5.1: The 27 significantly enriched KEGG pathways found by Wang et al (2016) in obese, MAFLD and 
NASH livers in humans (500). 
The pathways presented are those that were commonly enriched in all three groups and compared to non-
diseased hepatic controls (using p-value < 0.01). 
Significantly enriched KEGG pathways 
Bladder cancer Ubiquitin mediated proteolysis RNA degradation 
Ribosome Beta-alanine metabolism Tryptophan metabolism 
N-glycan biosynthesis Vibrio cholerae infection Nitrogen metabolism 
Epithelial cell signalling in 
Helicobacter pylori infection 




Focal adhesion Apoptosis Type-2 diabetes mellitus 
Prion disease P53 signalling pathway Endocytosis 
Steroid hormone biosynthesis Proteasome Fc gamma r-mediated phagocytosis 
Lysine degradation Propanoate metabolism Pathogenic Escherichia coli infection 
Renal cell carcinoma Complement and coagulation 
cascades 
PPAR signalling pathway 
 
 
Another study identified an increase in the ‘complement and coagulation cascade’ pathway in HF 
diet fed aged mice, which induced the activation of inflammatory mediators, and ECM deposition 
for collagen, laminin, hyaluron, elastin, and fibronectin, all of which contribute to the development 
of fibrosis (504). Similar findings were also reported from a study that used human livers from 
participants with MAFLD, where pathways for immune system activation, cell cycle progression and 
extracellular matrix (ECM) reorganisation were upregulated in addition to aforementioned 




Table 5.2: The significantly enriched GO or KEGG pathways found by Huang et al in MAFLD patients (502) 
 The pathway expressions were collated from 3 different Gene Expression Omnibus datasets and were 
compared against non-diseased hepatic controls (using p-value < 0.05). 
Significantly enriched GO ontology pathways 
Cellular lipid metabolic process Cell adhesion Transcription from RNA polymerase 
II promoter Signal transduction 
Significantly enriched KEGG pathways 




PI3K-Akt signalling pathway 
P53 signalling pathway Glycolysis/gluconeogenesis MAPK signalling pathway 
Apoptosis Cell cycle Wnt signalling pathway 
Pyruvate metabolism  
 
For the development of insulin resistance and type-2 diabetes in livers, there are common 
impairments in fatty acid metabolism, fatty acid oxidation, synthesis and storage, and 
gluconeogenesis (506). Significant increases in genes CD36, PPARA (encodes PPARα protein) and 
SLC2A2 (GLUT2 transporter) were also reported for diabetic livers. In a study that assessed gene 
expression differences in genetically obese mice that were either susceptible or resistant to 
diabetes, they found that de novo  lipogenesis (DNL) genes were actually reduced in the adipose 
and hepatic tissue of mice that developed diabetes, when compared to mice that exhibited insulin 
resistance but did not develop diabetes. These included genes for fatty acid synthase (FASN), 
stearoyl coenzyme A desaturase 1 (SCD1), glycerol 3-phosphate acyltransferase (GPAT), acetyl CoA 
carboxylase (ACC), sterol regulatory element binding protein-1c (SREBP1), and peroxisome 
proliferator activated receptor gamma (PPARG) (507). Meanwhile, there was an increase in 
inflammatory gene expression in the adipose tissue, which could act to impair DNL processes. 
Gluconeogenic genes such as phosphoenopyruvate carboxykinase (PEPCK) were also suppressed in 
the livers of pre-diabetic mice but were increased in the presence of diabetes; whilst fatty acid 
oxidation was decreased in several organs in obese diabetic mice but was low in obese non-diabetic 
mice. Interestingly, the level of steatosis did not correlate with diabetes onset, where the obese 
diabetic mice actually expressed reduced hepatic fat than the obese non-diabetic mice (507); this 
was in support of previous literature (508-511).  
Further changes in the expressions of genes for the development of hepatic insulin resistance 
commonly involve the IGFBP (insulin-like growth factor binding proteins) genes and matrix 
metalloproteinase-7 (MMP7) which transcribe proteins for binding to insulin and extracellular 




IGF-I (insulin-like growth factor-1) and IGF-II proteins, which causes a decreased binding of IGFs to 
their receptors and a reduction in insulin signalling; IGFBPs can also prolong the half-life of IGFs 
(512). IGFBP1 is expressed predominantly in the liver and is mostly regulated by insulin, but their 
levels fluctuate postprandially and are reduced in the presence of insulin resistance (513), whilst 
IGFBP-3 regulates the ratio of bound to unbound IGFs and also inhibits cytokine induced insulin 
resistance, where IGFBP-3 proteolysis positively correlates to obesity induced insulin resistance 
(514, 515). Furthermore, MMP-7 breaks down IGFBP-3 and promotes IGF-I binding to the insulin 
receptors to enhance insulin signalling in normoinsulinemic subjects (516). MMP-7 has been shown 
to be reduced in obese subjects but is restored upon weight loss (517, 518).  
 
5.2.2 Hepatic gene expression changes in diabetic models supplemented 
with flavanol-3-ol’s or flavonoid food extracts 
Assessment of the effects of flavan-3-ols on MAFLD have mostly been explored through the use of 
green tea extracts (GTE) (401, 519-522), cocoa polyphenols (199, 285, 341, 405, 439), 
epigallocatechin gallate (EGCG) (126, 281, 282, 401, 477, 523-527) and isolated EC (285, 338, 341, 
405, 528, 529). In general, these studies have demonstrated that all of these sources of flavan-3-
ols mitigate the onset of MAFLD by reducing gluconeogenesis, DNL, TGF-β/SMAD signalling, 
metabolism of fatty acids, pyruvate, and amino acids and by improving insulin signalling responses 
for ribosome pathways, cell cycle genes and cell proliferation, and in some cases an upregulation 
of PI3K/Akt signalling.  
In-vitro studies for MAFLD and hepatic insulin resistance have been explored through the use of 
HepG2 cells in a high glucose environment to mirror an insulin resistant state (530). Most protective 
effects by polyphenols were observed when the compounds were added to the cells and incubated 
prior to the addition of glucose. For in-vivo modelling of MAFLD there have been a variety of models 
selected which include SAMP6 mice (senescence-accelerate mouse prone 6), db/db mice (type-2 
diabetic and obese), ob/ob mice (obese mice), zucker-diabetic fatty (ZDF) rats, and C57BL/6J mice 
fed high-fat diets. All these models develop MAFLD and hepatic insulin resistance from high 
fat/carbohydrate feeding over a length of time (531). Therefore, by supplementing polyphenols 
into their diet or by means of injection it is possible to identify gene changes taking place in their 
tissues following sacrifice. A summary of previously reported changes in the expression of genes in 




In the case of EGCG, effects induced at a transcriptomic level in diabetic models and compared to 
treatments that expressed MAFLD and/or insulin resistance, includes a reduced expression of genes 
involved with fibrosis, inflammation, gluconeogenesis and DNL, and an increase in gene expression 
for insulin signalling and related pathways (Table 5.3 summarises this and includes the sources). 
 
Table 5.3: The effects of EGCG on changes in the expression of hepatic genes using in-vivo or in-vitro 
The data shows whether EGCG caused genes to be positively or negatively differentially expressed in liver 
tissues/cells when compared to MAFLD and/or insulin resistant control treatments, and it has been collated 
from several sources that have been referenced. 
Positively regulated Negatively regulated 
Fibrosis markers: TGF-β/SMAD signalling: TGFB1, SMAD1, SMAD2, 
SMAD4 (477, 519, 523), α-smooth muscle actin (ACTA2) (519, 523), 
type-I collage (COL1A1) (523, 524), matrix metalloproteinase-9 
(MMP9) (523) 
PI3K/AKT signalling (477) 
Pro-inflammatory markers: inducible nitric oxide synthase (iNOS), 
Prostaglandin-Endoperoxide Synthase 2 (COX-2), tumour necrosis 
factor-α (TNFα) (477, 523) 
Nuclear factor-κ B (NF-κB) signalling (477) 
Gluconeogenesis genes: PEPCK (126, 281, 525, 527), glucose-6-
phosphatase (G6PC) (126, 281, 525, 527), FOXO signalling (477) 
5' AMP-activated protein kinase (AMPK) 
signalling (282) 
DNL genes: SREBP-1c (126), FASN (126), ACC1 (126), cAMP-
response element binding protein (CREB) (126), PGC-1α (PPARGC1A 
gene) (126), and oxidative stress (477) 
Insulin signalling: insulin receptor (IR) (281), 
insulin receptor substrate-1 (IRS-1) (281) 
 
Table 5.4 shows the changes in the expression of hepatic genes reported for EC dietary 
supplementation in diabetic rodent models. There are several studies that support the same 
findings with regards to gene/protein expression changes by EC, but there are also a couple that 
show opposite effects with regards to NF-κB, JNK and PKC signalling. This is largely due to the 
experimental design used and the source of diet/media, for example, there was a reduction in the 
expression of these pathways when EC was supplied in combination with a high fructose diet and 
not for a HF diet in mice, because it is reported that fructose (carbohydrates) may have a greater 
impact on transcriptional changes than HF diets (532-534). Interestingly, there were no studies that 
observed fibrotic markers changed by EC supplementation, and so this is an area that requires 





Table 5.4: The effects of (−)-epicatechin on changes in the expression of hepatic genes using in-vivo or in-
vitro models 
The data shows whether (−)-epicatechin caused genes to be positively or negatively differentially expressed in 
liver tissues/cells when compared to MAFLD and/or insulin resistant control treatments, and it has been 
collated from several sources that have been referenced. 
Positively regulated Negatively regulated 
NF-κB pathway: IκB kinase (IKK) (528), and nuclear factor erythroid 2-
related factor 2 (NRF2) (528) 
Gluconeogenesis genes: PEPCK (285, 341), 
and glycogen synthase kinase-3 (GSK-3) 
(285, 341) 
PI3K/AKT signalling (285, 338, 341, 405, 528, 529) DNL genes: SREBP-1c (405), and FASN (405) 
Extracellular signal-regulated kinase (ERK) signalling (338, 528, 529) JNK signalling: JNK1 (338), JNK2 (338) 
c-Jun N-terminal kinases (JNK) signalling: c-JUN (AP-1) (528, 529) PKC signalling (338) 
Protein kinase C (PKC) signalling: PKC (529), and AMPK signalling (341, 
405) 
Inflammatory mediators: TNFα (338) 
Insulin signalling: IR (285, 341), IRS-1 (285, 338, 341), and IRS-2 (285, 
341)  
PPAR signalling: PPARα (405) 
 
 
Use of GTEs in studies is common. GTEs are rich in polyphenol content, with high concentrations of 
EGCG, and lower levels of EGC, ECG and EC (535). Because of the polyphenol mixture, it cannot be 
determined what the active compound(s) are in green tea with regards to hepatic transcriptional 
changes, but it does provide a valuable insight into this widely consumed drink and its potential 
health benefits. GTEs have been shown to induce most of the changes in the expression of genes in 
livers that have been mentioned previously, as listed in Table 5.5. 
To briefly put into context some of the changes in the expression of genes induced by the presence 
of polyphenol extracts, a few studies shall now be described in more detail. Previous evidence has 
highlighted EGCGs ability to inhibit PKC, a protein that is stimulated by fatty acids to phosphorylate 
and inhibit the insulin receptor (IR) (525). Consequently, EGCG increased insulin signalling 
downstream of IR activation. Similar events have also been found following the treatment of HepG2 
cells with EC and cocoa polyphenols, where IR, IRS-1, IRS-2 and proteins in the PI3K/Akt pathway 
were increased, and so counteracted the decreases caused by a high glucose environment (285, 
341). Similarly, in a diabetic mouse model (338) and in ZDF rats (199), EC supplemented into their 





Table 5.5: The effects of green tea extracts on changes in the expression of hepatic genes using in-vivo or 
in-vitro models 
The data shows whether green tea extracts caused genes to be positively or negatively differentially expressed 
in hepatic tissues/cells when compared to MAFLD and/or insulin resistant control treatments, and it has been 
collated from several sources that have been referenced. 
Positively regulated Negatively regulated 
Insulin signalling: INSR (521), and IRS2 (521) Fibrosis markers: TGFβ/SMAD signalling: TGFB1 (519, 520, 
536), SMAD1 (519), SMAD2 (519), COL1A1 (536), and α-
SMA (519, 520) 
FOXO signalling (521) ERK signalling (519) 
 JNK signalling: c-JUN (AP-1) (520) 
DNL genes: SREBP1-c (401, 526), FASN (401, 526), SCD-1 
(401, 526), and hormone-sensitive lipase (HSL; LIPE gene) 
Gluconeogenesis genes: PEPCK (527), and G6PC (527) 
 
 
In addition, cocoa polyphenols exhibit high concentrations of EC and catechins, which are second 
to proanthocyanins, and also possess lower concentrations of anthocyanins (24). The reported 
hepatic gene expression changes caused by cocoa polyphenols in insulin resistant models are 
presented in Table 5.6.  
 
Table 5.6: The effects of cocoa polyphenols on changes in the expression of hepatic genes using in-vivo or 
in-vitro models 
The data shows whether cocoa polyphenol extracts caused genes to be positively or negatively differentially 
expressed in hepatic tissues/cells when compared to MAFLD and/or insulin resistant control treatments, and 
it has been collated from several sources that have been referenced. 
Positively regulated Negatively regulated 
Glucose transporters: GLUT-2 (199, 341) Gluconeogenesis genes: PEPCK (199, 285, 341), and 
GSK-3 (199, 285, 341) 
Insulin signalling: IR (341) (285), IRS-1 (199, 285, 341), and 
IRS-2 (285, 341) 
DNL genes: SREBP-1c (405), and FASN (405) 
PI3K/AKT signalling (285, 341) PKC signalling (405) 
AMPK signalling (341, 405)  
 
 
There are therefore many overlapping hepatic gene and pathway changes that have been reported 




against MAFLD and insulin resistance. However, there are also some reports that contradict these 
findings, consequently, further research and gene expression analyses are required to conclude 
how specific polyphenols provide protective effects and how translatable these effects are from 
the foods that are consumed. 
There are no reports describing the effects of HPVLs per se on insulin resistance and MAFLD – this 




5.3 Aims and approach 
Chapters 3 and 4 have reported evidence for modest protective effects of 34DHPVL on maintaining 
glucose homeostasis in HF diet fed mice, accompanied with increases in blood insulin and hepatic 
lipid accumulation. It is thus important to analyse the changes in the expression of genes to 
understand pathways through which 34DHPVL acts to induce these phenotypical and physiological 
effects when compared to the EC supplemented and non-supplemented HF diet. Therefore, liver 
tissue was selected to perform a genome-wide transcriptomic analysis because it is a highly 
metabolic organ that develops MAFLD and insulin resistance and is exposed to high concentrations 
of 34DHPVL. The overall aim of the research reported in this chapter was to explore the possible 
effects of 34DHPVL using a non-targeted (hypothesis-generating) approach and to compare against 
the effects of EC. This was achieved using two different dietary backgrounds (HF or LF) with or 
without EC or 34DHPVL supplementation and use of RNA-sequencing to investigate possible effects 
on gene expression. To investigate this, the below approaches were taken:  
(1) Quantify differential gene expression changes in response to different dietary 
treatments. RNA samples were sent and analysed for transcriptomic profiling by RNA-
Sequencing for: HF versus LF, HF+EC versus HF, HF+34DHPVL vs HF, LF+EC vs LF, and 
LF+34DHPVL vs LF treatments.  
(2) Identify significantly enriched pathways in response to the treatments using gene set 
enrichment analysis.  
(3) Assess the genes and pathways where changes had taken place in response to 
polyphenol treatments and how they impact specifically on MAFLD and insulin sensitive 
pathways.  
(4) Analyse these changes with reference to the biological changes seen in chapter 3 and 4 
for the GTT and histology analyses.  
The data produced were used to address the following questions: (1) do changes in gene and 
pathway expressions induced by the HF diet reciprocate those seen in previous studies for the 
induction of MAFLD and hepatic insulin resistance? (2) Does 34DHPVL alter hepatic gene expression 
in a HF diet, and if so, are any of these linked to the biological effects observed in the previous 
chapters? (3) Are the changes in hepatic gene expression caused by 34DHPVL different to those 
caused by EC supplementation? (4) Do the gene expression changes assist with understanding how 
34DHPVL and EC affect MAFLD and insulin resistance? To answer these questions, the following 




(1) The HF diet will induce similar pathway changes to those previously published for the 
induction of MAFLD and hepatic insulin resistance.  
(2) 34DHPVL will cause changes in gene expression to protect against HF diet induced 
metabolic disease. 
(3) Based on the findings in the previous chapters, EC will reverse/mitigate the pathway 





All the methods detailed were performed in-house unless otherwise indicated. 
 
5.4.1 RNA extraction from mice livers 
The left lobe of livers from the mice harvested as outlined in chapter 3, Table 3.2 and stored in 
RNAlater, were homogenised into a fine powder under liquid nitrogen using a pestle and mortar. A 
mass of 30 mg was transferred to homogenising tubes with glass beads and 1 mL of QIAzol Lysis 
reagent (Qiagen, UK), and homogenised using the Precellys 24 lysis & homogeniser at 6000 rpm for 
4 cycles for 30 secs (Bertin Technologies, France). Total RNA was later extracted using Qiagen’s 
RNeasy Lipid Tissue Mini Kit according to the manufacturer’s protocol. Total RNA concentration was 
assessed using the Nanodrop 1000 (ThermoScientific, UK).  
 
5.4.2 RNA-Sequencing of hepatic mouse tissue 
5.4.2.1 Quality control and Illumina NovaSeq 
RNA was first checked for quality on the 2100 Bioanalyzer (Agilent, USA) using Agilent RNA 6000 
Nano Reagents. Only high-quality RNA was sent for sequencing. To ensure this, the following criteria 
were used: RNA Integrity value (RIN) had > 7, no visual evidence of cirrhosis, and livers that 
expressed extreme glucose values (greater than the 95 % confidence intervals) during the GTT were 
excluded from the analysis. Once this was taken into consideration, seven liver RNA samples from 
each of the six treatment groups were selected at random and sent to Macrogen (South Korea) for 
sequencing. Macrogen generated cDNAs and ligated them to Illumina adapters at the 3’ and 5’ ends 
using a TruSeq library preparation kit with PolyA pulldown. cDNA libraries were fractionated on 
agarose gels, and 150 bp fragments were excised and PCR (polymerase chain reaction) amplified. 
For cluster generation, the library was loaded into a flow cell where fragments were captured onto 
a lawn of surface-bound oligos complementary to the library adapters. Each fragment was then 
amplified into distinct clonal clusters by bridge amplification in the Illumina NovaSeq 6000 for a 40 
million read depth.  
 
5.4.2.2 Processing, differential gene expression and gene set enrichment analysis 
The following was then performed in house by myself, the default parameters were used when not 




(version 2.1b), using the parameter paired_out (537). Quality control was done with Trim Galore 
(version 0.5.0_dev) and FASTQ (538) to remove: adaptor sequences, short sequences that were 
shorter than 60 bp, and low quality reads < 30. The reads were then mapped to the reference 
genome for Mus Musculus GRCm38.97, where the gene transcripts were extracted from Ensembl 
database (539), using HISAT2 (version 2.1.0) (540), and further assembled into full length transcripts 
by the use of StringTie (version 1.3.5) (541). Finally, raw gene counts were estimated using a python 
script provided by the authors (542). The analysis for differential expression was then performed in 
R Studio, version 3.6.1, using the DESeq2 package (543) alongside other packages listed in Table 
5.7. The analysis started with the raw gene counts.   
Very low level expressed genes were removed by only retaining genes with at least 10 counts for 7 
samples or more (as each group contained 7 samples). Differential expression analysis was then 
performed to determine whether the different dietary treatments had an impact on the gene 
expression profile of the sample, according to the DESeq2 protocol (543, 544). The Wald test was 
used to estimate differentially expressed genes between the control groups (LF or HF) and the 
treatments (EC or 34DHPVL). Further testing was performed for differentially expressed genes 
between the LF and HF control groups by adding these as a dietary group factor in the analysis. The 
Benjamini-Hochberg (545) adjustment was then performed to calculate adjusted p-values by 
setting the adjusted p-value threshold to 0.1. Log2FC shrinkage was then performed for an adjusted 
p-value < 0.1. Following this, independent filtering was performed to filter genes that had little or 
no chance of showing significance; this was done by setting the adjusted p-value < 0.1. The p-values 
calculated by DESeq2 were used to rank all the expressed genes, which was then used to perform 
a gene set enrichment analysis. Gene Set Enrichment Analysis (GSEA, Broad Institute, USA) (546) 
was used for KEGG and REACTOME gene set collections.  
 
5.4.2.3 Data availability 
All raw RNA-sequencing data was uploaded to NCBI’s Sequence Read Archive (SRA) and is accessible 
at the following link http://www.ncbi.nlm.nih.gov/bioproject/686430 with BioProject ID 
PRJNA686430 and BioSample accession numbers SAMN17117538-SAMN17117579 with a release 





5.4.2.4 R Studio packages and versions 
Table 5.7: R packages and versions used for RNA-sequencing analysis 
Package Version Package Version 
affy 3.26.7 ggbeeswarm 0.6.0 
AnnotationDbi 2.40.5 ggplot2 1.46.1 
apeglm 1.32.0 Glimma 1.66.0 
genefilter 1.1-2 glmpca 3.8.2 
gskb 1.12.0 KEGG.db 0.8.8 
org.Mm.eg.db 2.2.2 KEGGREST 1.62.0 
pheatmap 1.3.0 magrittr 0.3.3 
BiocManager 1.3.1 msigdbr 1.16.0 
biomaRt 1.30.10 pathfindR 7.0.1 
clusterProfiler 1.24.0 pathview 3.12.0 
dendsort 1.5 PoiClaClu 1.24.0 
DESeq2 0.1.0 RColorBrewer 1.4.0 
devtools 1.0.2.1 ReactomePA 1.4.0 
dplyr 0.8.5 readxl 1.28.0 
edgeR 3.3.0 reshape 1.24.1 
enrichplot 1.0.12 tidyverse 3.2.3 
ggbio 1.6.0 UpSetR 1.4.2 
 
 
5.4.3 cDNA synthesis and Real-time quantitative PCR  
For cDNA synthesis, 200 ng of RNA was reverse transcribed using the Precision NanoScript Reverse 
Transcription kit (Primerdesign, UK) in a final volume of 20 μL according to the manufacturer’s 
instructions. Primers were designed targeting 28 pairs of intron-spanning genes (Table 5.8). This 
was performed by using the Roche probe library software tool 
(https://lifescience.roche.com/en_gb/brands/universal-probe-library.html) and the specificity 
checked against the NCBI BLAST database (https://blast.ncbi.nlm.nih.gov/Blast.cgi). Primers were 
synthesised by Integrated DNA Technologies (IDT, Belgium).  
For qRT-PCR, a 7.5 μL final reaction volume was prepared consisting of 3.33 μL of 2X ImmoMix 
(Bioline, UK, BIO-25020), 0.40 μL 0.1 % bovine serum albumin (Sigma Aldrich, UK, A2153), 0.07 μL 
of 37.5 mM MgCl2, 0.04 μL of 100-fold diluted SYBR Green (Sigma Aldrich, UK, S9430), 0.07 μL of 10 
nM reverse primer, 0.07 μL of 10 nM forward primer, 0.07 μL of 50X ROX reference dye 
(ThermoFisher, UK), 1.21 μL of RNAse free water (totalling to 5.27 μL reaction mix) and 1.73 μL of 
the mouse hepatic cDNA. The reaction mixture was placed into 384-well PCR plates (Applied 




using the following conditions: initial denaturation at 95 °C for 10 mins, followed by amplification 
and data acquisition for 40 cycles for both 95 °C for 15 sec and annealing/extension at 60 °C for 1 
min. This was then followed by a melt curve stage of 95 °C for 15 secs, 60 °C for 1 min and 95 °C for 
15 secs. For each gene, the melt curves and standard curves were performed to determine the 
primer specificity, amplification efficiencies and linearity respectively (Table 5.8). All samples were 
run in triplicate with a no template control for each gene. 
 
Table 5.8: Primers used for qRT-PCR analysis 
The R2 efficiencies and amplification efficiencies correspond to the primer results from the VIIA7 qRT-PCR 
machine. 
Gene Full Gene Name Gene ID Product 
Size 






































































































Table 5.8: Primers used for qRT-PCR analysis (continued) 
Gene Full Gene Name Gene ID Product 
Size 























































































































Table 5.8: Primers used for qRT-PCR analysis (continued) 
Gene Full Gene Name Gene ID Product 
Size 







































































ITGAM Integrin Subunit 
Alpha M (also 





























5.4.4 qRT-PCR housekeeping gene validation and statistical analysis 
To validate the most stably expressed housekeeping gene prior to data analysis, 12 sets of primer 
pairs were selected: ACTB, EIF2A, YWHAZ, TBP1, GAK, RPL27, HMBS, RPLP0, GAPDH, B2M, RPL4, 
and OAZ1 (listed in Appendix Table 1), and were designed and purchased according to that 
described in section 5.4.3. Bestkeeper, Normfinder and GeNorm programmes (547-549) were then 
used to validate the most stably expressed pairs of housekeeping genes, where EIF2A was found to 
be the most stable and ACTB was the second most stably expressed gene. Changes in gene 
expressions were calculated using the delta CT method (2-ΔCT) (550) for the housekeeping genes 
EIF2A and ACTB, and then statistical analysis was performed as described previously in chapter 3, 
section 3.4.7. Please see Table 5.9 for the transformations made on the delta CT values and the 
linear method applied to the data in R studio. For fold-change analysis, all treatments were 
compared against their respective controls; for example, for a LF+34DHPVL vs LF comparison the 
LF+34DHPVL mean group average delta CT was divided against the LF mean group average delta 
CT. 
 
Table 5.9: Transformations performed on qRT-PCR gene expression data for statistical analysis and the R 
packages used 
Gene Transformation R Package used Gene Transformation R Package used 
ACTB Log2 NA GBE1 Log2 nlme 
EIF2A Log2 NA IGFBP1 Log2 lmer 
ACADM Log2 nlme STEAP4 Log2 lmer 
ALD3HA2 Log2 lmer ENPP2 Log2 nlme 
ACAA1A Log2 lmer SOCS5 Log2 nlme 
ALDH7A1 Log2 lmer TNF Log2 lmer 
PDHA1 Log2 nlme BAX Log2 lmer 
SUCLG1 Log2 lmer CASP9 Log2 lmer 
PPARG Log2 lmer PTEN Log2 nlme 
PPARA Log2 lmer CHUK Log2 lmer 
PPARD Log2 lmer AKT1 Log2 lmer 
FABP2 Log2 lmer ITGAM Log2 lmer 
SLC2A2 Log2 lmer CD86 Log2 lmer 
AGL Log2 lmer CD14 Log2 lmer 





5.5.1 RNA-sequencing data analysis and identification of treatment 
clustering 
A total of seven hepatic RNA samples per dietary treatment from the intervention study were sent 
for RNA-sequencing (RNA-seq). The raw RNA-seq data was processed according to the protocol by 
Pertea et al (2016) (551) to estimate raw gene counts using the Norwich Bioscience Institute’s (UK)  
high-performance computers (HPC). The gene counts were loaded and analysed in R studio. First, 
removing lowly expressed genes and keeping only those genes with at least 7 out of the 42 samples 
expressing a count of 10 or more for annotated and non-annotated genes. The data was then 
analysed using the DESeq2 package, this was selected over the commonly used edgeR package 
because it accounts for gene specific normalisation factors to reduce technical bias towards high 
GC content, gene length, and amongst others (552, 553). Although edgeR was initially trialled on 
the dataset, it was soon apparent that this package would not be suitable due to a higher variation 
in the data spread within groups, as later explained. Using DESeq2, each gene was treated 
separately to calculate gene wise dispersion estimates and later shrunk (LFCshrink) through an 
empirical Bayes approach to obtain final dispersion values; DESeq2 performs this by estimating the 
width of the prior distribution of the data and controlling the level of shrinkage automatically from 
the observed data properties, thereby reducing the occurrence of false positives. It is these 
shrunken LFCs (log-fold change) and standard errors that were used to discover differentially 
expressed genes (section 5.5.2). Significance testing was applied using the Wald test by DESeq2 and 
adjusted for multiple testing by Benjamini and Hochberg (545).  
Data was then transformed for visualisation using regularised logarithm (rlog) (543) and variance 
stabilising transformation (vst) (554-556) and assessed for heteroscedasticity (Figure 5.1). Heatmap 
of the Euclidean distance of the samples was created using the rlog transformed data, as the rlog 
transformation uses the same empirical Bayes approach applied by DESeq2 and creates a matrix 
with a coefficient for each sample. Whilst vst looks for a trend in the variance and mean of the 
dataset, applying a transformation to remove the trend, and does not consider the differences in 
size factors. Figure 5.1 shows that the rlog transformation versus the vst transformation had the 
same range of variance at different ranges of mean values, this is ideal for exploratory analysis.   
Figure 5.2 highlights the unnormalised versus the normalised box plots. Samples 23.2 (LF diet), 3.2, 
20.2 (LF+34DHPVL diet), 19.1 and 19.2 (LF+EC diet) (where the first number represents the cage 
number and the second number represents the mouse ID in the cage, i.e. 23.2 corresponds to cage 




transformation in comparison to the rest of the dataset. When Euclidean distance heatmaps (Figure 
5.3), and principal components analysis (PCA) plots were inspected (Figures 5.4 and 5.5), it was 
obvious that samples 23.2, 3.2, 20.2, 19.1 and 19.2 did not fit with the rest of the samples within 
their dietary groups, as shown mapped to the left of the image (Figure 5.4). This was the major 
reason that DESeq2 was selected over edgeR as it can cope with these datasets without them 
interfering with downstream statistical testing. Nonetheless, these samples were investigated 
further with a bioinformatician (Dr Perla Rey, QIB, UK), and in doing so, it was shown that these 
particular samples expressed a higher read count coverage to the reference genome, in addition to 
expressing more zero count values versus the other samples (data not shown). By way of caution, 
the data was then assessed differently to see if these samples would affect the overall outcome of 
the data prior to exclusion: (1) the raw RNA-Seq data was processed to obtain raw gene counts for 
only annotated genes, and later processed for differential expression values; (2) the ‘outlier’ 
samples were removed completely from the analysis, and the remaining samples were processed 
for differential gene expression. In performing both the above two steps, it did not affect the 
outcome results for differential gene expression. The changes were so negligible that they did not 
have any substantial effects, and so there was not felt a need to exclude them. Therefore, all the 
42 samples sent off for sequencing were processed in the final downstream analysis to provide 
differential gene expression data and gene set enrichment analysis outcomes.   
The generalised version for a PCA plot (Figure 5.4), highlights the groupings for the LF versus the HF 
diets, showing that these two diets distinctively induced hepatic transcriptional changes. In 
contrast, there were no distinctive groupings revealed for the inclusion of either EC or 34DHPVL 
into the LF or HF diets. This suggests that there may be some transcriptional changes induced by EC 







Figure 5.1: Gene expression profiles for different transformations of RNA-sequenced data by Log2, vst or rlog 





Figure 5.2: Boxplots for the Log2 datasets of RNA-Sequenced raw gene counts and normalised gene counts 
These data are from RNA-sequenced mouse livers from the dietary intervention study and plotted in R Studio. Each number represents an individual mouse ID, where the first 
number represents the cage number and the second number represents the mouse ID in the cage, i.e. 23.2 corresponds to cage 23 and the 2nd mouse in the cage. LF: low fat; 
LF.EC: low fat supplemented with (−)-epicatechin; LF.GVL: low fat supplemented with 3’,4’-dihydroxyphenyl-γ-valerolactone; HF: high fat; HF.EC: high fat supplemented with 




 Figure 5.3: Euclidean distance heatmap for each sample/treatment transformed by rlog 
These data are from RNA-sequenced mouse livers from the dietary intervention study and this plot was performed using R package pheatmap. Each number represents an 
individual mouse ID, where the first number represents the cage number and the second number represents the mouse ID in the cage, i.e. 23.2 corresponds to cage 23 and 
the 2nd mouse in the cage. Control - LF: low fat; EC - LF: low fat supplemented with (−)-epicatechin; GVL - LF: low fat supplemented with 3’,4’-dihydroxyphenyl-γ-valerolactone; 





Figure 5.4: Generalised principal component analysis (PCA) plot on raw count data for first and second dimensions 
These data are from RNA-sequenced mouse livers from the dietary intervention study and plotted in R Studio. Each number represents an individual mouse ID, where 
the first number represents the cage number and the second number represents the mouse ID in the cage, i.e. 23.2 corresponds to cage 23 and the 2nd mouse in the 








Figure 5.5: Principal component analysis (PCA) plot on rlog transformed data separated for DietType (HF or LF treatments) 
These data are from RNA-sequenced mouse livers from the dietary intervention study and plotted in R Studio. Each number represents an individual mouse ID, where the first 
number represents the cage number and the second number represents the mouse ID in the cage, i.e. 23.2 corresponds to cage 23 and the 2nd mouse in the cage. LF: low fat; 




5.5.2 Differential expression analysis highlights significant changes 
conferred by EC but not by 34DHPVL supplementation of HF and LF diets 
As detailed above (section 5.5.1), differential expression analysis was performed on the gene counts 
via DESeq2’s LFCshrink and adjusted for multiple testing by Benjamini and Hochberg. The aim was 
to investigate (1) whether 34DHPVL causes changes in gene expression, (2) if so, are the changes 
observed different to those caused by EC, and (3) do the gene expression changes assist with 
understanding how EC and 34DHPVL affect MAFLD and insulin resistance.  
A total of seven pairwise-comparisons were performed to identify differentially expressed genes as 
follows: (where LF or HF fed mice acted as controls respectively) 
1. HF fed mice versus LF control fed mice 
2. HF+EC fed mice versus HF control fed mice 
3. HF+34DHPVL fed mice versus HF control fed mice 
4. LF+EC fed mice versus LF control mice 
5. LF+34DHPVL fed mice versus LF control mice 
6. HF+EC fed mice versus LF control fed mice 
7. HF+34DHPVL fed mice versus LF control fed mice 
Table 5.10 highlights the number of genes differentially expressed per comparison at different 
significance levels (q-value). At a significance level of 0.05 there were a total of 1445 differentially 
expressed genes for the HF vs LF comparison, indicating that the HF diet caused many changes at a 
transcription level. On the other hand, EC caused 77 gene changes at 0.05 significance in the HF 
diet, increasing to 112 at 0.1 significance. Therefore, EC induced changes transcriptionally for a 
small proportion of genes. In contrast, 34DHPVL only altered 6 genes at 0.05 significance in the HF 
diet, and only increased to 7 genes at 0.3 significance. 
Additionally, in the LF diet group, EC supplementation was only able to induce 5 transcriptional 
changes at 0.05 significance, with only 1 more gene expression change when 0.3 significance level 
was applied. Therefore, EC caused modest changes in gene expression when supplemented into 
the LF diet, but it was stronger at causing changes in gene expression when supplemented into the 
HF diet. Conversely, 34DHPVL caused more changes in gene expression when supplemented into 
the LF diet, more strongly than its supplementation into the HF diet (using a 0.3 significance level). 
Above all, there were many transcriptional changes for the HF+EC and HF+34DHPVL vs LF 
comparisons at a 0.05 significance threshold. Nonetheless, the changes were fewer than the HF vs 




induced 560 transcriptional changes and the HF+34DHPVL vs LF diets induced 940 transcriptional 
changes.  
 
Table 5.10: Differential gene expression changes for pairwise comparisons 
Performed using the DESeq2 package for q-values 0.05-0.3. Up corresponds to the number of genes found to 
be upregulated for the comparison, and down corresponds to downregulated genes. 
q-value ≤ 0.05 ≤ 0.1 ≤ 0.2 ≤ 0.25 ≤ 0.3 
Altered expression Up Down Up Down Up Down Up Down Up Down 
HF.Control vs LF.Control 732 713 1024 1163 1514 1990 1791 2466 2086 2873 
HF.EC vs HF.Control 68 7 102 10 169 29 206 51 253 73 
HF.34DHPVL vs HF.Control 2 4 2 4 2 5 2 5 2 5 
LF.EC vs LF.Control 2 3 2 4 2 4 2 4 2 4 
LF.34DHPVL vs LF.Control 2 1 8 6 14 10 41 26 76 46 
HF.EC vs LF.Control 326 234 512 416 878 883 1069 1144 1261 1419 
HF.34DHPVL vs LF.Control 533 407 775 673 1141 1246 1334 1557 1521 1832 
 
 
5.5.3 Gene set enrichment analysis identifies significantly altered pathways 
for each pairwise-comparison 
Following processing of the RNA-Seq dataset, only annotated genes were considered and the 
pairwise comparisons were ranked according to their p.value multiplied by the sign of the log2-fold 
change. The ranked list was then input to Broad Institute’s gene set enrichment analysis (GSEA) 
software (546) for REACTOME and KEGG pathway analysis. This was performed by collapsing the 
mouse gene symbols to be remapped to human symbols via use of the Chip platform 
‘Mouse_ENSEMBL_Gene_ID_to_Human_Orthologs_MSigDB.v7.1.chip’ for 1000 permutations. This 
computed the pathways that were significantly altered in the liver for a positive or negative 
direction by the dietary comparisons. In total, 16,413 genes were input into GSEA and 12,682 had 
genes mapped to gene symbols for analysis. Table 5.11 illustrates the number of gene sets found 
to be enriched per pairwise comparison at different FDR (false discovery rate) q-values (0.05, 0.1 





Table 5.11: Summary of numbers of significantly enriched KEGG pathways 
Data were obtained from GSEA, Broad Institute, for 0.05, 0.10 and 0.25 FDR q-values. Up corresponds to the 
number of pathways found to be upregulated for the comparison, and down corresponds to downregulated 
pathways. 
q-value ≤ 0.05 ≤ 0.10 ≤ 0.25 
Altered expression Up Down Up Down Up Down 
HF.Control vs LF.Control 24 1 33 2 44 4 
HF.EC vs HF.Control 6 10 7 23 15 34 
HF.34DHPVL vs HF.Control 0 0 0 0 2 0 
LF.EC vs LF.Control 33 0 42 0 56 2 
LF.34DHPVL vs LF.Control 37 0 39 1 59 2 
HF.EC vs LF.Control 16 4 23 4 42 14 
HF.34DHPVL vs LF.Control 28 2 32 2 49 2 
 
 
Table 5.12: Summary of numbers of significantly enriched REACTOME pathways 
Data were obtained from GSEA, Broad Institute, for 0.05, 0.10 and 0.25 FDR q-values. Up corresponds to the 
number of pathways found to beupregulated for the comparison, and down corresponds to downregulated 
pathways. 
q-value ≤ 0.05 ≤ 0.10 ≤ 0.25 
Altered expression Up Down Up Down Up Down 
HF.Control vs LF.Control 39 24 56 36 104 86 
HF.EC vs HF.Control 40 16 60 20 88 52 
HF.34DHPVL vs HF.Control 0 0 0 0 19 0 
LF.EC vs LF.Control 56 5 98 7 220 9 
LF.34DHPVL vs LF.Control 128 16 177 22 325 62 
HF.EC vs LF.Control 59 21 79 33 170 126 
HF.34DHPVL vs LF.Control 40 43 51 55 121 80 
 
 
For GSEA analysis, the FDR q-values were selected over the nominal p-values, because the FDR q-
values are an estimated probability that the normalised enrichment score will represent as a false 
positive finding. For example, using the recommended 0.25 q-value indicates that the result will be 
valid 3 out of 4 times as it is adjusted for gene set size and multiple hypothesis testing. Conversely, 
the nominal p-value estimates statistical significance of the enrichment score for a single gene set, 




briefly summarise the results for ≤ 0.25 q-value: there were 48 KEGG and 190 REACTOME pathways 
significantly enriched for the HF versus LF diet comparison; 49 KEGG and 140 REACTOME pathways 
significantly enriched for the HF+EC versus HF diet comparison; 2 KEGG and 19 REACTOME 
pathways significantly enriched for the HF+34DHPVL versus HF diet comparison; 58 KEGG and 229 
REACTOME pathways significantly enriched for the LF+EC versus LF diet comparison; 61 KEGG and 
387 REACTOME pathways significantly enriched for the LF+34DHPVL versus LF diet comparison; 56 
KEGG and 296 REACTOME pathways significantly enriched for the HF+EC versus LF diet comparison; 
and 51 KEGG and 201 REACTOME pathways significantly enriched for the HF34DHPVL versus LF diet 
comparison. Ultimately, EC supplied in combination with the HF diet of mice significantly affected 
many hepatic pathways, as it did when supplied to the LF diet. On the other hand, 34DHPVL had 
almost no significant effects on pathways under HF diet fed conditions but had a large effect under 
LF diet fed conditions. 
The top 10 upregulated and top 10 downregulated KEGG and REACTOME pathways affected by the 
diets are displayed in Appendix Tables 2-15. The sign in front of the normalised enrichment score 
(NES) indicates whether the specific pathway was up or downregulated. The top hepatic pathways 
upregulated for the HF versus LF diets include: amino acid metabolism, fatty acid metabolism, drug 
metabolism and the PPAR signalling pathway, all of which are strongly linked to the pathogenesis 
of MAFLD, whilst the top downregulated pathways include a reduction in gene transcriptions 
associated with cell adhesion molecules, tight junctions and cell cycle progression (Appendix Tables 
2 & 9). In contrast, the HF+EC diet compared to the HF diet reversed some of these changes by 
downregulating amino acid, fatty acid, starch and sucrose metabolic pathways as well as PPAR 
signalling and transcriptome which are involved in the citrate cycle. This therefore suggests the 
protective effects that EC confer on hepatic tissues to reduce MAFLD, including lipid storage, and 
glucose production, which in return have favourable outcomes of mitigating insulin resistance 
(Appendix Tables 3 & 10). Interestingly, supplementation of EC into the HF diet also upregulated 
genes involved in immune response and inflammatory pathway activation such as toll like receptor 
signalling (TLR), Jak-Stat signalling, NOD like receptor signalling, cytokine-cytokine signalling, 
amongst others, whilst also increasing the expression of the ‘ribosome’ pathway, which has been 
shown to have antifibrotic effects as well as supporting cell cycle progression, apoptosis and DNA 
damage responses (557).  
No enriched pathways were detected for the HF+34DHPVL versus HF diet comparison as can be 
seen by the large FDR q-values (Appendix Table 4). The only two KEGG pathways that had an FDR 
q-value < 0.25 are involved in the increased regulation of mismatch repair and base excision repair 




DNA, most likely caused by the HF diet and MAFLD. All other pathways listed were not significantly 
enriched. This result was also confirmed in the REACTOME pathway analysis of the pairwise 
comparison (Appendix Table 11).  
Like the effects of EC supplemented into the HF diet, EC supplemented into the LF diet and 
compared to the LF control caused an increase in pathways involved with immune response and 
inflammation. For pathway downregulation, oxidative phosphorylation was a significantly enriched 
KEGG pathway (Appendix Table 7). REACTOME pathway analysis also confirms these results, in 
addition, there was also a significant downregulation in ‘CHREBP metabolic gene expression’ 
(Appendix Table 14) which is involved in DNL processes.  
Although 34DHPVL did not cause pathway changes under HF diet fed conditions, it was able to 
significantly increase the expression of many pathways, particularly with regards to inflammation 
and immune responses, and decreased pathway expression for amino acid metabolism, oxidative 
phosphorylation, and CHREBP under LF diet fed conditions (Appendix Tables 8 & 15). Therefore, 
34DHPVL caused gene expression changes comparable to those caused by EC under LF diet fed 
conditions.  
The pathways enriched for the comparisons of HF+EC versus LF (Tables 7 & 14), and HF+34DHPVL 
versus LF (Tables 8 & 15), illustrates the general changes for the effects of HF diets on hepatic 
transcription for: raising amino acid, fatty acid, pyruvate, and lipid metabolism as well as the citric 
acid cycle, but reduces the expressions for cell cycle and ribosomal genes. Nonetheless, these 
effects were weaker in HF+EC conditions when compared to HF or HF+34DHPVL conditions, and 
their expression was downregulated when compared to the HF diet.  
 
 
5.5.4 qRT-PCR confirms differential expression changes identified via RNA-
sequencing  
To validate the changes seen from differential gene expression following RNA-seq, qRT-PCR was 
run on a selection of 28 genes for validation of different pathways for genes: SOCS5, TNF, ITGAM 
(encoding CD11B), CD86, CD14, BAX, CASP9, PTEN, CHUK, SLC2A2, ENPP2, ALDH7A1, ACADM, 
ALD3HA2, ACAA1, AGL1, GYS2, GBE1, PDHA1, SUCLG1, PPARG, PPARA, PPARD, FABP2, IGFBP1, 
STEAP4, AKT1, and housekeeping genes EIF2A and ACTB. These represent pathways involved in 
cytokine signalling, inflammation, P53 signalling, glucose transporters, lipid metabolism, fatty acid 




and MAPK signalling; all reported to be involved in the development of MAFLD and type-2 diabetes. 
As qRT-PCR is a more sensitive method for determining gene expression values, it was of interest 
to determine how close the RNA-seq gene expression fold changes were to qRT-PCR fold changes 
for sequenced only samples in addition to all of the mice samples used in the intervention, in order 
to determine if the samples selected were reflective of the overall sample size.  
Changes in gene expressions were calculated using the delta CT method for the housekeeping gene 
EIF2A, this was validated to be the most stably expressed gene for hepatic tissues from this dietary 
intervention study (Appendix Table 1). Although ACTB was also validated as the 2nd most stably 
expressed gene, the results were almost identical following delta CT calculations, so only the results 
optimised relative to EIF2A have been shown here. These data were then transformed (natural 
logarithm) to produce the graphs in Figure 5.6, and statistical analyses were performed by linear 
regression models in R studio. To summarise statistical significance, upregulated changes were 
found for HF versus LF pairwise comparison for the following genes: P53 signalling - PTEN (p = 
0.0007), CHUK (p = 0.0024); lipid metabolism - ENPP2 (p < 0.0001); fatty acid metabolism - ALDH7A1 
(p = 0.0003), ACADM (p = 0.0001), ACAA1 (p = 0.0006); starch and sucrose metabolism - AGL1 (p = 
0.0316), GYS2 (p = 0.0019), GBE1 (p = 0.0136); citric acid cycle - PDHA1 (p = 0.0006), SUCLG1 (p = 
0.0024), and PPAR signalling - PPARG (p < 0.0001), and FABP2 (p = 0.0195).  
For HF+EC versus HF comparison, the following genes were significantly downregulated: cytokine 
signalling - SOCS5 (p = 0.0459); P53 signalling - PTEN (p = 0.0807), CHUK (p = 0.030); lipid metabolism 
- ENPP2 (p = 0.0207); and citric acid cycle - PDHA1 (p = 0.0386). None of the genes investigated by 
qRT-PCR were significantly altered for the HF+34DHPVL versus HF comparison.  
For the LF+EC and LF+34DHPVL versus LF comparison, only one gene was significantly 
downregulated according to the qRT-PCR data, this was for the inflammatory marker CD86 (p < 
0.05).  
Graphs were then plotted to visualise the Log2 fold change for pairwise comparisons from: RNA-
Seq differential expression values, qRT-PCR data on only the samples used for RNA-Seq, and finally 
following qRT-PCR from all the mice liver samples obtained from the intervention. As can be seen 
in Figure 5.7 and Table 5.13, the general change in regulation for most of the genes was consistent 
for each of the data points, indicating that the samples used for RNA-Seq were representative of 
the whole population of mice from the intervention. The few cases where this did not apply are 
highlighted in red in Table 5.13. For example, with regards to the HF vs LF comparison for SOCS5, 
differential expression from RNA-Seq highlights an increased regulation, whilst qRT-PCR highlighted 




the intervention. Although there are some highlighted expressions that have opposing regulations, 












Figure 5.6: qRT-PCR delta CT expressions of genes 
Bar graphs for genes amplified via qRT-PCR from the hepatic tissues of the mice from the dietary intervention study. All data is presented as Log2 transformations 
for the expressions of genes relative to the housekeeping gene EIF-2α. Error bars represent standard error. A) Genes involved in cytokine signalling; B) Genes 
involved in inflammation; C) Genes involved in P53 signalling; D) Genes involved with glucose transporters and lipid metabolism; E) Genes involved in fatty acid 
metabolism; F) Genes involved in starch and sucrose metabolism; G) Genes involved in the citric acid cycle; H) Genes involved in PPAR signalling; I) Genes 
involved in insulin resistance and MAPK signalling. Significance * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared to LF diet. +p < 0.05, ++ p < 0.01, 








Figure 5.7: qRT-PCR Log2 fold changes and differential expressions of  genes per treatment comparison 
Bar graphs for genes from the hepatic tissues of the mice from the dietary intervention study: from RNA-Seq differential gene expressions (DGE) (bars with dots); amplified 
via qRT-PCR for the 42 samples sent off for sequencing (bars with no pattern); amplified by qRT-PCR for the mice livers harvested (bars with horizontal lines). All data is 
presented as Log2 fold-changes for gene expressions (DGE data), relative to the housekeeping gene EIF-2α (qRT-PCR data), per pairwise comparison. A) Genes involved in 
cytokine signalling; B) Genes involved in inflammation; C) Genes involved in P53 signalling; D) Genes involved with glucose transporters and lipid metabolism; E) Genes involved 
in fatty acid metabolism; F) Genes involved in starch and sucrose metabolism; G) Genes involved in the citric acid cycle; H) Genes involved in PPAR signalling; I) Genes involved 





5.5.5 Hepatic genes and pathway expressions increased in response to HF 
diet fed mice for MAFLD  
Following differential gene expression and GSEA results, this section will focus on the genes and 
pathways that have been induced and downregulated in response to a HF fed diet when compared 
to the LF fed conditions. It will then explore how EC mitigated these changes whilst 34DHPVL caused 
no significant impact.  
Some of the most significantly enriched KEGG pathways (FDR q-value ≤ 0.25) upregulated in this 
current study and shown to be linked to MAFLD are: ABC transporters, amino acid metabolism 
(butanoate, glycine, serine, threonine, valine, tryptophan, leucine and isoleucine), citrate cycle, 
ether/glycerolipid/pyruvate/starch and sucrose metabolism, fatty acid metabolism, 
glycolysis/gluconeogenesis, metabolism of xenobiotics by cytochrome P450, oxidative 
phosphorylation, peroxisome, PPAR signalling, and steroid biosynthesis. The top downregulated 
pathways includes ribosome and spliceosome, with subtle decreases for cell-cycle, cytokine 
receptors, MAPK signalling, NOD like receptor signalling, phosphatidylinositol signalling and T-cell 
receptor signalling. Therefore, the development of MAFLD is strongly associated with increased 
metabolism including oxidative phosphorylation, and PPAR signalling, and decreased ribosomal 
activity. A comparison of these effects to a published study is provided later (section 5.6.1). 
In contrast, the addition of EC into the HF diet and compared to the HF treatment group reversed 
expression in all of the aforementioned pathways except for PPAR signalling, cell cycle, and steroid 
biosynthesis. This suggests that EC had protective effects against insulin resistance and MAFLD by 
modifying these pathways/functions. Moreover, although in the majority of cases the effects were 
not significant, the addition of 34DHPVL into the HF diet and compared to the HF treatment group 
also reversed nearly all of the aforementioned pathways except for spliceosome, cell cycle, ABC 
transporters, pyruvate metabolism, and metabolism of xenobiotics by cytochrome P450. However, 
the effects were not as strong as those induced by EC which was seen by the higher FDR q-values, 
but it does provide evidence that 34DHPVL provides a level of protection against MAFLD.  
 
5.5.6 (−)-Epicatechin and 3’,4’-dihydroxyphenyl-γ-valerolactone 
supplementation caused improvements in insulin sensitivity in both the high-
fat and low-fat diets 
The overarching aim of the investigation was to determine whether 34DHPVL could mitigate against 




showed altered expression. In chapter 3, a GTT experiment in mice revealed whether they were 
insulin resistant or insulin sensitive, and the HF+EC fed mice exhibited slightly lower blood insulin 
levels than the HF fed mice but responded more quickly in lowering their glucose levels. Contrary 
to expectations, HF+34DHPVL fed mice exhibited substantially increased insulin levels but lower 
glucose concentrations throughout the GTT. Gene expression analysis has provided insights to help 
explain these results. 
From investigating genes involved in insulin signalling, there was a clear reduction in gene 
expression in the HF versus LF comparison, and included PRKAA1, PRKAB1, PRKAB2, PRKAG1, LEPR, 
CREB1, MMP7, H19, IRS2, PIK3CB, PIK3CD, PIK3CG, HMGA1, SHC1, SHC2, AKT1 and IGFBP1. 
Meanwhile, genes that are involved in causing a reduction in insulin signalling included FAS, FOXO1, 
FOXO3, FOXO4, PD1, PDK2, PDK3, PDK4, MAPK9 (JNK2), and SOCS5, (Table 5.15). The insulin 
signalling KEGG pathway was also negatively enriched (NES = -0.78, FDR q-value = 1.00).  
In contrast, EC in the HF diet altered the expression levels for most of these genes to promote 
insulin sensitivity, by increasing the expression of genes linked to insulin signalling for PRKAB1, 
PRKAG1, LEPR, CREB1, STEAP4, MMP7, IRS2, PIK3CB, PIK3CD, PIK3CG, INSR, SHC1, SHC2, GRB2, 
IGFBP1 and AKT1. Whilst there was a decrease in gene expression linked to promote insulin 
resistance for PDK1, PDK2, PDK3, PDK4, MAPK8 (JNK1), MAPK9 (JNK2) and SOCS5. The insulin 
signalling KEGG pathway was also positively enriched (NES = 1.08, FDR q-value = 0.66).  
The addition of 34DHPVL into the HF diet induced an increase in a few insulin signalling genes, but 
with weaker fold-change effects in comparison to EC (not significant) for PRKAB1, PRKAB2, LEPR, 
STEAP4, H19, PIK3CD, PIK3CG, HMGA1, SHC1, SHC2, GRB2, and AKT1. In addition, there was a 
reduction in the expression for genes that promote insulin resistance for PDK1, PDK3, MAPK8 
(JNK1), MAPK9 (JNK2) and SOCS5. Despite this, the combination of gene changes in favour of insulin 
resistance was associated with the insulin signalling KEGG pathway being negatively regulated (NES 
= -0.90, FDR q-value = 1.00), although this was not significant. To further explain the lower 
circulatory glucose concentrations throughout the GTT, there was a large fold change for the 
increase in gene SLC2A1 that encodes protein GLUT-1 and is primarily involved in the uptake of 
glucose into hepatocytes (558). Furthermore, there was a large decrease in fold change for SLC2A2, 
coding for protein GLUT-2 and has been reported to primarily regulate glucose efflux from 
hepatocytes (558).  
To investigate whether the dietary interventions impacted against insulin degradation for 
decreased insulin clearance from the blood, the gene CEACAM1 was examined. Although the gene 




was a decreased fold change in CEACAM1 for these comparisons: HF vs LF (Log2FC = -0.01), 
HF+34DHPVL vs HF (Log2FC = -0.04), LF+EC vs LF (Log2FC = -0.09) , LF+34DHPVL vs LF(Log2FC = -0.23), 
and HF+34DHPVL vs LF (Log2FC = -0.05). The reduction in expression for these comparisons is 
consistent with the decreased hepatic insulin clearance in MAFLD and insulin resistance, it also 
highlights a possible reason why 34DHPVL decreased insulin clearance in both LF and HF diets 
where the effects were seen to be greater than the HF vs LF comparison, but the changes were 
stronger when 34DHPVL was supplemented into the LF diet.  
When having assessed gene changes linked to insulin signalling for the LF+EC and LF+34DHPVL 
versus LF treatments, genes for insulin signalling expressed an increase in Log2FC for PRKAA1, 
PRKAA2, CREB1, FOXO3, STEAP4, MMP7, H19, IRS2, PIK3CA, PIK3CD, PIK3CG, HMGA1, SHC2, GRB2, 
IGFBP1, and AKT1, and in addition to a decreased expression for genes linked to insulin resistance 
(PDK1, PDK2, PDK3, PDK4, and MAPK9 (JNK2)). The fold changes were always larger in EC fed mice 
compared to 34DHPVL fed mice.  
Further gene changes and pathways were also assessed that are directly or indirectly linked to the 
onset/prevention of insulin resistance. These included genes and pathways involved with oxidative 
phosphorylation, gluconeogenesis (mentioned in section 5.5.8), amino acid metabolism, P53 
signalling and the starch and sucrose metabolic pathway. Oxidative phosphorylation was increased 
for the HF versus LF treatment (NES = 1.58, FDR q-value = 0.058) and was linked to an increase in 
the citric acid cycle (NES = 1.79, FDR q-value = 0.09) which are consistent with the onset of insulin 
resistance. In contrast, EC in the HF diet (oxidative phosphorylation: NES = -1.15, FDR q-value = 
0.442; citric acid cycle: NES = -1.80, FDR q-value = 0.023) and in the LF diet (oxidative 
phosphorylation: NES = -1.71, FDR q-value = 0.150; citric acid cycle: NES = -0.91, FDR q-value = 
0.851) reversed pathway expressions for oxidative phosphorylation and the citric acid cycle which 
contributes to improving insulin sensitivity. Similarly, 34DHPVL also lowered the expression of these 
pathways, but not significantly (oxidative phosphorylation: NES = -0.69, FDR q-value = 1.00; citric 
acid cycle: NES = -0.82, FDR q-value =1.00). 
The ‘starch and sucrose metabolism’ KEGG pathway is closely linked to gluconeogenesis because it 
metabolises carbohydrates for glucose production and it was shown to be increased by the HF diet 
when compared to the LF diet, as represented by gene expression increases in AGL, AMY1, GYS2, 
PGM1, and GBE1, (Table 5.15). All of these HF diet-induced gene and pathway changes were 
reversed when EC was supplemented into the HF diet (NES = -1.86, FDR q-value = 0.014) and LF diet 
(NES = -0.95, FDR q-value = 0.875), whilst 34DHPVL only reversed these in the HF diet (NES = -1.11, 




In addition to alterations in the citric acid cycle and oxidative phosphorylation, amino acid 
metabolism is also impaired in the presence of MAFLD and strongly correlates to insulin resistance 
(559). This has been demonstrated in this study for the HF versus LF treatment comparison where 
the following increases in enrichments for the following pathways were observed: ‘valine, leucine 
and isoleucine degradation’ (NES = 2.56, FDR q-value = 0.000), ‘lysine degradation’ (NES = 1.77, FDR 
q-value = 0.012), ‘arginine and proline metabolism’ (NES = 1.55, FDR q-value = 0.068), ‘proteasome’ 
(NES = 1.88, FDR q-value = 0.004), ‘selenoamino acid metabolism’ (NES = 0.78, FDR q-value = 0.961), 
‘phenylalanine metabolism’ (NES = 1.15, FDR q-value = 0.397), ‘tryptophan metabolism’ (NES = 2.09, 
FDR q-value = 0.000), ‘tyrosine metabolism’ (NES = 0.91, FDR q-value = 0.785), ‘alanine, aspartate 
and glutamate metabolism’ (NES = 1.43, FDR q-value = 0.127), all of which are substrates for the 
citric acid cycle for energy production and linked to increases in oxidative phosphorylation.  
To support EC’s role in mitigating insulin resistance effects and the development of MAFLD, amino 
acid KEGG pathways were reversed for: ‘valine, leucine and isoleucine degradation’ (NES = -2.53, 
FDR q-value = 0.000), ‘lysine degradation’ (NES = -1.36, FDR q-value = 0.201), ‘arginine and proline 
metabolism’ (NES = -0.75, FDR q-value = 1.000), ‘phenylalanine metabolism’ (NES = -0.90, FDR q-
value = 0.857), ‘tryptophan metabolism’ (NES = -1.79, FDR q-value = 0.022), and ‘tyrosine 
metabolism’ (NES = -0.97, FDR q-value = 0.738), in HF diet fed conditions. Additional evidence to 
support an effect of 34DHPVL in protecting against insulin resistance in HF fed conditions, was 
downregulation of the following KEGG pathways: ‘valine, leucine and isoleucine degradation’ (NES 
= -1.69, FDR q-value = 0.422), ‘lysine degradation’ (NES = -0.94, FDR q-value = 0.965), ‘arginine and 
proline metabolism’ (NES = -0.73, FDR q-value = 1.000), ‘tryptophan metabolism’ (NES = -0.74, FDR 
q-value = 1.000), ‘proteasome; (NES = -1.10, FDR q-value = 0.791), and ‘alanine, aspartate and 
glutamate metabolism’ (NES = -1.04, FDR q-value = 0.869). Both EC and 34DHPVL in LF conditions 
caused a reduction in a couple of the amino acid KEGG pathways listed, whilst the others had no 
change. So, although there were not any significantly enriched pathways found for the HF+34DHPVL 
versus HF treatment, the collective observations of gene and pathways changes could possibly 
increase the sensitivity of hepatocytes to insulin. 
The P53 signalling pathway has been shown to negatively regulate the influx of glucose into tissues 
via GLUT transporters (560). Here it was shown for the HF versus LF comparison that there was an 
increase in P53 signalling (NES = 0.83, FDR q-value = 0.944), but this was decreased by the presence 
of EC in combination with the HF treatment (NES = -1.05, FDR q-value = 0.59) and compared to the 
HF treatment. Despite this, in the LF interventions, the addition of EC (NES = 1.00, FDR q-value = 




for P53 signalling. These changes also suggest a lower uptake of glucose into hepatic tissue from 
the circulation.  
 
5.5.7 Hepatic genes and pathway expressions enriched with regards to 
fibrosis 
Chapter 4 reported evidence that there were signs of fibrosis in several mice on LF fed diets, and 
thus gene expression changes were analysed in relation to fibrosis and the following was 
discovered.  
Genes involved in the development of hepatic fibrosis were overall more highly expressed in LF diet 
fed mice compared to HF diet fed mice, and these were particularly linked to the TGF-β and PDGF 
pathways that ultimately lead to an increase in the rate of hepatic fibrosis (Table 5.15). As an 
overview of the results, for the HF versus LF comparison there was a negative Log2FC for differential 
gene expression for the vast majority of genes related to fibrosis (EGFR, VEGFA, TGFB1, TGFB2, 
BMP2, BMP4, BMP5, BMP6, SMAD1, SMAD4, ACTA2, COL1A1, HGF, NFKB1, NFKB2, PDGFA, PDGFB, 
PDGFC, PDGFD, PDGFRA, PDGFRB, MMP2, SEL1L3, and LOXL1), where there was a decrease in the 
KEGG ‘TGF-β signalling pathway’ (NES = -1.37, FDR q-value = 0.66). Meanwhile, the genes that exert 
anti-fibrotic effects and were upregulated included: PPARA, SMAD6, CEBPA, HORMAD2, and APOF. 
The adjusted p-values have been provided in Table 5.15 to highlight the level of significance of these 
gene changes. These data largely support the notion that the LF (also high in carbohydrate) diet 
induces hepatic fibrosis more strongly than the HF diet.  
The inclusion of EC into the HF diet and compared to the HF control caused changes in expression 
for a reduction in genes involved in the development of hepatic fibrosis (albeit insignificantly), 
including PRKCA, CDC42, TGFB1, TGFB2, SMAD2, SMAD5, PDGFD, and COL1A1, and there was an 
increase in anti-fibrotic genes (C1QTNF2, IFNGR2, HORMAD2, and APOF). However, there was also 
an increase in pro-fibrotic genes (EGFR, VEGFA, BMP4, SMAD1, HGF, NFKB1, NFKB2, PDGFC, 
PDGFRA, PDGFRB, and SEL1L3), and a decrease in anti-fibrotic genes (PPARA and SMAD6). 
Nonetheless, the TGF-β signalling pathway was downregulated when compared to the HF control 
(NES = -0.88, FDR q-value = 0.889), but this was not significant. Therefore, the overall effects of EC 
on hepatic fibrosis within the HF diet background suggests that it could be protective against the 
development of hepatic fibrosis. 
In contrast, although there were not significant changes in fibrosis related genes for the 




ACTA2, COL1A1, HGF, NFKB2, PDGFA, PDGFB, PDGFC, PDGFRA, PDGFRB, MMP2, SEL1L3, and LOXL1. 
However, the TGF-β signalling pathway was downregulated (NES = -1.43, FDR q-value = 0.451). 
Despite this, the increase in the above changes in the expression of genes would explain the 
marginally increased mean values for Sirius red staining presented in chapter 4, which stains for 
fibrotic tissues.  
The addition of EC into the LF diet and compared to the LF control did not induce any significant 
gene changes. But, there were several Log2FC changes similar to those seen for EC supplemented 
into the HF diet in mice and caused an overall reduction in the expression of the TGF-β signalling 
pathway (NES = -1.23, FDR q-value = 0.72). Moreover, the addition of 34DHPVL into the LF diet and 
compared to the LF control induced a reduction in Log2FC for EGFR, VEGFA, BMP5, SMAD1, ACTA2, 
COL1A1 and LOX1, implying that it could provide a protective effect from the HC diet on fibrosis, 
despite the fact there were increases in PDGF and TGF signalling genes (TGF-β signalling pathway, 
NES = 1.03, FDR q-value = 0.59). 
 
5.5.8 High-fat diet fed mice experienced more gluconeogenesis and reduced 
de novo lipogenesis compared to low-fat high carbohydrate fed mice 
Gene expression and pathway analysis was assessed for changes in DNL and gluconeogenesis. This 
is because there is an existing body of evidence supporting the notion that LF (high carbohydrate 
(HC)) diets can induce DNL more strongly than HF diets, while HF diets will induce gluconeogenesis 
genes more strongly. Thus, genes were assessed from the mouse livers to determine if such findings 
have been reciprocated in this study.  
The extent to which LF HC diets can extensively affect DNL is discussed later in this chapter. Here, 
the gene changes confirming the effects of HC on DNL are listed in Table 5.15. For the HF versus LF 
diets, there was a downregulation in the following genes: SREBF (SREBP-1c), MLXIPL (ChREBP), 
G6PC, INSIG1, ACACA, AACS, AGPAT1, GPAM (GPAT1), SCAP, PRKAA1, PRKAB1, PRKAB2, and 
PRKAG1. The combination of these gene changes suggests a reduction in DNL processes which is 
linked to the pathway change seen for an increase in the enrichment for ‘fatty acid metabolism’ 
KEGG pathway (NES = 2.50, FDR q-value = 0.000), and its associated genes (ACOX1, ACADM, ACAA1, 
ECI2, ALDH3A2, and ALDH7A1; significantly upregulated, p < 0.001) (to list but a few of the genes). 
A consequence of increased fatty acid metabolism is an increase in glucose production via 




EC supplemented into the HF diet reduced the expression of genes involved in DNL more than the 
HF diet alone (although they were not significantly altered), and there was a reduction in the 
expression of SREBF, G6PC, LIPE, INSIG1, AACS, GPAM, PRKAA1, PRKAA2, PRKAB2, and PRKAG2. 
Additionally, there were reductions in the expression of genes for fatty acid metabolism (ACOX1, 
ACADM, ACCA1, ECI2, ALDH3A2, and ALDH7A1) where the KEGG pathway was also significantly 
downregulated (NES = -2.27, FDR q-value = 0.000). In turn, this highlights that EC induced a 
protective effect on hepatocytes by reducing the production of lipids, and ultimately mitigating 
against the severity of hepatic steatosis effects induced by HF diets.  
HF+34DHPVL fed mice compared to HF fed mice exhibited an overall increase (but not statistically 
significant) in the expression of DNL genes including MLXIPL, INSIG1, ACACA, AACS, AGPAT1, GPAM, 
PRKAB1, PRKAB2, and PRKAG1. Interestingly, there was a decrease in the expression of fatty acid 
metabolism genes (ACOX1, ACADM, ACAA1, ECI2, and ALDH7A1), and although the KEGG pathway 
was not significantly enriched (NES = -1.33, FDR q-value = 0.523), it was still one of the top 20 
downregulated pathways.  
With regards to gluconeogenesis there were several genes that were shown to be changing in the 
pairwise comparisons (Table 5.15). In the HF versus LF comparison, the KEGG ‘gluconeogenesis-
glycolysis’ pathway was significantly enriched (NES = 1.55, FDR q-value = 0.070), and the 
gluconeogenesis genes that were upregulated included (but were not limited to) PCK1 (PEPCK), 
FOXO1, FOXO3, FOXO4, ALDH3A2, ALDH7A1, PDHA1, and CEBPA. Meanwhile PPARGC1A, coding for 
protein PGC-1α (peroxisome proliferator-activated receptor γ coactivator 1α) was downregulated.  
In contrast, EC in the HF diet reversed the gluconeogenesis process, showing a significant reduction 
in its KEGG pathway (NES = -1.49, FDR q-value = 0.118), and also caused a reversal in gene 
expressions for: PPARGC1A, CREB1, FOXO1, FOXO3, FOXO4, ALDH3A2, ALDH7A1, PDHA1 and 
CEBPA.  
Interestingly, HF+34DHPVL fed mice in comparison to HF fed mice showed a downregulation in 
gluconeogenic genes (PCK1, PPARGC1A, G6PC, CREB1, FOXO1, FOXO3, FOXO4, ALDH7A1, PDHA1, 
and CEBPA), whereas the KEGG pathway was upregulated for glycolysis linked genes (NES = 1.47, 
FDR q-value = 0.361), but not for gluconeogenic genes, although none of these changes reached 
statistical significance. 
In contrast to the HF diet, EC supplemented into the LF diet and compared to the LF control induced 
a slight increase in the expression of gluconeogenic genes except for PPARGC1A, FOXO4, ALDH7A1, 




the gluconeogenesis-glycolysis KEGG pathway was not significantly enriched (NES = 0.84, FDR q-
value = 0.854). Similar observations applied to mice provided diets of 34DHPVL in combination with 
the LF diet, where genes except for PPARGC1A, G6PC, FOXO1, ALDH7A1, PDHA1 and CEPBA were 
increased (not significant) and the gluconeogenesis-glycolysis KEGG pathway was not significantly 




Table 5.13: Log2FC values for changes in gene expression following qRT-PCR or RNA-sequencing analysis 
For each pairwise comparison shown are gene expressions from the liver tissues of the mice from the dietary intervention study: from RNA-Seq differential gene expressions 
(DGE); amplified via qRT-PCR for the 42 samples sent off for sequencing; amplified by qRT-PCR for all the mice livers harvested. Only genes targeted by qRT-PCR have been 
presented here alongside the main biological pathways they are involved with. Red text highlights genes that have non-consistent regulation as detected by qRT-PCR or RNA-
Seq; for example; the ITGAM gene for comparison HF+34DHPVL vs HF shows positive regulation by RNA-Seq and qRT-PCR of only the samples sent for sequencing, whilst there 
was a negative regulation when performing qRT-PCR on all of the mice livers harvested. 










































































































































































































SOCS5 1.66 0.00 0.00 -0.66 -0.36 -0.37 -2.13 -0.17 -0.24 1.33 0.08 0.08 1.77 0.03 0.22 1.00 -0.37 -0.37 -0.47 -0.18 -0.24 
TNF -0.40 -0.95 -1.21 0.14 0.99 0.35 0.39 0.77 0.18 1.48 0.47 -0.44 2.75 1.53 0.57 -0.25 0.04 -0.85 -0.01 -0.17 -1.03 
Inflammati
on 
ITGAM -0.82 -0.16 -0.14 0.45 0.22 -0.06 0.43 0.14 -0.16 0.71 0.83 0.49 1.24 0.82 0.73 -0.37 0.06 -0.20 -0.39 -0.02 -0.30 
CD86 0.19 0.39 0.27 0.22 0.02 0.27 -0.06 -0.07 0.18 0.80 0.63 0.71 1.33 1.14 1.17 0.41 0.40 0.38 0.13 0.32 0.45 
CD14 -0.66 -0.77 -0.98 1.50 1.64 0.72 0.34 0.74 0.07 1.43 0.59 -0.30 1.85 0.42 -0.22 0.84 0.86 -0.26 -0.33 -0.03 -0.91 
P53 
signalling 
BAX 0.41 0.33 0.59 -0.31 -0.34 -0.62 -0.16 0.11 -0.38 -0.16 0.29 0.29 -0.08 0.12 0.22 0.09 -0.01 -0.02 0.25 0.43 0.22 
CASP9 0.20 0.53 0.62 -0.15 -0.40 -0.57 -0.01 -0.16 -0.46 -0.16 -0.11 -0.32 -0.14 -0.39 -0.46 0.05 0.13 0.05 0.20 0.37 0.16 
PTEN 0.20 0.55 0.47 -0.20 -0.28 -0.23 -0.21 -0.19 -0.14 -0.15 0.15 0.12 -0.02 0.10 0.17 0.00 0.26 0.25 -0.01 0.35 0.33 
CHUK 0.24 0.69 0.69 -0.18 -0.37 -0.45 -0.16 -0.27 -0.39 -0.12 0.11 0.08 0.02 0.13 0.17 0.07 0.32 0.25 0.08 0.42 0.31 
Glucose 
transporter 
SLC2A2 0.44 0.76 0.37 -0.48 -0.48 -0.14 -0.25 -0.41 -0.05 -0.10 0.00 -0.12 -0.06 0.09 0.13 -0.04 0.28 0.23 0.20 0.35 0.32 
Lipid 
metabolism 
ENPP2 0.86 1.32 1.22 -0.40 -0.53 -0.43 -0.22 -0.34 -0.30 0.20 0.43 0.25 0.12 0.16 0.19 0.46 0.79 0.79 0.63 0.98 0.92 
Fatty acid 
metabolism 
ALDH7A1 0.43 1.77 1.91 -0.12 0.81 0.71 -0.10 0.82 0.72 -0.08 1.03 1.01 -0.04 0.87 0.95 0.31 1.43 1.35 0.33 1.45 1.36 
ACADM 0.86 1.07 0.99 -0.35 -0.33 -0.23 -0.10 -0.24 -0.27 0.07 0.11 0.06 0.23 0.09 0.13 0.51 0.75 0.76 0.77 0.83 0.73 
ALDH3A2 1.77 1.80 1.67 -0.55 -0.51 -0.37 0.01 -0.18 -0.26 0.12 0.21 0.14 0.29 0.28 0.37 1.22 1.29 1.30 1.78 1.62 1.41 





Table 5.13: Gene expression Log2FC values for differential gene expression or qRT-PCR (continued)  











































































































































































































AGL1 0.51 0.65 0.59 -0.42 -0.41 -0.39 -0.27 -0.32 -0.37 0.04 0.04 -0.08 0.09 -0.02 -0.04 0.09 0.24 0.21 0.24 0.32 0.22 
GYS2 0.71 1.08 0.90 -0.42 -0.54 -0.39 -0.24 -0.35 -0.23 -0.07 0.06 0.04 0.21 0.20 0.26 0.29 0.54 0.51 0.47 0.73 0.67 
GBE1 0.53 0.95 0.73 -0.37 -0.43 -0.36 -0.13 -0.23 -0.32 -0.09 0.09 -0.11 0.28 0.26 0.14 0.16 0.52 0.38 0.40 0.72 0.41 
Citric acid 
cycle 
PDHA1 0.49 0.85 0.80 -0.32 -0.48 -0.45 -0.12 -0.23 -0.39 -0.08 0.07 -0.03 -0.01 -0.07 -0.01 0.18 0.37 0.35 0.38 0.61 0.41 
SUCLG1 0.44 0.90 0.86 -0.24 -0.38 -0.39 -0.03 -0.26 -0.41 0.04 0.26 0.21 0.12 0.02 0.10 0.21 0.52 0.47 0.41 0.63 0.45 
PPAR 
signalling 
PPARG 1.53 2.04 1.99 -0.56 -0.65 -0.57 0.07 -0.12 -0.36 0.22 0.36 0.15 0.78 0.73 0.62 0.97 1.39 1.43 1.60 1.92 1.63 
PPARA 1.01 1.17 1.18 -0.20 -0.47 -0.48 0.04 -0.29 -0.40 0.12 -0.08 -0.24 -0.02 -0.03 -0.09 0.82 0.70 0.70 1.05 0.88 0.78 
PPARD -1.06 -2.26 -2.00 0.23 -0.20 -0.34 0.07 -0.53 -0.37 0.16 1.34 1.23 -0.04 -1.89 -1.21 -0.83 -2.46 -2.34 -0.99 -2.78 -2.36 
FABP2 1.30 1.13 1.20 -0.46 -0.58 -0.52 -0.04 -0.23 -0.50 -0.03 0.69 0.62 0.26 -0.62 -0.37 0.84 0.55 0.68 1.25 0.91 0.70 
Insulin 
resistance 
IGFBP1 -2.08 -1.40 -1.57 2.52 1.59 0.98 0.69 0.03 -0.22 1.34 1.60 1.17 1.14 1.29 0.76 0.44 0.18 -0.59 -1.39 -1.37 -1.79 
STEAP4 0.41 0.77 0.80 2.12 1.87 1.42 0.13 0.11 0.18 0.64 0.84 0.85 0.53 0.59 0.57 2.54 2.64 2.22 0.54 0.88 0.98 
MAPK 
signalling 






Table 5.14: Gene set enrichment analysis KEGG pathway changes for data obtained by me (Helleur) and compared to Teufel et al (561) 
The KEGG pathways listed are those seen to be enriched in both the current study and in Teufel’s study. Whilst the current study shows the GSEA results for the livers of high-
fat diet (HFD) versus low-fat diet (LFD) fed mice treatments, Teufel’s study is for GSEA results from the livers of: healthy obese humans, human livers exhibiting MAFLD, human 
livers exhibiting NASH, mice livers fed HFD for 12-weeks/18-weeks/30 weeks, and all compared to ‘normal’ control subjects. This table highlights the strong similarities seen 
from the current study and a published study with regards to pathway changes on HF diets. KEGG pathways highlighted in: red – reflects pathways that are not expressed in 
the same direction for my data in the current study versus any of Teufel’s data; green – reflects pathways that are expressed in the same direction for data in the current study 
and for at least one sample of Teufel’s human data and one sample of their mice data; blue – pathways that are expressed in the same direction for data in the current study 
and at least one of Teufel’s mice data. FDR q-values higlighted in red corresponds to those pathways that are seen to be significantly enriched, where q < 0.25 was set as the 
threshold 
 
Helleur's data Teufel et al's data 
GSEA Treatments  HFD vs LFD mice 
Healthy obese 
humans 




























































































































ABC TRANSPORTERS up 0.058 up 0.606 up 0.034 up 0.355 up 0.863 up 0.012 down 0.854 
ALLOGRAFT REJECTION  down 0.993 up 0.891 up 0.211 up 0.022 down 0.774 up 0.460 up 0.547 
ANTIGEN PROCESSING AND PRESENTATION  down 1.000 up 1.000 up 0.060 up 0.025 down 0.133 up 0.368 up 0.087 
ARGININE AND PROLINE METABOLISM up 0.068 down 0.659 down 0.260 down 0.040 down 0.098 down 0.843 down 0.965 
ARRHYTHMOGENIC RIGHT VENTRICULAR 
CARDIOMYOPATHY (ARVC) 
down 0.647 up 0.211 up 0.061 up 0.024 down 0.961 down 0.960 down 0.933 
ASTHMA down 0.979 down 0.839 up 0.121 up 0.046 down 0.416 up 0.101 up 0.178 
AUTOIMMUNE THYROID DISEASE down 1.000 up 0.326 up 0.050 up 0.008 down 0.821 up 0.354 up 0.501 
AXON GUIDANCE down 0.808 up 0.118 up 0.047 up 0.053 up 0.818 down 0.960 down 0.951 
B CELL RECEPTOR SIGNALING PATHWAY  up 1.000 up 0.057 up 0.004 up 0.002 up 0.940 up 0.992 down 0.974 
BLADDER CANCER down 0.429 down 0.688 up 0.171 up 0.001 up 0.831 down 0.908 down 0.879 
BUTANOATE METABOLISM up 0.000 down 0.885 up 0.914 down 1.000 down 0.126 up 0.003 up 0.109 





Table 5.14: Gene set enrichment analysis KEGG pathway changes for data obtained by me (Helleur) and compared to Teufel et al (561) (continued) 
 Helleur's data Teufel et al's data 
GSEA Treatments 
 
HFD vs LFD mice 
Healthy obese 
humans 




























































































































CELL CYCLE down 0.590 down 0.122 up 0.191 up 0.000 down 0.914 down 0.680 up 0.914 
CHEMOKINE SIGNALING PATHWAY down 0.971 up 0.569 up 0.115 up 0.004 up 0.829 up 0.604 down 0.857 
CHRONIC MYELOID LEUKEMIA down 0.848 up 0.827 up 0.345 up 0.028 up 0.732 down 0.965 down 0.905 
CITRATE CYCLE (TCA CYCLE) up 0.009 down 0.905 down 1.000 down 1.000 down 0.000 up 0.583 up 0.124 
COLORECTAL CANCER down 0.768 up 0.608 up 0.116 up 0.017 up 0.891 down 0.971 up 0.792 
COMPLEMENT AND COAGULATION Cascades up 0.606 up 0.172 up 0.018 up 0.175 down 0.010 down 0.004 up 0.281 
CYTOKINE-CYTOKINE RECEPTOR INTERACTION down 0.792 down 0.387 up 0.099 up 0.004 down 0.819 up 0.612 up 0.753 
DNA REPLICATION up 0.957 down 0.989 up 0.013 up 0.000 up 0.924 down 0.680 up 0.417 
ECM-RECEPTOR INTERACTION down 0.137 up 0.170 up 0.000 up 0.000 up 0.917 up 0.359 up 0.135 
EPITHELIAL CELL SIGNALING IN HELICOBACTER 
PYLORI INFECTION 
down 1.000 up 0.781 up 0.410 up 0.044 down 0.829 up 0.497 up 0.265 
ERBB SIGNALING PATHWAY down 0.777 up 0.419 up 0.490 up 0.023 up 0.844 up 0.976 up 0.736 
ETHER LIPID METABOLISM up 0.091 up 0.350 up 0.181 up 0.323 up 0.931 up 0.326 up 0.007 
FATTY ACID METABOLISM up 0.000 up 0.496 up 0.749 up 0.666 down 0.068 up 0.014 up 0.012 
FC EPSILON RI SIGNALING PATHWAY down 1.000 up 0.055 up 0.000 up 0.001 down 0.972 up 0.775 up 0.943 
FC GAMMA R-MEDIATED PHAGOCYTOSIS down 0.635 up 0.113 up 0.003 up 0.000 down 0.919 up 0.583 up 0.817 
FOCAL ADHESION down 0.335 up 0.082 up 0.000 up 0.000 up 0.906 up 0.504 up 0.286 
GLIOMA down 0.879 up 0.545 up 0.195 up 0.021 up 1.000 up 0.669 up 0.877 
GLUTATHIONE METABOLISM up 0.440 down 0.060 down 0.041 down 1.000 down 0.024 up 0.085 up 0.003 




Table 5.14: Gene set enrichment analysis KEGG pathway changes for data obtained by me (Helleur) and compared to Teufel et al (561) (continued) 
 Helleur's data Teufel et al's data 
GSEA Treatments 
 
HFD vs LFD mice 
Healthy obese 
humans 




























































































































GLYCINE, SERINE AND THREONINE metabolism up 0.318 up 0.541 down 1.000 down 0.498 down 0.027 up 0.517 down 0.791 
GLYCOLYSIS_GLUCONEOGENESIS up 0.070 up 0.417 up 0.019 up 0.107 down 0.020 down 0.553 up 0.440 
GNRH SIGNALING PATHWAY  down 0.839 up 0.173 up 0.068 up 0.025 up 0.907 down 0.843 up 0.851 
GRAFT-VERSUS-HOST DISEASE  down 1.000 up 0.887 up 0.179 up 0.010 down 0.122 down 0.839 up 0.751 
HEMATOPOIETIC CELL LINEAGE  down 0.773 up 0.494 up 0.013 up 0.000 down 0.273 down 0.661 down 1.000 
HOMOLOGOUS RECOMBINATION down 1.000 up 0.651 up 0.104 up 0.002 down 0.785 down 0.993 down 0.995 
HUNTINGTON'S DISEASE up 0.818 down 0.401 down 0.027 down 0.035 down 0.009 down 0.695 up 0.003 
INTESTINAL IMMUNE NETWORK FOR IGA 
PRODUCTION 
up 1.000 up 0.766 up 0.067 up 0.018 down 0.613 up 0.338 up 0.695 
LEISHMANIA Infection down 0.801 up 0.170 up 0.000 up 0.000 down 0.455 down 0.683 down 0.968 
LEUKOCYTE TRANSENDOTHELIAL MIGRATION down 0.690 up 0.128 up 0.002 up 0.000 up 0.930 up 0.349 up 0.517 
LINOLEIC ACID METABOLISM up 0.167 up 0.542 up 0.775 down 0.986 down 0.789 up 0.265 up 0.041 
MAPK SIGNALING PATHWAY down 0.817 up 0.169 up 0.093 up 0.014 up 0.839 down 0.686 down 0.862 
MELANOMA up 0.660 up 0.770 up 0.402 up 0.084 up 0.751 up 0.924 up 0.738 
METABOLISM OF XENOBIOTICS BY 
CYTOCHROME P450 
up 0.106 down 0.591 down 0.039 down 0.038 down 0.025 up 0.008 up 0.002 
NATURAL KILLER CELL MEDIATED CYTOTOXICITY down 1.000 up 0.341 up 0.019 up 0.004 up 0.779 up 0.601 down 0.868 
NEUROTROPHIN SIGNALING PATHWAY down 0.798 up 0.389 up 0.209 up 0.023 down 0.629 down 0.667 down 0.884 
NOD-LIKE RECEPTOR SIGNALING PATHWAY down 1.000 down 1.000 up 0.170 up 0.004 down 0.190 down 0.605 down 0.936 
NON-SMALL CELL LUNG CANCER down 1.000 up 0.209 up 0.078 up 0.012 up 1.000 up 0.918 up 0.932 
OLFACTORY TRANSDUCTION down 0.787 down 0.439 up 0.000 down 0.006 up 1.000 up 0.963 down 0.893 




Table 5.14: Gene set enrichment analysis KEGG pathway changes for data obtained by me (Helleur) and compared to Teufel et al (561) (continued) 
 Helleur's data Teufel et al's data 
GSEA Treatments 
 
HFD vs LFD mice 
Healthy obese 
humans 




























































































































P53 SIGNALING PATHWAY up 0.944 down 0.165 down 0.919 up 0.045 up 0.798 down 0.838 down 0.982 
PANCREATIC CANCER down 0.760 up 0.501 up 0.033 up 0.000 up 0.780 up 0.610 down 0.908 
PARKINSON'S DISEASE up 0.089 down 0.662 down 0.033 down 0.018 down 0.000 down 0.780 up 0.001 
PATHOGENIC ESCHERICHIA COLI infection down 0.873 down 0.430 down 0.839 up 0.768 down 0.001 down 0.548 up 0.041 
PATHWAYS IN CANCER down 0.831 up 0.376 up 0.094 up 0.002 up 0.765 up 0.502 up 0.694 
PENTOSE PHOSPHATE PATHWAY down 0.827 down 0.997 up 0.955 up 1.000 down 0.050 down 0.677 down 0.932 
PEROXISOME up 0.000 up 1.000 up 0.485 up 1.000 down 0.017 up 0.000 up 0.111 
PHOSPHATIDYLINOSITOL SIGNALING SYSTEM down 0.763 up 0.061 up 0.018 up 0.011 up 0.826 down 0.872 down 0.839 
PPAR SIGNALING PATHWAY up 0.001 up 0.383 up 0.000 up 0.000 up 0.814 up 0.015 up 0.462 
PRIMARY BILE ACID BIOSYNTHESIS up 0.008 up 0.123 up 0.099 up 0.093 up 0.692 up 0.026 up 0.064 
PRIMARY IMMUNODEFICIENCY down 0.817 down 0.821 up 0.351 up 0.026 up 0.907 up 0.985 down 0.902 
PRION DISEASES down 1.000 up 0.011 up 0.013 up 0.083 down 0.188 down 0.349 up 0.374 
PROPANOATE METABOLISM up 0.000 down 0.901 down 0.947 down 0.617 down 0.043 up 0.004 up 0.096 
PROSTATE CANCER down 0.755 down 0.895 up 0.282 up 0.045 up 0.686 up 0.641 up 0.910 
PROTEASOME up 0.004 down 0.408 down 0.230 down 0.976 down 0.097 down 0.915 up 0.003 
PROTEIN EXPORT down 0.785 up 1.000 down 1.000 down 1.000 down 0.000 down 0.000 up 0.321 
PROXIMAL TUBULE BICARBONATE reclamation down 1.000 up 0.997 down 1.000 up 0.972 down 0.025 down 0.337 down 0.861 
PYRIMIDINE METABOLISM up 0.374 down 0.752 up 0.926 up 0.699 down 0.436 down 0.917 up 0.379 
PYRUVATE METABOLISM up 0.021 up 1.000 up 0.101 up 0.095 down 0.025 up 0.375 up 0.786 
REGULATION OF ACTIN CYTOSKELETON down 0.694 up 0.205 up 0.082 up 0.008 up 0.887 up 0.619 up 0.732 




Table 5.14: Gene set enrichment analysis KEGG pathway changes for data obtained by me (Helleur) and compared to Teufel et al (561) (continued) 
 Helleur's data Teufel et al's data 
GSEA Treatments 
 
HFD vs LFD mice 
Healthy obese 
humans 




























































































































RIBOSOME down 0.000 down 0.179 down 0.001 down 0.003 down 0.000 down 0.000 up 0.084 
RNA POLYMERASE down 0.991 down 0.405 down 0.075 down 0.208 down 0.631 down 0.098 down 0.985 
SMALL CELL LUNG CANCER down 0.757 up 0.349 up 0.000 up 0.000 up 0.752 up 0.491 up 0.548 
SNARE INTERACTIONS IN VESICULAR transport up 0.669 up 0.956 up 0.790 up 0.096 down 0.055 down 0.347 up 0.298 
SPHINGOLIPID METABOLISM up 0.414 down 0.897 up 0.349 up 0.391 up 0.944 down 0.783 up 0.020 
SPLICEOSOME down 0.085 down 0.996 down 0.151 down 0.891 down 0.328 down 0.009 down 0.876 
STARCH AND SUCROSE METABOLISM up 0.187 up 0.368 up 0.085 up 0.032 down 0.088 down 0.225 up 0.773 
STEROID BIOSYNTHESIS up 0.349 up 0.105 up 0.192 up 0.111 down 0.026 up 0.000 down 0.156 
STEROID HORMONE BIOSYNTHESIS up 0.368 up 0.377 up 0.107 up 0.470 down 0.626 up 0.214 up 0.378 
SYSTEMIC LUPUS ERYTHEMATOSUS down 1.000 down 0.679 up 0.482 up 0.405 down 0.026 down 0.120 up 0.173 
T CELL RECEPTOR SIGNALING PATHWAY down 1.000 up 0.381 up 0.066 up 0.002 down 0.799 down 0.957 down 0.871 
TOLL-LIKE RECEPTOR SIGNALING PATHWAY down 1.000 down 0.824 up 0.194 up 0.002 down 0.508 up 0.509 up 0.548 
TRYPTOPHAN METABOLISM up 0.000 up 0.758 down 0.743 down 0.739 down 0.016 up 0.210 up 0.160 
TYROSINE METABOLISM up 0.785 up 0.220 down 1.000 down 1.000 down 0.038 down 0.407 down 0.997 
VALINE, LEUCINE AND ISOLEUCINE degradation up 0.000 up 0.997 down 1.000 down 1.000 down 0.027 up 0.007 up 0.028 
VASCULAR SMOOTH MUSCLE CONTRACTION down 0.996 up 0.081 up 0.100 up 0.026 down 0.797 down 0.921 down 0.920 
VEGF SIGNALING PATHWAY down 0.916 up 0.079 up 0.010 up 0.041 up 0.779 up 0.668 up 0.661 




Table 5.15: Differential gene expression results for some important genes highlighted to be of importance for MAFLD and hepatic insulin resistance 
All data is obtained following DESeq2 analysis of RNA-Sequencing data from the livers of mice from the dietary intervention study. Genes selected were chosen based on their 
involvement in pathways/metabolic functions altered in metabolic syndrome. p.adj = adjusted p-value. A negative Log2FC corresponds to a downregulation of the gene for 
the pairwise comparison, and vice versa. 
Pairwise comparison HF vs LF HF+EC vs HF 
HF+34DHPVL vs 
HF 
LF+EC vs LF 
LF+34DHPVL vs 
LF 




the gene is involved in 


















































De novo lipogenesis 




0.869 -0.132 1.000 -0.005 0.997 -0.028 1.000 -0.412 0.958 -0.173 0.905 -0.138 0.872 -0.160 
De novo lipogenesis 
Carbohydrate response 
element binding protein 
MLXIPL 
(CHREBP) 




Glucose 6-phosphatase G6PC 0.759 -0.241 0.983 -0.124 0.998 -0.346 1.000 0.046 0.958 -0.171 0.695 -0.365 0.426 -0.587 
De novo lipogenesis/ anti-lipolysis 
Hormone sensitive lipase 
(HSL) 
LIPE 0.040 0.507 0.971 -0.089 0.998 -0.065 1.000 -0.181 0.845 -0.200 0.167 0.418 0.114 0.442 
De novo lipogenesis Insulin induced gene 1 INSIG1 0.733 -0.203 0.993 -0.054 0.998 0.088 1.000 0.300 0.817 -0.384 0.728 -0.258 0.895 -0.116 
De novo lipogenesis/Apoptosis Acetyl-coa carboxylase 1 ACACA 0.012 -0.853 0.995 0.030 0.998 0.095 1.000 -0.399 0.674 -0.452 0.032 -0.822 0.045 -0.758 
De novo lipogenesis 
Acetoacetyl-coa 
Synthetase AACS 0.301 -0.802 0.995 -0.059 0.998 0.092 1.000 -0.178 0.158 -1.752 0.343 -0.861 0.448 -0.711 






AGPAT1 0.240 -0.305 0.843 0.202 0.998 0.219 1.000 -0.103 0.507 -0.395 0.819 -0.103 0.849 -0.086 






0.718 -0.223 0.906 -0.290 0.998 0.110 1.000 -0.310 0.547 -0.697 0.400 -0.513 0.904 -0.113 





Table 5.15: Differential gene expression results for some important genes highlighted to be of importance for MAFLD and hepatic insulin resistance (continued) 
 
Pairwise comparison HF vs LF HF+EC vs HF 
HF+34DHPVL vs 
HF 
LF+EC vs LF 
LF+34DHPVL vs 
LF 




the gene is involved in 


















































De novo lipogenesis /inhibits glycogen 
synthesis, increases glucose uptake, 
increases fatty acid uptake but reduces 




Subunit Alpha 1 (AMPK1) 
PRKAA1 0.521 -0.118 0.976 -0.048 0.998 -0.113 1.000 0.085 0.735 0.166 0.424 -0.166 0.180 -0.232 
De novo lipogenesis/inhibits glycogen 
synthesis, increases glucose uptake, 
increases fatty acid uptake but reduces 




Subunit Alpha 2 (AMPK2) 
PRKAA2 0.880 0.064 0.972 -0.093 0.998 -0.153 1.000 0.070 0.864 0.197 0.967 -0.029 0.867 -0.089 
De novo lipogenesis/inhibits glycogen 
synthesis, increases glucose uptake, 
increases fatty acid uptake but reduces 




Subunit beta 1 (AMPK) 
PRKAB1 0.493 -0.115 0.717 0.163 0.998 0.116 1.000 -0.008 0.930 0.067 0.866 0.048 0.999 0.000 
De novo lipogenesis/inhibits glycogen 
synthesis, increases glucose uptake, 
increases fatty acid uptake but reduces 




Subunit beta 2 (AMPK) 
PRKAB2 0.285 -0.636 0.998 -0.031 0.998 0.085 1.000 0.196 1.000 -0.006 0.342 -0.667 0.446 -0.552 
De novo lipogenesis/inhibits glycogen 
synthesis, increases glucose uptake, 
increases fatty acid uptake but reduces 




Subunit gamma 1 (AMPK) 
PRKAG1 0.330 -0.162 0.822 0.134 0.998 0.053 1.000 0.142 0.890 -0.095 0.934 -0.028 0.621 -0.109 
De novo lipogenesis/inhibits glycogen 
synthesis, increases glucose uptake, 
increases fatty acid uptake but reduces 
Protein Kinase AMP-
Activated Catalytic 
Subunit gamma 2 (AMPK) 




Table 5.15: Differential gene expression results for some important genes highlighted to be of importance for MAFLD and hepatic insulin resistance (continued) 
 
Pairwise comparison HF vs LF HF+EC vs HF 
HF+34DHPVL vs 
HF 
LF+EC vs LF 
LF+34DHPVL vs 
LF 




the gene is involved in 


















































their synthesis/positive for insulin 
signalling 
Fatty acid metabolism/PPAR 
signalling/Fatty acid beta oxidation 
Acyl-coa Oxidase 2 ACOX1 0.000 0.979 0.731 -0.251 0.998 -0.114 1.000 0.036 0.998 0.007 0.000 0.728 0.000 0.865 
Fatty acid metabolism/PPAR signalling 
Acyl-coa Dehydrogenase 
Medium Chain 
ACADM 0.000 0.862 0.291 -0.354 0.998 -0.095 1.000 0.068 0.692 0.226 0.005 0.508 0.000 0.767 
Fatty acid metabolism/PPAR signalling 
Acetyl-coa 
Acyltransferase 1 
ACAA1 0.000 0.959 0.518 -0.352 0.998 -0.121 1.000 -0.096 0.920 0.219 0.008 0.606 0.000 0.838 
Fatty acid metabolism 
Enoyl-coa Delta 
Isomerase 2 
ECI2 0.020 0.670 0.933 -0.171 0.998 -0.195 1.000 0.042 0.871 0.216 0.170 0.499 0.177 0.475 
Lipolysis/lipid transport 
Retinoic Acid Receptor 
Alpha 
RARA 0.681 0.137 0.930 -0.142 0.998 0.176 1.000 -0.219 0.987 -0.023 0.993 -0.005 0.317 0.313 
Lipolysis (INHIBITS SREBP/ChREBP) 
Nuclear Receptor 
Subfamily 1 Group I 
Member 2 (pregnane x 
receptor) 
NR1I2 (PXR) 0.943 -0.030 0.887 0.170 1.000 0.003 1.000 0.231 0.944 -0.103 0.738 0.141 0.965 -0.026 
Lipolysis (INHIBITS SREBP)/Liver fibrosis 
Nuclear Receptor 
Subfamily 1 Group H 




0.405 0.349 0.956 -0.157 0.998 -0.082 1.000 -0.259 0.915 0.206 0.767 0.192 0.624 0.266 
Lipolysis Lipoprotein lipase LPL 0.002 -1.814 0.997 0.046 0.998 0.331 1.000 0.486 0.892 0.421 0.006 -1.768 0.027 -1.483 
Lipolysis/Ether lipid metabolism 
Phospholipid 
Phosphatase 2 
PLPP2 0.139 -0.522 0.942 0.173 0.998 0.498 1.000 0.447 0.328 0.685 0.466 -0.350 0.978 -0.025 
Lipolysis/Ether lipid metabolism 
Phospholipase A2, group 
VI 
PLA2G6  0.082 0.320 0.351 -0.326 0.998 0.185 1.000 0.027 0.950 0.067 0.990 -0.006 0.003 0.505 




ENPP2 0.000 0.855 0.344 -0.399 0.998 -0.223 1.000 0.200 0.925 0.118 0.060 0.456 0.002 0.632 
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Fatty acid beta oxidation 
Carnitine 
palmitoyltransferase 1 
CPT1A 0.001 0.702 0.942 -0.123 0.998 -0.100 1.000 0.049 0.972 -0.054 0.020 0.579 0.010 0.602 
Fatty acid beta oxidation 
Carnitine 
palmitoyltransferase 2 
CPT2 0.006 0.406 0.976 0.052 0.998 0.016 1.000 0.058 0.967 0.040 0.003 0.459 0.006 0.423 
Fatty acid Biosynthesis 
Monoacylglycerol O-
acyltransferase 1 
MOGAT1  0.000 3.825 0.664 -1.053 0.998 0.313 1.000 -0.251 0.947 0.341 0.000 2.771 0.000 4.138 
Fatty acid Biosynthesis 
Cell death-inducing DNA 
fragmentation factor 
CIDEA  0.000 7.114 0.822 -1.645 0.998 1.198 1.000 2.120 0.526 3.175 0.004 5.469 0.000 8.312 
Fatty acid Biosynthesis 
Microfibril Associated 
Protein 2 
MFAP2 0.239 -2.110 0.995 -0.154 0.998 0.879 1.000 0.204 0.987 0.155 0.277 -2.264 0.612 -1.231 
Fatty acid biosynthesis Stearoyl-coa desaturase SCD1 0.003 -1.676 0.978 -0.179 0.998 0.671 1.000 -0.879 0.856 -0.487 0.002 -1.854 0.168 -1.005 
Reduces fatty acid 
oxidation/Programmed cell  
death/Type I diabetes mellitus/Insulin 
resistance/ 
P53 Signalling pathway/Apoptosis 
Fatty cell surface death 
receptor 
FAS 0.065 0.498 0.991 0.044 0.998 0.071 1.000 0.285 0.656 0.345 0.070 0.542 0.040 0.568 
Apoptosis (in damaged cells)/ Cell 
survival & proliferation (in healthy 
proliferative cells) 
Jun Proto-Oncogene, AP-
1 Transcription Factor 
Subunit 
JUN (AP-1) 0.130 -0.760 0.34 0.873 1.000 0.218 1.000 0.504 0.950 0.183 0.920 0.115 0.400 -0.540 
Fatty acid Biosynthesis Fatt acid synthase FASN 0.062 -1.283 0.998 0.036 0.998 0.158 1.000 -0.582 0.319 -1.416 0.113 -1.247 0.150 -1.125 
Liver regeneration 
Hepatocyte growth factor 
receptor 
MET 0.540 0.370 0.999 -0.003 0.998 -0.078 1.000 -0.365 0.938 -0.225 0.641 0.367 0.713 0.292 
Liver fibrosis Protein kinase C α PRKCA 0.671 0.147 0.727 -0.299 0.998 0.067 1.000 0.069 0.988 0.023 0.738 -0.152 0.569 0.214 
Liver fibrosis Cell division cycle 42 CDC42 0.958 0.013 0.784 -0.141 0.999 0.002 1.000 0.053 0.817 0.127 0.549 -0.127 0.965 0.015 
Liver fibrosis 
Vascular endothelial 
growth factor A 
VEGFA 0.074 -0.397 0.790 0.217 0.998 -0.011 1.000 -0.112 0.441 -0.396 0.603 -0.181 0.085 -0.409 
Liver fibrosis/TGF pathway 
Transforming growth 
factor B 1 
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Liver fibrosis/TGF pathway 
Transforming growth 
factor B 2 
TGFB2 0.319 -1.032 0.884 -0.680 0.998 -0.372 1.000 0.266 0.996 0.049 0.105 -1.712 0.189 -1.404 
Liver fibrosis/TGF pathway E2F Transcription Factor 4 E2F4 0.012 -0.393 0.708 0.202 0.998 0.078 1.000 -0.035 0.864 -0.124 0.409 -0.191 0.080 -0.316 
Liver fibrosis/TGF pathway/lipogenesis 
Bone morphogenic 
protein 2 
BMP2 0.359 -0.260 0.998 0.005 0.998 -0.256 1.000 -0.039 0.891 0.157 0.467 -0.255 0.043 -0.516 
Liver fibrosis/TGF pathway/lipogenesis 
Bone morphogenic 
protein 4 
BMP4 0.178 -0.465 0.775 0.333 0.998 0.202 1.000 -0.113 0.966 -0.084 0.833 -0.132 0.572 -0.264 
Liver fibrosis/TGF pathway/lipogenesis 
Bone morphogenic 
protein 5 
BMP5 0.171 -0.432 0.998 0.017 0.998 0.086 1.000 -0.022 0.737 -0.319 0.268 -0.415 0.373 -0.346 
Liver fibrosis/TGF pathway/lipogenesis 
Bone morphogenic 
protein 6 
BMP6 0.044 -0.550 0.965 -0.107 0.998 0.030 1.000 -0.181 0.972 0.059 0.022 -0.656 0.081 -0.519 
Liver fibrosis/TGF pathway/lipogenesis SMAD Family Member 1 SMAD1 0.000 -0.456 0.731 0.173 0.999 -0.003 1.000 -0.065 0.859 -0.113 0.099 -0.283 0.001 -0.459 
Liver fibrosis/TGF pathway/lipogenesis SMAD Family Member 2 SMAD2 0.779 0.124 0.932 -0.170 0.998 -0.343 1.000 -0.103 0.972 -0.065 0.949 -0.047 0.633 -0.219 
Anti-fibrogenic/TGF pathway SMAD Family Member 3 SMAD3 0.631 -0.179 0.976 -0.088 0.998 0.046 1.000 -0.148 0.794 0.276 0.530 -0.267 0.790 -0.134 
Liver fibrosis/TGF pathway/lipogenesis SMAD Family Member 4 SMAD4 0.804 -0.053 0.964 -0.057 0.998 -0.154 1.000 0.104 0.946 0.059 0.636 -0.109 0.224 -0.207 
Liver fibrosis/TGF pathway/lipogenesis SMAD Family Member 5 SMAD5 0.646 0.234 0.933 -0.218 0.998 -0.217 1.000 -0.063 0.947 0.150 0.987 0.016 0.986 0.017 
Liver fibrosis Α‐smooth muscle actin ACTA2 0.245 -0.656 0.995 0.045 0.998 0.488 1.000 -0.005 0.735 -0.573 0.378 -0.611 0.869 -0.168 
Liver fibrosis Type I collagen COL1A1 0.180 -1.453 0.970 -0.360 0.998 0.735 1.000 0.101 0.964 -0.274 0.119 -1.813 0.645 -0.719 
Liver fibrosis Hepatocyte growth factor HGF 0.436 -0.530 0.859 0.458 0.998 0.414 1.000 0.359 0.984 0.075 0.960 -0.072 0.925 -0.115 
Liver fibrosis/inflammation Nuclear factor kappa B 1 NFKB1 0.690 -0.188 0.666 0.442 0.998 0.021 1.000 0.258 0.909 0.205 0.658 0.254 0.783 -0.167 
Liver fibrosis/inflammation Nuclear factor kappa B 2 NFKB2 0.646 -0.417 0.400 1.176 0.998 0.281 1.000 0.740 0.869 0.492 0.426 0.759 0.928 -0.136 
Liver fibrosis 
Platelet derived growth 
factor alpha 
PDGFA 0.215 -0.516 0.995 0.035 0.998 0.269 0.872 -0.042 0.975 -0.077 0.340 -0.481 0.684 -0.247 
Liver fibrosis 
Platelet derived growth 
factor beta 
PDGFB 0.683 -0.376 0.998 0.006 0.998 0.200 0.145 0.668 0.795 0.651 0.763 -0.370 0.902 -0.176 
Liver fibrosis 
Platelet derived growth 
factor c 
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Platelet derived growth 
factor d 
PDGFD 0.468 -0.440 0.785 -0.513 0.998 -0.248 0.860 0.059 0.999 0.008 0.101 -0.952 0.266 -0.688 
Liver fibrosis 
Platelet derived growth 
factor receptor alpha 
PDGFRA 0.240 -0.906 0.965 0.274 0.998 0.205 0.214 0.588 0.959 0.209 0.552 -0.632 0.467 -0.701 
Liver fibrosis 
Platelet derived growth 
factor receptor beta 




MMP2 0.047 -1.589 0.994 0.085 0.998 0.420 1.000 0.312 0.976 0.152 0.105 -1.504 0.229 -1.169 
Liver fibrosis SEL1L Family Member 3 SEL1L3 0.006 -0.556 0.475 0.358 0.998 0.253 1.000 0.182 0.967 -0.055 0.561 -0.198 0.269 -0.303 
Liver fibrosis Lysyl Oxidase Like 1 LOXL1 0.120 -1.340 0.998 0.040 0.998 0.487 1.000 0.167 0.967 -0.206 0.197 -1.300 0.450 -0.853 
Anti-fibrogenic C1Q and TNF related 2 C1QTNF2 0.112 -0.759 0.912 0.297 0.998 0.280 1.000 -0.123 0.972 -0.097 0.485 -0.461 0.439 -0.479 
Anti-fibrogenic/anti-inflammatory 
Peroxisome proliferator 
activated receptor alpha 
PPARA 0.046 1.014 0.965 -0.197 0.998 0.040 1.000 0.120 0.997 -0.018 0.189 0.818 0.050 1.055 
Anti-fibrogenic SMAD Family Member 7 SMAD7 0.004 -0.654 0.994 -0.029 0.998 -0.171 1.000 -0.433 0.737 -0.270 0.005 -0.683 0.000 -0.825 




IFNGR1 0.730 -0.229 0.989 -0.081 0.998 -0.080 1.000 0.036 0.987 -0.046 0.700 -0.310 0.679 -0.309 
Anti-fibrogenic 
Interferon gamma 
receptor 2 (non ligand 
binging of beta chain) 




HORMAD2 NA 0.586 0.995 0.122 0.998 0.450 1.000 0.791 0.935 0.675 NA 0.708 0.633 1.037 





CEBPA 0.607 0.212 0.998 0.003 0.999 0.006 1.000 -0.316 0.791 -0.311 0.690 0.216 0.661 0.219 
Anti-oxidative defence/(reduced in DNL) 
anti-fibrotic/protective 




0.423 0.242 0.725 -0.296 0.999 0.004 1.000 -0.020 0.960 0.074 0.927 -0.054 0.486 0.246 
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PCK1 0.534 0.390 0.831 0.450 0.998 -0.095 1.000 0.619 0.904 0.306 0.161 0.839 0.724 0.295 
Gluconeogenesis (when fasting)/ fatty 
acid beta  
oxidation/reduced in MAFLD and insulin 
resistance 
Peroxisome proliferator-
activated receptor γ 
coactivator 1α (PGC-1a) 
PPARGC1A 0.271 -0.512 0.959 0.176 0.998 -0.143 1.000 -0.039 0.870 -0.298 0.613 -0.337 0.176 -0.655 
Gluconeogenesis/Insulin secretion 
Camp response element 
binding protein 
CREB1 0.970 -0.044 0.954 0.300 0.998 -0.156 1.000 0.612 0.873 0.469 0.848 0.256 0.884 -0.200 
Gluconeogenesis/Raised insulin 
resistance/De novo lipogenesis 
Forkhead box class Os 1 FOXO1 0.191 0.276 0.998 0.006 0.998 -0.256 1.000 0.074 0.967 -0.050 0.248 0.282 0.967 0.020 
Gluconeogenesis/Raised insulin 
resistance/De novo lipogenesis 
Forkhead box class Os 3 FOXO3 0.001 0.671 0.741 -0.254 0.998 -0.256 1.000 0.328 0.972 0.050 0.111 0.417 0.097 0.414 
Gluconeogenesis/Raised insulin 
resistance/De novo lipogenesis 
Forkhead box class Os 4 FOXO4 0.284 0.215 0.844 -0.152 0.998 -0.139 1.000 -0.131 1.000 0.002 0.864 0.064 0.819 0.076 
Glycogenolysis/gluconeogenesis 
Glycogen Synthase Kinase 
3 Alpha 
GSK3A 0.630 -0.060 0.860 0.077 1.000 0.095 1.000 -0.040 0.800 -0.090 0.940 0.016 0.850 0.034 
Glycogenolysis/gluconeogenesis 
Glycogen Synthase Kinase 
3 Beta 
GSK3B 0.400 0.353 0.950 -0.170 1.000 -0.110 1.000 0.252 0.950 0.131 0.780 0.182 0.660 0.246 
Fatty acid metabolism/ Gluconeogenesis 
Aldehyde dehydrogenase 
3 family member A2 
ALDH3A2 0.000 1.768 0.537 -0.549 0.999 0.008 1.000 0.121 0.845 0.292 0.000 1.220 0.000 1.776 
Fatty acid metabolism/Pyruvate 
metabolism/Gluconeogenesis 
Aldehyde dehydrogenase 
7 family member A1 
ALDH7A1 0.004 0.431 0.883 -0.122 0.998 -0.103 1.000 -0.084 0.971 -0.038 0.105 0.309 0.063 0.328 
Gluconeogenesis/Pyruvate 
metabolism/Citric acid cycle 
Pyruvate Dehydrogenase 
E1 Subunit Alpha 1 
PDHA1 0.000 0.494 0.243 -0.316 0.998 -0.115 1.000 -0.083 0.990 -0.013 0.414 0.179 0.015 0.379 
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SDHA 0.032 0.377 0.783 -0.182 0.998 -0.177 1.000 0.077 0.982 -0.028 0.446 0.195 0.412 0.200 





PPARG 0.007 1.532 0.826 -0.557 0.998 0.069 1.000 0.222 0.668 0.775 0.193 0.975 0.006 1.601 
PPAR signalling pathway/Fatty acid 
oxidation 
Peroxisome proliferator 
activated receptor alpha 
PPARA 0.046 1.014 0.965 -0.197 0.998 0.040 1.000 0.120 0.997 -0.018 0.189 0.818 0.050 1.055 
PPAR signalling pathway 
Peroxisome proliferator 
activator receptor delta 
PPARD 0.046 -1.061 0.959 0.226 0.998 0.067 1.000 0.156 0.993 -0.038 0.201 -0.835 0.088 -0.994 
PPAR signalling pathway 
Fatty acid binding protein 
2 
FABP2 0.000 1.298 0.600 -0.459 0.998 -0.044 1.000 -0.029 0.847 0.261 0.012 0.839 0.000 1.253 
PPAR signalling pathway/Fatty acid 
Biosynthesis 
Fatty acid binding protein 
5 
FABP5 0.000 -4.180 0.313 1.377 0.998 0.319 1.000 -0.152 0.448 -1.310 0.000 -2.804 0.000 -3.861 
Starch and sucrose metabolism 
Amylo-1,6-glucosidase, 4-
alpha-glucanotransferase 
AGL 0.012 0.511 0.288 -0.416 0.998 -0.270 1.000 0.035 0.947 0.088 0.820 0.095 0.408 0.242 
Starch and sucrose metabolism Amylase 1, salivary AMY1  0.005 0.607 0.567 -0.344 0.998 -0.154 1.000 -0.117 0.999 0.005 0.434 0.262 0.079 0.453 
Starch and sucrose metabolism Glycogen synthase 2 GYS2 0.028 0.709 0.676 -0.423 0.998 -0.238 1.000 -0.071 0.903 0.206 0.584 0.286 0.246 0.471 
Starch and sucrose metabolism Phosphoglucomutase 1 PGM1 0.001 0.488 0.802 -0.164 0.998 -0.080 1.000 -0.062 0.883 0.113 0.094 0.323 0.015 0.408 
Starch and sucrose metabolism 
Glucan (1,4-alpha-), 
branching enzyme 1 
GBE1 0.095 0.531 0.710 -0.374 0.998 -0.129 1.000 -0.085 0.819 0.280 0.782 0.157 0.306 0.402 
Insulin signalling/Cell growth Insulin-like growth factor 
binding protein 1 
IGFBP1 0.024 -2.079 0.035 2.522 0.998 0.691 1.000 1.342 0.700 1.145 0.805 0.443 0.228 -1.388 
Insulin signalling/Cell growth Insulin-like growth factor 
binding protein 3 
IGFBP3 0.620 -0.210 0.930 -0.180 1.000 0.352 1.000 -0.150 1.000 -0.150 0.380 -0.400 0.820 0.140 
Insulin signalling STEAP family member 4 STEAP4 0.642 0.414 0.003 2.122 0.998 0.128 1.000 0.641 0.850 0.530 0.000 2.536 0.590 0.541 
Insulin signalling Matrix metalloproteinase 
7 




Table 5.15: Differential gene expression results for some important genes highlighted to be of importance for MAFLD and hepatic insulin resistance (continued) 
 
Pairwise comparison HF vs LF HF+EC vs HF 
HF+34DHPVL vs 
HF 
LF+EC vs LF 
LF+34DHPVL vs 
LF 




the gene is involved in 


















































Insulin signalling H19 Imprinted Maternally 
Expressed Transcript 
H19 0.020 -3.902 0.979 -0.497 0.998 0.764 1.000 0.380 0.987 0.198 0.015 -4.399 0.106 -3.138 
Insulin signalling 
Insulin receptor substrate 
1 
IRS1 0.584 0.185 0.775 -0.268 0.998 -0.388 1.000 -0.225 0.939 -0.121 0.885 -0.083 0.609 -0.203 
Insulin signalling 
Insulin receptor substrate 
2 (more significant) 




Catalytic Subunit ALPHA 
(PI3K) 




Catalytic Subunit BETA 




Catalytic Subunit delta 




Catalytic Subunit Gamma 
PIK3CG 0.121 -1.019 0.853 0.526 0.998 0.445 1.000 0.527 0.778 0.608 0.623 -0.493 0.510 -0.574 
Insulin signalling Insulin receptor INSR 0.922 0.100 0.984 0.121 0.998 -0.153 1.000 -0.078 0.967 -0.156 0.858 0.221 0.973 -0.053 
Insulin signalling 
High mobility group AT-
Hook 1 
HMGA1 0.52 -0.29 0.98 -0.1 1.00 0.23 1.00 0.137 0.770 0.373 0.450 -0.400 0.940 -0.060 
Insulin signalling/cell growth SHC adaptor protein 1 SHC1 0.531 -0.117 0.817 0.138 0.998 0.115 1.000 0.166 0.916 -0.086 0.954 0.021 0.998 -0.001 
Insulin signalling/cell growth SHC adaptor protein 2 SHC2 0.012 -3.594 0.998 0.072 0.998 1.980 1.000 1.031 0.966 0.394 0.028 -3.521 0.428 -1.614 
Insulin signalling/cell growth 
Growth factor receptor-
bound protein 2 
GRB2 0.019 0.147 0.770 0.069 0.998 0.027 1.000 0.025 0.451 0.115 0.000 0.216 0.005 0.174 
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CEA Cell Adhesion 
Molecule 1 
 
CEACAM1 0.980 -0.010 0.980 0.054 1.000 -0.040 1.000 -0.090 0.770 -0.230 0.930 0.044 0.920 -0.050 
Decreased insulin signalling/decreased 
fatty acid synthesis (higher levels in 
MAFLD) 
Pyruvate dehydrogenase 
kinase 2 (main PDK in 
liver) 
PDK2  0.048 0.429 0.940 -0.115 0.998 0.011 1.000 -0.201 0.737 -0.237 0.255 0.314 0.057 0.440 
Decreased insulin signalling/decreased 




PDK4 0.534 -0.561 0.993 -0.098 0.998 0.315 1.000 0.817 0.880 0.492 0.547 -0.659 0.864 -0.246 
Decreased insulin signalling/JNK 
pathway 
Mitogen-activated 
protein kinase 8 
MAPK8 
(JNK1) 
0.980 -0.010 0.740 -0.130 1.000 -0.110 1.000 -0.030 0.870 0.079 0.400 -0.130 0.470 -0.110 
Decreased insulin signalling/JNK 
pathway 
Mitogen-activated 
protein kinase 9 
MAPK9 
(JNK2) 
0.100 0.587 0.860 -0.280 1.000 -0.290 1.000 0.174 0.820 0.308 0.580 0.302 0.560 0.296 
P53 Signalling pathway/Apoptosis BCL2-associated X protein BAX 0.068 0.405 0.577 -0.314 0.998 -0.157 1.000 -0.160 0.951 -0.080 0.833 0.091 0.401 0.248 
P53 Signalling pathway/Apoptosis Caspase 9 CASP9 0.379 0.205 0.870 -0.153 0.999 -0.006 1.000 -0.160 0.876 -0.138 0.910 0.052 0.470 0.199 
P53 Signalling pathway/Apoptosis 
Phosphatase and tensin 
homolog 
PTEN 0.285 0.200 0.706 -0.203 0.998 -0.207 1.000 -0.146 0.986 -0.020 0.995 -0.002 0.989 -0.006 
P53 Signalling pathway/Apoptosis 
Conserved helix-loop-
helix ubiquitous kinase 
CHUK 0.166 0.243 0.760 -0.178 0.998 -0.160 1.000 -0.117 0.987 0.019 0.841 0.066 0.768 0.084 











NDUFA10 0.000 0.426 0.364 -0.245 0.998 -0.106 1.000 -0.012 0.977 0.026 0.315 0.181 0.021 0.320 
Oxidative phosphorylation/Insulin 
resistance 
Atpase H+ Transporting 
V1 Subunit D 
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signalling/insulin signalling/Liver fibrosis 
Epidermal growth factor 
receptor 




Protein Kinase 7 
MAPK7 0.010 -0.947 0.917 0.249 0.998 0.494 1.000 0.078 0.988 0.036 0.132 -0.698 0.388 -0.452 
MAPK signalling/TGF-Beta signalling 
Transforming Growth 
Factor Beta 3 
TGFB3 0.100 -1.319 0.998 0.030 0.998 0.419 1.000 0.077 0.921 -0.426 0.168 -1.289 0.381 -0.900 
Inflammatory genes 
Integrin Subunit Alpha M 
(also known as CD11B) 
ITGAM 0.477 -0.823 0.952 0.451 0.998 0.434 1.000 0.714 0.647 1.241 0.844 -0.372 0.826 -0.389 
Inflammatory genes CD86 antigen CD86 0.823 0.189 0.963 0.223 0.998 -0.061 1.000 0.802 0.220 1.328 0.650 0.412 0.915 0.128 
Cytokine mediated signalling pathway 
/inhibits IRS-1 in insulin signalling 
Suppressor of cytokine 
signaling 5 
SOCS5 0.012 1.657 0.817 -0.657 0.032 -2.131 1.000 1.330 0.186 1.770 0.268 1.000 0.676 -0.474 
Cytokine mediated signalling pathway Tumour necrosis factor TNF 0.863 -0.396 0.994 0.142 0.998 0.387 1.000 1.481 0.355 2.748 0.940 -0.254 0.998 -0.009 
Glucose transporters (glucose influx) 
 solute carrier family 2 
(facilitated glucose 
transporter), member 1 
SLC2A1 
(Glut-1) 
0.863 -0.113 0.957 0.177 0.998 0.324 1.000 0.074 0.608 0.581 0.949 0.064 0.765 0.210 
Glucose transporters (glucose efflux, 
increased in type-2 diabetes)) 
 solute carrier family 2 
(facilitated glucose 
transporter), member 2 
SLC2A2 
(Glut-2) 
0.327 0.441 0.704 -0.481 0.998 -0.245 1.000 -0.101 0.981 -0.062 0.969 -0.039 0.774 0.196 
Glucose transporters 
 solute carrier family 2 
(facilitated glucose 
transporter), member 3 
SLC2A3 
(Glut-3) 
0.501 -0.573 0.919 0.431 0.998 0.447 1.000 0.440 0.944 0.292 0.929 -0.142 0.932 -0.126 
Glucose transporters 
 solute carrier family 2 
(facilitated glucose 
transporter), member 4 
SLC2A4 
(Glut-4) 
0.058 -1.755 0.994 0.096 0.998 -0.289 1.000 -1.702 0.674 -1.153 0.124 -1.659 0.031 -2.044 
Glucose transporters 
 solute carrier family 2 
(facilitated glucose 
transporter), member 8 
SLC2A8 
(Glut-8) 




Table 5.15: Differential gene expression results for some important genes highlighted to be of importance for MAFLD and hepatic insulin resistance (continued) 
 
Pairwise comparison HF vs LF HF+EC vs HF 
HF+34DHPVL vs 
HF 
LF+EC vs LF 
LF+34DHPVL vs 
LF 




the gene is involved in 


















































Glucose transporters (increased in type-
2 diabetes) 
 solute carrier family 2 
(facilitated glucose 
transporter), member 9 
SLC2A9 
(Glut-9) 






Here, RNA-seq and qRT-PCR was employed followed by differential expression analyses and GSEA 
to understand how EC and 34DHPVL could protect against HF diet induced insulin resistance and 
MAFLD. Several metabolic and signalling pathways have been shown to be affected by these 
polyphenol treatments and how these may act in synergy to induce the overall changes. The main 
observations from this study include the following: 
(1) MAFLD and insulin resistant mice, from the HF diet, expressed a significant increase in 
genes involved in gluconeogenesis and a decrease in DNL compared to mice on LF HC diets, 
contributing to increased circulatory glucose concentrations. 
(2) EC but not 34DHPVL reversed the expression of a large number of differentially 
expressed genes and pathways enriched in HF fed conditions. 
(3) 34DHPVL caused an increase in gene expression in favour of promoting insulin sensitivity 
and leptin sensitivity, although the changes were not significant, the combination of gene 
changes across different pathways could act in synergy to enhance the response to insulin, 
or independently of insulin, in lowering blood glucose. 
(4) EC significantly increased gene expression in favour of insulin signalling and decreased 
gene expression in favour of inducing insulin resistance. 
(5) LF HC diets induced significant gene changes involved in hepatic fibrosis development 
over the 15-week intervention, more so than the LC HF diets. 
 
5.6.1 The effects of high-fat and high-carbohydrate diets on de novo 
lipogenesis and gluconeogenesis 
Subjects with MAFLD and insulin resistance are known to exhibit increased hepatic gluconeogenesis 
and DNL. In this study, the HF fed mice without polyphenols displayed a significant increase in 
gluconeogenesis than LF fed mice, but also exhibited a reduction in DNL gene expression. The 
reduction in DNL gene expression was most likely caused by the HC content of the LF diet which 
can be more powerful than HF diets in the induction of DNL (438, 484, 562, 563). Here, a discussion 
of the gene changes that occurred to support DNL and gluconeogenesis will be detailed for HF and 
LF HC dietary treatment groups, and later it will discuss a paper that directly complements the 




Please refer to chapter 4, Figure 4.2, for the pathway of DNL and chapter 1, Figure 1.8 for the 
gluconeogenesis pathway. DNL is activated primarily by SREBP-1c (SREBF gene) and ChREBP 
(MLXIPL gene) to stimulate enzyme activation for lipogenesis, which include: ACC, FASN, SCD-1, 
PKLR, GPAT1 (GPAM gene), AGPAT1, and others (564). CHREBP is a transcription factor increased 
in response to HC diets for DNL activation (564). In this current study, it was shown that the LF HC 
diet caused a much higher expression of several genes involved in DNL processes than the HF 
treatment group, including MLXIPL and SREBF. Previous studies support this finding where it has 
been shown that mice fed a HC diet from a fasted state expressed a 20-fold increase in hepatic 
GPAT1 mRNA, namely because of SREBP-1c activation (565). The effects of reduced DNL processes 
in the HF diet fed mice compared to the LF diet fed mice in this current study, caused an increase 
in fatty acid metabolism that can increase blood glucose levels via stimulating gluconeogenesis 
(566).  
In contrast, HF diets cause hepatic lipid accumulation through the actions of insulin. Insulin will 
activate SREBP-1c and subsequent lipogenic enzymes whilst repressing the activity of glucose-6-
phosphatase (G6Pase), which is also a mechanism of ‘selective insulin resistance’ in type-2 diabetics 
(567). When there are high nuclear levels of SREBP-1c, this stimulates the synthesis of fatty acids, 
and consequently causes lipid storage in the liver, and an increase in the secretion of vLDLs into the 
plasma, which can directly influence insulin resistance in muscles and adipose tissues (567). 
The effects of the HF diet compared to the LF diet in this study were to significantly raise genes and 
pathway expressions involved in gluconeogenesis, which is well reported in cases such as MAFLD 
because the circulating insulin levels are ineffective at inhibiting gluconeogenesis due to the 
presence of insulin resistance (568). Just a few of the gene changes seen to be increased in the HF 
versus LF comparison included FOXO, PCK1 (PEPCK) and CEBPA. The roles that the proteins 
transcribed by these genes perform in gluconeogenesis are now described and explain why they 
are more highly expressed under HF conditions. FOXO is phosphorylated and rendered inactive by 
insulin, as a consequence it binds directly with G6Pase and PEPCK proteins and inhibits their role in 
gluconeogenesis and promotes glycogenesis (569), therefore, active FOXO is known to stimulate 
gluconeogenesis. However, PEPCK converts oxaloacetate to phosphoenolpyruvate, whilst G6Pase 
acts to convert glucose-6-phosphate to glucose (outlined in chapter 3, section 3.2.1), both of which 
are inhibited by insulin in the fed state and stimulated by glucagon during fasting (570). Insulin 
inhibits the actions of FOXO via the activation of PI3K, PDK-1 and Akt (571), but this does not happen 
in insulin resistant cells (569) and therefore explains why FOXO is more highly expressed under HF 
conditions. Furthermore, FOXO can directly interact with C/EBPa (CEBPA gene) to drive gene 




gluconeogenesis (572). Moreover, C/EBPa can induce PPARγ expression, known to be the master 
regulator of adipogenesis (572), but C/EBP levels are increased in insulin resistant mice (572, 573). 
Moreover, PPARGC1A, coding for protein PGC-1α (peroxisome proliferator-activated receptor γ 
coactivator 1α) was downregulated for HF versus LF treatment groups, which is known to occur in 
the presence of MAFLD and insulin resistance and is also shown to regulate the ratio of IRS1 and 
IRS2 (66-69).  
To add to these findings, in this current study, the HF diet fed mice expressed a reduced expression 
in CREB, and PXR (pregnane x receptor; NR1I2 gene: nuclear receptor subfamily 1 group I member 
2) in conjunction with PPARGC1A (encoding PGC-1α) and a rise in PCK1 (encoding PEPCK) levels, but 
not for G6PC, when compared to the LF treatment. This data is supported by Li et al (2018) (126) in 
diabetic mice where they expressed raised levels of protein and mRNA levels for PEPCK and G6Pase 
and a decrease in protein and mRNA levels of CREB and PGC-1α expression. These gene changes 
can be driven by PXR binding to CREB (cAMP responsive element binding protein) and PGC-1α to 
suppress gluconeogenic gene activation (PEPCK and G6PC) (126). Therefore, for the HF diet fed mice 
in this current study, the lower levels of PXR, PPARGC1A and CREB prevented gene suppression for 
gluconeogenesis processes such as PCK1.  
Pyruvate dehydrogenase kinase (PDK) enzymes are also highly important in the gluconeogenesis 
process, and it has been shown in this study that PDK2 was more highly expressed and PDK4 was 
more lowly expressed in the livers of the HF treatment group when compared to the LF treatment. 
In the liver PDK inhibits the enzyme ‘pyruvate dehydrogenase’, that acts to convert pyruvate to 
acetyl-CoA, and so, insulin acts to inhibit PDK, and when this protein is directly targeted it can 
partially improve insulin sensitivity in diabetics (574). From all four PDK proteins that are present, 
the liver expresses highest levels of PDK2 than other variants and its levels have been shown to be 
higher in the livers of HF diet fed mice in conjunction with a reduction in PDK4 levels (575), which 
has also been shown in this current study. As a result of the raised PDK2 levels there are spared 
gluconeogenic substrates for glucose production which can progress to insulin resistant 
hepatocytes (575). 
With regards to MAFLD, it was clear that the HF diet increased the expression levels for several 
pathways involved in its pathogenesis in this current study, which have been commonly reported 
by several authors (501-505, 561, 576, 577). Across these studies, there was not a complementary 
change for specific genes in MAFLD development, but there were similar pathways that were 
regulated, which was vastly due to the experimental design and model used, where humans have 




The length of dietary intervention is also important, where Teufel et al (2016) showed that the 
length of HF diet feeding in C57BL6/J mice can determine which pathways become upregulated or 
downregulated over time; where an enrichment of a hepatic pathway could be upregulated after 
12-weeks of feeding but then downregulated after 18-weeks of feeding, and vice versa (561). 
Additionally, Teufel et al compared the differences in the hepatic GSEA profile in the livers of 
humans who either were obese, had MAFLD or had NASH, and in livers from HF diet mice fed for 
12-weeks, 18-weeks and 30-weeks (561). As such, Table 5.14 shows a composite table for the 
pathways that have been found to be enriched in humans and mice from Teufel et al’s study in 
conjunction with being enriched in the hepatic tissue in this current mouse intervention study. A 
total of 89 KEGG pathways were enriched in both this study for HF vs LF fed mice and in the human 
and mice livers from the study by Teufel et al. A total of 76 out of the 90 KEGG pathways were 
complementary (upregulated or downregulated) to the human and mice study by Teufel et al (561). 
Pathways highlighted in blue show complementarity to the mouse samples (47 confirmed 
pathways), whilst pathways highlighted in green show complementarity to both human and mouse 
samples (30 confirmed pathways), and pathways in red correspond to no pathway crossover 
between all treatments (13 confirmed pathways) (complementarity refers to the pathways 
expressed in this current study by HF versus LF fed mice and to those specified by Teufel et al). Both 
this study (60 % kcal fat and 20 % kcal carbohydrates) and the study by Teufel et al supplied mice 
with similar diets, with the exception that Teufel et al supplied their carbohydrate source into 
drinking water rather than the pellets (59 % kcal fat and 26 % kcal carbohydrates); this is therefore 
a positive indication for the large similarity of enriched pathways between the studies. Although 
other studies have highlighted several pathways enriched following their treatments, Teufel et al’s 
study is the closest study that matches the current study with regards to dietary composition, 
intervention length and mouse breed and age. Please refer to the results section 5.5.5 for the 
description of hepatic pathways regulated by HF diets, but overall, they are involved mostly in 
metabolic processes.  
 
5.6.2 The mechanisms underlying the effects of EC in lowering hepatic DNL 
and lipogenesis processes to protect against steatosis 
In this study, it was evident that EC protected against HF diet induced hepatic steatosis by lowering 
the expression of genes involved in DNL and gluconeogenesis pathways, and there was also 
evidence to suggest that 34DHPVL complemented the reduction in gluconeogenesis, but with a 




discussed in relation to previous evidence for the actions of polyphenols on the aforementioned 
processes.  
Although it was shown that the HF diet lowered the expression of genes involved in DNL when 
compared to the LF diet, the effects were far greater when EC was supplied into the HF diet. To 
summarise just a few of the genes changes that arose following EC supplementation into the HF 
diet, these included the reduction in the expressions of SREBF, G6PC and AMPK and several genes 
involved in the fatty acid metabolic pathway. As mentioned previously, a reduction in fatty acid 
metabolism causes a reduction in gluconeogenesis and therefore lowers blood glucose levels and 
protects against insulin resistant effects. Meanwhile, phosphorylated AMPK (active) is known to be 
a negative regulator of DNL by inhibiting the expression of ACC, and FASN and reducing the 
expression of SREBP-1c, in return promoting fatty acid uptake, β-oxidation and downregulating 
gluconeogenesis (578). However, the presence of MAFLD is shown to reduce hepatic 
phosphorylated AMPK levels, whilst polyphenols have been reported to upregulate them and thus 
mitigate liver lipid accumulation (579), as has been shown in this current study and supports the 
previous findings in chapter 4 for the reduced liver lipid mass for HF+EC mice compared to HF mice. 
Evidence for when this has been reported to occur by polyphenols and the mechanisms that 
underlie them, has been previously demonstrated using EGCG, where it was reported to activate 
AMPK at concentrations of ≤ 1 μM in isolated hepatocytes through the upstream stimulation of 
Ca2+/calmodulin-dependent protein kinase kinase (CaMKK), which is one of two known mediators 
of AMPK, and initiated by ROS production (282). In further studies, cocoa polyphenols or EC have 
been provided as treatments in diabetic cells or animal models to assess DNL and gluconeogenesis 
(199, 285, 338, 341, 405, 439, 440). As such, it was reported that the treatment of insulin resistant 
HepG2 cells with either cocoa polyphenols or EC re-activated (phosphorylated) the AMPK and PI3K 
pathways (341, 405), and in the hepatic tissue of Zucker diabetic fatty (ZDF) rats fed with 10 % cocoa 
polyphenols (405).  
Moreover, both EC and 34DHPVL in this study were shown to reduce the expression of DNL genes 
FASN and SREBF in all LF intervention fed mice but not in all HF intervention fed mice. This was most 
likely because the LF HC interventions caused a much higher expression of DNL genes than the HF 
diet, and thus the compounds were more effective at counteracting this increase in the LF diet. For 
AMPK expression, only some of their subunits were more highly expressed by both EC and 34DHPVL 
when supplied into the LF diet, and so it would be more conclusive to assess AMPK at a protein 
level to determine whether their abundance and activity was affected. Previous reports for the 




or 10 % cocoa polyphenols supplemented into ZDF rats and insulin resistant HepG2 cells (10 μM EC) 
(405).  
This current study also revealed a reduction in the expression of gene SCD-1 by EC in the LF and HF 
dietary interventions but only in the LF intervention by 34DHPVL. SCD-1 is a rate limiting enzyme 
for the synthesis of fatty acids (522), and the gene expression changes by EC in this current study 
are supported by several studies, such as when EGCG was supplemented into the diets of HF fed 
mice (522), and in EGCG supplemented high fructose fed rats (526) and diabetic mice (126) for a 
dose dependent reduction in hepatic gene expressions: SCD-1, SREBP-1c (SREBF gene), FASN, and 
PPARG. The PPARγ protein (encoded by the PPARG gene) can drive lipogenic gene transcription 
including SREBF, both of which were decreased in this current study when EC was supplied in 
combination with the HF diet. In contrast, a further study investigated the effects of green tea 
extracts (GTE) in genetically obese mice, and found no reductions in hepatic SREBF, FASN and SCD-
1 expression, however these same genes were significantly reduced in the adipose tissue of these 
same mice, however the GTE concentration used was lower than those used in other studies (401).  
The addition of either EC or 34DHPVL into the HF diet induced a decreased expression of FOXO 
genes, which was discussed previously to cause a reduction in circulatory glucose concentrations 
(section 5.6.2). For the CEBPA gene, EC and 34DHPVL were only successful in lowering its expression 
levels when supplemented into the LF diet and not for the HF diet. Therefore, in this current study, 
EC and 34DHPVL targeted specific genes in the gluconeogenic pathway to reduce glucose 
production. To continue, the expression of genes PIK3CD, PIK3CG (isoforms of PI3K) and AKT1 was 
reduced in the HF versus LF treatment, and were more highly expressed in all EC and 34DHPVL 
supplemented diets, but the polyphenols had greater effects on changes in gene expression in the 
HF diets. This is evidence to support the stimulation of the PI3K/Akt pathway by EC and 34DHPVL, 
where Akt can directly phosphorylate and inactivate FOXO to reduce the transcription of 
gluconeogenic genes (569). 
The addition of EC into the HF diet also caused an increase in the expression of PPARGC1A and in 
both the HF and LF diets for CREB and PXR. The regulations of these genes and their impact were 
briefly mentioned in section 5.6.2, but their increase is reported to slow down gluconeogenesis 
processes. To add to the aforementioned effects in the changes in expression of these three genes, 
CREB1 has been previously shown to positively regulate gluconeogenesis by activating PGC-1α 
(569), in addition to regulating insulin secretion in pancreatic β-cells (580, 581), however, in the 
liver it is commonly linked to insulin resistance. As CREB also drives the transcription of PEPCK 




consumed EC supplemented into HF diets, this could also explain why this group exhibited a rise in 
blood glucose equal to that of the HF diet fed mice within 15 mins of the GTT, because EC caused 
an increase in a few gluconeogenic genes. However, the increase in genes for insulin signalling 
(detailed in section 5.5.6) counteracted the increased glucose production later in the GTT. In 
contrast, Koyama et al (2004) who fed mice a 0.15 % EGCG diet for 7-days discovered that their 
hepatic mRNA levels for PEPCK were significantly reduced, but in keeping with the observations 
from this current study, their G6PC levels were also reduced in the presence of EGCG (527). These 
results were further reiterated in rat hepatoma cells treated with EGCG via the activation of the 
PI3K pathway (281), and in a diabetic mouse model through an increase in PXR (pregnane x 
receptor; NR1I2 gene: nuclear receptor subfamily 1 group I member 2) protein and mRNA 
expression levels following EGCG supplementation (126). 
This current study reports an increase in the expression of several gluconeogenesis genes when EC 
and 34DHPVL were supplemented into LF HC diets of mice, which is a result that cannot be 
explained by this study because polyphenols have been mostly reported to decrease HC diet 
induced gluconeogenesis (241) and requires further investigation. 
Further changes in the expression of gluconeogenic genes in this study following EC 
supplementation included an increase in PCK1 levels in both the LF and HF diets and a reduction in 
G6PC (encoding G6Pase) by both EC and 34DHPVL supplementation in the HF treatment groups. 
These dual action effects suggest that EC may have upstream effects on different signalling 
pathways. Additionally, this study has shown that the gene GSK3B, a subunit of GSK-3 (glycogen 
synthase kinase 3), had raised expression levels in the HF versus LF treatment, but reduced 
expression levels following the addition of EC or 34DHPVL into the HF diet; subsequently, this would 
promote glycogen formation from glucose in the polyphenol supplemented treatment groups. This 
finding is supported by studies that assessed the hepatic protein levels following EC and cocoa 
polyphenol treatments in HepG2 cells, where a reduction in PEPCK was observed, accompanied 
with an increase in GSK-3 phosphorylation levels, thus causing an inhibition of its actions on 
inhibiting glycogen synthase, i.e. GSK-3 inhibition promotes the synthesis of glycogen (285, 341). In 
addition, the phosphorylated levels of Akt and AMPK rose with polyphenol addition, which also 
stimulated the phosphorylation of GSK-3 and the suppression of PEPCK and G6Pase (285). Similarly, 
when cocoa was supplemented into the diets of ZDF rats, it prevented the inactivation of hepatic 
glycogen synthase and reduced PEPCK levels and increased glucokinase levels (alike hexokinase but 




Because HF diet fed mice in this study expressed much higher levels of PDK2 than LF diet fed mice 
(discussed in section 5.6.1), it was exciting to discover that when EC was supplemented into the HF 
and LF diet it caused a reduction in the expression of PDK2, whilst 34DHPVL was successful at 
lowering its levels only in the LF intervention. Ultimately, this change caused by EC would promote 
the synthesis of fatty acids from glucose precursors and to reduce blood glucose levels (574), which 
to our knowledge is the first time a catechin has been reported to induce this effect. 
In addition, it was highlighted that the starch and sucrose metabolic pathway was upregulated in 
HF versus LF diet fed mice and decreased following the addition of EC in both the LF and HF diets, 
and by 34DHPVL in the HF diet. The rise in starch and sucrose metabolism in the HF vs LF diet could 
be because of the limited carbohydrate content of the diet, and therefore almost all of the 
carbohydrates that were consumed were directed into the citric acid cycle for acetyl-CoA synthesis, 
which was another pathway more highly expressed in the HF vs LF treatment. These effects would 
increase the production of glucose from carbohydrates because it is linked to gluconeogenesis 
processes.  
The effects reported following the supplementation of 34DHPVL in the diets of mice in this study 
have been briefly covered in this section. However, to summarise its effects, 34DHPVL caused an 
increase in several DNL genes (section 5.5.8) when combined with the HF diet in mice, and as such 
this supports the effect for an increase in hepatic lipid build-up, which was reported in chapter 4 
(section 4.5.3) following the quantification of liver lipids. Furthermore, although the decrease in the 
expression of genes for fatty acid metabolism and gluconeogenesis by 34DHPVL in HF diet fed mice 
did not reach statistical significance, the gene changes supports the physiological evidence found 
in chapter 3 for the reduction in blood glucose levels when compared to those in HF diet fed mice. 
For example, the gene ACOX1 (acyl-CoA oxidase-1) encodes an enzyme that is the rate limiting step 
for fatty acid β-oxidation (583), and so a reduction in its expression levels would have effects on 
the production of acetyl-CoA and later on for glucose. In addition, there were modest increases in 
the expression of genes PRKAB1, PRKAB2, and PRKAG2, which encode the AMPK protein and can 
stimulate glucose uptake to drive glycolysis and inhibit gluconeogenesis via inhibition of 
gluconeogenic enzymes, such as ACC (584). Furthermore, there is evidence to suggest increased 
leptin sensitivity by 34DHPVL in the HF diet of mice which promotes the reduction of 
gluconeogenesis and stimulation of glycogenesis, as discussed in section 5.6.4. 
In summary, this study has shown that EC, and in some cases 34DHPVL, can mitigate gluconeogenic 
gene transcription events in HF insulin resistant mice and DNL gene transcription events in LF HC 




literature for how EGCG, cocoa polyphenols, GTE or EC cause changes in the liver transcriptome for 
gluconeogenesis and DNL, whilst also providing new evidence for gene changes that are more 
specifically assigned to EC and 34DHPVL. In addition, the gene changes caused by EC when 
supplemented in HF diet fed mice has supported the findings reported in chapter 3 of this thesis 
for the reduction in blood glucose levels and hepatic lipid accumulation.  
 
5.6.3 Gene transcription targets for (−)-epicatechin and 3’,4’-
dihydroxyphenyl-γ-valerolactone in mitigating insulin resistance effects 
Previous sections have demonstrated the specific pathways that may impact insulin sensitivity and 
downstream insulin signalling. These changes will now be discussed, with a particular focus on how 
the addition of EC or 34DHPVL into HF and LF diets may have caused the physiological changes 
observed in chapter 3, and how the current literature supports these changes.  
Several gene changes were shown to be altered following the addition of EC or 34DHPVL into the 
HF diet for P53 signalling processes, where the HF compared to LF diet raised the expression of 
genes involved in this pathway, whereas the addition of EC reversed these effects. P53 signalling is 
very important in the development of insulin resistance and MAFLD, as shall now be explained. The 
severity of hepatic steatosis is closely associated to the expression of P53 signalling proteins/genes 
(585) mostly because of DNA damage and apoptotic stimulation. Reviews by Kung et al (2016) (586) 
and Strycharz et al (2017) (587) have summarised the involvement of P53 in metabolic syndrome, 
which includes the stimulation of gluconeogenic genes (588), and the negative regulation of the 
IGF-I/Akt pathway (589). This was demonstrated to occur in diabetic mice which exhibited higher 
expression of the P53 pathway when compared to non-diabetic mice, and subsequently this 
induced gluconeogenesis that caused a rise in their blood glucose levels and triggered insulin 
receptor desensitisation to glucose (590). These events are very likely to have occurred here in this 
current study because the HF versus LF mice had a higher expression of P53 signalling and these 
mice also presented with high blood glucose levels and high expressions of gluconeogenesis genes, 
whereas the addition of EC reversed all these effects and 34DHPVL partially reversed them. 
Moreover, P53 has been reported previously to negatively repress glucose influx through lowering 
the expression of glucose transporters GLUT1 and GLUT4 (560) and indirectly repressing GLUT3 
through a reduction in NF-κB signalling caused by the reduction in glycolysis (591). These changes 
were also confirmed in this current study where the HF versus LF diet caused a decrease in the 
expression of genes NFKB1, NFKB2, SLC2A1 (encodes proteins GLUT1), SLC2A3 (encodes proteins 




addition of 34DHPVL reversed all except for SLC2A4. Therefore, both EC and 34DHPVL promoted an 
increase in the uptake/binding of glucose to the receptors for influx into hepatocytes and reduced 
its efflux, which would explain the lower glucose levels during the glucose tolerance test in chapter 
3. The combination of these changes alongside the reduced expression for some gluconeogenic 
genes could be sufficient to lower circulatory glucose levels and somewhat counteract the negative 
effects of insulin resistance. Of course, this is just one theory of mechanism behind this and more 
functional experimental validation and protein expression data would be required to prove this.  
However, when EC and 34DHPVL were combined with the LF diet in mice in this current study, there 
was an increase in P53 pathway expression. This could be explained by the greater hepatic damage 
that was seen in mice on the LF diets than the HF diets in chapter 4, where it is understood that 
stimulation of the P53 pathway is in aid to stimulate repair of damaged tissue via apoptosis to 
remove damaged cells. These changes have also been reported in previous studies following the 
treatment of EGCG with damaged hepatocellular carcinoma cell lines (592), as well as in colon 
cancer (593) and lung cancer cells (594) for an increase in P53 signalling. The evidence reported in 
this current study supports the notion that EC and 34DHPVL could have protected against the 
development of hepatocellular carcinoma by raising P53 signalling.  
The HF insulin resistant mice in this current study exhibited an increase in the expression of 
pathways: oxidative phosphorylation, citric acid cycle and fatty acid β-oxidation, when compared 
to LF diet fed mice. Whereas, the addition of EC into the HF diet reversed all these pathway 
expressions which are known to be interconnected. The higher expression of the citric acid cycle 
would re-direct more acetyl-CoA to the mitochondria for oxidative phosphorylation of fatty acids, 
which in return would raise ROS levels that are associated with the pathogenesis of MAFLD and 
insulin resistance (595). These aforementioned pathways have also been reported to be more 
highly expressed in subjects with type-2 diabetes  (595-597). Moreover, an increase in fatty acid β-
oxidation is commonly linked to an increase in genes encoding PPARα and PPARβ (PPARA and 
PPARB respectively), which were also shown to be significantly increased in this current study for 
the HF vs LF treatment, but were significantly reduced by the addition of EC but not 34DHPVL into 
the HF diet. A consequence of the high ROS levels produced by these pathway activations in the HF 
diet provides a negative feedback mechanism to enhance insulin resistance effects, most likely 
through triggering P53 signalling, known to also feedback and activate β-oxidation, oxidative 
phosphorylation and gluconeogenesis (587). Thus, all these pathways are strongly linked to the 
onset of MAFLD and insulin resistance (586) and could be another mechanism explaining how EC 
protects against their pathogenesis in this current study (please refer to chapter 3 and chapter 4 




In this current study, the HF diet caused a reduction in the expression of gene CREB1 compared to 
the LF diet, and significantly increased the expression of PPARG, NR1H4 (encoding protein FXR) and 
CD36, whereas the addition of EC, but not 34DHPVL, reversed these changes, which is indicative of 
an improved insulin sensitivity in these mice, as shall now be explained. The expression of CREB has 
been shown to play pleiotropic roles, where its reduction (598) and increase (599) has been 
reported to be associated with improved insulin sensitivity, however, this current study supports 
its increase for improved insulin sensitivity by EC. Phosphorylated CREB is also reported to inhibit 
PPARγ in the liver (600), and so all of these aforementioned proteins/genes directly or indirectly 
regulate another, as now described. The mRNA and protein expressions of CD36 levels are 
associated with hepatic fatty acid uptake which could contribute to hepatic steatosis, as has been 
shown in this study and also by Liu et al (2017) (599) in mice fed the exact same HF diets over an 
almost identical study length. And the mRNA and protein expressions for CD36 were seen to be 
much greater in HF diet fed mice than in mice on LF HC diets in both this study and Liu et al (599). 
CD36 mediated hepatic fatty acid uptake is transcriptionally regulated by PXR, LXR, PPARγ (601) and 
FXR (602); but Liu et al found that PPARγ was responsible for the increase in CD36 (599). They also 
showed that the addition of the natural polyphenol curcumin into the diets caused a decrease in 
CD36 expression at both a protein and mRNA level, as well as a decrease in PPARγ and an increase 
in CREB protein and mRNA levels (599). This process could be translated to the findings in this 
current study where EC most likely influenced lipid metabolism to limit hepatic fat build-up via 
eliciting an increase in total and phosphorylated CREB levels, which would cause the inhibition of 
PPARγ and lower the synthesis of CD36, ultimately causing a reduction in triglyceride synthesis 
(599). However, because this current study also reports higher expression levels of NR1H4 
(encoding protein FXR) in the HF compared to LF diet fed mice, it is not possible to establish whether 
CD36 levels were only affected by PPARG, or whether it was a combination effect from both NR1H4 
and PPARG. Nonetheless, the increase in CREB1 gene expression levels were associated with 
improved insulin sensitivity rather than a decreased sensitivity by EC in the HF diet, as indicated by 
the lower blood glucose levels in chapter 3.  
The findings for reduced expression levels of IGFBP1 and IGFBP3 have been shown in this study for 
insulin resistant HF diet versus LF diet fed mice, whereas the addition of EC into the diet caused a 
significant increase in the expression of IGFBP1 but a further decrease for IGFBP3; this is a normal 
response when insulin signalling is being restored because IGFBP-1 is mostly regulated by insulin, 
but is reduced in the presence of insulin resistance (513), and IGFBP-3 can inhibit cytokine induced 
insulin resistance (514, 515) (please see section 5.2.1 for the roles of IGFBPs). Furthermore, MMP-




insulin signalling (516), and MMP7 levels were largely reduced in this current study for HF diet fed 
mice when compared to LF diet fed mice, but their levels were only modestly increased when EC 
was supplemented into the HF diet but more highly expressed when supplemented into LF diet fed 
mice. It is not possible to identify why this occurred without having assessed protein expression 
levels for MMPs and TIMPs (tissue inhibitor of metalloproteinase), but it could be linked to 
extracellular matrix (ECM) remodelling in the liver or further downstream effects such as IGFBP 
degradation. The only case where MMP-7 levels were reported to increase following EGCG 
addition, was in colorectal cancer cells through the activation of JNK1/2 and c-JUN (AP-1) (603). 
Because the expression levels of JUN were also shown to be increased in this current study by EC 
when supplemented in HF diets of mice, this could explain why MMP7 levels were raised.  
For gene changes that are directly involved in the insulin signalling pathway and seen in this current 
study, included an increase in the expression of genes IRS2, PI3K, AKT, and MAPK, and a decrease 
in PRKCA (PKC-α protein) only following the supplementation of EC and occasionally 34DHPVL into 
the HF diet and compared to HF diet fed mice. These results imply a greater insulin sensitivity in the 
livers of mice following supplementation of the HF diet with EC and 34DHPVL, and it would explain 
why both groups exhibited lower glucose levels during the glucose tolerance test (as described in 
chapter 3). For a comparison of these changes to the literature, it has been reported that EGCG can 
inhibit PKC, an inhibitory protein of the insulin receptor (IR) (525), and that EC and cocoa 
polyphenols stimulated IR, IRS-1, IRS-2 and proteins in the PI3K/Akt pathway when treated in insulin 
resistant HepG2 cells (285, 341) (described in more detail in section 5.2.2).  
Finally, chapter 3 of this thesis reported significantly higher blood insulin levels in 34DHPVL 
supplemented HF diet fed mice and it discussed this against a plausible scenario of impaired hepatic 
clearance of insulin rather than hypersecretion. To identify whether there was any evidence from 
the RNA-seq data for this, the gene CEACAM1 (CEA cell adhesion molecule 1) was assessed and it 
was shown to exhibit a lower expression in HF+34DHPVL and HF treatment groups when compared 
to HF and LF treatment groups, respectively; but the effects were stronger when 34DHPVL was 
present. Although the changes were not significant, it could possibly explain the significantly higher 
levels of blood insulin in the 34DHPVL combined with HF diet fed mice (chapter 3). Because the liver 
is the main site for insulin degradation (604, 605) and CEACAM1 mediates insulin degradation by 
binding to and internalising the insulin bound insulin receptor for enzymatic degradation (357, 358), 
it can provide an indirect measure for hepatic insulin clearance. It is understood that obesity and 
type-2 diabetes are associated with a reduced hepatic clearance of insulin (358), and that there is 
an association between hepatic fat concentration and impaired insulin clearance (358, 364) 




phenotypical observations in the mice. However, this study also showed a higher expression of 
CEACAM1 in HF+EC versus HF mice, which suggests that this group would be more responsive to 
insulin bound receptors for internalisation and degradation. To confirm if insulin degradation was 
really affected by the different dietary interventions in this study, more tests would be required as 
outlined in chapter 4, but the differential expression data has provided a valuable start to generate 
hypotheses for future experiments 
Overall, this study has shown that EC mitigates HF diet induced insulin resistance and MAFLD, which 
was shown by increases in the expressions of genes directly linked to insulin signalling and the 
PI3K/Akt pathway as well as for other metabolic genes and pathways. This therefore highlights the 
protective effects of EC on transcriptomic changes caused by HF diets and is currently the first study 
to have assessed gene expression changes by EC at an RNA-seq level. Moreover, this current study 
provides evidence for modest protective effects of 34DHPVL against HF diet induced insulin 
resistance by causing changes in the expression of genes involved in insulin signalling and indirectly 
via gluconeogenesis, leptin metabolism (discussed in section 5.6.4) and the citrate cycle. Although 
the changes in the expressions of genes caused by 34DHPVL were not as strong as those caused by 
EC, it does support the physiological reductions in blood glucose levels following glucose challenge 
in HF+34DHPVL fed mice in comparison to HF fed mice. Therefore, 34DHPVL could be partly 
responsible for mitigating the insulin resistant effects as a metabolite of EC, but it is not responsible 
for the mitigation of MAFLD in the mice livers. Again, this is the first study of its kind to investigate 
the effects of 34DHPVL in an in-vivo model of insulin resistance, as such, the gene expression data 
is invaluable for hypothesis generating and designing future experiments with this compound. 
 
5.6.4 Does 3’,4’-dihydroxypenyl-y-valerolactone improve leptin sensitivity to 
aid the lowering of blood glucose levels in high fat diet fed mice? 
Leptin is an important regulator of food intake, energy homeostasis and glucose metabolism and 
its effects depend on its binding to the leptin receptor (LEPR). In the liver, leptin enhances glycogen 
storage and inhibits gluconeogenesis, but it also has critical regulatory effects in the hypothalamus 
(606). In chapter 3, it was demonstrated that 34DHPVL drastically increased the levels of insulin in 
HF diet fed mice and caused the lowering of glucose levels compared to HF fed controls. The rise in 
insulin could be because of hypersecretion or impaired clearance, but 34DHPVL may affect 
pathways independent of insulin for the glucose lowering effects. Although leptin levels were not 
measured in this current study, there was evidence for a significant reduction in the expression of 




are regularly reported in obesity (607, 608). The increased leptin levels act to decrease appetite and 
increase satiety (607), the effects of which cause leptin resistance. A reduced response to leptin 
stimulates hepatic DNL and an increase in gluconeogenesis (609). This current study shows that EC 
and 34DHPVL supplementation into the HF diet and compared to HF controls caused a modest 
increase in the expression of the LEPR gene. It cannot be established whether this was also 
associated with changes in leptin levels without having investigated this, but it could imply greater 
sensitivity to leptin. 
Leptin is reported to increase insulin sensitivity in subjects with type-2 diabetes and lower 
gluconeogenesis to favour a reduction in blood glucose independently of blood insulin levels (610-
612). Leptin regulates insulin levels in a dual hormonal feedback loop mechanism (adipoinsular 
axis), i.e. high leptin lowers insulin secretion, and insulin stimulates leptin production in adipocytes. 
Leptin signals through the JAK/STAT (primarily JAK2/STAT3) pathway to stimulate Akt/PI3K to 
promote insulin signalling, and STAT3 also suppresses the expression of gluconeogenic genes (613). 
Alongside the marginal increases in LEPR expression in this current study for EC and 34DHPVL 
supplemented HF diet fed mice, was the increase in STAT3 expression, and the decrease in the 
leptin signalling inhibitor, SOCS3 (613, 614) for 34DHPVL but not EC supplemented HF diet fed mice. 
In fact, there were rises in SOCS3 expression levels in the presence of EC, when compared to HF 
control fed mice. The lowering of SOCS3 expression in 34DHPVL supplemented HF diet fed mice 
could explain why there was an increase in several cytokine genes by 34DHPVL in the HF diet 
(namely TNFA and interleukin genes variants: CXCL) because it suppresses their expression under 
inflammatory conditions (615). These changes would favour an increase in leptin signalling in 
34DHPVL supplemented HF diet fed mice, more so than in the EC supplemented diets, which 
consequently could contribute to explaining the lower glucose levels in the mice during the fasted 
glucose challenge.  
Although the high insulin levels in mice on 34DHPVL supplemented HF diets cannot be clarified from 
the data in this study, if it occurred via hypersecretion by the pancreas, then this could possibly be 
explained by higher leptin levels, because leptin promotes insulin secretion, and because the mice 
appeared to have a better sensitivity to leptin (from the gene expression changes) which would 
increase the uptake of glucose into the liver for glycogenesis. Furthermore, higher leptin levels can 
also increase adipose lipolysis which consequently could increase hepatic steatosis through the 
higher uptake of FFAs (616, 617). This could also be another mechanism to explain how 34DHPVL 




5.6.5 The effects of low-fat high-carbohydrate diets on hepatic fibrosis  
It has been discussed previously in chapter 4, section 4.6.3, the effects of high carbohydrate diets 
and the induction of liver fibrosis and DNL. Therefore, this section will discuss in more detail the 
possible pathways and gene changes affected by the LF HC diets and how it may explain the 
phenotypical changes observed and discussed in chapters 3 and 4. 
In this current study, it was clear that the LF HC diet induced DNL more strongly than the HF diet in 
mice (as discussed in section 5.6.1), and the effects of this are understood to induce hepatic fibrosis 
more strongly, which was shown by visual observation of the LF HC fed mice hepatic tissues (chapter 
4) and also confirmed here for gene expression changes. Gene expressions that are reported to be 
linked to the development of fibrosis involve those in the TGFβ-BMP-SMAD pathway (618), and it 
was identified that the transcriptional events for a large selection of genes in this pathway were 
more highly expressed by the mice on the LF HC diet than the HF diet in this study (section 5.5.7). 
Some of these gene changes will now be explained with explanation to their contribution to fibrosis, 
specifically with regards to the TBFβ-BMP-SMAD pathway. In the presence of liver damage, hepatic 
stellate cells (HSCs) are activated to initiate repair processes and it does so via the synthesis of TGF-
β (618). It was clear that TGF-β transcription levels were higher in the LF mice than the HF mice in 
this study because there was higher expression levels of genes TGFB1, TGFB2 and TGFB3. The TGF-
β protein then binds to initiate the phosphorylation of SMAD2 and SMAD3 proteins that now bind 
to SMAD4 and translocate to the nucleus to activate gene transcription for the production of 
extracellular matrix proteins, like α-smooth muscle actin (αSMA, ACTA2 gene) and type-I collagen 
(COL1A1) (618), both of which were expressed at much higher levels in the LF mice in this study 
compared to HF diet fed mice. Furthermore, the LF fed mice in this study showed lower expression 
levels of SMAD2 and higher levels of SMAD3 and SMAD4 compared to HF diet fed mice. These 
changes can be explained because SMAD3 phosphorylation is crucial for activating gene 
transcription and is pro-fibrogenic (619), where its inhibition inhibits type-I collagen production, 
whereas SMAD2 has been shown to be anti-fibrogenic where its upregulation promotes HSC 
apoptosis and its decrease further promotes collagen production (620). An additional role of TGF-
β1 in supporting fibrosis development is to suppress MMP activity and thereby inhibit ECM 
degradation (621). Alternatively, the BMP pathway can be activated to stimulate ECM gene 
transcription, and in this study the genes for BMP2-6 were more highly expressed in the LF diet 
compared to the HF diet, further supporting fibrosis development. However, BMP proteins signal 
through the downstream activation of SMAD1, SMAD5 and SMAD8 proteins (622), but only SMAD1 




Further genes that are involved in the development of fibrosis and were shown to be more highly 
expressed in the LF versus HF diet includes EGFR and VEGFA. This is because EGFs are known to 
bind to its receptor EGFR and stimulate the proliferation and migration of hepatic stellate cells 
(HSC), and subsequently the deposition of ECM (623). Whereas, VEGF is known for its role in being 
pro-angiogenic, where angiogenesis has been shown to be a pre-requisite for MAFLD and fibrosis 
(624, 625), in addition, VEGF supports the proliferation of HSC’s.  
In addition, the genes SEL1L3, and LOXL1 were more highly expressed in the LF versus HF diet fed 
mice in this study, and APOF and HORMAD2 were more lowly expressed. The expression of genes 
HORMAD2 and APOF have also been reported by Ryaboshapkina and Hammer (2017) to be 
decreased in cases of increasing hepatic fibrosis severity, in addition to increased expression levels 
of LOXL1 (503), previously shown to stimulate TGF-βI induced ECM deposition (626), and its 
inhibition retarded liver fibrosis (627). Additionally, the expression of SEL1L3 has been reported to 
increase with fibrosis severity and is associated with hepatic ballooning (503). This is further 
evidence supporting the ideology that the LF HC diet induced hepatic fibrosis more strongly than 
the HF diet in mice in this study. 
 
5.6.6 How (−)-epicatechin protected against high-fat but not high-
carbohydrate diet induced TGF-β activation for fibrosis 
HF fed diets and insulin resistance have been shown to induce an increase in TGF-β signalling 
through upregulation of TGF-β1 (628). Despite the LF HC diet having induced fibrotic genes more 
strongly than the HF diet, the protective effects were seen by EC when supplemented into the HF 
diet for the reversal of fibrotic genes, which is suggestive that EC can protect against HF diet induced 
hepatic fibrosis, as shall now be discussed.  
In this study, it was observed that EC supplemented HF diet and compared to HF diet fed mice 
caused a reduction in the differential expression for genes TGFB1 (TGF-βI), TGFB2 (TGF-βII), SMAD2-
5, COL1A1 (type-I collagen) and increased the expression for NFKB1 (NF-κB), NFKB2 (NF-κB), AKT1, 
PIK3CB (PI3K), PIK3CD (PI3K), PIK3CG (PI3K), and JUN (AP-1) but not for NRF2. This supports the 
evidence reported by previous authors with regards to the effects of EC stimulating the PI3K/Akt 
and NF-κB pathways, but this is new evidence to indicate that EC can reduce TGF-β/SMAD and type-
I collagen transcriptional events. Furthermore, this study showed that these gene changes caused 
by EC in the HF diet marginally reversed the expression of the KEGG TGF-β signalling pathway. These 




pathway expressions for NF-κB (528), PI3K/Akt (528, 529), ERK (529), AP-1 and NRF2 (528) in HepG2 
cells. These specific gene changes caused by EC were shown to arise by (1) rises in IKK (IκB kinase) 
and phosphorylated IκBα stimulated NF-κB, where the absence of IKK caused extensive liver 
damage due to apoptosis (528); (2) EC counteracted the rise in ROS levels and stimulated cell 
survival/proliferation through the PI3K/Akt pathway (528, 529), along with the sustained 
enhancement of the AP-1 transcription factor (c-JUN gene) (528), which is known to trigger 
apoptosis in damaged cells, and their survival/proliferation in capable cells, and low ROS stimulated 
NRF2 for cell survival functions (528). Overall, these pathways have been shown to retard fibrosis 
development.  
There are several other studies that support the changes in the expression of fibrotic genes by EC 
when supplemented into HF diets in mice in this current study, and also provides evidence for 
changes in protein levels; although protein levels were not assessed in this study, the transcript 
levels can suggest a level of protein expression. Xiao et al (2012) investigated the effects of EGCG 
(50 mg/kg body weight) on hepatic fibrosis in HF diet fed rats for 8-weeks and found that EGCG 
counteracted the HF diet induced rise in active protein expression in the TGFβ-SMAD pathway for 
SMAD2, SMAD4, FOXO1, and NF-κB active levels and counteracted the decrease in PI3K and Akt 
active levels, which subsequently caused a reduction in α-SMA deposits (477). In addition, EGCG 
has been reported to lower the expression of genes encoding proteins TNF-α, IL-1β, TGF-βI, MMP-
9, α-SMA and COL1A1, and suppressed the phosphorylation of SMAD2 and SMAD3 in a fibrotic rat 
model and in HSCs (523). Moreover, EGCG and ECG have also been shown to dose dependently 
inhibit the production of type-I collagen as well as collagenase activity (MMP-1) in HSCs at a protein 
level whilst also transcriptionally increasing type-I collagen (COL1A1) and TIMP1 and reducing 
MMP1 (524) and EGFR (579). Similar changes were also shown by GTE in rats (519, 536). These 
studies therefore highlight the similar effects that both EC and EGCG had on hepatic pathway 
activation, specifically for PI3K/Akt and NF-κB stimulation and for the repression of TGFβ-SMAD 
signalling. 
In this study, the inclusion of EC and 34DHPVL into the HF and LF diet was able to increase 
differential gene expression for HORMAD2, which was mentioned in section 5.6.5 to be associated 
with the severity of hepatic fibrosis (503). However, the role HORMAD2 plays in the liver has not 
been investigated previously and there are no known effects of green tea polyphenols or catechins 
on altering the expression levels of this gene or of APOF, LOXL1 and SEL1L3. Thus, this would be 
interesting to investigate further, particularly as their expressions are altered in MAFLD and with 




Furthermore, in this study, EC significantly upregulated the ribosome KEGG pathway in the HF diet, 
which has also been shown to occur by EGCG in a previous study (557), because the ribosome 
pathway is involved in protecting the liver through cell cycle progression and responding to DNA 
damage, whereas MAFLD commonly causes a depression in the ribosome pathway to induce 
apoptosis and cell death (500, 557). 
In summary, the LF HC diet induced differential gene expression changes in favour of the 
development of liver fibrosis, more strongly than the HF diet, by significantly increasing the 
expression of genes involved in the TGF-β/SMAD pathway and subsequent ECM genes for type-I 
collagen and α-SMA, as well as other fibrosis linked gene changes. In this study, we have shown 
that EC supplementation in the LF and HF diet can cause changes in the expression of genes that 
favour the mitigation of fibrosis via a reduction in TGF-β/SMAD pathway and an increase in PI3K/Akt 
and NF-κB pathway related genes, which causes a reduction in apoptosis and promotes cell 
survival/proliferation and ROS scavenging (although these effects did not always reach statistical 
significance). This study also reports similar effects following dietary supplementation of 34DHPVL, 
however, the effects were seen to be stronger in the LF diet than the HF diet. 
 
5.6.7 Summary – bringing everything together 
This discussion has explained the evidence for the changes in the expression of hepatic genes 
following each dietary treatment with reference to the literature for how flavanols and their food 
extracts have caused changes in the expression of hepatic genes. This will now be summarised with 
the aid of Figures 5.8 and 5.9 to understand how the major pathways are interlinked.  
In the fed-state, the liver should respond metabolically as depicted in Figure 5.8, with a clear influx 
of glucose that then enters glycolysis for pyruvate production or glycogenesis to produce glycogen. 
Pyruvate then forms acetyl-CoA that enters the citric acid cycle or is directed to fatty acid 
biosynthesis and triglyceride formation (lipogenesis). In the presence of a LF HC diet there was a 
much higher expression of fatty acid biosynthesis and DNL than the HF diet because of the high 
concentration of carbohydrates that reached the liver, which can also induce hepatic damage and 
high circulatory lipid concentrations. When EC or 34DHPVL was combined with the LF diet there 
was an increase in gluconeogenesis, fatty acid metabolism, and a reduction in oxidative 
phosphorylation, DNL and citric acid cycle pathways; these favour an increase in glucose production 




However, during insulin resistance, the liver is unresponsive to insulin in lowering glucose levels 
following food consumption, and instead can stimulate gluconeogenesis to continue the production 
of glucose. This was mainly how the HF diet compared to the LF diet acted in mice in this study, as 
demonstrated by Figure 5.9. For this there was an increase in fatty acid metabolism, citric acid cycle, 
oxidative phosphorylation, amino acid metabolism and gluconeogenesis pathways, which all favour 
glucose production. Moreover, there was an increase in P53 signalling which can drive 
gluconeogenic genes (588) and suppress insulin signalling (589), and a decrease in PPAR signalling 
which can regulate fatty acid uptake and β-oxidation (629), and there was a decrease in the 
ribosome pathway which is inversely linked to the P53 signalling for a reduction in glycolysis (630), 
and there was a reduction in insulin signalling. However, the supplementation of EC and 34DHPVL 
to the HF diet reversed nearly all these processes, and favours the reduction of blood glucose levels 
seen in the mice in chapter 3, because they were more insulin sensitive and exhibited a reduction 
in the expression of pathways that drive gluconeogenesis. EC was more effective than 34DHPVL in 
counteracting the HF diet induced pathway changes. All these events are summarised in Figures 5.8 
and 5.9 and illustrates how the pathways are interlinked, Figure 5.9 also shows in detail the citric 





Figure 5.8: Liver metabolism in the well-fed state 
Hormones and fuels in the hepatic portal vein are directly delivered to the liver to stimulate processes for 
glycolysis, glycogenesis, fatty acid biosynthesis and lipogenesis. The hepatic pathway changes that all link to 
this process are highlighted for the LF versus HF, LF+EC versus LF, and LF+34DHPVL versus LF dietary fed mice, 
where the dashed boxes indicate where those respective pathways are. AA: amino acids; G6P: glucose-6-
phosphate; PEP: phosphoenolpyruvate; OAA: oxaloacetate; CAC, citric acid cycle; FFA: free-fatty acids; TG: 





Figure 5.9: Liver metabolism when insulin resistant 
Hormones and fuels in the hepatic portal vein are directly delivered to the liver, or from the general 
circulation (capillaries). Due to insulin resistance, there is a delayed response to insulin in lowering glucose 
levels, and therefore pathways for fatty acid, pyruvate, amino acid, and starch and sucrose metabolism are 
increased which stimulate gluconeogenesis for further glucose production. This is highly demonstrated in 
the HF versus LF treated mice. The hepatic pathway changes that all link to this process are highlighted for 
the HF versus LF, HF+EC versus HF, and HF+34DHPVL versus HF dietary fed mice, where the dashed boxes 
indicate where those respective pathways are. Blue text and blue arrows indicate amino acids. AA: amino 






Data presented in chapters 3 and 4 have aimed to investigate the phenotypical changes of HF diets 
in mice and their tissues to understand whether there were physiological effects of supplying EC 
and 34DHPVL into their diets. From this, it was then important to understand how these changes 
may arise from gene expression changes in the liver, where the liver was selected because: (1) it is 
a highly metabolic organ, (2) it comes into contact with high concentrations of the polyphenols and 
their metabolites following pellet consumption, (3) it is affected by HF diets to develop insulin 
resistance, and (4) it develops MAFLD in mice on the HF diet. The following conclusions can be made 
in this chapter:  
(1) HF diet fed mice that expressed MAFLD and insulin resistance demonstrated a 
significant increase in the expression of genes in gluconeogenesis and other metabolic 
pathways for starch and sucrose metabolism, amino acid metabolism, citrate cycle, and 
oxidative phosphorylation. 
(2) EC and sometimes 34DHPVL supplementation into HF diet fed mice was able to reverse 
these pathway changes and assist the lowering of blood glucose levels and regulate the 
expression of genes to promote insulin signalling, and thus improve insulin sensitivity. 
(3) The LF HC diet induced gene changes for DNL and fibrosis more strongly than the HF 
diet largely through increasing the expression of genes involved in the TGFβ-BMP-SMAD 
pathway; and could thus be a stronger driver for the development of hepatocellular 
carcinoma. 
(4) EC was shown to mitigate gene expression changes for fibrosis development and DNL 
on the LF and HF diets, whilst 34DHPVL exerted similar protective changes for fibrosis 
development but raised the expression of genes for DNL, explaining why HF+34DHPVL fed 
mice exhibited a higher average concentration of liver lipids.  
Overall, there is sufficient evidence from this dietary intervention study to conclude that EC 
protects the liver from damage induced by HC and HF diets and protects the liver from the 
development of MAFLD and insulin resistance through a reduction in hepatic lipogenesis and an 
increase in insulin signalling processes, respectively. The evidence obtained for 34DHPVL is more 
modest, where its inclusion in the HF diet was associated with an increase in hepatic lipogenesis 
but a decrease in circulating glucose through reduced gluconeogenesis, whilst there is some 
evidence to suggest improved insulin signalling responses in the livers of the mice. More 




34DHPVL in order to collate enough evidence to understand whether it protects against HF diet 












Chapter 6: General Discussion and further research 
recommendations 
6.1 Summary of main findings 
The purpose of the four methods and results chapters in this thesis were to investigate the following 
main aims (1) assess the pharmacokinetics of hydroxyphenyl-γ-valerolactones (HPVL) in plasma and 
urine over 24-hours when provided as an oral dose in mice, (2) investigate the physiological and 
phenotypical effects of (−)-epicatechin (EC) and 3’,4’-dihydroxyphenyl-γ-valerolactone (34DHPVL) 
when supplied in combination with a high-fat (HF) diet in a mouse model of high-fat diet induced 
insulin resistance and metabolic associated fatty liver disease (MAFLD), and (3) explore the hepatic 
gene expression changes induced by EC and 34DHPVL in HF diet fed mice to understand the 
mechanisms that underly their protective effects against HF diet induced hepatic insulin resistance 
and MAFLD. The main findings from these investigations include the following points: 
1. When HPVLs were provided as an oral dose in mice, they were rapidly absorbed and 
substantially conjugated to phase-II metabolites and were still detectable at 24-hours (the 
end of the study). 
2. EC supplemented into HF diets in mice mitigated HF diet induced insulin resistance, MAFLD, 
body weight gain and steatosis. EC was also successful in reversing the expression of several 
genes involved in the progression of liver fibrosis in both the HF and LF diets when 
compared to their respective controls. Finally, EC raised the expressions of hepatic genes 
involved in insulin signalling and reduced the expressions of genes involved in 
gluconeogenesis, consequently causing a more efficient reduction in blood glucose levels 
than HF diet fed mice. 
3. The main effects observed for 34DHPVL supplemented into HF diets in mice were to 
improve fasting glucose concentrations, raise blood insulin levels, increase liver lipids in line 
with rises in blood insulin, increase hepatic de novo lipogenesis (DNL), and increase the 
expressions of hepatic genes involved in insulin signalling and for leptin signalling and 
reduced the expressions of genes involved in fibrosis and gluconeogenesis, which all 
support the observations for lower blood glucose levels. However, 34DHPVL did not 
mitigate against HF diet induced body weight gain and did not alter the profile of plasma 
lipids. Evidence from the intervention suggests an impaired hepatic insulin clearance rather 




4. Mice fed a 60 % kcal diet from fat exhibited observational changes that were consistent 
with the literature compared to mice fed a 10 % kcal diet from fat, for the following: 
significant gain in body weight, development of insulin resistance, significantly higher 
plasma cholesterol and low-density lipoproteins (LDL), and hepatic gluconeogenesis. 
However, they also exhibited higher levels of plasma high-density lipoproteins (HDL) than 
LF fed mice.  
5. The overall level of hepatic damage was higher in mice on the LF compared to the HF diet, 
which corresponded with an increase in hepatic DNL and pathways involved in extracellular 
matrix production. 
The following sections in this chapter are to discuss the novelty and wider importance of the 
research presented in this thesis and to make some recommendations for future work. 
 
6.2 Developing evidence that hydroxyphenyl-γ-valerolactones are 
bioactive 
It is clear in this thesis and from previous publications (127, 128, 130) that EC supplemented into 
the diets of HF diet fed mice mitigated HF diet induced body weight gain and insulin resistance, and 
the data presented here supports that reported in previous publications. But this thesis has helped 
to answer whether the structurally related EC metabolites (SREMs) or whether the colonic ring 
fission metabolites (RFMs) are responsible for inducing the protective effects seen by EC 
consumption. The ingestion of EC gives rise to both SREMs and RFMs, whilst the ingestion of HPVLs, 
and in this case 34DHPVL will only give rise to RFMs and its conjugates, and so, this thesis has 
isolated a fraction of EC metabolites and investigated these in mice.  
To identify whether HPVLs possess bioactive properties, this thesis looked to compare the effects 
of 34DHPVL against those reported for EC following their consumption in mice for the following: (1) 
establish whether 34DHPVL caused the previously reported reductions by EC for weight gain and 
insulin resistance in mice fed HF diets, (2) assess the effects of 34DHPVL dietary supplementation 
on liver histology and liver biomarkers related to MAFLD for steatosis and fibrosis, and (3) assess 
the effects of 34DHPVL dietary supplementation on global hepatic gene expression via genome-





6.2.1 Do hydroxyphenyl-γ-valerolactones have biological activities and are 
they potentially beneficial? 
Although, there is an existing body of evidence to support the notion that HPVLs possess bioactive 
properties (covered in section 1.5 of chapter 1), they have not been investigated for their effects 
on insulin sensitivity, and so the findings in this thesis are completely novel with regards to the 
effects induced by HPVLs, in addition to the effects of both EC and HPVLs on hepatic transcriptomic 
effects at a high-throughput RNA-Sequencing level.  
The question for whether HPVLs ameliorate HF-diet induced insulin resistance has been partly 
answered by the research in this thesis. It has been reported here that the supplementation of 
34DHPVL into both HF and LF diets caused an overall reduction in blood glucose levels when 
compared to their respective controls during a glucose challenge in mice, but this did not reach 
statistical significance. This was later found to be accompanied by gene and pathway changes that 
favour a reduction in glucose production and an improvement in insulin signalling responses. This 
is evidence to support the notion that HPVLs contribute to ameliorating insulin resistance effects, 
however, the gene and pathway changes were not significantly different to the control treatments 
possibly due to the high variance in the group, and thus makes it difficult to conclude whether 
HPVLs exert protective effects. However, there were slight changes in the expressions of genes 
encoding proteins for rate limiting steps in pathways such as fatty acid metabolism and 
gluconeogenesis, and this evidence supports the notion that 34DHPVL has a beneficial effect on 
insulin resistance. Accompanying these changes for 34DHPVL fed mice were higher fasting blood 
insulin concentrations both prior to and during the glucose challenge, when compared to their 
controls. Although it was hypothesised that the high insulin concentrations occurred because of 
impaired hepatic insulin clearance, there was not enough evidence in this thesis to conclude this, 
and it could be because of high insulin secretion which would not favour the mitigation of insulin 
resistance. Consequently, there is not enough evidence from the research in these chapters to 
conclude whether HPVLs contribute to ameliorating HF diet induced insulin resistance, but there is 
some evidence that they have a modest protective effect.  
The power of the dietary intervention study in mice was based on the data reported by Cremonini 
et al (127) and this suggested a power of 60 %, which provided a minimum mouse sample size of 
12 per group. However, the changes observed when 34DHPVL was supplemented into the HF diet 
did not reach statistical significance. If the power of the study were designed at 80 % or more then 
there could have been greater effects observed by 34DHPVL to cause significant changes from the 




The research presented in this thesis suggests that structurally related EC metabolites (SREMs) are 
most likely the metabolic derivates that ameliorate insulin resistance effects following EC 
consumption, but does not exclude the possibility that ring fission metabolites (RFMs) also 
contribute, albeit less effectively; see section 6.4 where this is discussed in more detail.  
 
6.3 Evidence to support the biological effects induced by gut-
microbiota dependent metabolites derived from flavonoids 
This thesis reports some evidence to show that 34DHPVL and its metabolites have biological 
activities. The evidence from the fasted glucose tolerance test and biomarkers of insulin sensitivity, 
and from liver tissue histology highlight modest changes by supplementation of HF diet fed mice 
with 34DHPVL, but the effects were not statistically significant. However, transcriptomic analysis of 
the liver tissue of mice demonstrated that there were changes in gene expressions by 34DHPVL in 
HF diet fed mice for metabolic pathways that favour a reduction in insulin resistance and 
gluconeogenesis, but although these effects were not significant they support the changes 
observed in the mice throughout the GTT. Overall, these findings suggest that HPVLs may have 
modest effects on these processes, however, the beneficial effects on insulin-resistance and body 
weight gain on the HF diet following EC consumption were mostly driven by SREMs. But, is this also 
the case for other dietary flavonoids, or is there evidence to show that the gut microbiota 
metabolites of flavonoids are responsible for the beneficial effects associated with their 
consumption? 
Only about a third of humans in Western countries can metabolise the isoflavone daidzein into 
equol by the gut microbiota, whereas the prevalence is 40-60 % in Asian countries, and so, humans 
are termed as equol or non-equol producers (631). Although both equol and non-equol producers 
exhibit microbiota involved in the production of equol, the differences reported for whether or not 
equol is produced is in the abundance of equol producing gut microbiota (631, 632), and although 
the exact reasons defining this are not known, it is thought that the regularity and types of soy 
products consumed (631), as well as genetics, and overall dietary factors contributes to 
interindividual differences in the conversion of daidzein to equol (633). This is important because 
there is a strong relationship for positive health benefits for those that can produce equol at high 
concentrations for positive outcomes in vasomotor symptoms (634), protection against the loss of 
mineral bone density (635), a reduction in body weight (636), a reduced prostate cancer risk and 




possess anti-depressant properties (636). Therefore, this is evidence to suggest that metabolites 
derived from the metabolism of flavonoids by the gut microbiota have stronger bioactive properties 
than the parent compounds to initiate positive health effects.  
Furthermore, daidzein can also be metabolised to O-desmethylangolensin (DMA) by the gut 
microbiota, but DMA is less active than equol (637). Both equol and DMA are otherwise known as 
non-steroidal oestrogens for their high binding affinity to the oestrogen receptor (638-640) and 
consequently have been used to alleviate the symptoms of menopause (641). In-vitro studies with 
these metabolites have revealed strong anti-cancer effects such as the inhibition of cancer cell 
proliferation and migration and the promotion of cancer cell apoptosis (640, 642-644), in addition 
to exhibiting strong anti-inflammatory activities including the inhibition of iNOS and activation of 
eNOS (645-647). Very similar effects have been reported to be elicited by urolithins, which are 
catabolites of ellagitannins, and enterolactones and enterodiols, which are catabolites of lignans, 
and all exhibit similar bioactive properties to those of equol and DMA for oestrogen receptor 
binding, anti-inflammatory activity and inhibition of cancer cell development (648-655). However, 
the concentrations of catabolites produced and the strength of these beneficial effects is very much 
dependent on the age of the individual and their gut microbiotic signature (656, 657), for example, 
humans are split into three different urolithin producing metabotypes: non-producers, urolithin B 
producers, and urolithin A producers, and the health benefits differ considerably between these 
groups following ellagitannin consumption (658). 
Complex polyphenols such as anthocyanins and procyanidins are metabolised by the gut microbiota 
to form metabolites such as protocatechuic acid (PCA). The biological effects of PCA are stronger 
than the effects of its parent compounds in-vitro, such as cyanidin glycoside, and is more 
physiologically relevant because substantial levels of PCA are produced in-vivo (659). PCA has been 
reported to possess anti-inflammatory, antioxidant, anticancer and neuroprotective activities as 
well as protecting against hyperglycaemia and atherosclerosis, as reviewed by Masella et al (2012) 
(660). PCAs anti-atherogenic effects are thought to occur via its anti-inflammatory actions (661), 
and its anticancer effects due to its antiproliferative and pro-apoptotic actions (660). PCA also 
possesses anti-apoptotic effects and protects against mitochondrial dysfunction, which is important 
for protecting against neurodegenerative diseases (660). Moreover, PCAs antihyperglycemic 
activity has been demonstrated in-vivo where its administration (50-200 mg/kg body weight) orally 
to streptozotocin diabetic rats for 45-days prevented glucose and insulin rises and inhibited 




Carregosa et al (2001) reviewed the literature for the biological effects of flavonoid colonic 
metabolites on neuronal inflammation, and to briefly summarise, benzoic acids, cinnamic acids, 
phenylacetic acids and phenylpropionic acids inhibited lipopolysaccharide induced inflammatory 
activation for cytokine production such as interleukins, tumour necrosis factor-α, and signalling 
molecules involved in inflammatory pathway activation, such as p38, MAPK, NF-κB, and others 
(663). These metabolites could therefore exert similar protective effects in other tissues of the 
body.  
There are some metabolic derivatives of flavonoids that exert pleiotropic effects, such as 3,4-
dihydroxyphenylacetic acid which is a metabolite of quercetin and rutin, where it has been reported 
to possess anticancer (664, 665), anti-inflammatory (666), cardioprotective (664) and 
neuroprotective properties (667), however, it can also inhibit mitochondrial respiration and lead to 
mitochondrial dysfunction in the presence of NO radicals, which could contribute to the onset of 
Parkinson’s disease (668, 669).  
Overall, bacterial derived flavonoid metabolites possess bioactive properties that can protect 
against disease progression and onset, but the level of protection is very much concentration 
dependent and treatments on in-vitro models should look to use physiological concentrations to 
reflect those produced via the gut following food consumption.  
 
6.4 Structurally related (−)-epicatechin metabolites are responsible 
for ameliorating high-fat diet induced weight gain 
This thesis has reported evidence that when EC is supplemented into HF diets it mitigates HF diet 
induced body weight gain and liver weight gain, where the body weight was seen to be reduced by 
the reduction in epididymal fat mass, and liver weight was reduced because body weight was 
lowered. Following the consumption of EC, its metabolism and catabolism gives rise to SREMs and 
RFMs, where the effects on body weight could be attributed to each or both groups of metabolites. 
And so, by feeding mice 34DHPVL directly, this removed the production of SREMs in the mice, and 
allowed for the complete production of RFMs and its conjugates to identify whether they 
contributed to the protection against weight gain. The results of this showed that the 
supplementation of 34DHPVL into the HF diets of mice had no effect on preventing HF diet induced 
weight gain, and consequently this suggests that EC SREMs mediated protection and not RFMs. In 
fact, it was observed that 34DHPVL caused an increase in liver steatosis as determined by the 




under the pharmacokinetic curve of blood insulin levels. This finding was discussed in chapter 4 of 
this thesis with relevance to the literature for explanation, but it supports the gene changes for an 
induction of DNL processes in 34DHPVL supplemented into HF diet fed mice and compared to HF 
controls.  
Section 6.5 discusses how mouse models could be designed to identify whether SREMs are 
responsible for mitigating HF diet induced insulin resistance, but it should be recognised that there 
are very limited in-vivo and in-vitro models that use EC conjugates (SREMs) because they are 
extremely difficult and expensive to synthesise and are not available commercially (348, 670). 
 
6.5 Performing studies to identify whether structurally related (−)-
epicatechin metabolites are bioprotective against insulin 
resistance 
The findings in this thesis provide modest evidence to support an effect of HPVLs for protection 
against HF diet-induced insulin resistance, but no evidence that they protect against HF diet induced 
body weight gain, and therefore EC SREMs most likely contribute to the physiological changes seen 
following EC consumption. This also makes it interesting to query whether the physiological 
changes induced by EC following its consumption would be greater in ameliorating insulin 
resistance if the production of RFMs and HPVLs were limited (and in doing so the absorption of EC 
would be maximised). But to fully investigate this, different animal models would be required as 
detailed below. 
Because ECs give rise to SREMS and RFMs, a study would need to be performed that completely 
prevented the production of RFMs from EC, which is somewhat difficult to perform. To do this, 
there could be two approaches used, first a germ-free mouse model, and second an antibiotic 
treated mouse model. For the former, mice are kept and maintained in a completely sterile 
environment to avoid exposure to microorganisms and can be used to model mice with the 
complete absence of microorganisms or for the generation of gnotobiotic mice with specific strains 
only (671). To generate gnotobiotic mice, it would first need to be identified which colonic 
microorganisms are involved in the metabolism of EC and its conjugates to produce RFMs. Only 
then could a mouse model be designed for the absence of those microorganisms. A gnotobiotic 
mouse model containing no gut microbiota involved in RFM production from EC would only allow 
for the production of SREMs and for their circulation and excretion, and would not affect other 




intervention with EC in combination with a HF diet would then allow for the identification of 
whether SREMs were responsible for ameliorating HF diet induced insulin resistance. However, at 
present, very few bacterial species are reportedly involved in the production of RFMs and HPVLs 
specifically (57) but there could be many others. And so, until the full microbiota profile involved in 
EC catabolism has been identified, this model is not a realistic one, unless the mice were germ-free. 
However, to maintain germ-free and gnotobiotic mice it is very expensive, labour intensive and it 
requires the right skills, which can make this model inaccessible to many researchers (671).  
Alternatively, an antibiotic treated mouse model could be used which overhauls most of the 
difficulties associated with maintaining gnotobiotic and germ-free mice. However, one 
disadvantage includes that antibiotics almost completely deplete the gut microbiota and does not 
allow for strain specific species to colonise (671). In addition, it is hard to completely eradicate the 
gut microbiota, so there could still be species present that are involved in EC catabolism. More 
importantly, antibiotics have been shown to affect glucose tolerance in diabetic mouse models by 
improving glycaemic control (672), and because this is a primary marker recorded to identify insulin 
resistance it would be hard to establish if positive changes occurred as a result of EC or the 
antibiotics in HF diet fed mice. Despite these drawbacks, antibiotics could be used to deplete 
different members of the gut microbiota with specific functions, for example, vancomycin depletes 
gram-positive bacteria (671).  
Both germ-free and antibiotic mouse models require routine validation for the depletion of 
bacterial species, of which there are several methods to choose from (671). Nonetheless, the best 
model that could be used to identify whether SREMs mediate the mitigation of HF diet induced 
insulin resistance from EC consumption would be the germ-free model, because all bacteria have 
not currently been identified for their involvement in EC catabolism to be targeted with antibiotics. 
This would then allow for the identification of whether SREMs provided a greater effect for 
physiological changes in EC fed mice once the production of RFMs were removed.  
Another approach would be to investigate the effects of SREMs in cell culture models of insulin 
resistance. This would prove to be more beneficial than incubating EC directly with the cells because 
EC is not absorbed into the circulation of humans unmetabolized, and thus SREM treatments would 
be physiological and best reflect the in-vivo situation. However, as mentioned previously, SREMs 
are not commercially available and are hard to synthesise which explains why there are very few 
studies reported ((673) this is one study that incubates SREMs in different cell models to determine 





6.6 Recommendations for future work 
A number of recommendations for future work to clarify whether HPVLs are protective against HF 
diet induced insulin resistance or have other health-protective biological activities are summarised 
here.  
Firstly, the results reported in this thesis and from previous published reports suggests that the LF 
high carbohydrate low fibre diet induced hepatic gene expression increases in mice for DNL, which 
was accompanied by stronger phenotypical and physiological evidence for hepatic fibrosis and 
lower plasma HDL levels when compared to HF diet fed mice. All of these effects from the LF HC 
low fibre diet support the notion that this model is not ideal to use as a ‘normal’ control treatment 
group (488), because it proves difficult to compare how the HF diet induces changes against the 
‘normal’ physiological and phenotypical displays in mice. Instead, it is recommended that a control 
‘standard’ diet should be used which is not high or low in either carbohydrates or fats, such as the 
standard SDS diet (RM3, UK) the mice were on prior to their placing on a LF intervention for 2-
weeks. This would then provide a better comparison for how the HF diet induces changes from the 
typical baseline values seen in mice.  
Secondly, the glucose tolerance test showed mice that consumed 34DHPVL in combination with the 
HF diet exhibited significantly higher fasting baseline insulin concentrations than the HF treatment 
groups. However, it would be of interest to determine whether this occurred because of impaired 
hepatic insulin clearance or because of insulin hypersecretion by the pancreas which would help 
identify whether 34DHPVL provided a greater protection against insulin resistance, i.e. mice on 
diets of 34DHPVL in combination with HF displayed lower blood glucose levels and high insulin 
because of impaired hepatic insulin clearance would suggest that 34DHPVL protects against HF diet 
induced insulin resistance, whereas if it was because of hypersecretion of insulin then it could 
favour a progression of insulin resistance. To determine this, plasma C-peptide levels should be 
recorded in mice who consume 34DHPVL in combination with the HF diet. Since C-peptides and 
insulin are released in equimolar amounts by the pancreas, and insulin is only cleared by the liver, 
it will provide a direct measure to identify whether hepatic insulin clearance or insulin 
hypersecretion by the pancreas is the cause of the high blood insulin levels (354).  
Furthermore, 34DHPVL induced hepatic gene expression changes that favour an increase in leptin 
sensitivity when supplemented into HF diets of mice. This could provide evidence for the lowering 
of blood glucose levels in this group independently of insulin. However, blood and tissue leptin 
levels would also need to have been recorded to confirm whether this was plausible. Moreover, 




treatments, measuring leptin levels would provide another physiological parameter to confirm 
whether this occurred because of changes in this satiety hormone.  
In future mouse polyphenol interventions that model diabetes and/or insulin resistance, it is 
recommended to harvest the pancreas and assess protein and gene expression levels of β-receptors 
and other markers involved in the production and secretion of insulin. This thesis has reported in 
detail the hepatic gene expression changes from EC and 34DHPVL supplementation in HF diets of 
mice, which are also publicly available for other scientists to examine further genes of interest, but 
this study is lacking the assessment of hepatic protein changes and the assessment of the pancreatic 
tissue for markers involved in insulin resistance/sensitivity. Performing these extra analyses will 
provide a more detailed account for how EC protects against insulin resistance and whether HPVLs 
can influence pancreatic protein/gene expressions from a HF diet.  
In addition, it may be beneficial to measure bile acid production in future in-vivo models with HPVL 
supplementation, as it is reported that the composition and concentration of bile acids produced 
can influence hyperglycaemia (674). Bile acids are produced by hepatocytes, and chapter 5 of this 
thesis has highlighted the effects of 34DHPVL supplementation on gene and pathway expression 
changes in mice livers, and although we have not investigated the effects of bile acid production, 
the overall changes in gene expressions could influence the levels and types of bile acids produced 
by the liver and ultimately influence the regulation of glucose homeostasis (674).  
Finally, the models outlined in section 6.5 for either germ-free or gnotobiotic mouse models will 
allow identification for whether SREMs mediate the bioprotective effects seen from EC 
consumption because it will remove the production of HPVLs via the gut microbiota.  
Overall, the investigation of HPVLs is a new emerging research area with regards to the health 
benefits that polyphenols and their metabolites can induce. There is evidence to suggest that HPVLs 
possess bioactive properties, and this thesis has highlighted that they may confer protective effects 
against the onset of high-fat diet induced insulin resistance. However, further research is required 
into this interesting group of metabolites to elucidate their biological effects and to identify 
whether they do or do not contribute to the array of health benefits observed from the 
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This figure is with reference to the data in chapter 2. 
  
Appendix Figure 1: Hydroxyphenyl-γ-valerolactone standard curves for plasma and urine UPLC-MS2 
analysis  
A) Standard curves for hydroxyphenyl-γ-valerolactones that were spiked into plasma after processing 
using the protein precipitation method in section 2.4.7.3. The internal standard used was protocatechuic 
acid. B) Standard curves for hydroxyphenyl-γ-valerolactones that were spiked into urine after processing 
using the method outlined in section x. The internal standard used was taxifolin. Cx: Concentration of 
analyte spiked; CIS: concentration of internal standard spiked; Ax: area under the peak curve for the 
analyte following the UPLC-MS2 run; AIS: area under the peak curve for the analyte following the UPLC-
MS2 run. Error bars represent standard deviation of the standard replicates Line equations are stated 




This figure is with reference to the data in chapter 2. 
  
Appendix Figure 2: Plasma and urine pharmacokinetics of 3',4',5'-trihydroxyphenyl-γ-valerolactone 
(345THPVL) in mice 
Mice were oral gavaged with 2 mg of 3’,4’-dihydroxyphenyl-γ-valerolactone and the pharmacokinetic profile 
of 345THPVL was analysed over 24-hours in A) plasma , and B) urine. Error bars represent standard error of 




This figure is with reference to the data in chapter 4. 
 
Appendix Figure 3: Lipid fluorescence in the livers of LF intervention mice 
Livers from low-fat (LF) fed mice supplemented with or without (−)-epicatechin (EC) or 3’,4’-dihydroxyphenyl-γ-valerolactone (34DHPVL), were processed and stained 
for lipids using LipidToxTM (ThermoFisher) and imaged under a Zeiss Axiocam fluorescence microscope. Images were taken at 10x magnification and the scale bar is 




This figure is with reference to the data in chapter 4. 
Appendix Figure 4: Lipid and nuclei fluorescence in the livers of LF intervention mice 
Livers from low-fat (LF) fed mice supplemented with or without (−)-epicatechin (EC) or 3’,4’-dihydroxyphenyl-γ-valerolactone (34DHPVL), were processed and stained 
for lipids using LipidToxTM green(ThermoFisher) and the nuclei with DAPI and imaged under a Zeiss Axiocam fluorescence microscope. Images were taken at 10x 




This figure is with reference to the data in chapter 4. 
Appendix Figure 5: Lipid fluorescence in the livers of HF intervention mice 
Livers from high-fat (HF) fed mice supplemented with or without (−)-epicatechin (EC) or 3’,4’-dihydroxyphenyl-γ-valerolactone (34DHPVL), were processed and stained 
for lipids using LipidToxTM (ThermoFisher) and imaged under a Zeiss Axiocam fluorescence microscope. Images were taken at 10x magnification and the scale bar is 100 




This figure is with reference to the data in chapter 4. 
Appendix Figure 6: Lipid and nuclei fluorescence in the livers of HF intervention mice 
Livers from high-fat (HF) fed mice supplemented with or without (−)-epicatechin (EC) or 3’,4’-dihydroxyphenyl-γ-valerolactone (34DHPVL), were processed and stained 
for lipids using LipidToxTM (ThermoFisher) and the nuclei with DAPI imaged under a Zeiss Axiocam fluorescence microscope. Images were taken at 10x magnification and 




This figure is with reference to the data in chapter 4.  
 






Appendix Figure 7: Correlation analyses for plasma biomarkers against body weight (continued) 
Mouse plasma was assayed using clinical chemistry and regression analyses against body weight were 
plotted for A) Log ALT (alanine transaminases), B) Log AST (aspartate transaminases), C) HDL (high-




The following tables are with reference to the data in chapter 5. 
Appendix Table 1: Primers used to optimise housekeeping gene selection for the livers of mice from the 
dietary intervention study 
Liver cDNA of the mice from the dietary intervention study outlined in chapter 3 were analysed by qRT-PCR 
for the following list of primers to optimise housekeeping gene selection. All primers accept YWHAZ provided 
a single melt curve with R2 values and amplification efficiencies as outlined below. EIF2A and ACTB were the 
top ranked most stable housekeeping genes and were used to normalise cDNA expression for further genes of 
interest.  


































































































































Appendix Table 2: Top 20 KEGG enriched pathways for the HF versus LF treatment 
The number of genes involved corresponds to the number of genes found to be significant out of the total 
number of genes involved in that pathway. Where the normalised enrichment score is a positive number then 
the pathway was upregulated for the comparison, and vice versa. The FDR q-value highlights how significantly 
enriched the pathway was. 







Valine Leucine and isoleucine degradation 32/37 2.56 0.000 
Peroxisome 46/73 2.53 0.000 
Fatty acid metabolism 20/35 2.50 0.000 
Butanoate metabolism 17/26 2.30 0.000 
Propanoate metabolism 18/28 2.20 0.000 
Beta alanine metabolism 12/20 2.10 0.000 
Tryptophan metabolism 14/30 2.09 0.000 
Drug metabolism other enzymes 16/28 2.02 0.001 
PPAR signalling pathway 20/56 1.97 0.001 
Limonene and pinene degradation 6/9 1.88 0.004 
Ribosome 32/77 -2.33 0.000 
Spliceosome 43/116 -1.75 0.085 
ECM receptor interaction 34/69 -1.68 0.137 
Notch signalling pathway 16/40 -1.68 0.106 
Focal adhesion 58/169 -1.55 0.335 
Cell adhesion molecules 23/96 -1.54 0.287 
Bladder cancer 24/37 -1.48 0.429 
Progesterone mediated oocyte maturation 31/73 -1.48 0.377 
Cell cycle 42/117 -1.41 0.590 






Appendix Table 3: Top 20 KEGG enriched pathways for the HF+EC versus HF treatment 
The number of genes involved corresponds to the number of genes found to be significant out of the total 
number of genes involved in that pathway. Where the normalised enrichment score is a positive number then 
the pathway was upregulated for the comparison, and vice versa. The FDR q-value highlights how significantly 
enriched the pathway was. 







Ribosome 43/77 2.15 0.000 
Toll like receptor signalling pathway 21/80 1.94 0.004 
Leishmania infection 11/53 1.84 0.015 
Jak-Stat signalling pathway 31/95 1.77 0.032 
Cytokine-cytokine receptor interaction 42/158 1.77 0.028 
Cytosolic DNA sensing pathway 15/38 1.73 0.038 
NOD like receptor signalling pathway 10/51 1.66 0.081 
Acute myeloid leukaemia 18/56 1.63 0.104 
Apoptosis 19/80 1.59 0.137 
Spliceosome 35/116 1.53 0.218 
Valine Leucine and isoleucine degradation 23/37 -2.53 0.000 
Fatty acid metabolism 17/35 -2.27 0.000 
Butanoate metabolism 14/26 -2.22 0.000 
Propanoate metabolism 15/28 -2.19 0.000 
Peroxisome 33/73 -1.97 0.004 
Starch and sucrose metabolism 13/29 -1.86 0.014 
PPAR signalling pathway 16/56 -1.83 0.018 
Citrate cycle (TCA cycle) 15/28 -1.80 0.023 
Tryptophan metabolism 14/30 -1.79 0.022 






Appendix Table 4: Top 20 KEGG enriched pathways for the HF+34DHPVL and HF treatment 
The number of genes involved corresponds to the number of genes found to be significant out of the total 
number of genes involved in that pathway. Where the normalised enrichment score is a positive number then 
the pathway was upregulated for the comparison, and vice versa. The FDR q-value highlights how significantly 
enriched the pathway was. 







Notch signalling pathway 15/40 1.67 0.730 
DNA replication 7/33 1.67 0.370 
Other glycan degradation 6/15 1.65 0.312 
Hematopoietic cell lineage 17/64 1.63 0.262 
ECM receptor interaction 29/69 1.59 0.320 
Ribosome 22/77 1.57 0.309 
Amino sugar and nucleotide sugar metabolism 19/41 1.57 0.267 
Mismatch repair 4/21 1.56 0.247 
Base excision repair 15/30 1.56 0.227 
Histidine metabolism 9/25 1.53 0.261 
Valine Leucine and isoleucine degradation 19/37 -1.69 0.422 
Primary bile acid biosynthesis 10/13 -1.53 0.780 
Regulation of autophagy 10/18 -1.50 0.655 
Drug metabolism other enzymes 16/28 -1.49 0.516 
Riboflavin metabolism 10/12 -1.47 0.478 
Terpenoid backbone biosynthesis 7/12 -1.43 0.526 
TGF beta signalling 19/72 -1.43 0.451 
Ubiquitin mediated proteolysis 33/126 -1.39 0.515 
Butanoate metabolism 13/26 -1.36 0.536 






Appendix Table 5: Top 20 KEGG pathways for the LF+EC versus LF treatment 
The number of genes involved corresponds to the number of genes found to be significant out of the total 
number of genes involved in that pathway. Where the normalised enrichment score is a positive number then 
the pathway was upregulated for the comparison, and vice versa. The FDR q-value highlights how significantly 
enriched the pathway was. 







Leishmania infection 34/53 2.28 0.000 
Natural killer cell mediated cytotoxicity 40/86 2.25 0.000 
Chemokine signalling pathway 61/147 2.19 0.001 
Epithelial cell signalling in helicobacter pylori infection 28/59 2.14 0.001 
Antigen processing and presentation 30/47 2.13 0.001 
NOD like receptor signalling pathway 22/51 2.01 0.004 
Cell adhesion molecules 41/96 2.00 0.004 
Graft versus host disease 15/21 1.95 0.014 
T-cell receptor signalling pathway 34/92 1.94 0.015 
Cytokine-cytokine receptor interaction 61/158 1.92 0.023 
Parkinsons disease 50/94 -1.78 0.138 
Oxidative phosphorylation 53/99 -1.71 0.150 
Regulation of autophagy 6/18 -1.56 0.347 
RNA polymerase 9/26 -1.52 0.337 
Maturity onset diabetes of the young 7/12 -1.50 0.313 
Folate biosynthesis 4/8 -1.48 0.306 
Spliceosome 32/116 -1.43 0.342 
Glycosaminoglycan biosynthesis keratin sulfate 5/10 -1.40 0.365 
Riboflavin metabolism 6/12 -1.38 0.376 






Appendix Table 6: Top 20 KEGG enriched pathways for the LF+34DHPVL versus LF treatment 
The number of genes involved corresponds to the number of genes found to be significant out of the total 
number of genes involved in that pathway. Where the normalised enrichment score is a positive number then 
the pathway was upregulated for the comparison, and vice versa. The FDR q-value highlights how significantly 
enriched the pathway was. 







Leishmania infection 32/53 2.31 0.000 
FC Epsilon RI signalling pathway 23/59 2.25 0.000 
Natural killer cell mediated cytotoxicity 36/86 2.25 0.000 
Cytokine-cytokine receptor interaction 78/158 2.20 0.000 
B cell receptor signalling pathway 33/74 2.17 0.000 
Cell adhesion molecules 42/96 2.14 0.000 
Leukocyte transendothelial migration 47/93 2.11 0.000 
Hematopoietic cell lineage 31/64 2.11 0.000 
Graft versus host disease 18/21 2.10 0.000 
NOD like receptor signalling 29/51 2.08 0.000 
Maturity onset diabetes of the young 56/147 2.08 0.000 
Glycosaminoglycan biosynthesis heparan sulfate 6/12 -1.93 0.021 
Basal cell carcinoma 10/19 -1.60 0.390 
Terpenoid backbone biosynthesis 10/41 -1.57 0.313 
Selenoamino acid metabolism 7/12 -1.54 0.304 
Glycine serine and threonine metabolism 17/27 -1.54 0.243 
Oxidative phosphorylation 47/99 -1.51 0.257 
Melanogenesis 11/75 -1.48 0.271 
Sulfur metabolism 5/9 -1.44 0.305 






Appendix Table 7: Top 20 KEGG pathways for the HF+EC versus LF treatments 
The number of genes involved corresponds to the number of genes found to be significant out of the total 
number of genes involved in that pathway. Where the normalised enrichment score is a positive number then 
the pathway was upregulated for the comparison, and vice versa. The FDR q-value highlights how significantly 
enriched the pathway was. 







Peroxisome 40/73 2.41 0.000 
Valine leucine and isoleucine degradation 24/37 2.39 0.000 
Fatty acid metabolism 19/35 2.28 0.000 
Proteasome 23/41 2.02 0.002 
Tryptophan metabolism 16/30 1.95 0.003 
Butanoate metabolism 15/26 1.90 0.006 
Beta alanine metabolism 14/20 1.80 0.024 
Pantothenate and COA biosynthesis 9/13 1.78 0.029 
Drug metabolism other enzymes 13/28 1.74 0.041 
Propanoate metabolism 15/28 1.72 0.046 
Ribosome 37/77 -2.01 0.003 
Cell cycle 51/117 -1.81 0.044 
ECM receptor interaction 34/69 -1.79 0.039 
TGF beta signalling pathway 25/72 -1.77 0.039 
Focal adhesion 70/169 -1.63 0.141 
Arrhythmogenic right ventricular cardiomyopathy 18/52 -1.63 0.125 
Cell adhesion molecules 16/96 -1.61 0.125 
Progesterone mediated oocyte maturation 31/73 -1.59 0.133 
Oocyte meiosis 28/93 -1.59 0.121 






Appendix Table 8: Top 20 KEGG enriched pathways for the HF+34DHPVL versus LF treatments 
The number of genes involved corresponds to the number of genes found to be significant out of the total 
number of genes involved in that pathway. Where the normalised enrichment score is a positive number then 
the pathway was upregulated for the comparison, and vice versa. The FDR q-value highlights how significantly 
enriched the pathway was. 







Valine leucine and isoleucine degradation 29/37 2.47 0.000 
Fatty acid metabolism 21/35 2.45 0.000 
Peroxisome 35/73 2.43 0.000 
Butanoate Metabolism 17/26 2.29 0.000 
Tryptophan metabolism 12/30 2.21 0.000 
Propanoate metabolism 21/28 2.16 0.000 
Drug metabolism cytochrome P450 14/35 2.01 0.000 
Beta alanine metabolism 12/20 1.97 0.000 
PPAR signalling pathway 28/56 1.94 0.001 
Ascorbate and aldarate metabolism 4/8 1.84 0.001 
Ribosome 51/77 -2.23 0.000 
Spliceosome 52/116 -2.07 0.000 
TGF beta signalling pathway 23/72 -1.60 0.330 
Basal transcription factors 13/29 -1.58 0.281 
Arrhythmogenic right ventricular cardiomyopathy 19/52 -1.57 0.262 
RNA degradation 23/55 -1.54 0.274 
Notch signalling pathway 18/40 -1.52 0.282 
Bladder cancer 15/37 -1.47 0.370 
Hypertrophic cardiomyopathy HCM 26/57 -1.43 0.426 






Appendix Table 9: Top 20 REACTOME enriched pathways for the HF versus LF treatments 
The number of genes involved corresponds to the number of genes found to be significant out of the total 
number of genes involved in that pathway. Where the normalised enrichment score is a positive number then 
the pathway was upregulated for the comparison, and vice versa. The FDR q-value highlights how significantly 
enriched the pathway was. 







Protein localisation 67/153 2.54 0.000 
Peroxisomal protein import 36/58 2.46 0.000 
Mitochondrial fatty acid beta oxidation 21/30 2.45 0.000 
Fatty acid metabolism 53/145 2.39 0.000 
Peroxisomal lipid metabolism 15/26 2.27 0.000 
The citric acid cycle and respiratory electron transport 75/145 2.26 0.000 
Respiratory electron transport ATP synthesis by 
chemiosmotic coupling and heat production by uncoupling 
proteins 
54/101 2.23 0.000 
Respiratory electron transport 47/82 2.23 0.000 
Glyoxylate metabolism and glycine degradation 14/26 2.21 0.000 
Branched chain amino acid catabolism 14/18 2.21 0.000 
Eukaryotic translation elongation 35/81 -2.31 0.000 
Response of EIF2AK4 GCN2 to amino acid deficiency 48/91 -2.31 0.000 
SRP dependent co-translational protein targeting to 
membrane 
59/101 -2.26 0.000 
Nonsense mediated decay 56/104 -2.24 0.000 
Influenza infection 57/135 -2.21 0.000 
Eukaryotic translation initiation 60/108 -2.19 0.000 
Extracellular matrix organisation 114/232 -2.14 0.000 
RRNA processing 87/188 -2.14 0.000 
Selenoamino acid metabolism 49/106 -2.11 0.000 






Appendix Table 10: Top 20 REACTOME enriched pathways for the HF+EC versus HF treatments 
The number of genes involved corresponds to the number of genes found to be significant out of the total 
number of genes involved in that pathway. Where the normalised enrichment score is a positive number then 
the pathway was upregulated for the comparison, and vice versa. The FDR q-value highlights how significantly 
enriched the pathway was. 







SRP dependent co-translational protein targeting to 
membrane 
57/101 2.22 0.000 
Eukaryotic translation elongation 45/81 2.15 0.000 
Response of EIF2AK4 GCN2 to amino acid deficiency 47/91 2.15 0.000 
Interferon alpha beta signalling 22/44 2.13 0.000 
Antimicrobial peptides 9/20 2.08 0.000 
Selenoamino acid metabolism 65/106 2.07 0.000 
Regulation of TLR by endogenous ligand  8/18 2.07 0.000 
Toll like receptor cascades 36/144 2.03 0.001 
RRNA Processing 82/188 2.02 0.001 
Interleukin 10 signalling 14/31 2.01 0.001 
Mitochondrial fatty acid beta oxidation 16/30 -2.30 0.000 
Peroxisomal lipid metabolism 15/26 -2.02 0.022 
Fatty acid metabolism 44/145 -1.97 0.038 
Mitochondrial fatty acid beta oxidation of saturated fatty 
acids 
6/9 -1.95 0.034 
Class I peroxisomal membrane protein import 10/19 -1.92 0.043 
Beta oxidation of decanoyl COA to octanoyl COA  4/6 -1.91 0.044 
The citric acid cycle and respiratory electron transport 52/145 -1.89 0.048 
Branched chain amino acid catabolism 11/18 -1.89 0.043 
Mitochondrial fatty acid beta oxidation of unsaturated fatty 
acids 
6/6 -1.89 0.040 






Appendix Table 11: Top 20 REACTOME enriched pathways for the HF+34DHPVL versus HF treatments 
The number of genes involved corresponds to the number of genes found to be significant out of the total 
number of genes involved in that pathway. Where the normalised enrichment score is a positive number then 
the pathway was upregulated for the comparison, and vice versa. The FDR q-value highlights how significantly 
enriched the pathway was. 







Polymerase switching 5/13 1.96 0.151 
Lagging strand synthesis 5/19 1.93 0.128 
Polymerase switching on the C strand of the telomere 5/15 1.88 0.153 
O glycosylation of TSR domain containing proteins 16/31 1.88 0.126 
DNA strand elongation  14/31 1.87 0.116 
Assembly of collagen fibrils and other multimeric structures 29/52 1.81 0.187 
PCNA dependent long patch base excision repair 4/19 1.79 0.230 
Extracellular matrix organisation 114/232 1.77 0.242 
ECM proteoglycans 34/59 1.77 0.217 
Carboxyterminal post translational modifications of tubulin 13/24 1.75 0.244 
FOXO mediated transcription of cell cycle genes 7/15 -1.89 0.488 
Neurotransmitter release cycle 7/33 -1.87 0.292 
FOXO mediated transcription of oxidative stress metabolic 
and neuronal genes 
13/25 -1.83 0.365 
Signalling by BMP 12/25 -1.78 0.512 
Regulation of FOXO transcriptional activity by acetylation 4/10 -1.74 0.651 
Dopamine neurotransmitter release cycle 4/17 -1.72 0.624 
Signalling by Hippo 6/18 -1.72 0.564 
Deadenylation of mRNA  11/24 -1.70 0.592 
UB specific processing proteases 50/163 -1.69 0.603 






Appendix Table 12: Top 20 REACTOME enriched pathways for the LF+EC versus LF treatments 
The number of genes involved corresponds to the number of genes found to be significant out of the total 
number of genes involved in that pathway. Where the normalised enrichment score is a positive number then 
the pathway was upregulated for the comparison, and vice versa. The FDR q-value highlights how significantly 
enriched the pathway was. 







Immunoregulatory interactions between a lymphoid and a 
non-lymphoid cell 
51/78 2.45 0.000 
Interferon alpha beta signalling 20/44 2.14 0.001 
RHO GTPases activate NADPH oxidases 12/21 2.11 0.001 
Interleukin 10 signalling 21/31 2.10 0.001 
ROS and RNS production in phagocytes 15/28 2.08 0.002 
Interleukin 4 and interleukin 13 signalling 55/85 2.06 0.002 
FCGR3A mediated IL-10 synthesis 17/34 2.05 0.002 
Semaphorin interactions 25/59 2.02 0.003 
Antimicrobial peptides 13/20 2.01 0.004 
Signalling by interleukins 156/364 2.00 0.004 
Respiratory electron transport 52/82 -2.43 0.000 
Respiratory electron transport ATP synthesis by 
chemiosmotic coupling and heat production by uncoupling 
proteins 
54/101 -2.323 0.000 
Complex I biogenesis 31/44 -2.25 0.000 
Mitochondrial translation 41/94 -2.14 0.001 
Class I peroxisomal membrane protein import 10/19 -1.96 0.040 
The citric acid cycle and respiratory electron transport 72/145 -1.92 0.056 
CHREBP activates metabolic gene expression 8/8 -1.87 0.085 
RNF mutants show enhcanced Wnt signalling and 
proliferation 
4/7 -1.80 0.169 
HIV transcription elongation 21/40 -1.76 0.247 






Appendix Table 13: Top 20 REACTOME enriched pathways for the LF+34DHPVL versus LF treatments 
The number of genes involved corresponds to the number of genes found to be significant out of the total 
number of genes involved in that pathway. Where the normalised enrichment score is a positive number then 
the pathway was upregulated for the comparison, and vice versa. The FDR q-value highlights how significantly 
enriched the pathway was. 







Immunoregulatory interactions between a lymphoid and a 
non-lymphoid cell 
48/78 2.52 0.000 
Interferon gamma signalling 35/65 2.34 0.000 
DAP12 interactions 14/31 2.30 0.000 
RHO GTPases activate NADPH oxidases 12/21 2.22 0.000 
Interleukin 4 and interleukin 13 signalling 37/85 2.21 0.000 
Interleukin 10 signalling 28/31 2.20 0.000 
Signalling by interleukins 168/364 2.20 0.000 
GPVI mediated activation cascade 17/33 2.20 0.000 
Signalling by the B cell receptor BCR 64/108 2.19 0.000 
Neutrophil degranulation 167/396 2.18 0.000 
Formation of the beta catenin TCF transactivating complex 24/54 -2.21 0.000 
Respiratory electron transport 51/82 -2.21 0.000 
Activation of gene expression by SREBF SREBP 17/41 -2.20 0.000 
Respiratory electron transport ATP synthesis by 
chemiosmotic coupling and heat production by uncoupling 
proteins 
54/101 -2.19 0.000 
Regulation of cholesterol biosynthesis by SREBP SREBF 20/54 -2.18 0.001 
HDACS deacetylate histones 21/50 -2.10 0.003 
Complex I biogenesis 29/44 -2.06 0.005 
CHREBP activates metabolic gene expression 8/8 -2.02 0.007 
HATS acetylate histones 39/97 -1.98 0.011 






Appendix Table 14: Top 20 REACTOME enriched pathways for the HF+EC versus LF treatments 
The number of genes involved corresponds to the number of genes found to be significant out of the total 
number of genes involved in that pathway. Where the normalised enrichment score is a positive number then 
the pathway was upregulated for the comparison, and vice versa. The FDR q-value highlights how significantly 
enriched the pathway was. 







Peroxisomal protein import 30/58 2.37 0.000 
Mitochondrial fatty acid beta oxidation 19/30 2.34 0.000 
Protein localisation 75/153 2.34 0.000 
Metabolism of polyamines 31/57 2.12 0.001 
Interleukin 15 signalling 5/13 2.08 0.002 
Interleukin 1 signalling 45/95 2.04 0.005 
Peroxisomal lipid metabolism 11/26 2.04 0.004 
Interleukin 20 family signalling 5/14 2.04 0.004 
Branched chain amino acid catabolism 12/18 2.03 0.004 
Fatty acid metabolism 48/145 2.03 0.004 
ECM proteoglycans 33/59 -2.04 0.011 
Eukaryotic translation elongation 46/81 -2.00 0.012 
Collagen chain trimerization 28/32 -1.99 0.010 
Eukaryotic translation initiation 37/108 -1.98 0.010 
RHO GTPases activate formins 50/123 -1.97 0.008 
Extracellular matrix organisation 97/232 -1.96 0.007 
Nonsense mediated decay 38/104 -1.95 0.008 
Resolution of sister chromatid cohesion 45/109 -1.94 0.009 
Influenza infection 65/135 -1.93 0.011 
SRP dependent co-translational protein targeting to 
membrane 






Appendix Table 15: Top 20 REACTOME enriched pathways for the HF+34DHPVL versus LF treatments 
The number of genes involved corresponds to the number of genes found to be significant out of the total 
number of genes involved in that pathway. Where the normalised enrichment score is a positive number then 
the pathway was upregulated for the comparison, and vice versa. The FDR q-value highlights how significantly 
enriched the pathway was. 






Protein localisation 67/153 2.37 0.000 
Fatty acid metabolism 56/145 2.35 0.000 
Peroxisomal protein import 28/58 2.32 0.000 
Mitochondrial fatty acid beta oxidation 21/30 2.28 0.000 
The citric acid and respiratory electron transport 53/145 2.21 0.000 
Peroxisomal lipid metabolism 15/26 2.16 0.000 
Pyruvate metabolism and citric acid cycle 22/48 2.13 0.000 
Branched chain amino acid catabolism 12/18 2.08 0.001 
Respiratory electron transport ATP synthesis by 
chemiosmotic coupling and heat production by uncoupling 
proteins 
54/101 2.07 0.001 
Glutathione conjugation 10/27 2.00 0.004 
Nonsense mediated decay 64/104 -2.32 0.000 
RRNA processing 107/188 -2.32 0.000 
Eukaryotic translation initiation 70/108 -2.31 0.000 
Eukaryotic translation elongation 55/81 -2.30 0.000 
Influenza infection 70/135 -2.29 0.000 
SRP dependent co-translational protein targeting to 
membrane 
60/101 -2.27 0.000 
Response of EIF2AK4 GCN2 to amino acid deficiency 56/91 -2.26 0.000 
Processing of capped intron containing pre-mRNA  103/222 -2.19 0.000 
RRNA modification in the nucleus and cytosol 32/58 -2.18 0.000 
Selenoamino acid metabolism 58/106 -2.15 0.000 
 
 
